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Abstract
Although existing clinical evidence shows that 
the transfusion of blood components is becoming 
increasingly safe, the risk of transmission of known 
and unknown pathogens, new pathogens or re-
emerging pathogens still persists. Pathogen reduction 
technologies may offer a new approach to increase 
blood safety. The study is the output of collaboration 
between the Italian National Blood Centre and the 
Post-Graduate School of Health Economics and 
Management, Catholic University of the Sacred Heart, 
Rome, Italy. A large, multidisciplinary team was 
created and divided into six groups, each of which 
addressed one or more HTA domains.
Plasma treated with amotosalen + UV light, 
riboflavin + UV light, methylene blue or a solvent/
detergent process was compared to fresh-frozen 
plasma with regards to current use, technical features, 
effectiveness, safety, economic and organisational 
impact, and ethical, social and legal implications. 
The available evidence is not sufficient to state which 
of the techniques compared is superior in terms of 
efficacy, safety and cost-effectiveness. Evidence on 
efficacy is only available for the solvent/detergent 
method, which proved to be non-inferior to untreated 
fresh-frozen plasma in the treatment of a wide range 
of congenital and acquired bleeding disorders. With 
regards to safety, the solvent/detergent technique 
apparently has the most favourable risk-benefit 
profile. Further research is needed to provide a 
comprehensive overview of the cost-effectiveness 
profile of the different pathogen-reduction techniques. 
The wide heterogeneity of results and the lack 
of comparative evidence are reasons why more 
comparative studies need to be performed. 
Keywords: health technology assessment, pathogen 
reduction, pathogen inactivation, fresh-frozen plasma, 
transfusion safety.
The health problem and current use of the 
technologies
Human plasma accounts for about 55% of the 
body's total blood volume1. Plasma is a complex 
mixture of water, inorganic salts, nutrients (such as 
carbohydrates, lipids and amino acids), organic waste 
products, peptides, enzymes, hormones, and more 
than 1,000 proteins1,2. There are four major categories 
of plasma proteins3: (i) albumins; (ii) globulins; 
(iii) fibrinogen; and (iv) coagulation factors (factor 
[F] II, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIII, 
antithrombin, von Willebrand factor [VWF], plasmin 
inhibitor, protein C and free protein S). Since the 
separation of plasma from whole blood became 
standard practice, the amount of frozen plasma used 
started to increase steadily4,5. Currently, human 
plasma may be used as a therapeutic product, known 
as clinical plasma or fresh-frozen plasma (FFP), or as 
source material for the production of pharmaceutical 
fractionated products (also called plasma products 
or plasma-derived medicinal products)6,7. Plasma 
units for transfusion may be obtained by separation 
of the plasma from collected whole blood or by 
apheresis procedures2. Plasma units contain many 
biologically active molecules8. Among these, labile 
coagulations factors, especially FV and FVIII, are 
unstable molecules because of their short half-lives9. 
To achieve the maximum yield of FVIII, plasma 
should be frozen to −30 °C or below10. 
Several plasma products are available for transfusion 
or for industrial fractionation: four frozen plasma 
products and two liquid-state plasma products. 
The frozen plasma products are: (i) FFP, (ii) frozen 
plasma (FP), frozen within 24 hours of phlebotomy, (iii) 
cryoprecipitate-reduced plasma and (iv) cryoprecipitate. 
FFP and FP differ with regards to the time before 
freezing (6-8 hours -depending on the plasma source 
and manufacturer- for the former, 24 hours for the 
latter). Both products have a shelf-life of 24 hours 
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once thawed5,8. In FP, the levels of FVIII, alone, are 
lower (65-80% respect to FFP), although adequate for 
haemostasis8. Cryoprecipitate-reduced plasma is also 
known as "cryo-poor plasma" and "cryosupernatant". 
It is prepared by centrifuging frozen plasma after 
thawing. Supernatant plasma (cryoprecipitate-
reduced plasma) must be removed and the remaining 
plasma is refrozen as cryoprecipitate at −20 °C. The 
cryoprecipitate must be refrozen within 1 hour of the 
initial thawing. As a result, all plasma proteins remain 
in the cryoprecipitate and FVIII, VWF and fibrinogen 
are concentrated2. The cold-insoluble portion of plasma 
that precipitates when plasma is thawed between 1 
and 6 °C is referred to as cryoprecipitate in European 
countries and as cryoprecipitated antihaemophilic 
factor in North American States11. 
The two liquid-state plasma products are: (i) thawed 
plasma and (ii) liquid plasma5,8. These products differ 
because thawed plasma is made from a frozen product 
(FFP or FP) and has a short shelf-life, when stored at 
refrigerated temperatures (1 to 6 °C), of 5 days, whereas 
liquid plasma is never frozen and has a refrigerated 
shelf-life (26 or 40 days) that is determined by the 
manufacturing process5,8. 
Indications
Plasma
Plasma has been available for transfusion since 
the 1940s and was initially often used as volume 
replacement. With the availability of "plasma 
expanders" (e.g. crystalloids and colloids) and purified 
albumin, its use as a volume expander has progressively 
declined8. It is now usually indicated for the treatment 
of congenital and acquired coagulation factor 
deficiencies, coagulopathy resulting from liver disease, 
massive blood loss, and thrombotic thrombocytopenic 
purpura (TTP or Moschowitz syndrome). In addition, 
plasma may be used to prepare cryoprecipitate for 
fibrinogen replacement and the treatment of von 
Willebrand's disease. The typical therapeutic use 
of plasma for correction of coagulopathy involves 
transfusion of approximately 10 to 20 mL/kg per 
transfusion, resulting in exposure to multiple donors. 
Plasma exchange with fluid replacement is the most 
effective treatment for acute idiopathic TTP12-14. 
Cryoprecipitate
Cryoprecipitate is an allogeneic blood product 
prepared from human plasma. It contains FVIII, VWF, 
fibrinogen, fibronectin and FXIII. Its use was first 
reported in the 1960s for the treatment of patients with 
FVIII deficiency. Nowadays cryoprecipitate is used to 
replace fibrinogen in patients with acquired fibrinogen 
deficiency11.
Inappropriate indications
Plasma should not be used13,15: (i) to expand the 
circulatory volume; (ii) to correct hypoproteinaemia; 
(iii) to correct an immune deficiency; (iv) for nutritional 
purposes; (v) to correct congenital or acquired deficiencies 
of clotting factors in the absence of haemorrhage, or for 
the correction of disorders of haemostasis in patients with 
chronic liver disease who are not bleeding.
Adverse reactions to plasma transfusion
Adverse reactions to plasma transfusion can be 
classified as follows13,14: (i) allergic reactions (from mild 
urticaria to severe anaphylaxis); (ii) transfusion-related 
acute lung injury (TRALI); (iii) febrile reactions; (iv) 
citrate toxicity; (v) transfusion-transmitted infections 
(TTI); (vi)  transfusion-associated circulatory overload 
(TACO); and (vii) formation of inhibitors against a 
deficient coagulation factor. 
Target condition
The history of Transfusion Medicine is essentially 
that of a continuous and relentless pursuit of procedures 
to make blood transfusion and its products safe and 
effective. Safety is based on the prevention of the two 
main risks associated with allogeneic transfusion, 
which are infectious and immunological risks. Despite 
various approaches to blood safety (more stringent 
donor screening, introduction of new exclusion 
criteria, registries of previously deferred donors, 
various specific serological and nucleic acid tests 
[NAT], traceability and haemovigilance procedures 
and appropriate clinical use of blood), TTI still occur16. 
In the last decades blood banks, as well as the plasma 
manufacturing industry, have aggressively pursued 
strategies to reduce the risks of TTI. The continuous 
advances in procedures for the collection, preparation 
and storage of blood products have led to a constant 
improvement of the quality of blood components, 
resulting in more effective transfusion therapy17. 
Indeed, as shown by studies on incidence, transfusion-
related transmission of pathogens has decreased 
significantly in the past years18,19. 
Table I reports the relative risks of the most common 
TTI.
Although the risk of TTI from the blood supply is 
currently low, processes to inactivate contaminating 
viruses, bacteria and protozoa may improve the safety 
of transfusion even further20. Nowadays, human plasma 
proteins, clotting factors in particular, have a high 
margin of viral safety as a result of three complementary 
approaches: (i) the selection of safe blood donors on 
the basis of their history and clinical evaluation; (ii) 
systematic screening of units of blood for transfusion; 
and (iii) the treatment of blood and blood products to 
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inactivate infectious agents that, for various reasons, 
have escaped screening21. 
Donor selection is of paramount importance, but its 
limits are well known, even if conducted in accordance 
with the most stringent criteria; in fact, infected 
asymptomatic individuals and people who are not aware 
of adopting risk behaviours serve as an asymptomatic 
reservoir and a potential source of transmission of 
pathogens to blood recipients22. 
The traditional serological tests for the detection 
of donor carriers of antigens of infectious agents, and/
or their respective antibodies, have been progressively 
improved over years and especially in the last decade16. 
In 2009, the World Health Organization (WHO) strongly 
recommended pre-transfusion blood tests for human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), 
hepatitis C virus (HCV) and syphilis23. Nonetheless, 
in some cases these tests may not detect the marker of 
infection, usually because a blood donation is made 
during the potentially infectious "window period", early 
in the course of the infection. NAT have contributed to 
the reduction of the risk of TTI since NAT technologies 
have the potential to detect viraemia earlier than 
serological methods, which are based on seroconversion. 
Since viraemia precedes seroconversion by several days 
in the case of HIV and several weeks in the case of HCV, 
tests that detect viral nucleic acids are considered a 
significant technological advance and an additional step 
in achieving the goal of zero risk for blood transfusion 
recipients24. Viral NAT are meant to overcome the still 
existing limits of serological screening of units for 
transfusion, namely: (i) lack of a positive correlation 
between the "surrogate" marker (for example, alanine 
aminotransferase levels and anti-HBc for HBV) and 
the presence of the virus in the donor; (ii) employment 
of insensitive tests; (iii) no or low antibody response; 
and (iv) presence of mutant forms of hepatitis B surface 
antigen (HBsAg)25. Despite the progress made in 
screening for blood-transmitted diseases, both the post-
infection diagnostic window and the appearance of novel 
infective agents remain critical issues for the safety of 
blood transfusions26. Furthermore, many pathogens that 
have the potential to invade the blood supply are not yet 
screened for because of the low prevalence of the disease 
in the general population, the unknown transmission 
rate of infection through transfusion, or the lack of a 
readily available test for the agent. In order to overcome 
the deficiencies of the above-mentioned tests, other 
procedures for the prevention of viral infection risk have 
been proposed and implemented. One of these consists 
in storing the donated plasma unit for a longer time than 
the window period for HIV, HBV and HCV, until the 
donor is confirmed to be negative for these TTI. This 
procedure, referred to as "quarantine" (Q), can reveal 
viral agents that escaped previous screening performed 
during the window period. Adopted in Germany since 
1995 and approved by the American Food and Drug 
Administration (FDA) in 1998, it is applied to the 
plasma obtained by decomposition of whole blood, but 
is also suitable for productive plasmapheresis, at shorter 
intervals than the whole blood donations. The most 
appropriate name for the plasma that, regardless of the 
collection procedure is used only after repetition of the 
investigation of the donor serological tests for viruses 
is "donor-retested plasma" or "Q plasma"27. Q plasma, 
which is not submitted to any chemical treatment, retains 
the protein content and therapeutic efficacy of standard 
plasma28. Although Q plasma could potentially eliminate 
the window period by repeated donor testing within 
4 to 6 months, it still carries the risk of transmitting 
blood-borne infections that are not detected by screening 
methods and the safety of the approach depends on test 
sensitivity. Furthermore, the risk of emerging infections 
is currently challenging the use of this approach. Finally, 
an important contribution to the prevention of infectious 
(and immunological) risks is offered by leucodepletion 
of whole blood units, especially if universal pre-storage 
leucodepletion is the method applied29. The importance 
of this procedure derives not only from the possibility of 
reducing the risk of transmitting viruses that are carried 
by leucocytes (cytomegalovirus [CMV], Epstein-Barr 
virus [EBV] and human T-lymphotropic virus [HTLV] 
1 or 2), but also of reducing the risk of transmitting 
bacteria. Although these synergic actions (recruitment of 
donors, testing, storage, quarantine and leucodepletion) 
have increased the safety of blood components prepared 
for transfusions, the risk of transmitting pathogens 
by transfusion persists30. Pathogens such as West 
Nile virus (WNV) and Chikungunya virus, or variant 
Creuzfeldt-Jakob disease (vCJD) prion have recently 
emerged as transfusion-transmissible infectious agents, 
demonstrating that new infectious agents continue to 
enter the donor population and may pose significant risks 
to recipients before they can be completely identified 
and avoided by sensitive tests31-34. 
Table I - Relative risk of the most frequent transfusion-
transmitted infections in Europe.
Pathogen Risk in Europe
Viruses
   Human immunodeficiency virus 1 in 909,000-5,500,000
   Hepatitis C virus 1 in 2,000,000-4,400,000
   Hepatitis B virus 1 in 72,000-1,100,000
Bacteria
   Bacterial contamination 1 in 38,500 for red blood cells
1 in 5,000 for platelets
Source: modified from reference 18.
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In this framework, pathogen reduction technologies 
(PRT) may offer a new approach to increase blood 
safety. In fact, these technologies are able to reduce 
the risk of known and unknown pathogens. The major 
pathogen reduction methods currently available for 
plasma involve the use of a solvent/detergent (SD) 
treatment, methylene blue (MB), and an amotosalen 
(A) or riboflavin (R) based photochemical process35-41. 
Recently, a new method for pathogen reduction, which is 
based on ultraviolet C (UVC) light without the use of any 
photoactive substance for the inactivation of pathogens 
and leucocytes in human platelet concentrates, has 
been introduced. This technology, called Theraflex® 
UV-Platelets system, was developed by the Research 
Foundation of the German Red Cross Blood Services 
(Forschungsgemeinschaft der DRK-Blutspendedienste 
e.V.) in cooperation with MacoPharma International 
GmbH. As the procedure for UVC irradiation applied to 
plasma units has not been fully validated and its clinical 
use is under preliminary evaluation, this method is not 
discussed in this HTA42.
"Pathogen reduction" and "pathogen inactivation" are 
terms commonly used interchangeably in the scientific 
literature. The greatest advantage of these technologies is 
their proactive nature with the potential to eliminate the 
threat deriving from unknown pathogens40. The principle 
of all PRT is to use an inactivating agent capable of 
destroying or reducing the burden of pathogens in the 
blood components. These pathogens may be intracellular 
or extracellular. Inactivation techniques must also avoid 
causing any significant chemical or biological alterations 
to the therapeutic products. Thus, the efficiency of 
a technique is based on the destruction of a targeted 
functional element of the pathogen; this element is not 
present or not involved in the functionality of the blood 
component39. Most PRT use agents that target membranes 
or envelopes of the pathogens or their nucleic acids. Agents 
that destroy membranes or coverings, such as detergents 
and organic solvents, may be used for cell-free products. 
They are more effective against non-enveloped viruses. 
The agents with a mechanism of action targeting nucleic 
acids, such as photosensitive chemicals and alkylating 
agents, have a potentially broader spectrum of use. 
Functional synthesis, as well as microbial proliferation, are 
stopped by blocking transcription and translation without 
affecting the cell membranes of therapeutic products. 
Thus, most pathogens, including viruses, bacteria, fungi, 
parasites and donor leukocytes, may be destroyed39. 
A more evidence-based approach to the assessment 
of the safety and efficacy of these new pathogen-reduced 
plasma products is required2. The guidelines and 
instructions for the use of pathogen-inactivated plasma 
are currently the same as those for FFP, since there are 
no dedicated guidelines at present43. 
Utilisation
Some PRT for plasma have been licensed and are 
being used in Europe and elsewhere. In Europe, the 
opinions concerning PRT are discordant; some consider 
these technologies safer than bacterial screening, others 
claim that they can be risky and do not recommend their 
use until further research shows a favourable risk-benefit 
profile, in light of the single patient's health state. The 
utilisation of these technologies must be appraised 
country by country in relation to the different approaches 
to reduce the risks from pathogens in transfused blood 
components and the use of products made "in house". 
In general, European countries have totally or partially 
adopted at least one PRT. The situation is more complex 
in developing countries. In these countries, the principal 
transfused component is whole blood and there is a lack 
of data on their real capacities to adopt PRT44. 
The results of a survey carried out in 2010, which 
investigated the use of PRT in 51 countries, including 
47 members of the Council of Europe, showed that 16 
member states of the Council of Europe employed PRT 
for plasma. Nine of these countries used a mixture of 
quarantine and PRT: Austria, Germany, Greece, Italy, 
Poland, Portugal, Spain, Switzerland and the United 
Kingdom. Seven countries used PRT alone: Belgium, 
Finland, France, Ireland, Luxembourg, Norway and 
Sweden. MB plasma was used in Russia in 2009 and 
SD plasma has been used in Turkey since 1995. The 
most frequent PRT were solvent/detergent treatment 
and exposure to MB44. 
Pathogen reduction technologies for plasma for 
clinical use in Europe
Austria
Austrian health authorities decided to switch from 
Q plasma to MB technology for pathogen-inactivation 
of plasma. PRT are currently applied to plasma (SD 
treatment and MB treatment) and are being evaluated 
for platelets44. 
Belgium 
In Belgium, pathogen reduction of plasma became 
mandatory in 1994, with the adoption of the SD method. 
Because of the risk of vCJD, the application of PRT to 
individual plasma units has been preferred since 2002 
and became mandatory in 2003. In 2004, MB treatment 
was approved. The use of A plasma was introduced in the 
Blood Transfusion Centre of Mont Godinne in October 
2003, and was then used for plasma apheresis in 2007, 
followed by buffy coat platelets in 200945. 
Finland
Finland started to use SD plasma in 2007 and since 
2013 all units administered are pathogen-reduced by SD 
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treatment. SD plasma has been transfused to all groups of 
patients and has also been used to prepare reconstituted 
blood for exchange transfusion in neonates44. 
France
In France, three types of plasma are authorised by 
the Agence Nationale de Sécurité du Médicament et 
des Produits de Santé and issued by the Établissement 
Français du Sang for clinical use46:
- Q plasma; 
- SD plasma;
- A plasma. 
A haemovigilance survey of 2005-2009 raised 
concerns because of the high rates of allergic reactions 
following transfusion of MB plasma. Consequently, 
the French regulatory authority decided to discontinue 
the use of MB plasma and prohibited its transfusion 
from March 201247-50. However, when haemovigilance 
data from a French region over a 10-year period were 
considered, statistical analysis of the updated 2010 
data did not confirm a significantly higher incidence 
of severe allergic reactions with MB plasma than with 
other types of plasma49. A recent analysis, including 
the 2007-2009 haemovigilance data, revealed a trend, 
with borderline significance, towards a higher incidence 
of severe allergic reactions with MB plasma50. The 
variability of these data demonstrates that differences 
in utilisation rates and slight variations in incidences 
of statistical outcomes need to be appraised cautiously 
when interpreting data on very rare events. Amotosalen 
treatment was introduced in 2006 for apheresis and buffy 
coat platelets, then used for plasma in 200744. 
Germany
MB treatment to inactivate viruses in plasma was 
originally developed by the German Red Cross Blood 
Centre, Springe, Germany and MB plasma was first 
produced routinely for clinical use in 199251. The MB 
system allows treatment of individual units of plasma. 
Over the years since it was introduced, the process has been 
modified and the current system (Theraflex MB® plasma 
system, MacoPharma, Tourcoing, France) has a number of 
improved features and is used routinely by blood centres in 
several countries52. In 2007, the German Red Cross Blood 
Centre also received approval from the German authorities 
to use plasma prepared with the Theraflex MB® plasma 
system52. Germany is waiting for the outcomes of ongoing 
research on the effectiveness, safety and cost-effectiveness 
of the amotosalen/riboflavin photochemical processes 
before introducing these technologies.
Greece
The Greek National Authority approved PRT for 
40% of plasma, although only 11.7% is pathogen-
reduced with MB. Greece has 5 years of experience 
with MB plasma: during this period 8,500 units of MB 
plasma were compared with 54,435 units of untreated 
plasma given to patients with a similar range of clinical 
conditions53. The Blood Transfusion Committee 
Implementation of Pathogen Reduction Technologies 
for Blood Components has strongly recommended 
the implementation of PRT for plasma and platelet 
concentrates44. 
Ireland
Since 2002, over 99% of FFP transfused in Ireland 
has been subjected to SD pathogen reduction; all the 
plasma for this product used in Ireland comes from the 
South Texas Blood and Tissue Centre in San Antonio 
(TX, USA)54. 
Italy
In Italy, SD plasma (Plasmasafe®), introduced in 
2005 by Kedrion S.p.A (Castelvecchio Pascoli - Barga, 
Lucca, Italy), can be acquired as a "service": Blood 
Transfusion Units give the raw material, FFP, to the 
manufacturers, who return the pathogen-inactivated 
product charging the Blood Transfusion Units for the 
cost of the processing. This treatment is carried out by 
Kedrion S.p.A using an industrial process involving 
two filtration phases (1 μm and 0.22 μm)55. Only in 
some Italian regions have specific indications for the 
use of SD plasma been given, taking into account the 
cost faced by the Blood Transfusion Units for this 
activity55. In contrast, since 2002, MB treatment of 
plasma can be performed "in-house", in single Blood 
Transfusion Units that acquire all the necessary 
equipment, reagents and materials55,56. With respect 
to the use of photochemical processes (involving 
amotosalen or riboflavin), the Italian experience is 
limited to studies on platelet concentrates and the use 
of these processes for plasma is limited to a few centres 
or to clinical studies15. 
Norway
Norway has used SD plasma since 1993, even in 
children. Since 2005, the Health Authorities have also 
accepted single donor plasma treated with PRT and Q 
plasma44. 
Spain
In Spain, the Health Authorities of each of the 17 
Autonomous Regions can choose between Q plasma and 
MB plasma as the preferred method for reducing the risk 
of virus transmission by plasma transfusion. Hospitals 
that are not allowed to arrange the supply of blood 
products within their Autonomous Region of competence, 
involve blood banks outside their jurisdiction. For this 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
292
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
reason, clinical teams have a very limited influence 
on the kind of plasma they use. Until 2009, plasma 
inactivated with MB was used in approximately 61% of 
the autonomous communities, whereas Q plasma was 
used in the remaining ones57. Currently, at a national level 
around 250,000 units of plasma are transfused annually 
and MB plasma (introduced in 1999) accounts for 65% 
of transfused plasma, while Q plasma accounts for the 
remaining 35%51. R plasma and A plasma are also used 
by customers in Spain58,59. 
United Kingdom
Imported plasma for internal use is currently 
pathogen-reduced with MB technology. SD plasma 
is also sourced from other countries. Since 2004, the 
United Kingdom Blood Services have been importing 
FFP from the USA for all neonates and children born 
after 1 January 1996. The decision is a precautionary 
approach to the risk of transfusion-transmitted vCJD44. 
Switzerland
Switzerland is moving towards nationwide 
application of PRT to plasma and platelets. SD 
treatment of plasma for clinical use has been licensed 
and is currently being used60. MB-treated plasma has 
been registered since 200751. Swissmedic has decided 
that the implementation in each blood centre will 
depend on the centres' resources and has approved 
amotosalen treatment for platelets and plasma44. No 
patients are excluded, so the products are used for 
all patients including neonates, children, pregnant 
women, patients undergoing stem cell transplantations 
and patients receiving very strong chemotherapeutical 
treatment61. 
Pathogen reduction technologies for plasma for 
clinical use outside of Europe
PRT are less implemented in developed countries 
outside Europe44.  
Table II presents the use of pathogen-inactivated 
plasma in different countries.
Australia and New Zealand 
In Australia and New Zealand, pathogen reduction/
inactivation strategies employed by the American Red 
Cross Blood Services include epidemiological control 
of donors and leucocyte depletion, complemented by 
routine serological and NAT of the final product. MB 
plasma, R plasma and A plasma are currently not used 
in either country62. 
Canada
In Canada, plasma for transfusion is available as 
either FP, frozen within 24 hours of collection or FFP, 
frozen within 6-8 hours of collection. FP and FFP can be 
used interchangeably. There is no SD plasma currently 
available in Canada. A particular type of SD plasma, 
named PLAS+SD®, which was manufactured by V.I. 
Technologies, Inc. (Vitex, Watertown, MA, USA) was 
once available, but it is no longer made. The European 
SD plasma named Octaplas® (Octapharma, Vienna, 
Austria) was introduced into Canada in 1992. The 
Canadian Health Authority recently licensed Octaplas® 
SD plasma, which can be considered as an alternative 
to standard plasma for certain indications63. 
United States of America
In January 2013, the FDA approved the use of the 
SD plasma named Octaplas® in the USA for plasma 
exchange in patients with TTP and for the replacement 
of multiple clotting factors in patients with acquired 
deficiencies64. In December 2014, the use of A plasma 
was also approved65. This is the first step towards the 
resolution of an unmet need. The USA regulatory 
agencies have set an extremely high threshold for the 
approval of any new plasma product for the American 
market, including even minor changes to existing 
manufacturing conditions2. The SD plasma named 
PLAS+SD® (Vitex, Watertown, MA, USA), was licensed 
in the USA in 1998 but was subsequently withdrawn 
from the market. In spite of the fact that both products 
are treated by similar SD methods, significant product 
differences, which can be ascribed to the production 
methods and type of plasma used, have been reported. 
PLAS+SD®, along with a number of thromboembolic 
adverse reactions that had not been observed with 
European SD plasma, resulted in the interruption of SD 
plasma production in the USA in 2002-200366. 
Current management of blood safety
There are two main strategies to ensure the safety 
of the blood supply: (i) procedures based on rigorous 
selection of donors and on screening each unit of 
blood or blood component, and (ii) elimination 
procedures, which aim to inactivate pathogens and 
reduce pathogen load67. The WHO, the International 
Federation of Red Cross and Red Crescent Societies, 
the Council of Europe, the International Society of 
Blood Transfusion, the International Federation of Blood 
Donor Organizations and a number of other international 
and national organisations have defined voluntary non-
remunerated blood donation as a founding and guiding 
principle68. Additional measures that minimise the risk 
of TTI include: selection of low-risk donors through a 
comprehensive system of donor health and behavioural 
screening, with consequent temporary or permanent 
deferral of high-risk donors; skin disinfection procedures 
and use of diversion pouches to prevent contamination 
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Table II - Use of pathogen-inactivated plasma in different countries.
Country Pathogen-inactivated plasma
A-plasma R-plasma MB-plasma SD-plasma
Australia x
Austria x x
Azerbaijan x
Bahrain x
Belarus x x
Belgium x x x x
Canada x
Chile x
Czech Republic x x
Finland x
France x
Germany x x x
Greece x x x
Hong Kong x x
Hungary
Ireland x
Italy x x x x
Kazakhstan x x x
Kuwait x
Luxemburg x x
Malaysia x x
Malta x
Mexico x
Netherlands x
New Zealand x
Norway x x
Oman x
Poland x x
Portugal x
Qatar x x
Romania x
Russia x x x
Saudi Arabia x
Serbia x
Singapore x
Slovakia x
Spain x x x
Sweden x
Switzerland x
Turkey x
Ukraine x x
United Arab Emirates x x
United Kingdom x x
United States of America x* x
Yemen x
* Approved by the FDA on 12/16/2014. A-plasma: amotosalen-treated plasma; R-plasma: riboflavin-treated plasma; MB-plasma: methylene blue-treated 
plasma; SD-plasma: solvent/detergent-treated plasma. Source: modified from reference 94.
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from skin flora; routine serological screening for HBV, 
HCV, HIV 1-2, HTLV 1-2 and syphilis; routine NAT for 
HIV, HBV, and HCV; targeted testing for malaria and 
CMV; routine bacterial decontamination screening of 
platelet concentrates23,69; and the promotion of appropriate 
transfusion practices via education and clinical research 
to minimise patients' exposure to transfusions70. 
More recently, measures against potential TTI by 
prions (infectious proteins) have been introduced. 
In 2003, the first evidence of human-to-human 
transmission of vCJD via a blood transfusion was 
obtained in the United Kingdom, and two other cases 
were subsequently confirmed71. 
Early in 2004, the UK Department of Health, in 
addition to universal leucodepletion of all donated 
blood, excluded from blood donation all subjects known 
to have had blood transfusions since 198071. Given the 
concerns about the possible transmission of vCJD and 
the unavailability of testing for this disease, individuals 
who lived in the United Kingdom for a total period of 6 
or more months between 1980 and 1996 and individuals 
with a history of receiving transfusion in the United 
Kingdom after 1980 are ineligible to donate blood. 
Many countries have adopted a system of 
leucodepletion at the point of collection, prior to storage 
(pre-storage filtration). Leucodepletion may reduce the 
risk of transmission of vCJD via the blood supply but 
there is some uncertainty regarding the efficacy of this 
method as infectious prions may reside in the plasma, 
as well as the white cell component of whole blood72-74. 
Gamma or X-irradiation of blood components, by 
validated systems, is already a well-established practice 
to prevent the development of transfusion-associated 
Graft-versus-Host disease (GvHD)  and studies have 
been conducted to determine the virological and 
bacteriological safety of irradiated blood products and 
protein blood preparations75. Gamma irradiation can 
act by two different mechanisms. The first is the direct 
rupture of covalent bonds in target molecules, including 
both proteins and nucleic acids. The second is an indirect 
mechanism that uses water to produce reactive free 
radicals and other active radiolytic products, which 
in turn can react with a variety of macromolecules, 
including both proteins and nucleic acids. Indirect 
reactions can be reduced by adding radical scavengers, 
removing water by lyophilisation, and/or working at cold 
temperatures. More recently and for the same total dose 
of radiation, reducing the dose rate has been reported to 
improve the balance between protein recovery and virus 
inactivation. The kinetics of viral killing is typically 
linear in a semi-logarithmic plot of virus titre versus 
radiation dose, suggesting that inactivation occurs with 
a single hit of radiation that is absorbed directly by the 
nucleic acids. The principal challenge in using gamma 
irradiation is the inactivation of the desired quantity of 
virus while maintaining the structural and functional 
integrity of proteins76. 
As a result of these strategies, morbidity and 
mortality from TTI, including parasites, are exceedingly 
rare. There is still a residual risk of infections by 
pathogens for which no detection system currently 
exists (e.g. emerging pathogens) or for those with a 
short "window period", when blood levels of specific 
disease markers are too low for detection. NAT has 
markedly reduced but not completely eliminated this 
risk. Meanwhile, bacterial contamination, especially of 
platelet concentrates (because of their storage at ambient 
temperature allowing for bacterial proliferation), is 
recognised as the most common cause of TTI.
New screening tools are being developed not only 
to verify the functional integrity and quality of blood 
products, but also to assess the success of the pathogen 
reduction processes. Proteomics, the large-scale study 
of protein structure and function using technologies 
such as mass spectrometry, has the potential to play 
a crucial role in quality-control processes, but is not 
currently used in routine clinical practice because of 
its high costs and the lack of specialised personnel. 
High throughput systems, such as DNA microarrays, 
will also enable the simultaneous detection of a large 
number of pathogens; however, these systems currently 
rely on the amplification of target DNA and are not 
suitable for large-scale blood banking use77. Biosensors, 
nanoparticle-based DNA and protein bio-barcode 
amplification assays are some emerging diagnostic tools 
that may be used for screening donated blood78,79. 
Only plasma that is serologically and NAT negative 
for HIV-1, HBV and HCV is provided to industry for 
treatment. As regards the production of plasma-derived 
medicinal products, the FDA in the United States and 
the European Medicines Agency (EMA) in Europe have 
enforced the related regulations, leading to stricter2 
requirements for donor selection and donation screening 
since the 1970s, as well as for validated virus removal 
and/or inactivation during the production processes since 
the 1990s. In addition, since 2005, in Europe there is 
a requirement to report and assess the epidemiological 
data of the donor population in reference to the risk of 
infection80. 
In 2011, the EMA guidelines on epidemiological 
data assessment were enhanced. With regards to 
plasma fractionation, the assessment of epidemiological 
data in the framework of marketing authorisation for 
plasma-derived medicinal products is included in the 
Plasma Master File in Europe. In the United States, 
epidemiological data are evaluated, but out of the 
scope of marketing authorisation for plasma-derived 
medicinal products. There has been some harmonisation 
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of regulations in the USA, Europe, and Japan, through 
the International Conference of Harmonization, but 
further work is needed81. 
Current pathogen-reduction methods cannot, 
however, inactivate or destroy most spores and non-
conventional agents such as prions39. That is why 
adoption of so-called "double viral elimination" 
procedures has been encouraged for plasma-derived 
medicinal products. Enhanced safety can be achieved 
through protein purification methods, such as antibody-
mediated affinity chromatography, or the incorporation 
of "nanofilters" with a sufficiently small pore size so 
as to trap viruses while permitting the passage of the 
desired proteins, or the incorporation of a second viral 
inactivation step41. 
It must be ensured that the pathogen inactivation 
techniques affecting the integrity of nucleic acids do not 
cause toxicity in the transfused patients43. 
Methods of pathogen removal used by industry (but 
not by blood centres)
Pasteurisation
Pasteurisation by heating proteins in an aqueous 
stabilised solution at 60 °C for ~10 hours inactivates 
both lipid membrane-enveloped and a range of non-
enveloped viruses. Since coagulation factors are heat 
sensitive, stabilisers (usually sugars, amino acids, or 
acetate) are added to preserve protein integrity and are 
removed after pathogen inactivation. The homogeneity 
of temperature throughout pasteurisation must be 
validated by temperature mapping techniques76. Studies 
on inactivation of HIV, hepatitis A virus (HAV), and 
parvovirus B19 (PVB19) by pasteurisation in a FVIII/
VWF concentrate have demonstrated viral reduction 
of at least 6.4, 4.2, and at least 3.9 log, respectively. 
Additional studies have demonstrated that pasteurisation 
inactivates a wide range of enveloped and non-enveloped 
viruses, including bovine viral diarrhoea virus (BVDV; a 
specific model virus for HCV), pseudorabies virus (PRV; 
a non-specific model virus for HBV), herpes simplex 
virus-1, WNV, and poliovirus82. 
Dry heat treatment of lyophilised products
Most plasma-derived concentrates are lyophilised 
and, especially those treated with SD, subsequently 
treated with dry heat to inactivate non-enveloped viruses 
that resist the SD treatment. Lyophilisation inactivates 
viruses to a certain degree83; the moisture content of 
lyophilised products undergoing dry heat treatment 
should be kept low (typically <2%), as residual moisture 
may affect product stability, even though higher levels 
may enhance inactivation of some viruses37. Dry heat 
treatment of lyophilised products has been demonstrated 
to give favourable results regarding inactivation of 
relevant or model viruses of HAV, HBV, HCV, and 
HIV38,83. Dry heating of a lyophilised FVIII product 
at 80 °C for 72 hours inactivated a wide range of 
viruses; dry heating of FVIII or FIX concentrates 
reduced the risk of HCV transmission. An additional 
study demonstrated that terminal dry heating of a 
lyophilised FVIII concentrate at 100 °C for 30 minutes 
inactivated HAV and HIV to below detectable levels 
within 10 minutes, while retaining approximately 
95% of FVIII activity; whereas heating a lyophilised 
FVIII and VWF concentrate at 100 °C for 120 minutes 
reduced a wide array of viruses (HIV, Sindbis virus, 
PRV, reovirus type-3, HAV, and PVB19) by more than 
4 log81,84. Although PVB19 was reduced by dry heat 
in validation studies, the reduction factor may not be 
sufficient for complete inactivation of the virus load in 
the final product; indeed, asymptomatic PVB19 infection 
was detected in a patient who received FVIII concentrate 
treated at 80 °C for 72 hours82. 
Vapour heat
A drawback to lyophilisation, in addition to that of 
stabilising coagulation factors, is the removal of water 
that can also stabilise potentially infectious viruses in the 
product. By adding water vapour to lyophilised products 
before heating, higher levels of virus inactivation 
can be achieved at equivalent temperatures. Vapour 
heating of lyophilised products targets enveloped and 
non-enveloped viruses and has been demonstrated to 
inactivate hepatitis viruses and HIV. Lyophilisation and 
vapour heat at 60 °C inactivated approximately 6 log of 
HAV in spiked FVIII concentrates within 8 to 10 hours 
and similarly reduced HAV titres in FIX concentrates 
within 3 hours. Among 20 patients with haemophilia 
who received vapour-heated FIX infusions, none 
developed markers for infection with HCV or HIV 
during 6 to 15 months of follow-up, suggesting that 
vapour heat-treated concentrates may be associated 
with a low risk of viral infection. However, vapour 
heat at 60 °C may be insufficient to inactivate HBV 
completely, depending on the viral load in the starting 
material (batch-related) and the amount of product 
given to non-vaccinated patients against HBV; HBV 
infections have been reported in four non-vaccinated 
haemophiliacs who vapour-heated FVIII concentrate82. 
Iodine
Iodine is a strong oxidising agent and, therefore, 
a powerful microbicidal agent. However, it is not 
sufficiently selective in its free form. When bound to 
polymers such as polyvinylpyrrolidone, cross-linked 
starch, or dextran chromatographic medium, the 
virucidal action of iodine is more controlled. In these 
bound forms, the iodine is slowly released into the protein 
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solution and virus inactivation occurs over hours. Starch-
bound iodine at a concentration of 1.05 mg/mL resulted in 
more than 7 log10 inactivation of model lipid-enveloped 
and non-enveloped viruses, while more than 70% of the 
activity of the clotting factors in plasma was retained. 
In another implementation, protein was passed through 
a bed of iodine-cross-linked dextran gel followed by a 
bed of cross-linked dextran gel used to trap and remove 
free iodine76. 
Partition processes: fractionation and chromatography
Besides being inactivated, viruses can be physically 
removed from plasma-derived products by fractionation 
(precipitation or chromatography) and filtration. Before 
the 1980s, plasma fractionation was mainly considered 
as a step in protein purification; no dedicated viral 
reduction step (except for pasteurisation of human 
albumin) was implemented during the manufacturing 
process. Although ethanol precipitation is the most 
widely used plasma fractionation method worldwide, 
it is not used for the production of coagulation factor 
concentrates, as this treatment denatures the desired 
proteins. After initial cryoprecipitation, many clotting 
factor concentrates are purified chromatographically75. 
Most viral reduction treatments are integrated with the 
protein fractionation process ("in-process" treatments), 
but some currently based on heat inactivation procedures 
are applied to products in their final container (terminal 
treatment)43. 
In-process viral inactivation treatments
SD treatment remains the most frequent viral 
inactivation procedure for plasma products. Typically, 
lipid-enveloped viruses are inactivated in a few minutes 
and the functional activity of even the most labile 
plasma proteins (with the possible exception of some 
serine protease inhibitors) is well preserved, but non-
enveloped viruses are not inactivated. The SD agents 
are reduced to a level of a few parts per million, usually 
by chromatographic adsorption or specific precipitation 
of proteins, or selective adsorption on hydrophobic 
chromatographic support. Pasteurisation, another 
common viral inactivation procedure, is heat treatment of 
protein solutions for 10 hours at 60 °C. It denatures viral 
proteins and inhibits virus replication. Pasteurisation 
can inactivate both enveloped and non-enveloped 
viruses; however, the stabilisers, which are needed to 
limit the loss of protein functionality, may decrease the 
rate and the extent of viral inactivation. Stabilisers can 
be removed by ultrafiltration, protein precipitation, or 
chromatography. Vapour heat has also been used by one 
company; the extent of viral inactivation is influenced 
by the temperature, duration, and pressure during the 
treatment. The risk of neo-antigen formation, which can 
enhance protein immunogenicity, should be considered 
when using heat-based inactivation processes82. 
Low pH incubation, usually at pH 4, at 30 °C to 37 °C 
for more than 20 hours, was introduced in the early 
1980s to allow the intravenous infusion of IgG. This 
form of treatment was subsequently found to inactivate 
most lipid-enveloped viruses. Caprylic (octanoic) acid 
precipitation/incubation at a pH below 6 is a recent 
treatment of human IgG that can inactivate lipid-
enveloped viruses. Some products are further purified 
using affinity chromatography mediated by an antibody 
against the protein of interest. It is worth clarifying 
that when re-using chromatography columns, viruses 
that adhere to resins cannot be completely washed out. 
Equipment and materials must, therefore, be sanitised 
with validated chemical and/or physical treatments 
to inactivate and remove viruses to ensure no cross-
contamination of subsequent batches of the product.
Terminal viral inactivation treatments
Heat treatment of lyophilised products (dry heat) is 
used in modern plasma fractionation; however, due to 
the limitations of this treatment, it is mainly utilised as 
a secondary viral inactivation step rather than the core 
inactivation method. The treatment is applied to some 
coagulation factor concentrates. Performed at 80 °C 
for 72 hours or at 100 °C for 30 minutes and generally 
in the presence of protein stabilisers, it provides added 
safety against HAV and other heat-sensitive viruses but 
may not be sufficient to exclude PVB19 transmission. 
Terminal (liquid) pasteurisation at 60 °C for 10 hours is 
the "gold standard" treatment of albumin preparations. 
The fatty acids, caprylate, and tryptophanate, which 
protect albumin from heat denaturation, are added at 
doses compatible with therapeutic use and, therefore, 
are not removed before product infusion82. 
Viral filtration
Nanofiltration is a specific viral filtration process 
applied to protein solutions. It involves multilayer 
membranes of 15 to 75 nm, or equivalent systems, 
to remove viruses mostly by a sieving mechanism. It 
was introduced in the early to mid-1990s and reached 
wide acceptance as a robust viral removal step for all 
products, apart from albumin. Nanofiltration is used to 
complement the core viral inactivation treatment and to 
provide enhanced safety against non-enveloped viruses 
or other resistant infectious agents. Viruses can also 
be removed incidentally during protein precipitation, 
chromatography, or filtration steps. These steps contribute 
to lowering the viral load from the protein production 
stream; they are difficult to monitor and do not, therefore, 
guarantee, as stand-alone procedures, a sufficient safety 
margin82. Viruses may be removed from clotting factor 
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concentrates by filtration, employing retentive filters with 
smaller pores than the diameter of the viruses85. Filtration 
may not be feasible for products containing proteins of 
a size comparable to or larger than the viruses or pores 
of the filter; thus, filtration is mainly limited to smaller-
molecular-weight coagulation factors (e.g., FIX or FVIII). 
However, a VWF concentrate filtered through 35 nm pore 
membranes had a reduction of enveloped viruses (HIV, 
BVDV and PRV) of at least 5.0 log, although filtration 
removed large VWF multimers as well. Filtration of 
a FVIII concentrate using 35 nm or 15 nm sequential 
filtration resulted in removal of both enveloped viruses 
(HIV, BVDV, and PRV) and non-enveloped ones (HAV 
and PPV). Viral filtration alone resulted in virus reduction 
factors of at least 3.6 log10, while a combination of SD, 
chromatography and viral filtration yielded reduction 
factors of at least 5.1 log for all tested viruses. Viral 
filtration of a FXIII concentrate using a 20 nm filter 
resulted in a reduction of enveloped (HIV, BVDV, PRV) 
and non-enveloped (HAV) viruses by a factor of at least 
5.5 log and a reduction of a non-enveloped parvovirus 
by 3.4 log. In a safety study of FIX concentrate, a final 
viral filtration step was added following fractionation, 
chromatography, and SD treatment. The 35- to 15-nm 
sequential filtration step resulted in a reduction of at least 
6.8 log for HAV and at least 6.6 log for BVDV. Filtration 
of another FIX concentrate using two filters (20 nm mean 
pore size) in series removed enveloped and non-enveloped 
viruses very effectively76. 
Life cycle of the technologies
The use of PRT for labile blood components is 
increasing slowly but steadily. Concerns about reduced 
component quality and toxicity have, however, limited 
or prevented the routine use of PRT in many countries. 
In a variety of clinical situations, the supportive and 
often prophylactic nature of blood component therapy 
complicates the clinical evaluation of novel blood 
products. An increasing use and development of these 
novel technologies suggests that pathogen reduction has 
entered a stage of maturity that could further increase 
the safety margin in haemotherapy86. 
In Europe, PRT are now widely available with 
multiple CE-marked products to treat both plasma for 
transfusion (Intercept®, Mirasol®, Octaplas®, Octaplas 
LG®, Plasmasafe®, Theraflex®, Uniplas®) and platelets 
(Intercept®, Mirasol®). 
Since the beginning of the 1990s, considerable 
progress has been made in the development of PRT and 
some of them are already employed in current clinical 
practice. Such PRT are based on photosensitisers that 
are added during processing and, after being activated, 
generate active oxygen species or utilise electron transfer 
processes, which are oxygen independent, to damage 
predominantly nucleic acids (photodynamic reactions). 
Another class of agents forms irreversible covalent 
cross-links in nucleic acids (photochemical reactions) 
to prevent transcription, translation, and proliferaton of 
the pathogen. The rationale of targeting nucleic acids is 
that pathogens and white blood cells require nucleic acid 
function that is not required for the therapeutic effects 
of platelets, plasma, and red blood cells. The reduction 
capacity should reach at least 4-6 log10. Currently, the 
most important substances with photodynamic properties 
studied for clinical application are the essential vitamin B2 
(riboflavin), the phenothiazine derivative MB, psoralens 
such as S-59 (amotosalen) and S-303 or the inactive PEN 
110. The latter compounds also interfere with nucleic 
acids by alkylation chemistry but become activated by 
mechanisms other than an external light source, i.e. upon 
pH shift, which is important for red blood cells, since their 
haemoglobin absorbs UV light strongly87,88. 
The use of MB technology for viral reduction of 
single plasma units was originally developed by the 
Blood Centre of the German Red Cross, Springe, 
Germany; and MB plasma was first produced routinely 
for clinical use in 1992. The emerging Theraflex® MB 
plasma system has a number of improved features and 
has been successfully and routinely used by blood 
centres in several countries52. After addition of MB 
to the plasma, the plasma is exposed to white-light to 
inactivate viruses and then, in more recent approaches, 
filtered to reduce the MB89. 
The SD method to inactivate enveloped viruses in 
plasma protein preparations was first developed in the 
early 1980s and as a pooled standardised pharmaceutical 
product with extensive in-process control was first 
described by Horowitz and Colleagues in 199290,91. 
The SD process is the most widely used, best validated 
and robust pathogen inactivation technology currently 
known; many million doses of SD plasma proteins have 
been transfused91. 
Intercept®-treated plasma (Cerus Corporation, 
Concord, CA, USA) is a pathogen-reduced product, 
CE-marked in Europe, and gradually being adopted in 
blood centres in Spain, France, Belgium, Switzerland, 
and other European countries. A pathogen inactivation 
process employing the synthetic psoralen amotosalen 
HCl (S-59) and UVA light has been developed for the 
treatment of single units of plasma and apheresis or 
pooled platelet units92 and is followed by the removal of 
the amotosalen and its breakdown products through the 
use of a filter compound absorption device1. Intercept® 
plasma was extensively studied before being released 
on the market and the published data on this product 
include in vitro and animal toxicology studies93. 
Mirasol®-treated plasma (CaridianBCT, Inc., 
Lakewood, CO, USA) has been available on the 
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European market for more than a decade, while the 
option of using Mirasol® to treat previously FP has 
been validated more recently and enables sites to treat 
products already in their inventory. Single units of 
apheresis or whole blood plasma are treated and frozen 
within 8 hours of collection. Although Mirasol®-treated 
plasma is being used for clinical purposes in some 
European countries, few data have been published on 
its clinical efficacy and safety2. 
Regulatory status of the technologies
Several PRT for plasma and platelets have been 
licensed and are in use in Europe and elsewhere. Some 
countries (e.g. Switzerland and Belgium) have adopted 
PRT nationwide, whereas other countries (e.g. France, 
Germany and Spain) only perform pathogen reduction 
in some regional blood transfusion services86. Blood 
components for transfusion are classified differently 
across European countries. In Germany, they are 
considered as pharmaceutical drugs and must meet 
the latest pharmaceutical research and development 
standards. Plasma production licenses are issued by 
local authorities and marketing authorisations by the 
competent federal authority. Therefore, major changes 
require that transfusion services apply for a new license. 
Similar systems are in place in other countries, such 
as Switzerland and France. Moreover, while European 
blood directives define quality and safety standards 
for the testing, processing, storage, and distribution 
of human blood and components, individual Member 
States are free to adopt higher standards than those set 
by the European Union directives. Therefore, as one 
might expect, stages of accreditation as well as opinions 
on the scientific/clinical, regulatory and economic 
aspects, vary widely across Europe. A recent survey 
revealed that 80% of European countries routinely 
use pathogen-inactivated plasma, while a further 50% 
plan to introduce it or to expand the current portfolio 
in the near future94. 
With regards to coming developments, the landscape 
of PRT in Europe is multifaceted, since regulation 
varies and decision makers have different scientific, 
medical and political viewpoints. Nevertheless, in 
principle the regulatory framework setting high 
standards for establishing pathogen inactivation and 
harmonising the procurement of safe blood in Europe 
is in progress.
In the early 1990s, SD plasma was considered a 
blood product in Germany and France. In most of the 
other European countries, it is treated as a medicinal 
product95. SD plasma was first introduced in the 
German Federal State of North Rhine-Westphalia in 
1991. In Norway, SD plasma replaced plasma in 1993 
following a successful clinical trial in 199296. Currently, 
ordinary medicinal licensing is required for SD plasma 
in European countries except in France, where it is 
classified as a labelled blood product. Octaplas® is now 
a licensed biopharmaceutical product in 29 countries 
worldwide. Recently, the FDA approved the use of 
Octaplas® (ligand gel)64, which is a SD-treated, blood 
group-specific, pooled human plasma product developed 
by Octapharma (Vienna, Austria). In several European 
countries and in Australia, OctaplasLG® has been 
marketed since 2009 and its previous versions since 
1992. Confirmatory studies on the claimed capacity to 
remove prions have been requested by some countries 
and are currently approaching completion60. Octapharma 
has also developed Uniplas®/UniplasLG®, a non-blood 
group-specific SD plasma. Uniplas®/UniplasLG® differs 
from Octaplas®/OctaplasLG® only in that anti-A and 
anti-B antibodies are removed; thereby, making it 
universally transfusable. Uniplas®/UniplasLG® is not 
licensed for use in the USA or European Union97. 
Regulatory approval was long delayed in the USA 
compared to Europe. The FDA's attitude toward SD 
plasma began to change in 1990-1991. In 1998 VITEX 
(V.I. Technologies, Watertown, MA, USA) was selected 
as the sole distributor of PLAS+SD® plasma60. The 
introduction of PLAS+SD® with the American Red 
Cross logo and the fact that the American Red Cross was 
the exclusive US distributor provoked strong reactions 
from members of America's Blood Centres, who collect 
and distribute half of the nation's blood supply59.
Additionally, the American Red Cross set the price for 
PLAS+SD® 30% higher than expected and remarkable 
differences between PLAS+SD® and the European SD 
plasma were demonstrated2. This issue, along with a 
number of thromboembolic adverse reactions that had 
not been observed with European SD plasma, resulted 
in the termination of SD plasma production in the USA 
in 2002-200360. 
A promising development is the use of MB for viral 
reduction of single plasma units. This technology was 
originally developed by the German Red Cross Blood 
Centre in Springe, Germany and MB plasma was first 
produced routinely for clinical use in 199251. The 
emerging Theraflex® MB plasma system (MacoPharma, 
Tourcoing, France) has a number of improved features 
and has been used routinely by blood centres in several 
countries. According to information from MacoPharma, 
the national authorities that have already given regulatory 
approval worldwide for the use of Theraflex® MB 
plasma are: Paul Ehrlich Institute (Germany), Agence 
Française de Sécurité Sanitaire des Produits de Santé 
(France), Swissmedic (Switzerland), Administración 
Nacional de Medicamentos, Alimentos MacoPharma 
Tecnología Médica-ANMAT (Argentina), Ministerio de 
Salud Pública (Uruguay), Agence de la Santé Publique 
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du Canada (Canada), Agency for Medicinal Products 
and Medical Devices (Croatia), Agência Nacional de 
Vigilância Sanitária (Brazil), and the Ministries of 
Health of Russia, Mexico, Kazakhstan, Belarus, Hong 
Kong, Singapore and Ukraine. 
The current legislation in the United Kingdom does 
not require independent formal pathogen reduction 
validation other than occasional studies on individual 
pathogens. The UK Department of Health recommended 
that plasma given to neonates and children born on 
or after 1st January 1996 should be obtained from an 
area free of bovine spongiform encephalopathy and 
subjected to pathogen-reduction procedures. In 2012, 
this approach was extended to recipients aged 16 years 
or more by the Advisory Committee on the Safety of 
Blood, Tissues and Organs. Imported plasma is treated 
with MB as a pathogen reduction step and is currently 
recommended for use in all patients. Patients with TTP 
have high donor exposure and should be treated with 
non-UK virus-treated plasma and it is recommended 
that SD plasma is used98. 
In Spain approximately 250,000 units of plasma 
are transfused annually and 65% are MB plasma. The 
Springe method is currently used in Spain by Grifols 
(Parets del Vallés, Spain)99. The Intercept® Blood 
System gained the CE mark for platelets in 2002 and 
for plasma in 2006, allowing market distribution in 
Europe for both components. The Intercept® Blood 
System has been registered with a class III CE mark 
as a drug-device combination59. It has been approved 
by the French regulatory authority, Agence Francaise 
de Securite Sanitaire des Produits de Sante and is used 
for clinical purpose in four French regions: Ile de la 
Réunion, Martinique, Guadeloupe-Guyane and Alsace. 
In Germany, the first blood centre marketing 
authorisation was approved by the Paul Ehrlich Institute 
for the Intercept® Blood System for Platelets in 2007 
and for the System for Plasma in 2011. The approval by 
the Paul Ehrlich Institute allows the use of Intercept® as 
an alternative to gamma-irradiation and to omit CMV 
serology. The Intercept® Blood System for Platelets 
was approved by Swissmedic in 2009 and the Plasma 
System in 201061. 
In the United States, the FDA approved the Intercept® 
Blood System for the preparation of plasma in order to 
reduce the risk of TTI65. 
The Mirasol® system for plasma for transfusion is 
currently approved and used in Europe for the treatment 
of platelets and plasma100. It received a CE mark in 
August 2008, after the initial CE-mark approval of the 
Mirasol PRT System® for Platelets in October 2007101. 
The Mirasol® system (mostly for platelet treatment) 
is currently used in more than 50 blood centres in 
15 countries throughout Europe, the Middle East 
and Africa; it is not available for sale in the USA102. 
Mirasol®-treated plasma (R plasma) shows high overall 
protein retention under a broad range of blood banking 
conditions and meets the Council of Europe guidelines. 
The option of treating FP with Mirasol® has also been 
validated and enables sites to treat products already in 
their inventory103. 
Description and technical characteristics of the 
technologies
An effective method for pathogen reduction must 
fulfil at least three essential criteria: first of all, it must 
physically remove viruses and blood cells that contain 
viruses; secondly, it must penetrate selectively into 
blood cells without damaging them and finally, it must 
effectively inactivate free viruses, viruses attached to 
cells and intracellular viruses35. The SD method of 
treatment is standardised and is generally not carried 
out in individual sites but usually occurs in a centralised 
manufacturing centre in which plasma is processed as 
a large pool (500-2,500 donations). The other three 
procedures are used to treat single-donor units of 
plasma at the blood bank itself. The MB and A methods 
generally involve a final step in which the reactive agent 
is removed (such as the SD method). The R method is 
the only one in which removal of the active reagent is 
not required35. 
Solvent/detergent method
The SD method to inactivate enveloped viruses in 
plasma protein preparations was first developed in the 
early 1980s90. The method proved to be effective in 
the processing of coagulation factor concentrates by 
disrupting the membranes of lipid-enveloped viruses, 
cells and most protozoa, while leaving the labile 
coagulation factors intact. Its efficacy with respect to 
bacteria is generally more variable, and it is ineffective 
against non-lipid-enveloped viruses91. SD treatment is 
the only current technology for viral inactivation of 
pooled plasma86. The SD process is the most widely 
used, best validated and robust pathogen inactivation 
technology known today, and many million doses 
of SD-treated plasma proteins have been transfused 
without any report of transmission of enveloped 
viruses91,104. 
The procedure generally consists in incubating 
protein solutions for 1-6 hours with 0.3-1% of an 
organic solvent, tri(n-butyl) phosphate (TNBP), and 
one or several detergents, generally Tween-80, Triton 
X-100, or sodium deoxycholate105. The SD treatment 
is preceded by filtration with a 1 μm filter to remove 
cells and debris, followed by sterile filtration into bags 
or vials using a 0.2 μm filter and aseptic filling106. The 
SD treatment requires that plasma is thawed rapidly and 
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treated for 4 hours at ~30 °C with TNBP solvent and 
Triton X-100 (or Tween-80) detergent107, both at 1%. 
The TNBP is then removed by extraction with ricin oil 
and the Triton X-100 by hydrophobic chromatography; 
these processes are followed by sterile filtration and 
packaging in units of 200 mL. Complete inactivation 
of an added virus inoculum typically occurs within the 
first 15 minutes of the 4-hour procedure108. A castor-oil 
extraction and separation phase are performed to remove 
TNBP, this is followed by a clear filtration. 
Over the years, starting from the initial method 
proposed by Bernhard Horowitz in 1986-1987 the 
SD plasma method has undergone several changes. 
Octapharma introduced the process to its factory 
in Vienna and licensed it to the French Transfusion 
Service, which began the manufacture of SD plasma at 
its Regional Blood Transfusion Centre in Bordeaux in 
1992109,110. In 1991-1992 manufacturing of SD plasma 
began, initially at Melville Biologics (a division of 
the New York Blood Center), using many of the same 
procedures pioneered in Europe by Octapharma.
The manufactured product was characterised in 
1992, when Horowitz and his collaborators published 
their results37,111. Later, due to the lack of adequate 
resources at the New York Blood Center, manufacturing 
was transferred to a spin-off, V.I. Technologies, Inc. 
VITEX (Watertown, MA, USA), which subsequently 
produced the American SD plasma, PLAS+SD®. In 
the second half of the 1990s, the National Bioproducts 
Institute of Pinetown, South Africa, developed ABO-
independent, universal plasma (Bioplasma FDP®) 
using the SD treatment manufacturing process licensed 
by Octapharma60. Biesert and Shartono subsequently 
validated the robustness of SD plasma treatment in 
their study of the viral safety of Octaplas® (Octapharma 
AG, Lachen, Switzerland)112. A universal SD plasma 
(Uniplas®) has been developed by Octapharma 
PPGmbH, Vienna, Austria. Uniplas® is obtained by 
optimal mixing of plasma of different blood groups 
in order to neutralise unwanted anti-A and anti-B 
antibodies (of both IgM and IgG classes). Kedrion 
(Castelvecchio Pascoli, Italy) introduced SD plasma 
(Plasmasafe®) in 200555, also using Octapharma's 
licensed manufacturing process. Production of SD 
plasma at the German Red Cross Center in Hagen ended 
in 200660. Except for differences in the plasma pool size 
(60 L in France, 200 L in Germany and South Africa, 380 
L in Austria and up to 650 L in the USA), SD plasma has 
so far been manufactured by similar, albeit not identical 
methods. Octapharma has launched OctaplasLG®, an 
SD plasma whose manufacture involves an additional 
chromatographic step combining a specific prion-
binding ligand gel with SD treatment, time-reduced 
from 4 to 1-1.5 hours113. Recently, a SD plasma viral 
inactivation treatment for transfusion and minipool 
cryoprecipitate (5-10 L of plasma) was developed 
to address such viral transmission concerns114. This 
treatment uses 1% TNBP as the solvent and 1% Triton 
X-45 instead of the Triton X-100 or Tween-80 detergent 
widely used in the plasma fractionation industry. The 
SD treatment is then performed at 31 °C for 4 hours, 
followed by two or three oil extraction steps optionally 
followed by hydrophobic chromatography. For pathogen 
reduction by solvent only (2% TNBP), the incubation 
temperature is increased to 37 °C115. The data confirm 
that the treatment at 31 °C is effective at inactivating 
lipid-enveloped viruses in plasma and cryoprecipitate115. 
This "mini-pool" system was pioneered by Burnouf, 
in collaboration with Egyptian blood bankers, for use 
under Good Manufacturing Practice (GMP) conditions 
of blood banks in developing countries116. 
Table III shows a comparison of the main features 
of the various SD plasma products currently available.
In vitro studies have demonstrated that the SD 
method applied to plasma eliminates all lipid-enveloped 
viruses, including WNV, with high safety margins; the 
exception is vaccinia virus, which is relatively resistant 
to this inactivation treatment. The existing literature 
demonstrates the inactivation of several marker viruses 
(vesicular stomatitis virus, Sindbis virus, Sendai virus) 
and other viruses such as HIV and HBV. The SD plasma 
production process also eliminates bacteria, protozoa, 
cells and cellular fragments; however, it has no effect 
on non-lipid-enveloped viruses. Finally, laboratory, 
preclinical and clinical evidence indicates that FVIII and 
other proteins present in the preparation are unaffected 
by SD treatment117. Although SD treatment has no effect 
on non-lipid-coated viruses, it prevents transmission 
of HAV and PVB19. Moreover, it contributes, along 
with neutralising antibodies in the initial plasma 
pools, lowering the virus concentration by pooling, 
and the hydrophobic chromatography, to eliminating 
the residual risk of clinically apparent infections with 
PVB19 and HAV118. SD treatment can be preceded 
by nanofiltration to remove cells, cell fragments and 
membrane-associated viruses, and followed by sterile 
filtration and aseptic filling119. The production process 
for OctaplasLG®, Octapharma's second-generation 
SD plasma product, includes an affinity ligand 
chromatography step designed to bind prion agents at 
the level of prion infectivity, thus potentially reducing 
the risk of transmission of prion disease120, 121. 
Methylene blue method
The first procedure described for inactivating 
pathogens in plasma involved the use of MB. 
MB is a positively charged phenothiazine derivative. 
It consists of a thiazine ring and two dimethylamino 
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Pathogen reduction technologies of plasma: HTA
groups. Its chemical name is: 3,7-bis(dimethylamino)
phenothiazine-5-ylium chloride. At room temperature, 
MB is an odourless dark green powder and is soluble in 
cold water. The alternative colourless leucomethylene 
blue is readily oxidized into MB in the presence 
of oxygen52. The virucidal action of illuminated 
phenothiazines, such as MB, was recognised in the 
early 1930s122. MB intercalates with nucleic acid 
strands. Visible light excites the phenothiazine dye 
and, by energy transfer, produces highly reactive 
singlet oxygen. The latter oxidizes guanosine and 
thereby breaks nucleic strands, preventing pathogen 
replication123. 
An experiment on HIV showed that MB treatment 
also acts on other target sites such as the envelope, core 
proteins, and reverse transcriptase enzyme124. The MB 
system does not remove the viral nucleic acid that has 
been inactivated. As a result, assays that are based on 
NAT could remain positive, even though the treated 
plasma is no longer infectious. Similarly, assays based 
on specific antibodies could also detect inactivated 
viral particles. Consequently, infectivity assays using 
cell cultures or animal models are most suitable for 
assessing the pathogen inactivation capacity of the 
MB system124. Finally, the rationale for the use of 
phenothiazine for pathogen inactivation of blood 
components is based on the absence of nucleic acids 
in red cells or plasma; the potential for preferential 
binding of phenothiazine to viral nucleic acid over 
binding to lipids or proteins of plasma or red cells; 
and limited diffusion of reactive, oxidizing species 
produced by illuminated dyes122. 
In 1991, Lambrecht et al. described a method to 
inactivate virus in plasma using MB dye and visible 
light125. Two different methods for MB treatment of 
human plasma for viral reduction are currently in 
use. The original "Springe" method, developed by the 
Blood Centre of the German Red Cross Chapters of 
Lower Saxony, Saxony-Anhalt, Thuringia, Oldenburg 
and Bremen, Institute Springe and commercialised by 
Grifols S.A. (Barcelona, Spain) and the Theraflex® MB 
method originally designed by MacoPharma (Mouvaux, 
France). 
The inactivating process can be divided into five 
steps: (i) intercalation of MB; (ii) excitation of the MB 
by visible light; (iii) formation of singlet oxygen; (iv) 
oxidation of guanosine; and (v) strand breakage.
The Springe process requires a 1 μM concentration 
of the photosensitiser and a red light (600-700 nm) 
fluency rate of approximately 10 mWcm−2. The original 
protocol was in use for more than a decade and over 
one million MB plasma units were transfused before 
the Paul Ehrlich institute withdrew the license126. The 
original Springe MB plasma process, described by 
Lambrecht51, used freezing and thawing of plasma units 
to disrupt leucocytes and thereby release intracellular 
viruses, because MB only partially penetrates cell 
membranes38. The recent introduction of blood collection 
packs that combine leucoreduction and addition of MB 
before inactivation of the plasma (Baxter Pathinact, 
Baxter Healthcare, Compton Newbury, Berkshire, UK, 
and MacoPharma Theraflex®, Middlesex, UK) has 
eliminated the need for freezing and thawing of the 
plasma38.
There are also differences among the systems to 
add MB to plasma. With two of the systems (Springe 
and Baxter), a variable dose of MB solution was 
added to achieve a standard final concentration of 1 
µM and, afterwards, the plasma bag was illuminated 
with fluorescent tubes on one side for 1 hour127. 
Table III - Features of different solvent/detergent-treated plasma products.
SD plasma Source Pool size Inactivation time and temperature
Octaplas® (Austria) Apheresis or recovered plasma 380 litres (630 apheresis units or 1,520 
recovered units)
4 h at 30 °C 
(1% TNBP + 1% Triton X-100)
Octaplas LG® (Austria) Apheresis or recovered plasma 380 litres (630 apheresis units or 1,520 
recovered units)
1-1.5 h at 30 °C 
(1% TNBP + 1% Triton X-100)
Uniplas® (Austria) Apheresis or recovered plasma 380 litres of plasma of different blood 
groups (1,000 apheresis units or 1,520 
recovered units)
1-1.5 h at 30 °C 
(1% TNBP + 1% Triton X-100)
Plasmasafe® (Italy) Apheresis or recovered plasma 380 litres (630 apheresis units or 1,520 
recovered units)
4 h at 30 °C 
(1% TNBP + 1% Triton X-100)
Plasma viro-atténué SD® 
(France)
Apheresis plasma 60 litres (100 apheresis units) 4 h at 30 °C 
(1% TNBP + 1% Triton X-100)
Bioplasma FDP® 
(South Africa)
Recovered plasma 200 litres 4 h at 30 °C 
(1% TNBP + 1% Triton X-100)
"Mini-pool" (for blood bank 
application in resource-limited 
countries)
Recovered plasma 5-10 litres 4 h at 31 °C 
(1% TNBP + 1% Triton X-45) 
or 4 h at 37 °C (2% TNBP)
SD: solvent/detergent; TNBP: tri(n-butyl)phosphate. Source: modified from reference 60.
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The efficiency of filtration is ensured by integrity 
testing during filter manufacturing and by routine 
monitoring of residual cell content and filtration 
time in the blood bank. The Blueflex® filter is acting 
as backup system for the PLAS4 filter, comprising 
an identical membrane52. In both Springe methods 
and the commercial system, the desired final MB 
concentration is 1 μM (~320 μg/L). In the Springe 
system this concentration is reached by addition 
of a MB stock solution (50 μM/L) calibrating the 
volume to the weight of the plasma pack to achieve 
precisely the same concentration of MB in every 
plasma pack127. The Theraflex® MB system, which 
is positioned in the tubing between the membrane 
filter and the illumination bag, incorporates an 85-µg 
(0.227 μM) pellet of MB hydrochloride per plasma 
unit: the concentration can, therefore, vary slightly 
(0.84-1.13 µM) depending on the plasma volume38. A 
plasma volume between 235 and 315 mL is acceptable, 
resulting in a final concentration of 0.72 to 0.97 
μM/L MB plasma. After adding MB, the plasma 
bags are exposed to visible wavelengths of light to 
activate the dye. In the Springe procedure, the bag of 
plasma supplemented with MB used to be placed on 
a transparent glass plate illuminated with an array of 
fluorescent tubes from beneath to achieve an intensity 
of approximately 17×103 lux at a distance of about 8 
cm for an illumination time of 60 minutes. This setup 
allowed already labelled units to be illuminated. In the 
Theraflex® MB system, the illumination device was 
equipped with high-intensity, low-pressure sodium 
lamps emitting yellow light at a wavelength of 590 
nm, and both sides of the plasma pack were exposed to 
the illumination. A microprocessor-controlled device 
(Macotronic V; Macropharma) was developed for the 
illumination of the Theraflex® MB system. Positioning 
low-pressure sodium lamps above and below the 
area of the bags allowed the illumination time to be 
reduced to about 20 minutes only (180 J/cm2)52. The 
latest version of the illumination device (Macotronic 
B; MacoPharma) exploits light-emitting diodes. The 
influence on the functional activity of plasma proteins 
is comparable to that seen after illumination with 
fluorescent tubes for 60 minutes52. 
The Theraflex® MB system also includes a Blueflex® 
filter to remove a substantial proportion of MB and its 
photo-degradation products (e.g. Azur B) from the MB 
plasma. This step results in a reduction of the final 
concentration of MB by approximately one log10 step. 
Illumination of the MB-supplemented plasma with 
visible light for about 20 minutes reduces the average 
concentration of MB from 890 nM/L plasma to 500 
nM/L plasma at the end of the illumination, indicating 
that the photodynamic process causes a decomposition 
of approximately 45%. The filtration further decreases 
the MB content in the plasma to a final concentration of 
about 19 nM/L, which is less than 2% of the initial MB 
concentration. These PRT involve a sterile connection 
to a bag system equipped with a leucocyte-reduction 
filter, addition of MB and filters to remove the residual 
MB and its by-products52.
The MacoPharma system is CE-marked and 
implemented under GMP in several European 
countries. However, there is still concern about 
the potential genotoxicity of MB. Indeed, various 
remaining intercalated proteins with phenothiazine-like 
dyes may have some long-term side effects128. 
The ability of MB to inactivate viruses is 
dependent on its binding to nucleic acids, being 
greater for double-stranded than single-stranded 
viruses, although viruses containing genomes of 
either type may be efficiently inactivated129. MB can 
also modify proteins and lipids, the relative rates 
depending on the concentrations of MB and local 
oxygen122. Virus-infected cells may be affected by 
reducing and detoxifying mechanisms. MB is not 
considered useful for inactivating intracellular viruses 
or for reducing bacteria and protozoa, even though it 
does penetrate cells. Its only application in transfusion 
has been to inactivate viruses in plasma, following 
cell removal by filtration or freeze-thaw lysis130. The 
reduction of enveloped viruses is at least 5 logs and 
the spectrum of affected viruses includes HIV, as 
well as model viruses for HBV and HCV. In addition, 
MB treatment is also effective against WNV32,127. For 
non-enveloped viruses, the efficacy is heterogeneous 
(e.g. approximately ≥4 logs for calicivirus and simian 
virus 40 and not effective against HAV or porcine 
parvovirus)127. Nevertheless, the MB plasma system 
has produced a reduction of ≥5 logs of PVB19 virus131. 
There is evidence that MB without illumination 
was also able to lower PVB19 levels by 1-2 log. 
Additional illumination enhances this by 3-4 log132. 
As for non-viral pathogens, a study on Trypanosoma 
cruzi using in vitro cultures and a mouse model 
showed that MB treatment provides a log reduction 
of >3.4 and 4.9-5.8, respectively, indicating that this 
pathogen reduction system could potentially prevent 
transfusion-transmitted Chagas disease133. Although 
the effect of the MB system on malaria, caused by 
an intracellular parasite, has not been characterised, 
leucocyte filtration and the freeze-thawing process 
remove and disrupt parasite-containing cells, thus 
preventing multiplication of the parasite. These 
benefits are also applicable to CMV and HTLV 1 and 
2. There have been reports that phenothiazines might 
destroy prions but the actual effect of the MB system 
on this pathogen needs further investigation134,135. 
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Amotosalen and light treatment 
The Intercept® Blood System is a photodynamic 
viral inactivation technique for pathogen reduction. This 
PRT utilises amotosalen, a synthetic psoralen (formerly 
S-59-HCl), as the active compound and long-wavelength 
UVA to reduce pathgens in plasma and platelet 
concentrates61. Psoralens such as 8-methoxypsoralen and 
trimethylpsoralen are naturally occurring photoactive 
substances found in a number of plants such as limes, 
celery and parsnips136. Amotosalen, like all psoralens, is 
a tricyclic molecule consisting of a furan and a pyrone 
moiety. It can thus quickly cross cell membranes, 
bacterial walls or viral envelopes and readily interact 
with nucleic acids without interacting with proteins or 
cellular lipids. The chemical structure of amotosalen is 
not changed by its entry into the cell and it is, therefore, 
also exceptionally well suited for the inactivation of 
intracellular pathogens, unlike the other photoactive 
compounds currently in use. It readily intercalates into 
double-helical structures of DNA or RNA where covalent 
bonds between its reactive groups and pyrimidine bases 
are formed upon UVA illumination. 
Even intrastrand reactions are possible. Thus, single-
stranded nucleic acids are also targets. The chemical 
interaction between amotosalen and pyrimidine bases 
occurs with very high frequency. Therefore, low 
concentrations of nucleic acids will specifically react 
even in the presence of large amounts of other biological 
materials. Theoretically, the formation of one cross-
link between the strands of nucleic acids is sufficient 
to prevent replication of the genome. The frequency 
of the interaction between amotosalen molecules and 
pyrimdines has been determined for different nucleic 
acids and organisms137. The reaction with nucleic acids 
does not depend on the generation of active oxygen 
species, which damage the cell, and is effective even in 
the absence of oxygen. The high frequency of interaction 
makes replication, the transcription of genes, impossible 
and inhibits DNA repair mechanisms. Amotosalen has 
no sequence specificity, thus it efficiently inactivates a 
broad spectrum of pathogens. In addition, amotosalen-
nucleic acid cross-linking occurs in the presence of 
UVA light, but not in its absence. This feature represents 
another unique safety measure as the reaction can be 
tightly controlled ex vivo simply by turning the light 
source on or off61. 
The Intercept® technology for pathogen inactivation 
of platelets or plasma components is based on two 
major steps: the alkylating agent (150 μmol/L, final 
concentration) penetrates cellular and nuclear membranes 
and binds to double-stranded DNA and RNA. When 
activated by low-energy UVA light (320-400 nm), 
amotosalen cross-links nucleic acids, thus blocking 
DNA/RNA replication86. A plasma unit is sterilely 
connected to an Intercept® plasma disposable set using 
the TSCD-II device. All the plasma is allowed to flow 
through the amotosalen solution container into the 
illumination container. After heat sealing and separation 
of the amotosalen container along with the original 
plasma bag from the Intercept® illumination container, 
the plasma mixture is illuminated with a R4R008 
illumination device (Cerus) at 3 J/cm for approximately 
7 minutes. After illumination, the plasma is passed 
through a compound adsorption device by gravity into 
the final storage containers. The adsorption step takes 
approximately 20 minutes138. The method includes 
an additional step for the removal of the residual 
amotosalen and its metabolites using a compound 
adsorbing device for a period of 16 hours139. However, 
it is still debated whether the residual amotosalen and 
its degradation products, as well as the potential binding 
to proteins, could have some long-term side effects. The 
system has recently been CE-marked and it is supposed 
to be implemented under GMP conditions in Europe66. 
The mechanism of action of the Intercept® 
technology, especially the fact that the interaction 
between amotosalen and DNA or RNA molecules 
is not sequence-specific, theoretically allows the 
inactivation of unknown pathogens. The spectrum 
of inactivation capacity includes intracellular as well 
as cell-free enveloped viruses (e.g. HIV-1 and HIV-
2). Other cell-associated viruses, such as HTLV and 
CMV, can be inactivated to a very marked extent61,140. 
The inactivation of intracellular viruses is becoming 
an increasingly important feature of the technology. 
Hepatitis viruses, including HBV and HCV, can be 
inactivated very effectively, as can HTLV-1 and HTLV-
2. The broad spectrum of enveloped viruses for which 
very efficient inactivation has been demonstrated also 
includes duck HBV, BVDV, PRV, vaccinia virus and 
the influenza strains H1N1 and H5N1141. Most of the 
studies generating this information were performed as 
infectivity studies in cell cultures and animal models. 
The efficiency of inactivation of non-enveloped viruses 
varies greatly among the different viruses. While 
adenovirus 5 and bluetongue virus are very susceptible 
to the treatment, PVB19 shows an intermediate level of 
inactivation, HAV is not susceptible to inactivation and 
calicivirus is only poorly susceptible. 
The capacity of the Intercept® technology to 
inactivate emerging and re-emerging pathogens is now 
of great interest. Highly effective inactivation has been 
demonstrated, for example, for a large panel of (re)-
emerging viruses. These include the coronavirus causing 
SARS, WNV, the previously mentioned influenza 
strains H1N1 and H5N1 as well as Chikungunya virus 
and dengue virus. The versatility and efficiency of the 
Intercept® Blood System was demonstrated in 2006, 
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when a Chikungunya epidemic occurred in the French 
overseas department of Ile de La Reunion142. 
Besides (re)-emerging pathogens, bacteria are a 
major threat to blood safety, especially for platelet 
components. Any technology for pathogen inactivation 
must, therefore, achieve the highest level of inactivation. 
In order to test the capacity of the Intercept® technology 
to inactivate bacteria, studies with a broad spectrum of 
aerobic and anaerobic Gram-positive and Gram-negative 
bacteria as well as spirochaetes, have been performed. In 
recent years, the number of reports concerning infections 
with emerging protozoa has been increasing. The 
protozoa of greatest concern are Plasmodium falciparum 
(malaria), Trypanosoma cruzi (Chagas disease), 
Leishmania spp. and Babesia microti143. Recently, it has 
been demonstrated that Intercept® technology can also 
inactivate these protozoa.
Riboflavin and light-treated plasma
Mirasol® (Terumo BCT, Lakewood, CO, USA) 
is a riboflavin/UV light-based PRT system used for 
pathogen reduction of plasma and platelets86. This 
new technology uses riboflavin as a photosensitiser 
in combination with UV light145. Riboflavin, also 
called vitamin B2, is a dietary nutrient with a known 
pharmacokinetic and toxicology profile145. This 
essential natural vitamin absorbs both visible and UV 
light86. Shortwave UVC light (285-365 nm) interacts 
directly with nucleic acids, resulting in the formation of 
pyrimidine dimers that block the elongation of nucleic 
acid transcripts146. Through exposure to UVA and UVB 
light, it mediates selective damage to nucleic acids 
without binding to cells or proteins. The chemistry, 
toxicity and ability of riboflavin to interact with 
nucleic acids after photo activation have been studied 
extensively86. Riboflavin associates with nucleic acids 
and mediates oxygen-independent electron transfer, 
causing irreversible damage to nucleic acids147. The 
impairment of nucleic acids by direct electron transfer 
together with the production of singlet oxygen and 
generation of hydrogen peroxide with the formation 
of hydroxyl radicals damage the pathogen DNA/RNA 
in the absence of oxygen. Single units of apheresis or 
whole blood plasma are treated and frozen within 8 
hours of collection148. This association of riboflavin/
UV light has been used for a very long time as standard 
phototherapy of neonatal jaundice, without any 
reported problem66. Therefore, R plasma promises high 
efficacy and low protein damage with little toxicity. 
Since naturally occurring vitamin B2 and its photo-
degradation products are considered to be non-toxic, 
the early prototype of the Mirasol® system is similar 
to that of Intercept®, with the difference that, in the 
former case, removal of residual by-products and 
metabolites is not necessary86. This new PRT facilitates 
processing and shortens the time of storage of plasma 
in the liquid state.
Riboflavin/UV light treatment has proven to be 
effective against a range of pathogens, including 
bacteria, enveloped viruses, protozoa (>4-6 log 
inactivation), leucocytes and some non-enveloped 
viruses103,144,149. On the other hand, HAV is resistant to 
inactivation and the evidence of bacterial inactivation 
depended on extremely low concentrations of organisms, 
at the time of treatment2. This PRT provides levels of 
viral reduction in excess of those required to successfully 
close the window period of transmission for HIV, HBV 
and HCV. Moreover, this method eliminates the viraemic 
period for WNV and possibly the chronic phase of 
transmission of human PVB19, bacteria and leucocytes 
associated with often fatal transfusion reactions and 
transfusion-associated GVHD, without substantial loss 
of plasma factors; features that make it suitable for 
both direct pathogen reduction for plasma and a useful 
supplement to SD plasma. 
Clinical studies using the Mirasol® PRT for plasma 
are underway66. Data from some studies indicate that 
the Mirasol® PRT system can effectively be used 
to inactivate dengue and Chikungunya viruses in 
contaminated plasma and platelets. Combined with 
data previously obtained for other pathogens, this study 
reaffirms the efficacy of Mirasol® PRT as a potential 
means to enhance the protection of the blood supply 
from emerging infectious disease threats34,150. On the 
other hand, few data have been published on the clinical 
efficacy and safety of the Mirasol® product, although the 
product has been reported to be in clinical use in some 
European countries. Further information from clinical 
studies is necessary to evaluate the risk-benefit ratio of 
Mirasol® plasma better. 
Table IV lists the infectious agents that can be 
inactivated using psoralen/UVA and riboflavin.
The different methods of pathogen inactivation in 
plasma are compared in Table V.
Investments and tools required to use the technologies
Several viral inactivation or removal methods 
for plasma for transfusion have been studied. MB 
illumination, psoralen-UVA and riboflavin-UV light 
are examples of treatments applicable to single 
plasma donations in a blood centre setting, whereas 
the SD plasma or pasteurisation processes have so 
far been developed for treating large plasma pools 
and require a plasma fractionation facility35. In 2006, 
Thierry Burnouf and co-workers developed a SD 
inactivation process for single-donor plasma or mini-
pools of plasma to be used in blood establishments in 
developing countries91,115. 
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Table IV - Inactivation of infectious agents in plasma and platelets using psoralen/UVA and riboflavin.
Classification Agents Log reduction
Viruses (enveloped) HIV-1/2, HTLV-I/II, HBV, CMV, DHBV, HCV, BVDV, WNV, SARS-CoV >4.5 to >6.8
Viruses (non-enveloped) PVB19, HAV, Human adenovirus-5 >5.1 to >6.8
Bacteria Gram-positive and Gram-negative >7.3
Spirochaetes Treponema pallidum, Borrelia burgdorferi >5.9 to >10.6
Protozoa Plasmodium falciparum, Trypanosoma cruzi, Babesia microti >5.0 to >6.9
UVA: ultraviolet A light; HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus; HBV: hepatitis B virus; CMV: cytomegalovirus; DHBV: 
duck hepatitis B virus; HCV: hepatitis C virus; BVDV: bovine virus diarrhoea virus; WNV: West Nile virus; SARS-CoV: severe acute respiratory syndrome 
coronavirus; PVB19: parvovirus B19; HAV: hepatitis A virus. Source: modified from reference 251. 
Table V - A comparison of methods of pathogen inactivation in plasma. 
SD-FFP MB-FFP A-FFP plus UVA R-FFP plus UV
Mechanism of action Disruption of lipid 
membranes
MB intercalates into nucleic 
acids and mediates the 
formulation of singlet oxygen 
upon illumination
Amotosalen (S-59) 
intercalates into nucleic 
acids and induces covalent 
cross-linking upon UVA 
exposure
Riboflavin associates with 
nucleic acids and mediates 
an oxygen-independent 
electron transfer upon UV 
exposure
Blood components Plasma Plasma Plasma and platelets Plasma and platelets
Products Octaplas®, OctaplasLG®, 
Uniplas® (Octapharma); 
Plasmasafe® (Kedrion); 
Plasmavitro-atténué solvent/
detergent (French Blood 
Service, EFS); Bioplasma 
FDP® (National Bioproducts 
Institute of Pinetown, South 
Africa); "Mini-pool" systems 
(V.I.P.S, SA; Switzerland) 
Theraflex® MB 
(MacoPharma);
Springe methods (Grifols)
Intercept® Blood system for 
plasma and platelets (Cerus)
Mirasol® PRT system 
for plasma and platelets 
(Terumo)
Product source Made from apheresis 
plasma frozen within 4 h of 
collection
Whole blood-derived plasma 
as single unit and apheresis 
plasma (apheresis must be 
split if >315 mL)
Apheresis jumbo collections 
up to 635 mL treatable 
as single unit; whole 
blood-derived at least two 
plasma units must be pooled 
together
Whole blood-derived 
plasma as single unit 
and apheresis plasma 
(apheresis plasma must be 
split if >360 mL)
Shelf life 4 years at below ‒18 °C 2 years at ‒30 °C 2 years at below −25 °C; 1 
year between −18 °C and 
−25 °C
2 years at −30 °C
Illumination time Not applicable 15 min new Mecotronic B2; 
20 min with older equipment
3-6 min for 2 bags 5-8 min for 1 bag
Primary target Lipid membranes Nucleic acids Nucleic acids Nucleic acids
Compound toxicity Low Low High None
Removal of
active compounds
Yes, oil extraction and 
hydrophobic chromatography
Yes, by special filter (not 
universal)
Yes, by compound 
absorbing device
Not required
Residual level of
active compounds
Undetectable or trace 
amounts far below the 
toxicity level
Very low levels of MB and 
photoproducts. Mutagenic 
effects improbable, but not 
excluded
Very low levels of free 
S-59 and photoproducts. 
Mutagenic effects 
improbable, but not excluded
Low levels of riboflavin and 
photoproducts are normally 
present in blood. Active 
compound not removed
Permanent binding to lipids 
and proteins in plasma
No binding to proteins or 
residual lipids
Proteins intercalated with 
phenothiazine-like dyes
Amotosalen bound to lipids 
and 2% to proteins
Does not appear to bind
SD-FFP: solvent/detergent-treated fresh-frozen plasma; MB-FFP: methylene blue-treated fresh-frozen plasma; A-FFP plus UVA: amotosalen-treated 
fresh-frozen plasma exposed to ultraviolet A light; R-FFP plus UV: riboflavin-treated fresh-frozen plasma exposed to ultraviolet light. Source: modified 
from reference 35.
Solvent/detergent method
SD treatment of plasma was the first method 
developed for the inactivation of viruses in plasma for 
transfusion. The current technology requires a plasma 
fractionation facility and is applied to large plasma pools, 
increasing the cost and risks of exposure to SD-resistant 
pathogens and lowering the content of protein S and α2-
antiplasmin115. SD plasma is produced by incubating pools 
of hundreds or thousands of plasma donations with 1% 
TNBP and 1% Triton X-100 at 30 °C for 4 hours. The SD 
agents are removed by a process including oil extraction 
and hydrophobic interaction chromatography. The pooled 
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SD plasma, which may be concentrated by ultrafiltration, 
is sterile-filtered and aseptically dispensed into its final 
containers41. Two SD treatment procedures for single 
donations or mini-pools of plasma have been developed 
with a single-use bag system115, 151:
- 2% TNBP treatment. For TNBP treatment, a solution 
of pure TNBP (Prolabo, VWR, Fontenay-sous-bois, 
France) is carefully added to the plasma in a sterile 
syringe (at a ratio of 4 mL to 200 mL, respectively), 
over at least 20 minutes and with a constant mixing 
resulting in a final concentration (v/w) of 2%. 
Subsequently the plasma-TNBP mixture is shaken 
vigorously for 5 minutes to ensure dispersion of the 
TNBP in the plasma. The processing bag is then 
completely immerged into a water bath to warm the 
TNBP-plasma mixture at 37 °C and then treated for 
4 hours under constant gentle stirring. The TNBP-
plasma mixture is then transferred aseptically in a 
biological cabinet into a 300-mL bag filled with 
15 mL of sterile castor oil (Fluka Chemie GmbH, 
Buchs, Switzerland). The TNBP-plasma/7.5% oil 
suspension is shaken vigorously for at least 1 minute 
and then put onto a shaker to ensure gentle stirring 
for at least 15 minutes. The bag is then suspended 
to ensure decantation between the oil phase (upper 
layer) and the plasma phase (lower layer). The plasma 
is transferred by gravity into a second bag filled with 
15 mL of castor oil, and the extraction procedure is 
repeated twice. The plasma bag is then centrifuged in 
a reverse position in a centrifuge (Jouan, St-Herblain, 
France) at 3,800 g for 30 minutes at 4 °C to clarify 
the plasma. The plasma is separated from the lipid 
layer, transferred into a final plastic bag, and put in 
a freezer at −30 °C.
- 1% TNBP and 1% Triton X-45 treatment. A 50-
50% mixture of TNBP and Triton X-45 (Merck, 
Darmstadt, Germany) is used to fill a syringe. 
Four millilitres of the mixture are carefully and 
aseptically added to 200 mL of plasma to reach a final 
concentration (v/w) of 2% (1% TNBP and 1% Triton 
X-45). The procedure is then performed as described 
for the 2% TNBP treatment, with the exception that 
the temperature of treatment is 31 °C and the final 
centrifugation step is not performed.
The SD treatment can be implemented on 
single-donor units or minipools of plasma (e.g., an 
approximately 2 L pool of 10 donations). It has been 
found that the implementation of the processes by 
operators trained in blood establishment practices is 
straightforward; possible automation of some of the 
steps (e.g., oil decantation and separation) would 
contribute to increase the throughput and convenience 
of the processes. This small-scale and disposable-bag 
approach has some practical advantages that may 
counterbalance the caution required when dealing with 
large-pool SD plasma115. 
The introduction of novel technologies into 
manufacturing processes may have an impact on 
the quality of plasma-derived products. A new 
chromatographic step for the selective binding of scrapie 
prion protein (PrPSc) to an affinity ligand, which was 
developed and optimised for PrPSc capture and attached 
to synthetic resin particles (by Pathogen Removal and 
Diagnostic Technologies Inc., USA), was introduced 
into the manufacturing process of the SD-treated 
biopharmaceutical plasma Octaplas®113. 
The Octaplas® manufacturing process is illustrated 
in Figure 1.
Uniplas® (Octapharma) is a novel, universally 
applicable, blood group-independent, prion-depleted, SD-
treated and human pooled plasma for infusion. Uniplas® 
can be given to all patients, irrespectively of their blood 
group, abolishing the risks and serious consequences that 
can result from a transfusion of an incompatible plasma 
unit. Uniplas® is obtained by optimal mixing of plasma 
of different blood groups in order to neutralise unwanted 
anti-A and anti-B antibodies (both IgM and IgG classes) 
by binding to free A and B substances152. Uniplas® and 
Octaplas®/OctaplasLG® plasma pool and final container 
samples are collected from routine batches manufactured 
at Octapharma PPGmbH. The Uniplas® manufacturing 
process is an exact copy of the OctaplasLG® process, 
except for the optimal mixing of plasma prior to SD 
treatment (i.e. universal plasma vs blood group-specific 
plasma). The differences between Uniplas®/OctaplasLG® 
and Octaplas® lie in the time of exposure to SD (i.e. 1-1.5 
hours vs 4 hours) and in the prion removal step (i.e. with 
vs without prion removal)155. 
In Italy, SD virus-inactivated plasma is derived 
from pooled FFP (from up to 2,500 blood donors) 
by treatment with TNBP solvent and Triton X-100 
detergent (PlasmaSafe®). The SD technique is an 
industrial process. Blood Transfusion Units give the 
plasma to the industry which returns the inactivated 
product after an industrial process involving two 
filtration phases (1 μ and 0.22 μ) 55. 
Methylene blue method
One of the attractions of the MB technique is that 
it is applied to single plasma units, without the need 
to pool plasma donations. Commercial systems that 
can be set up in standard blood centre GMP conditions 
are available, without requiring the installation of 
specialised plants127. 
The Springe method is currently used in Spain by 
Grifols (Parets del Vallés, Spain). This MB procedure 
starts with a freeze-thawing step to disrupt the 
membranes of residual cells in the plasma and to release 
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their intracellular content. In the Springe method, the 
desired final MB concentration is 1 μmol (~320 μg/L), 
which is reached by the addition of a MB stock solution 
(50 μmol/L) calibrating the volume to the weight of 
the plasma in order to achieve precisely the same MB 
concentration in every plasma pack. After adding the 
MB, the plasma bags are exposed to visible wavelengths 
of light to activate the dye and placed on a transparent 
glass plate illuminated with an array of fluorescent tubes 
for 60 minutes99. 
A modified procedure has been marketed as the 
Theraflex® MB-Plasma System with a CE class III mark 
(MacoPharma, Tourcoing, France).
The Theraflex® MB-Plasma System includes an 
active compound, which is integrated into the bag 
system as a pill containing 85 µg of MB, which yields 
a MB concentration in the range of 0.8 to 1.2 µmol/L 
of plasma. The system is composed of a Macotronic® 
illumination device, MacoPharma flexible filters 
(Plasmaflex® and Blueflex®) and treatment steps. It 
is a pathogen-inactivation system capable of treating 
both single units and pools of many plasma units 
(Figure 2)52. 
Theraflex® MB Plasma sets are available either as 
fully integrated systems for use from donation through 
to blood product storage, or as a range of dockable 
filtration and pathogen reduction systems for use in 
the laboratory with any unit of plasma. This allows 
full flexibility in the choice of the processing method 
to easily integrate with the laboratory workflow. 
Theraflex® MB Plasma pathogen reduction can be 
carried out on demand or as an integral part of routine 
laboratory processing (information supplied by the 
manufacturer)154. 
Before treatment, the donation number is recorded 
by a barcode reader or optionally by radio frequency 
identification. When the same donation number 
is scanned for a second time, the software rejects 
illumination. Plasma units that have been treated are 
indicated by a barcode label comprising all essential 
information on the illumination process. After treatment, 
over 90% of the residual MB combined with its photo-
activated products is removed by a specially designed 
filter (Blueflex®; MacoPharma). Thus, plasma is filtered 
twice (Plasmaflex PLAS4®; MacoPharma), resulting in 
virtually cell-free plasma155. 
Figure 1 - Octaplas® manufacturing process.
 FFP: fresh-frozen plasma; TNBP: tri(n-butyl) phosphate; PrP: prion protein. 
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The Blueflex® filter is simple and rapid to use, and 
available integrated with the Theraflex® MB Plasma 
System. Blueflex® reduces the concentration of MB 
and its derivatives in the treated plasma by more than 
1 log. The combined use of MB and Blueflex® ensures 
minimal exposure to MB or its derivatives154. 
Many blood establishments around the world use 
other "in house" methods based on MB treatment, 
including that first developed by Mohr and Lambrecht 
(the Springe method). This system, however, is not 
currently marketed by MacoPharma (Theraflex®). 
The fundamental differences between the Theraflex® 
process and the Springe method are reported in Table 
VI35. 
Amotosalen and ultraviolet light treatment
Intercept® is the most widely used pathogen 
inactivation system capable of treating both platelets 
and plasma components on a single platform.
The Intercept® Blood System for Plasma includes 
an active compound, the illumination device, a sterile 
connecting device and treatment steps. Each Intercept® 
processing set can produce up to three 200 mL 
transfusion units with less than 10 minutes hands-on 
System for treatment of single units
of leucodepleted plasma including
a BLUEFLEX® filter for MB and 
photoproduct retention and a MB pill.
System including a PLASMAFLEX® 
for leucodepletion, a BLUEFLEX® filter
for MB and photoproduct retention
and a MB pill.
Figure 2 - Schematic representation of two different kits for Theraflex® MB-Plasma system for leucodepleted plasma (on 
the left side of the figure) and for non-leucodepleted plasma (on the right side of the figure).
 MB: methylene blue. Source: modified from reference 124.
time per processing set. Up to 36 treated units can be 
produced per hour per Intercept® illuminator. Intercept® 
provides the flexibility to treat either freshly collected 
plasma or to treat FP that has been recently thawed. 
This option allows blood establishments to choose the 
most suitable processing timeline for their operations. 
(This information was extracted from the characteristics 
reported by the manufacturer)156. 
The Intercept® Blood System for Plasma is 
compatible with apheresis and whole blood plasma. 
Riboflavin and ultraviolet light treatment
The innovative process of Mirasol® technology 
involves adding riboflavin to the platelet or plasma 
product, which is then exposed to UV light for a short 
period of time. The system consists of a Mirasol® 
illuminator, disposable sets, fully integrated data capture 
and storage software157,158. The characteristics reported 
by the manufacturer are159:
- a single system for platelets and plasma;
- minimal training time;
- limited bag transfers; 
- less than 5 minutes hands-on time;
- less than 15 minutes total processing time;
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Clinical efficacy
Introduction
Blood plays a crucial role in the human body. 
Blood transfusion is a medical practice that can be life-
saving in patients affected by several diseases. Whole 
blood is fractionated into components such as plasma, 
platelets and red cell concentrates for replacement or 
prophylactic therapies. Plasma is a liquid suspension of 
several proteins, lipids and salts, and is the first labile 
blood component for which PRT were developed. Pre-
clinical and clinical studies and experience from post-
authorisation use of PRT have been used to investigated 
very relevant issues related to the clinical efficacy 
of these products. Four PRT use different methods 
of pathogen inactivation/reduction and, as described 
below, have been subjected to extensive study of their 
toxicological properties and clinical efficacy.
Methods
Search strategy and selection criteria
A domain-specific search for efficacy aspects was 
merged with a basic search on Medline to obtain efficacy 
data on technical approaches to pathogen inactivation in 
plasma for clinical use. The review was performed using 
grey literature and analysing previous HTA reports. 
In detail, since the objective was an evaluation of 
clinical efficacy, the basic search was refined using the 
following key words: treatment outcomes, efficacy and 
clinical effectiveness. The search strategy is reported below:
EFFICACY Search ((((("Treatment Outcome"[Mesh]) 
OR Efficac*) OR Efficacy) OR "Clinical Effectiveness")).
No publication date restrictions were applied and no 
safety-specific search was applied to the whole search 
- the system is adaptable, giving many options for 
implementing it into unique settings;
- intuitive, icon-based user interface;
- possibility of using one or several illuminators to 
support production requirements, on the basis of need; 
- multiple illuminators can be set up in the same work 
area or distributed throughout a facility for optimal 
workflow and equipment layout;
- illuminators can be networked for centralised data 
capture.
As far as concerns plasma treatment specifically, 
the process:
- can be used on single-unit plasma volumes;
- can be applied to both apheresis and whole blood-
derived plasma products;
- is validated for a variety of blood bank processing 
conditions for FFP;
- can treat previously FP, removing time constraints 
associated with plasma processing.
Future challenges
There is currently no universal pathogen reduction 
treatment for all different blood products. Consequently, if 
different inactivation techniques were to be introduced, this 
would have repercussions on both direct costs for equipment 
and materials, and indirect (logistical) costs. Apart from 
what the manufacturer would charge for the equipment 
and materials, the blood transfusion organisations would 
probably also charge for increased personnel costs and the 
expense of introducing the technique. 
In the light of the above-mentioned considerations, 
clinical studies using prototype devices for whole blood 
pathogen reduction are ongoing.
Table VI - Differences between the Springe method and the Theraflex® system for methylene blue treatment of plasma.
Container Studies carried out in unspecified bags 
and cell culture flasks
MacoPharma bag
Amount of MB used 95 µg 85 µg
Form of MB 5:1 mL solution Solid tablet form
Incubation time prior to treatment 60-90 min at 8-12 °C None instructed
Light source Broad-spectrum white light bulbs Fluorescent bulbs or LED; 590 nm light
Energy dose 60-65 min at >45,000 Lux=25.7 J/cm2 180 J/cm2
Level of residual air in bag* Not specified, likely considerable excess air in flask 
studies (only HIV study reported as being carried out 
in flasks)
Requires removal of residual air in IFU
Condition of plasma (pre-frozen) Pre-frozen to break up white blood cells to allow 
better access
Relies on filtration and leucoreduction. This does not 
break up residual cells and thus some are intact
Use of filter No Yes - leucoreduction
Pre-treatment No Yes - MB removal
Post-treatment - -
* Methylene blue (MB) relies on oxidative chemistry to achieve pathogen reduction. If air is present in the viral reduction studies, it can lead to greater 
levels of reduction. Conversely, if absent in the plasma protein quality studies, results on maintenance of protein quality would be better, but the pathogen 
reduction under these conditions may also be less. For this reason, it is essential to measure both protein quality and pathogen reduction under the actual 
conditions of commercial use. Source: modified from reference 35.
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strategy in the Cochrane and Call Detail Recording 
(CDR) databases. Some inclusion/exclusion criteria 
were defined: 
- language: papers in languages other than English 
were excluded;
- relevance: studies focusing on safety and/or lacking 
clinical data were excluded;
- study design: literature reviews were excluded.
Results
The study selection process is illustrated in Figure 3.
On the basis of the "Efficacy" domain string, 124 
articles were selected. 
The 124 articles were 95 articles from PubMed, three 
HTA reports and 26 articles from grey literature. Articles 
from the Cochrane Library were not included because 
they were not relevant to the aim of the current analysis. 
Forty-eight studies eventually met the inclusion 
criteria. Of these, 45 were clinical studies and three 
were HTA reports. The remaining 76 were excluded: 
five articles were excluded because they were written 
in a language other than English, 40 were not relevant, 
24 were not clinical studies, five did not consider the 
efficacy domain, one was not available as a full text and, 
finally, one record was a duplicate. The level of evidence 
of the selected studies was appraised by the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) scale.
Previous health technology assessments 
Table VII summarises the previous HTA reports 
included in this analysis.
Pathogen-inactivated/reduced plasma vs untreated plasma: 
clinical studies 
Three patients with acute TTP were studied by Evans 
et al. (1999)160. As primary treatment, they received 
SD-FFP plus prednisolone and all patients reached 
platelet counts of >50×109/L. Serum creatinine was also 
corrected. With intensive plasma exchange with SD-FFP, 
neurological features slowly resolved in one patient, 
and developed again during plasma infusion in another 
with a rapid reversal. All patients maintained a stable 
remission 1 year later and tolerated the SD-FFP infusion 
well, without developing febrile or other reactions and 
without becoming HIV-, HCV- or HBV-positive. 
In 1999, Williamson et al.161 assessed the efficacy of 
SD-FFP in correcting the coagulopathy associated with 
liver disease and liver transplantation. The 49 patients 
with coagulation deficits due to liver disease requiring 
FFP for invasive procedures or liver transplantation were 
randomly assigned to receive either FFP or SD-FFP. They 
were assessed for side effects, correction of coagulopathy 
over 24 hours, and seroconversion for viral markers 6 to 
18 months after treatment. Equal correction of clotting 
factors and partial thromboplastin time was observed with 
FFP and SD-FFP in both groups. The correction of the 
International Normalised Ratio in patients receiving SD-
FFP was greater (p=0.037), but this group of patients had 
higher baseline values than recipients of FFP (p=0.024). 
The use of other blood components during transplantation 
was identical in the two treatment groups. 
Flamholz et al. (2000)162 described a reduction of 
protein S activity (about 0.5 units/mL), in three patients 
with TTP infused with SD-FFP as the replacement 
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Figure 3 - Study selection process for clinical efficacy domain.
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fluid during repetitive therapeutic plasma exchange, if 
compared with activity levels in those given FFP. Each 
patient developed one or more deep vein thrombosis 
while receiving 100% SD-FFP or 50% SD-FFP and 
50% cryosupernatant plasma as replacement fluid. Their 
observations suggest that the use of SD-FFP alone or in 
50% combination with cryosupernatant plasma may lead 
to difficulty in maintaining safe protein S activity levels.
A randomised, double-blinded study to assess the 
ability of SDP-FFP and FFP to reduce a prolonged 
prothrombin time to ≤15 seconds in patients with 
acquired coagulation deficits was performed by Lerner 
et al. (2000)163. Forty-five patients (22 given SD-FFP 
vs 23 given FFP) were treated with 71 infusions and 
laboratory and clinical outcomes were compared. There 
were no significant differences in the mean dose of 
plasma infused (7.8 mL/kg for SD-FFP vs 8.0 mL/kg 
for FFP, p=0.46), in the percentage of patients whose 
prothrombin time was to ≤15 seconds (32% for SD-
FFP vs 26% for FFP, p=0.67), or in the percentage of 
patients whose bleeding ceased (27% for SD-FFP vs 
22% for FFP). No clinical or statistically significant 
differences were observed after infusion of SD-FFP or 
FFP in patients with acquired coagulation deficiencies.
Atance et al. (2001)164 compared the use of MB-FFP 
with FFP in 2,967 patients in different clinical settings. 
Most patients had undergone surgical procedures. The 
use of MB-FFP was associated with a 56% increase 
in the aggregated demand for plasma, whereas the 
transfusion of non-virus-inactivated cryoprecipitate 
doubled the first year and increased by three times the 
second year. The use of plasma increased in all the 
Table VII - Previous health technology assessments.
Reference Topic Main results Main references
Health Council of The 
Netherlands. Pathogen 
reduction in blood 
products. The Hague: 
Health Council of The 
Netherlands, 2003; 
publication n. 2003/16E.
In-vitro function of 
treated products
The quality of plasma treated with amotosalen 
or riboflavin was examined. Treatment resulted 
in a variable decline of between 0% and 30% in 
the activity of the plasma proteins. According to 
Goodrich, such a reduction is well within the accepted 
norm.
- Goodrich RP. The use of riboflavin 
for the inactivation of pathogens in 
blood products. Vox Sang 2000; 78 
(Suppl 2): 211-5.
- Alfonso R, Lin CY, Dupuis K. 
Inactivation of viruses with 
preservation of coagulation function 
in FFP. Blood 1996; 88 (Suppl 1): 
2092.
Clinical research Phase II study in which the amount of coagulation 
factor VII in the blood of healthy volunteers was 
artificially lowered. The increase in factor VII 
achieved through administration of amotosalen-
treated plasma was no different from the increase 
following administration of conventionally treated 
plasma. The first results of phase III research 
in a limited number of patients with hereditary 
abnormalities of blood coagulation have been 
published in abstract form. The authors concluded 
that the amotosalen treatment is an effective method 
for treating plasma.
- Hambleton J, Wages D, Radu-
Radulescu L, et al. Pharmacokinetic 
study of FFP photochemically treated 
with amotosalen (S-59) and UV light 
compared to FFP in healthy volunteers 
anticoagulated with warfarin. 
Transfusion 2002; 42: 1302-7.
- de Alarcon P, Benjamin R, Shopnick 
R, et al. Hemostatic response in 
congenital coagulation factor-
deficient patients transfused with 
FFP prepared by Helinx pathogen 
inactivation technology - the STEP 
CC trial. Transfusion 2001; 41 
(Suppl): 89S.
Pathogen inactivation in 
donated blood. Health  
Technology Assessment 
Section, Medical 
Development Division, 
Ministry of Health 
Malaysia; publication n. 
18/2010.
Effectiveness of 
Intercept®, Mirasol® 
and solvent/detergent 
processes for pathogen 
inactivation in plasma
i) Psoralen light treatment (amotosalen-HCl)
Fair evidence on the effectiveness of the Intercept® 
blood system when used on platelets-plasma.
ii) Riboflavin light treatment
Poor evidence on the effectiveness of riboflavin 
light treatment technology when used on plasma. 
Clinical studies using Mirasol® (riboflavin) pathogen 
inactivation technology is still underway.
iii) Solvent-detergent treatment
Fair evidence on the effectiveness of solvent- detergent 
technology, when used for plasma and fresh-frozen plasma.
- Solheim BG, Seghatchian J. Update 
on pathogen reduction technology 
for therapeutic plasma: an overview. 
Transfus Apher Sci 2006; 35: 83-90.
Pathogen reduction 
technologies for blood 
products: a review of the 
clinical effectiveness, 
cost-effectiveness, and 
guidelines. CADTH, 
October 13, 2009.
Intercept® blood system 
photochemical process
Overall, the available evidence indicates that the 
Intercept® blood system photochemical process 
(amotosalen + UVA light) does not adversely affect 
the clinical utility of the treated blood components, 
specifically plasma and platelet components. 
Intercept®-treated components were able to improve 
haemostasis in all of the included studies and 
had comparable adverse event profiles to those 
of conventionally-prepared plasma and platelet 
components.
- Membe SK, Coyle D, Husereau D, 
et al. Octaplas compared with FFP to 
reduce the risk of transmitting lipid-
enveloped viruses: an economic 
analysis and budget impact analysis 
[Technology report]. Ottawa: 
Canadian Agency for Drugs and 
Technologies in Health; 2011.
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categories studied. The consumption of MB-FFP was 
associated with a marked rise in the demand for plasma 
and cryoprecipitate, which was probably due to the low 
haemostatic quality of the new component.
In a study by De la Rubia et al. (2001)165, 20 patients 
with TTP underwent plasma exchange using either standard 
FFP (group A, n=13) or MB-FFP (group B, n=7). Group 
A showed higher bilirubin values (p<0.05) and a higher 
complete remission rate (69% vs 57% in group B), while 
the mean number of procedures (21±7 vs 11±3, p<0.01) and 
the number of FFP units transfused were higher in group B 
and the mean stay in hospital was also longer (37±12 days 
vs 22±11 days; p<0.01). The use of MB-FFP to treat TTP 
seems to be associated with a higher number of plasma 
exchange sessions and greater transfusion requirements 
without improving clinical results. 
Haubelt et al. (2002)166 assessed the effect of SD-FFP 
and FFP on haemostasis and fibrinolysis in open-heart 
surgery coagulopathy through a prospective trial. Sixty-
seven patients received 600 mL of SD-FFP (n=36) or 
600 mL of FFP (n=31) at an infusion rate of 30 mL/min. 
Before treatment and 60 minutes after termination of 
the plasma infusion prothrombin time, activated partial 
thromboplastin time, fibrinogen, FVIII, antithrombin, 
protein C, and free protein S levels, protein S activity, 
prothrombin fragments F1+2, D-dimers, fibrinogen 
degradation products, plasmin-plasmin inhibitor 
complexes, plasminogen, protease inhibitor and α1-
antitrypsin were measured. The rises in fibrinogen, FVIII, 
antithrombin, protein C, free protein, α-antitrypsin and 
plasminogen, and the decrease in prothrombin time 
and activated partial thromboplastin time did not differ 
significantly between the two study arms. However, 
although protein S activity did not increase after SD-FFP 
infusion, it was significantly elevated after the infusion of 
FFP. Protease inhibitor levels declined significantly after 
SD-FFP and remained uninfluenced by FFP. Neither SD-
FFP nor FFP had any significant influence on prothrombin 
fragments F1+2, D-dimers or fibrinogen degradation 
products. Significant reductions in plasmin-plasmin 
inhibitor complex levels caused by both types of plasma 
can indicate a reduction in hyperfibrinolysis. There was 
no significant difference in clinical haemostasis between 
the two treatment regimens. 
The study performed by Noddeland et al. (2002)167 
comprised 84 adult patients scheduled for elective 
open-heart surgery. Fifty-five of them received plasma 
transfusions, while 29 patients not given plasma 
transfusions functioned as controls. If plasma transfusion 
was indicated during the operation or following 2 days, 
patients were randomised 2:1 to receive Uniplas® or AB 
blood group Octaplas®. Activated clotting time, activated 
partial thromboplastin time and post-operative bleeding 
into chest drains were not significantly different between 
the transfused groups of patients. The median number 
of transfused units of Uniplas® was three (range: 1-23), 
while the median number of Octaplas® units was two 
(range: 1-11). These differences were not statistically 
significant. The authors concluded that Uniplas® has a 
similar effect as Octaplas® in the treatment of bleeding 
in patients undergoing open-heart surgery and may, 
therefore, substitute Octaplas® and reduce the risk of 
ABO-incompatibility.
A retrospective observational study (by de Jonge et al. 
2002)168 was performed to clarify an increased incidence 
of hyperfibrinolysis (75% vs 29%; p=0.005) observed 
during liver transplantation after the introduction of SD-
treated plasma (ESDEP®) instead of FFP. Intraoperative 
plasma samples from patients treated with FFP or 
ESDEP® were analysed. During the anhepatic phase, 
plasma levels of D-dimer (6.58 vs 1.53 g/mL; p=0.02) 
and fibrinogen degradation products (60 vs 23 mg/L; 
p=0.018) were significantly higher in patients treated 
with ESDEP®. After reperfusion, the levels increased 
to 23.5 vs 4.7 g/mL (D-dimer, p=0.002) and 161 vs 
57 mg/L (fibrinogen degradation products, p=0.001). 
The amount of plasma received per packed red blood 
cell concentrate, clotting tests, and levels of individual 
clotting factors were not significantly different between 
the groups. Alpha2-antiplasmin levels were, however, 
significantly lower in patients receiving ESDEP® during 
the anhepatic phase (0.37 vs 0.65 IU/mL; p<0.001) 
and after reperfusion (0.27 vs 0.58 IU/mL; p=0.001). 
Analysis of alpha2-antiplasmin levels in ESDEP® alone 
showed a reduction to 0.28 IU/mL (normal >0.95 IU/
mL) because of the SD treatment.
In a single-blind crossover study, Hambleton et al. 
(2002)92 compared post-infusion kinetics of FVII 
in photochemically treated FFP and standard FFP. 
Healthy volunteers donated plasma by apheresis: half 
of the collected plasma was treated with the psoralen 
amotosalen hydrochloride (A-FFP), and half was 
prepared as standard FFP. The same subjects received 
warfarin over 4 days to lower FVII levels then, on day 4, 
received 1 L of either pathogen inactivated or standard 
FFP. After 2 weeks, subjects underwent a regimen 
identical to that with the other type of FFP. After 
warfarin ingestion, the mean FVII concentration was 
0.33 IU/mL. Both types of FFP exhibited comparable 
FVII kinetics, with a mean peak increment of 0.10 to 
0.12 IU/mL occurring at the end of the infusion. The 
effect disappeared after 8 hours. Equivalent in vivo 
coagulation response was assessed. A 1 L dose of FFP 
in adults may provide an initial increment of FVII of 
0.10 IU/mL. In the absence of bleeding, FVII levels 
return to baseline after 8 hours.
In a retrospective study, Alvarez-Larrán et al. 
(2004)169 studied 56 episodes of TTP treated with MB-
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FFP (27 episodes) as an alternative to FFP (29 episodes). 
Patients who received MB-FFP had an higher risk of 
death from progressive TTP (OR=31; 95% CI: 1.2 to 
>100), than those treated with FFP, a greater number of 
recurrences while on plasma exchange therapy (OR=4,6; 
95% CI: 1.2-17), and a lower probability of remission 
within 9 days of starting plasma exchange (OR=5.2; 
95% CI: 1.3-20). The authors concluded that MB-FFP 
seems to be less effective than FFP in the treatment of 
TTP and suggested avoiding the use of MB-FFP while 
waiting for demonstration of its therapeutic equivalency 
to FFP through randomised controlled trials.
An open-label, multicentre trial was conducted by 
de Alarcon et al. (2005)170 to measure the kinetics of 
specific coagulation factors, haemostatic efficacy, and 
safety of photochemical treatment with amotosalen 
hydrochloride (S-59) FFP (A-FFP) in patients with 
congenital coagulation factor deficiencies (FI, FII, 
FV, FVII, FX, FXI, and FXIII and protein C). Post-
transfusion prothrombin time, partial thromboplastin 
time and clinical haemostasis were evaluated before 
and after the A-FFP transfusions. Thirty-four patients 
received 107 transfusions of A-FFP for kinetic studies 
or therapeutic indications (mean dose, 12.8±8.5 mL/kg). 
Incremental factor recoveries ranged from 0.9 to 2.4 
IU/dL per IU/kg (FII, FV, FVII, FX, FXI, and protein 
C). The mean pre-transfusion prothrombin time (20.7± 
22.2 seconds) was corrected after A-FFP (13.8±2.4 
seconds, p<0.001) as was the mean pre-transfusion 
partial thromboplastin time (51.2±29.3 seconds vs 
32.0±5.1 seconds, p<0.001). A-FFP provided as effective 
haemostasis as FFP and was well tolerated.
Garcia-Noblejas et al. (2005)171 reported a case of a 
patient who developed a pulmonary embolism during 
treatment with MB-FFP for a suspected haemarthrosis. 
The patient, without a family history of thrombosis, 
had homozygous inherited FV deficiency and two 
acquired factors predisposing to thrombosis: obesity 
and bed rest. He started anticoagulant treatment with 
low molecular weight heparin while the deficient factors 
were replaced with MB-FFP. After 8 days of treatment 
the patient developed severe respiratory failure and the 
anticoagulant therapy was suspended due to a suspicion 
of pulmonary haemorrhage, an inferior vena cava filter 
was placed and corticosteroid therapy was started. Spiral 
computed tomography and other investigations were 
performed, leading to a diagnosis of TRALI. The patient 
progressively improved, the inferior vena cava filter was 
removed 1 month later and after 5 months of follow up 
there were no visible sequelae. The authors consider 
that the infusion of MB-FFP was an important factor 
for the thrombosis (although other risk factors were also 
present), and to their knowledge this association had not 
been previously reported.
A randomised, controlled, double-blind phase III 
trial was conducted by Mintz et al. (2006)172 with A-FFP 
or control FFP for therapeutic plasma exchange in 
patients with TTP. Patients were treated with FFP for 
a maximum of 35 days until remission was achieved 
plus an additional 5 days after remission. Remission 
within 30 days, the primary end-point of the study, was 
achieved by 14 of 17 (82%) A-FFP recipients and 16 of 
18 (89%) control, FFP recipients (p=0.658). The 90% CI 
for treatment difference in remission rate between test 
and control patients was −0.291 to 0.163. There were 
no significant differences in time to remission, relapse 
rates, time to relapse, total volume and number of FFP 
units exchanged, and number of study plasma exchanges 
between the two groups. The improvements in VWF-
clotting protease activity and inhibitors were similar in 
both groups. No antibodies directed against amotosalen 
neoantigens were detected. Given the rarity of this 
condition, the trial was not powered to demonstrate 
small differences between treatment groups, although 
the comparable results observed in the two treatment 
groups suggest that therapeutic plasma exchange with 
A-FFP is safe and effective for the treatment of TTP.
Santagostino et  al .  (2006)173 s tudied the 
pharmacokinetics of deficient clotting factors and the 
haemostatic efficacy of SD-FFP treatment in 17 patients 
with recessively inherited coagulation disorders (1 with 
afibrinogenaemia, 4 with FV deficiency, 6 with combined 
FV and FVIII deficiencies, 1 with FX deficiency and 5 
with FXI deficiency) in an open-label, multicentre trial. 
In vivo recovery of the deficient coagulation factor was 
determined in a non-bleeding state in all patients and the 
mean values for FV, FVIII, FX, FXI and fibrinogen were 
1.3, 1.2, 1.5, 1.3 and 1.5 dL/kg, respectively. The mean 
plasma half-lives of FV, FVIII and FX were 18, 43 and 33 
hours, respectively. All patients underwent replacement 
therapy for elective procedures at risk of bleeding, except 
one who was treated for a central nervous system surgical 
emergency. SD-FFP treatment was judged fully effective 
in 13/16 cases (81%). In the remaining three cases, mild 
bleeding occurred after major surgery in a FV-deficient 
patient with a factor level of 43%, in a FXI-deficient 
patient when factor levels were between 20% and 41%, 
and, after minor surgery, in a patient with FV and FVIII 
deficiencies when the levels of these factors were 41% and 
18%, respectively. Bleeding was controlled by continuing 
or increasing treatment with SD plasma. The authors 
suggest that, even though the current absolute risk of 
blood-borne infections associated with FFP is relatively 
small, SD-FFP should be preferred in patients with 
recessively inherited coagulation disorders when virus-
inactivated single-factor concentrates are not available.
Scully et al. (2007)174 reviewed 50 acute TTP 
episodes in order to compare the efficacy and safety of 
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cryosupernatant and SD-FFP (Octaplas®). In 12 episodes 
only cryosupernatant was used, whereas in 15 episodes 
treatment was started with cryosupernatant and changed 
to Octaplas®. Once Octaplas® had been used, it was 
continued on further admissions. Cryosupernatant was 
used exclusively in 24% and Octaplas® exclusively in 
42% of all episodes. With regards to the episodes treated 
only with cryosupernatant or SD-FFP, there was no 
significant difference in the median number of plasma 
exchanges to achieve remission: 7,0 (interquartile 
range 5.0-8.8) and 8.0 (interquartile range 6.5-22.0), 
respectively. 
Politis et al. (2007)53 described 5 years of experience 
of pathogen inactivation of FFP with the MB-FFP system 
in a blood centre in Athens. During the study period, 
8,500 units of MB-FFP were issued for transfusion and 
88 units were evaluated for coagulation factor activity 
and cytokine concentrations after pathogen inactivation. 
The losses after MB inactivation and leucoreduction of 
these 88 units were all statistically significant (p<0.05) 
and ranged from 18% to 22% for coagulation factors 
and from 58% to 68% for cytokine concentrations. Post-
MB treatment values of fibrinogen and FV and FVIII 
appeared to be correlated with their pre-MB values. For 
fibrinogen (Pearson's correlation coefficient r=−0.43, 
p<0.001) and FV (r=−0.24, p=0.025) the correlation 
between pre- and post-MB treatment values was 
negative, suggesting that the loss was greater from the 
units with higher pre-MB values. For FVIII, however, 
this correlation was positive (r=0.25, p=0.020).
A multicentre cohort study was conducted by del 
Rio-Garma et al. (2008)28 to compare MB-FFP with 
Q-FFP in the treatment of TTP. MB-FFP was used in 63 
and Q-FFP in 39 of 102 episodes of idiopathic TTP. The 
treatment programme comprised daily plasma exchange 
and corticosteroids; the main end-point was remission 
status on day 8. Patients treated with MB-FFP required 
more plasma exchanges (median: 11 vs 5, p=0.002) and 
a larger volume of plasma (median: 485 mL/kg vs 216 
mL/kg, p=0.007) to achieve a remission, and had more 
recurrences while on plasma-exchange therapy than 
those receiving Q-FFP (29 of 63 vs 8 of 39, p=0.02). 
After adjustment for possible confounding factors, the 
use of MB-FFP was associated with a lower likelihood 
of remission on day 8 (OR: 0.17; 95% CI: 0.06-0.47) 
and a higher risk of recurrence while on treatment (OR: 
4.2; 95% CI: 1.6-10.8). 
A study performed by Mikkola et al. (2012)175 
suggested that when the various blood product 
transfusions instead of transfused units were included 
in the multivariable analysis, SD-FFP (Octaplas®) 
transfusion (OR: 2.149; 95% CI: 1.141-4.047), but not 
red blood cell transfusion, was significantly associated 
with post-operative stroke after coronary artery bypass 
surgery. Use of blood products ranging from no 
transfusion (stroke rate 1.6%) to combined transfusion 
of red blood cells, platelets and Octaplas® was associated 
with a significant increase in post-operative stroke 
incidence (6.6%, adjusted analysis: OR: 1.727; 95% CI: 
1.350-2.209). Patients who received more than two units 
of red blood cells, more than four units of Octaplas® and 
more than eight units of platelets had the highest stroke 
rate of 21%. Classification and regression tree analysis 
showed that increasing amount of transfused Octaplas®, 
platelets and history of extra-cardiac arteriopathy were 
significantly associated with post-operative stroke.
The same author, in another study176, found that 
blood product transfusion is independently associated 
with all-cause mortality (relative risk [RR])=1.678; 95% 
CI: 1.087-2.590) after coronary artery bypass surgery. 
Among various blood products, SD-FFP (Octaplas®) 
was the only one associated with an increased risk of 
all-cause mortality (RR=1.692; 95% CI: 1.222-2.344). 
Among blood products, perioperative use of FFP 
or Octaplas® seemed to be the main determinant of 
mortality.
A prospective, randomised controlled trial including 
60 patients who received transfusions of plasma 
was conducted by Stanojkovic et al. (2012)177. The 
experimental group (30 patients) were treated with 
Mirasol®-inactivated FFP and the control group (30 
patients) were transfused with non-inactivated FFP. 
Pre-transfusion and post-transfusion values and 
improvement in International Normalised Ratio in 
patients' plasma per one unit transfused were evaluated. 
A total of 68 units of FFP were transfused to patients 
in the control group (2.24±0.83 units/patient), while 
the experimental group received 84 units of Mirasol®-
inactivated plasma (i.e. 2.80±1.19 units/patient). The 
experimental group required a significantly higher 
number of plasma transfusions to normalise coagulation 
parameters compared to the control group (p=0.039). 
There was a significant improvement of International 
Normalised Ratio after every administration of a plasma 
unit application (p=0.046) and the relationship between 
pre-transfusion and post-transfusion International 
Normalised Ratio was linear (r=0.97; p<0.001). Plasma 
treated with riboflavin and UV light is haemostatically 
competent, but larger volumes are required compared to 
those necessary when using non-inactivated FFP.
Bindi et al. (2013)178 evaluated the efficacy of 
SD-FFP in patients undergoing orthotopic liver 
transplantation, comparing it with the efficacy of FFP. 
The 63 patients undergoing liver transplantation were 
divided into two groups depending on whether they 
were transfused with FFP or SD-FFP. Both groups 
achieved the thromboelastography goals but with a 
lower number of transfusions in the SD plasma group 
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(p<0.0001). At the end of surgery, FV, FXII, and protein 
S levels, International Normalised Ratio, activated 
partial thromboplastin time and antithrombin III levels 
were lower in the SD plasma recipients. The authors 
observed that in cirrhotic patients undergoing orthotopic 
liver transplantation, SD-FFP provides the same clinical 
results as FFP, but with a significant reduction in the 
amount of plasma transfused.
In 2013, Bartelmaos et al.179 performed a randomised, 
blinded trial in four French liver transplantation 
centres. They compared Q-FFP, MB-FFP and SD-FFP. 
The outcomes examined were the volume of plasma 
transfused during transplantation, intraoperative blood 
loss, correction of haemostasis variables, and adverse 
events. One hundred patients were randomly assigned to 
receive MB-FFP, 96 to receive SD-FFP, and 97 to receive 
Q-FFP. The median volumes of MB-FFP, SD-FFP, and 
Q-FFP transfused were 2,254, 1,905, and 1,798 mL, 
respectively, while the median numbers of transfused 
plasma units were 10, 10, and 8 units. After adjustment 
for bleeding risk factors, the difference between groups 
decreased and the excess plasma volume transfused 
with MB-FFP compared to Q-FFP was reduced from 24 
to 14%. Blood loss and coagulation factor corrections 
were not significantly different between the three study 
groups. These results suggest that the use of MB-FFP 
was associated with a moderate increase in volume 
transfused, partly explained by a difference in unit 
volume and bleeding risk factors, with respect to Q-FFP 
and SD-FFP. Fewer units of Q-FFP were transfused than 
either SD-FFP or MB-FFP. 
Table VIII summarises the clinical studies comparing 
pathogen-inactivated/reduced plasma to FFP.
Pathogen-inactivated/reduced plasma vs untreated 
plasma: in vitro studies
In 1998, 12 plasma pools, 12 batches of SD-treated 
plasma, and 12 units of Q-FFP were extensively analysed 
by Beeck and Hellstern180. The stability of fibrinogen, 
FV, FVII, and FVIII after thawing, storage at room 
temperature and storage at +4 °C was also examined. 
Plasma pools before and after SD treatment were 
appraised for parameters of coagulation and fibrinolysis, 
as were quarantined single-donor plasma units. After 
the SD-FFP treatment, all clotting factor activities 
and the activities of most inhibitors and other plasma 
proteins were in the normal range in all batches, Protein 
S and plasmin inhibitor activities decreased by 35 and 
76%, respectively; FVII resulted partially activated. 
However, markers of activated haemostasis did not 
increase significantly. The inter-individual variations 
of all proteins analysed were significantly lower in the 
SD-FFP than in the single-donor plasma units. After 8 
hours of storage, a marked decrease of FVIII activity was 
found without significant variations of fibrinogen, FV 
and FVII. No significant reductions of the activities of 
clotting factors and important plasma proteins due to the 
SD treatment were observed. The authors concluded that 
although the activities of protein S and plasmin inhibitor 
were reduced, the efficacy and safety of SD-FFP were 
maintained because the reductions of the activities of 
clotting factors and inhibitors were not critical. On the 
other hand, more standardised SD-FFP units would 
allow simplified dosage calculations and evaluation of 
clinical responses.
Aznar et al. (1999)181 studied the effects of viral 
inactivation by MB on the FVIII/VWF molecular 
complex, FXIII, and fibrinogen. FVIII function or 
activity, VWF activity, VWF antigen, VWF multimeric 
structure, fibrinogen, and FXIII were analysed in paired 
samples of control fresh (untreated) plasma and of the 
same fresh plasma treated with MB. Treated plasma was 
filtered (pore size 0.8-1.2 µm), mixed with a MB solution 
(300 µg/L), and illuminated at 50,000 lux for 30 minutes 
on both sides. The average loss of biological activity of 
the coagulation factors studied was 25% (FVIII function, 
29%; fibrinogen, 39%; FXIII, 16%; and VWF activity, 
18%). The reduction of VWF activity was significantly 
lower than that of FVIII function (p<0.05), and the VWF 
multimeric structure did not show alterations. MB-treated 
plasma and cryoprecipitates may be successful for 
replacement therapy in von Willebrand disease and 
deficiencies of FXIII and fibrinogen. The authors 
suggest that clinical studies are needed to confirm this.
Doyle et al. (2003)182 investigated the loss of clotting 
factors in SD-FFP by measuring procoagulant factors 
(fibrinogen, FV and FVIII), anticoagulant factors (protein 
C and protein S), prothrombin time and activated partial 
thromboplastin time in 48 single-donor units of FFP and 
in 16 units of SD plasma (Octaplas®). Prothrombin time, 
activated partial thromboplastin time, FVII and protein 
C levels were within the normal reference range for 
both SD plasma and FFP. FV (31%), FVIII (28%) and 
protein S (50%) levels were significantly reduced in 
SD plasma. Nevertheless, the difference in coagulation 
factor levels may have been further exacerbated by 
the smaller volume of the SD plasma units (200 mL) 
compared with the units of standard FFP (250 mL). 
These differences can play a critical role in treatment 
efficacy, particularly in patients with liver disease, 
constitutional FV deficiency and congenital or acquired 
protein S deficiency.
In a paired study (11 subjects/arm) by Garwood et al. 
(2003)38, plasma was frozen within 8 hours of collection, 
thawed, MB photo-inactivated, and then filtered using 
one of two MB removal filters. Fresh plasma (16 units) 
and plasma leucoreduced before freezing (19 units) 
were MB inactivated. Freeze-thawing resulted in a loss 
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f p
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ra
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 m
et
hy
le
ne
 b
lu
e-
tre
at
ed
 F
FP
 to
 tr
ea
t T
TP
 is
 a
ss
oc
ia
te
d 
w
ith
 a
 h
ig
he
r n
um
be
r o
f p
la
sm
a 
ex
ch
an
ge
s a
nd
 g
re
at
er
 tr
an
sf
us
io
n 
re
qu
ire
m
en
ts 
w
ith
ou
t i
m
pr
ov
in
g 
cl
in
ic
al
 re
su
lts
.
M
od
er
at
e
de
 Jo
ng
e 
J, 
20
02
Pa
tie
nt
s u
nd
er
go
in
g 
or
th
ot
op
ic
 li
ve
r 
tra
ns
pl
an
ta
tio
n 
20
 F
FP
 v
s 2
1 
so
lv
en
t/d
et
er
ge
nt
-
tre
at
ed
 p
la
sm
a 
(E
SD
EP
®
)
A
nh
ep
at
ic
 p
ha
se
: 
D
-d
im
er
, 6
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- c
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 d
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 p
at
ho
ge
ns
 a
s i
n 
sta
nd
ar
d 
FF
P.
Lo
w
SD
-F
FP
: s
ol
ve
nt
/d
et
er
ge
nt
-tr
ea
te
d 
fre
sh
-fr
oz
en
 p
la
sm
a;
 M
B-
FF
P:
 m
et
hy
le
ne
 b
lu
e-
tre
at
ed
 fr
es
h-
fro
ze
n 
pl
as
m
a;
 A
-F
FP
 p
lu
s U
VA
: a
m
ot
os
al
en
-tr
ea
te
d 
fre
sh
-fr
oz
en
 p
la
sm
a 
ex
po
se
d 
to
 u
ltr
av
io
le
t A
 li
gh
t; 
R-
FF
P 
pl
us
 U
V:
 ri
bo
fla
vi
n-
tre
at
ed
 fr
es
h-
fro
ze
n 
pl
as
m
a 
ex
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Pathogen reduction technologies of plasma: HTA
of activity of FXII and VWF of 0.06 and 0.04 units/
mL, respectively, without significant loss of activity of 
FII through to FXI or fibrinogen. After MB treatment, 
there was loss of activity of FII (0.07 IU/mL), FV (0.11 
U/mL), FVII (0.08 IU/mL), FVIII (0.28 IU/mL), FIX 
(0.12 IU/mL), FX (0.16 IU/mL), FXI (0.28 U/mL), 
FXII (0.15 U/mL), VWF antigen (0.05 IU/mL), VWF 
activity (0.06 U/mL), and fibrinogen (0.79 g/L). Losses 
due to this step were significantly (5-10%) less in fresh 
plasma than in frozen-thawed plasma. Neither MB 
removal filter resulted in significant loss of activity of 
any factor studied.
Depasse et al. (2005)183 studied the influence of 
MB treatment on fibrinogen activity and fibrinogen 
polymerisation indices. They split ten apheresis plasma 
bags into two equal aliquots, both of which were 
leucofiltered and virally inactivated in a standardised 
way, using the Theraflex® MB-Plasma photodynamic 
viral inactivation MacoPharma method. One was 
subsequently processed, using a Blueflex® MB removal 
filter to remove residual MB and its by-products. Control 
plasma samples were obtained after filtration but before 
MB light treatment. All samples were analysed for 
fibrinogen activity and antigen, thrombin clotting time, 
and alterations in fibrin polymerisation indices. After 
MB light treatment, the mean fibrinogen concentration 
increased slightly (2%) whereas functional activity 
decreased by 31%, as compared to that in control 
samples. Mean thrombin clotting time increased by 
6 seconds after MB light treatment, with no further 
changes after filtration to remove MB. A similar trend 
was observed when measuring reptilase time. Compared 
to the findings in control samples, both thrombin- and 
reptilase-triggered fibrin polymerisation was delayed 
and the polymerisation curve slopes were decreased 
slightly, with concomitant changes in fibrin opacity 
in samples subjected to MB light treatment and MB 
removal by filtration. 
The aim of Heger et al. (2005)184 was to study 
the quality of SD-FFP, Octaplas®, and single-donor 
FFP units during 48 hours of storage after thawing. 
Octaplas® bags of different blood groups and individual 
FFP units were thawed and stored at either +4 °C or 
at room temperature for 48 hours. Coagulation factor 
and protease inhibitor activities were investigated 
using standard coagulation and chromogenic assays. 
The generation of FVIIa was considered as a marker 
of coagulation factor activation. All investigated 
coagulation factors and protease inhibitors were stable 
for at least 8 hours during storage of Octaplas® at +4 
°C. FVIII levels started to decline earlier in FFP than 
in Octaplas® at both storage temperatures. The optical 
density values of stored Octaplas® were more stable 
during the storage period than those of FFP, whereas 
VWF multimeric patterns were comparably stable in 
both types of plasma. The study results suggest that 
Octaplas® maintains high quality levels for 8 hours when 
stored at +4 °C and for 6 hours when stored at room 
temperature. In general, there was more variability in 
coagulation factor levels among FFP units than among 
different Octaplas® batches.
In 2007, Heger et al.152 compared plasma derived 
from different sources. Twenty-four Octaplas® and 
three Uniplas® batches were selected for the study. 
ADAMTS13 activity was measured by fluorescence 
resonance energy transfer assay, ADAMTS13 antigen 
levels were measured using an enzyme-linked 
immunosorbent assay test kit, while factor H antigen 
levels were determined using a radial immunodiffusion 
method. In addition, VWF multimers were analysed. 
ADAMTS13 antigen and activity levels as well as factor 
H concentrations were normal in all the plasma samples 
studied, without significant differences. Furthermore 
Octaplas® and Uniplas® had VWF multimeric patterns 
similar to that of normal plasma and contained normal 
levels of ADAMTS13 with low variation among 
batches. The authors concluded that both products can 
substitute the missing or neutralised protease activity in 
TTP patients and thus limit VWF-dependent (platelet-
related) thrombosis. Furthermore both products can 
be used efficiently in the treatment of patients with 
haemolytic-uraemic syndrome, given their normal 
content of factor H.
The study by Singh et al. (2006)185 evaluated the 
pathogen-inactivation efficacy of A-FFP and the effect 
of photochemical treatment with the Intercept® Blood 
System on plasma function. Plasma function was 
evaluated through measurement of coagulation factor 
and antithrombotic protein activities. Factor activity 
after photochemical treatment, expressed as a proportion 
of pre-treatment (baseline) activity, was 72 to 73% of 
baseline fibrinogen and FVIII activity and 78 to 98% 
for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, 
protein S, antithrombin, and α2-antiplasmin. Levels of 
inactivation expressed as log-reduction were: cell-free 
HIV-1, greater than 6.8; cell-associated HIV-1, greater 
than 6.4; HTLV-I, 4.5; HTLV-II, greater than 5.7; HBV 
and HCV, greater than 4.5; duck HBV, 4.4 to 4.5; BVDV, 
6,0; severe acute respiratory syndrome coronavirus, 5.5; 
WNV, 6.8; bluetongue virus, 5.1; human adenovirus 
5, 6.8; Klebsiella pneumoniae, greater than 7.4; 
Staphylococcus epidermidis and Yersinia enterocolitica, 
greater than 7.3; Treponema pallidum, greater than 5.9; 
Borrelia burgdorferi, greater than 10.6; Plasmodium 
falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; 
and Babesia microti, greater than 5.3.
Pock et al. (2007)89 found impaired thrombin 
generation in single-donor FFP units inactivated by MB 
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dye and subsequently exposed to white light compared 
to that in non-MB-treated single-donor FFP, the 
licensed plasma product Octaplas®, and a product under 
development (Uniplas) independently of the recipients' 
blood group. Thrombin generation was more impaired 
following the use of local (''in-house'') MB inactivation 
systems in blood banks than following industrial MB 
treatment. Supplementation of functional fibrinogen 
to physiological levels did not normalise the altered 
thrombin generation capacity in MB-FFP, whereas 
addition of Octaplas® did. No clear-cut correlation 
between coagulation factor levels in MB-FFP and 
impaired thrombin generation capacity was found, 
suggesting a composite effect.
In their study Cid et al. (2008)138 analysed 36 FFP 
units obtained from whole blood donations that were 
used for 12 replicate experiments. For each replicate 
experiment, three ABO-matched FFP units were pooled 
and divided into three units containing different volumes 
of identical plasma. One unit was used as control FFP, 
one was treated with MB and one was treated with 
amotosalen and UVA light. In this study, the coagulation 
factor levels were better maintained in untreated FFP 
than in photochemically treated plasma. However, 
coagulation factor levels of MB or treated plasma met 
or exceeded the European Pharmacopeia requirements 
for therapeutic plasma. 
del  Rio-Garma et  al .  (2008)186 measured 
ADAMTS-13 activity levels and VWF antigen in 
plasma before and after MB treatment by either the 
Springe method or a commercial "in-house" system 
and also in cryoprecipitate-poor plasma and FFP (20 
units each). Levels of ADAMTS-13 activity in MB-FFP 
processed by the Springe method or the commercial 
"in-house" system were comparable to one another and 
did not differ significantly from levels found in FFP 
(median [range]: 114% [57-139%], 99% [74-123%], and 
106% [70-130%], respectively). ADAMTS-13 activity 
was significantly lower in cryosupernatant [median 
(range): 87% (70-107%)] than in FFP (p<0.05). Levels 
of VWF antigen decreased after photo-oxidation by both 
methods. In vitro ADAMTS-13 activity was conserved 
in MB-FFP processed by the two photo-oxidation 
methods and did not differ significantly from the activity 
found in FFP.
In a study performed by Lawrie et al. (2010)187, 
coagulation factors levels, physiological protease 
inhibitors, markers of activation and procoagulant 
microparticles were assessed in four production batches 
of standard Octaplas® and six of Octaplas LG®. Global 
haemostasis was assessed by a thrombin generation test 
and rotational thromboelastometry (ROTEM). Mean 
levels of factors II, V, VII, IX, X, XI, XII and XIII, 
VWF antigen, antithrombin, protein C and free protein 
S were all >75 U/dL. ADAMTS-13 activity levels were 
normal. FVIII and VWF ristocetin cofactor levels were 
>55 U/dL. Results of the thrombin generation test and 
ROTEM were comparable in both preparations, and 
microparticles were present at insignificant levels. The 
levels of D-dimer and thrombin-antithrombin complexes 
were normal in all batches, two units of OctaplasLG® 
only had slightly elevated levels of prothrombin 
fragments. This study suggests that the affinity 
chromatography procedure used in OctaplasLG® does 
not adversely affect the haemostatic quality of Octaplas®.
Theusinger et  al .  (2011)188 compared the 
concentrations of coagulation factors and cytokines 
in SD-FFP and FFP. Concentrations of the following 
parameters were measured in 25 SD-FFP and FFP 
samples: fibrinogen, FII, FV, FVII, FVIII, FIX, FX, 
FXIII, VWF, D-dimers, ADAMTS-13 protease, tumour 
necrosis factor-α, interleukin (IL)-1b, IL-6, IL-8, and 
IL-10. Mean fibrinogen concentrations in SD-FFP 
and FFP were similar, but the range was larger in FFP 
than in SD-FFP (p=0.01). Mean FII, FVII, FVIII, FIX, 
and FXIII levels did not differ significantly. Higher 
concentrations of FV (p<0.01), FX (p<0.05), VWF 
(p<0.01), and ADAMTS-13 (p<0.01) were found in 
FFP. With the exception of FVIII and FIX, the ranges 
of concentrations for all of these factors were smaller 
in SD-FFP than in FFP (p<0.05). Concentrations of 
tumour necrosis factor-α, IL-8, and IL-10 were higher 
in FFP than in SD-FFP (all p<0.01), again with greater 
variability and thus larger ranges (p<0.01). Coagulation 
factor contents in SD-FFP and FFP were similar, with 
the exceptions of less FV, VWF, and ADAMTS-13 in 
SD-FFP. Cytokine concentrations (tumour necrosis 
factor-α, IL-8, and IL-10) were significantly higher in 
FFP. The clinical relevance of these findings needs to 
be established in outcome studies.
Ettinger et al. (2012)189 evaluated the in-vitro 
protein quality of apheresis-derived plasma products 
processed between 8 and 8.5 hours after collection 
and stored at −18 °C for 6 months and 1 year. Plasma 
(205±5 mL) was combined with 35±5 mL of 500 
µM riboflavin, and exposed to UV light (6.24 J/mL). 
Overall, 14 plasma units were analysed using standard 
coagulation assays immediately following treatment, 
and after 6 months and 1 year of storage at −18 °C. 
Fibrinogen, total protein, FII, FVIII, FIX, FX and FXII 
levels were modestly affected by storage for 1 year 
at −18 °C. The average percent protein retention in 
R-FFP samples after 1 year of storage in comparison 
to control samples held under similar conditions were: 
total protein, 103%; FII, 88%; FVII and FXI, 62%; FV 
60%; FVIII and FIX, 77%; fibrinogen, 75%; FX, 85%; 
and FXII, 82%. The results after 6 months (double the 
European Union guidelines' recommended storage 
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time) and 1 year of storage at −18 °C (four times longer 
than the European Union guidelines' recommended 
storage time), demonstrated that all proteins were well 
preserved. The values in treated products stored under 
these conditions were the same as those reported for 
other pathogen-inactivated plasma products. 
Ettinger et al. (2012)190 evaluated the possibility 
of making pathogen-reduced cryoprecipitate from 
riboflavin and UV light-treated plasma that meets the 
quality requirements specified by United Kingdom 
and European guidelines for untreated cryoprecipitate. 
Plasma units were thawed over a 20-hour period at 4 
°C, and variable centrifugation settings (from 654 g 
for 2 minutes to 5,316 g for 6 minutes) were applied to 
identify the optimal centrifugation condition. Neither 
the centrifugation speed nor its time appeared to have 
an effect on the quality of the final cryoprecipitate 
product; however, the initial solubilisation of the 
cryoprecipitate product was found to be easier at the 
lower centrifugation setting (654 g for 2 min). A smaller 
quantity of protein was found in the cryoprecipitate 
units prepared from R-FFP than from untreated 
products, but this was on average 93 IU/unit, 262 
mg/unit and 250 IU/unit for FVIII, fibrinogen and 
VWF ristocetin cofactor activity, respectively. The 
study shows that cryoprecipitate products prepared 
from Mirasol®-treated plasma using an optimised 
centrifugation method contain levels of fibrinogen, 
FVIII and VWF ristocetin cofactor activity which meet 
both the European and the UK guidelines for untreated 
cryoprecipitate.
Keller et al. (2012)191 evaluated the stability of 
clotting factors and inhibitors in thawed SD-plasma 
stored at 4 °C for 6 days. Clotting factor levels and 
bacterial contamination were investigated using 20 
units of SD plasma. Fibrinogen, FII, FV, FVII, FVIII, 
FIX, FX, FXI, FXII, FXIII, antithrombin, VWF antigen, 
plasmin inhibitor, protein C and free protein S were 
analysed over time. After 6 days of storage the results 
were as follows: fibrinogen 270 mg/dL (−10mg/dL, 
p=0.0204), FII 75% (−5%, p<0.0001), FV 88% (−14%, 
p<0.0001), FVII 81% (−24%, p<0.0001), FVIII 70% 
(−16%, p<0.0001), FIX 96% (−8, p<0.0001), FX 92% 
(−1%, p<0.0001), FXI 119% (−4%, p=0.3666), FXII 
94% (−2%, p=0.3602), FXIII 89% (−1%, p=0.0019), 
free protein S 76% (−4%, p<0.0001), protein C 96% 
(+1%, p=0.0371), antithrombin 92% (−3%, p<0.0001), 
plasmin inhibitor 29% (−4%, p<0.0299) and VWF 
antigen 137% (+2%, p=0.2205). FVII and FVIII 
showed a critical drop of more than 20% or approached 
the lowest quality assurance threshold after storage for 
more than 24 hours. No bacterial contamination was 
found in SD plasma. All clotting factors in thawed SD 
plasma remained stable for up to 24 hours when stored 
at 4 °C. Storage of thawed SD plasma may improve 
the availability of this product in emergency situations.
Cid et al. (2013)192 analysed the quantity and quality 
of coagulation factors in cryoprecipitate prepared from 
A-FFP. Fibrinogen, FVIII, VWF antigen and activity, 
VWF cleavage protease activity (ADAMTS-13), 
and the multimeric structure of VWF were analysed. 
Fibrinogen, FVIII, and ADAMTS-13 content was lower 
in cryoprecipitates prepared from amotosalen-treated 
plasma than in cryoprecipitates prepared from untreated 
plasma (35, 40, and 18% loss, respectively). The 
quantity and quality of VWF, as well as VWF multimer 
patterns were not affected by the inactivation method. 
Cryoprecipitates prepared from A-FFP contained 
significantly reduced levels of fibrinogen, FVIII, and 
ADAMTS-13. However, VWF quantity and quality 
were well preserved. The authors concluded that VWF 
integrity was much better preserved when using A-FFP 
than when using either the original SD method or the 
MB method.
Table IX summarises the above-described in vitro 
studies, comparing technologies for the inactivation/
reduction of pathogens in FFP.
Amotosalen-treated plasma vs plasma treated with 
other pathogen-reduction technologies
Osselaer et al. (2008)45 compared plasma units made 
from a pool of two ABO-matched fresh apheresis units 
treated with either A-FFP or MB-FFP. A total of 12 
paired samples were evaluated. Plasma coagulation 
function was assessed immediately after treatment, 
after 30 days of frozen storage, and after an additional 
24 hours at 4 °C after thawing. The A-FFP and MB-
FFP parameters were compared using paired t-tests and 
p-values less than 0.05 were considered statistically 
significant. The mean levels of FII, FXII, FXIII, VWF 
antigen, ADAMTS-13, D-dimers, and protein C were 
statistically equivalent in A-FFP and MB-FFP at all 
three time points. Mean prothrombin time, activated 
partial thromboplastin time (two time points), and 
thrombin time of A-FFP were shorter than those of 
MB-FFP and A-FFP contained higher mean levels 
of fibrinogen, FXI, and protein S than MB-FFP. The 
retention of FV, FVII, FVIII, FX, and VWF activity 
in A-FFP was either equivalent to or greater than that 
in MB-FFP. MB-FFP contained higher mean levels 
of plasminogen, antithrombin, and plasmin inhibitor 
than A-FFP. Retention of FIX in MB-FFP was greater 
than that in A-FFP only after the 4 °C storage after 
thawing. There is adequate preservation of therapeutic 
coagulation factor activities in both A-FFP and MB-
FFP. Overall coagulation factor levels and stability 
were preserved better in A-FFP than in MB-FFP. 
Details of this study are provided in Table X.
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Solvent/detergent-treated plasma vs cryosupernatant 
plasma
Rock et al. (2013)193 reported on a series of TTP 
patients treated with SD plasma or cryosupernatant 
plasma and analysed the correlations between the 
patients' presentation, clinical response and outcome 
with the levels of ADAMTS-13, the inhibitor and VWF 
multimers. Plasma exchange was carried out in patients 
with a clinical diagnosis of acquired idiopathic TTP. 
ADAMTS-13 enzyme activity and inhibitor levels, VWF 
multimers and platelet count were analysed in correlation 
with patients' outcome. This randomised, controlled trial 
was intended to compare outcome in 280 patients treated 
with either cryosupernatant or SD plasma. The primary 
end-point was survival at 6 months. The study was closed 
prematurely due to removal of one of the interventional 
products from the market. ADAMTS-13 enzyme activity 
and inhibitor levels varied considerably among patients. 
At baseline, only 12/49 (24.5%) had ≤10% enzyme 
activity and 20/49 (41%) had levels ≥80%, whereas 
16/49 had ≥80% inhibitors, 19/49 had ≤10% inhibitors 
and 18/49 (37%) had no inhibitors. No unusually large 
VWF multimers were identified in any of the patients at 
presentation. The 6-month, all-cause mortality rates for 
patients randomised to receive cryosupernatant plasma vs 
SD plasma were 3/34 (9%; 95% CI: 3-23%) and 1/27 (4%; 
95% CI: 1-18%), respectively, with a difference of 5% 
(95% CI: –11-20%). ADAMTS-13 activity and inhibitor 
level at baseline could not differentiate the response of 
TTP to plasma exchange therapy. Details of this study are 
provided in Table XI.
Solvent/detergent-treated plasma: Uniplas LG® vs 
Octaplas LG® 
Jilma-Stohlawetz et al. (2011)194 evaluated the safety 
of a universal, virus-inactivated and prion-depleted, 
pharmaceutical-quality plasma through a randomised, 
double-blind, active-controlled, crossover, phase I trial. 
The 30 healthy adult volunteers (blood group A, B, or 
AB) were randomly assigned to transfusion of 1,200 mL 
of Uniplas LG® or 1,200 mL of Octaplas LG® or vice 
versa. In both periods, plasmapheresis (600 mL) preceded 
the infusion. Blood samples were drawn before and after 
plasmapheresis and 15 minutes, 2 hours, 24 hours, and 
7 days after the plasma transfusion, to assess safety and 
efficacy. The primary safety outcome was variation in 
haemoglobin concentration while the secondary outcomes 
were direct antiglobulin test, complement activation, 
free haemoglobin, haptoglobin, and indirect bilirubin 
which could reflect haemolytic transfusion reactions. 
Efficacy was assessed by evaluating coagulation 
variables. Variations of haemoglobin concentration were 
comparable between treatments and within the normal 
range; the 90% CI was within predefined limits of 
equivalence. No subject had a positive direct antiglobulin 
test and most adverse events were mild. By eliminating 
the risk of ABO incompatibility, the universal plasma may 
represent a progress over blood group-specific plasma. 
Details of this study are provided in Table XII. 
Solvent/detergent-treated plasma: Octaplas LG® vs 
Octaplas® 
Jilma-Stohlawetz et al. (2013)195 also compared the 
safety and tolerability of Octaplas LG® vs Octaplas®. In 
this comparative, block-randomised, open-label, active-
controlled, crossover phase I trial, 60 healthy adult 
volunteers received single transfusions of 1,200 mL of 
the parent product (Octaplas®) in period 1 and of the LG 
plasma product (Octaplas LG®) in period 2 or vice versa. 
In both periods, plasmapheresis (600 mL) preceded the 
transfusion. Blood samples were drawn before and after 
apheresis and 15 minutes, 2 hours, 24 hours, and 7 days 
after the end of plasma transfusion, to assess recovery, 
safety, and tolerability. The primary efficacy end-points 
were changes in coagulation factors and haemostatic 
variables compared to baseline; their relative recovery 
was computed in the per-protocol analysis (n=43). 
Safety and tolerability were assessed (n=60). Variations 
in coagulation factors and haemostatic variables over 
time were within the normal range and similar with the 
two treatments; 90% CI for the derived recovery data 
were within predefined limits of equivalence. Plasmin 
inhibitor concentrations increased significantly after 
transfusion in vivo. Octaplas LG® was bioequivalent to 
its predecessor with respect to recovery of clotting factors 
and demonstrated comparable safety and tolerability in 
healthy volunteers. Both products compensated well for 
the loss of clotting factors after apheresis. Details of this 
study are provided in Table XIII.
Studies of the clinical efficacy of pathogen reduction 
technologies without a comparator
In their study, De Silvestro et al. (2007)55 evaluated 
the clinical effectiveness of Plasmasafe® in 490 
patients (879 transfusion events); performed pre- and 
post-treatment monitoring of indices of coagulation 
(prothrombin time, activated partial thromboplastin 
time, fibrinogen, proteins S and C, FVIII) in 15 patients; 
and treated three TTP patients undergoing plasma-
exchange. The prothrombin time ranged from 50-120%, 
the activated partial thromboplastin time from 24-41 
seconds and the fibrinogen concentration from 1.42-
6.84 g/L. Seventy-six percent of the patients responded 
to the plasma administration. Moreover, two out of 
15 patients in whom protein S was assayed showed 
no increase in the concentration of this haemostatic 
protein. The TTP patients responded to plasma exchange 
treatment following four sessions of apheresis. During 
the observation period 8,422 PlasmaSafe® units were 
transfused and no adverse reactions were recorded. The 
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Pathogen reduction technologies of plasma: HTA
authors concluded that PlasmaSafe® is a pharmaceutical-
like product with a standardised content of coagulation 
factors and that it is effective in correcting coagulation 
defects and in treating patients with TTP. Details of this 
study are provided in Table XIV.
Discussion
The ever-present threat of emerging and re-emerging 
infectious diseases, as well as the risk of clinical 
conditions related to the transfusion of blood products, 
drives the need for innovation of new technologies. 
PRT offer a new approach to increase blood safety 
and they have been adopted gradually but steadily 
over the past decade. The numerous technologies 
and mechanisms discussed in this paper reflect the 
complexity of finding a balance between effective 
pathogen inactivation in blood products and maintaining 
acceptable quality and functionality of haemostatic 
components. 
The evidence-based indications for the use of 
plasma and PRT-treated plasma are few and specific. 
PRT-treated plasma has, in fact, been in clinical use 
Table X - Photochemical treatment of plasma with amotosalen (A-FFP) vs methylene blue (MB-FFP).
First author, 
year
Population N. of plasma 
samples
Outcomes/results Recommendation/
conclusions
Level of
evidence
Osselaer JC,
2008
Apheresis derived 
plasma units
Total 24:
12 A-FFP vs 
12 MB-FFP 
- Effect of pathogen inactivation on 
global coagulation assays: the mean 
thrombin time was shorter for A-FFP 
than for MB-FFP (p<0.05). 
- Effect of pathogen inactivation on 
coagulation factor activity: factor (F) 
XI higher in A-FFP than in MB-FFP 
(p<0.05). The mean retention of FV, 
FVII, FVIII, FX, and VWF:CoR in 
A-FFP was either equivalent or higher 
(p<0.05). MB-FFP exhibited higher 
FIX retention than the A-FFP after 24 
hours of storage at 4 °C after thawing 
(p<0.05). 
- Effect of pathogen inactivation on 
inhibitors of coagulation: the mean 
retention of protein S was higher in 
A-FFP than in MB-FFP (p<0.05).
There is adequate preservation 
of therapeutic coagulation factor 
activities in both A-FFP and 
MB-FFP. The overall coagulation 
factor levels and stability of A-FFP 
were better preserved than those of 
MB-FFP.
Moderate
VWF:CoR: von Willebrand factor activity.
Table XI - Solvent/detergent-treated plasma (SD-FFP) vs cryosupernatant plasma.
First author, 
year
Population N. of patients Outcomes/results Recommendations/conclusions Level of
evidence
Rock G, 
2013
Patients diagnosed 
with primary 
idiopathic TTP
89 (41 given SD-
FFP vs 48 given 
cryosupernatant 
plasma)
Survival at 6 months not significantly 
different between groups. Protein 
S, ADAMTS-13, the inhibitor and 
VWF multimers levels were not 
significantly different between groups.
Data suggest that ADAMTS-13 
activity and inhibitor level at baseline 
cannot differentiate TTP patients' 
response to plasma exchange therapy. 
The study was closed prematurely due 
to removal of one of the interventional 
products from the market.
Low/
moderate
TTP: thrombotic thrombocytopenic purpura; SD-FFP: solvent/detergent-treated fresh-frozen plasma; VWF: von Willebrand factor.
Table XII - Solvent/detergent-treated plasma: Uniplas LG® vs Octaplas LG®.
First author, 
year
Population N. of subjects Outcomes/results Recommendations/conclusions Level of
evidence
Jilma-
Stohlawetz P, 
2011
Healthy adult 
volunteers
30 subjects 
received single 
transfusions 
of 1,200 mL 
Uniplas LG® and 
Octaplas LG® or 
vice versa.
The primary safety outcome was 
change in haemoglobin (Hb) 
concentration; secondary safety 
outcomes were evaluation of the 
direct antiglobulin test, complement 
activation, free Hb, haptoglobin, and 
indirect bilirubin: no differences.
Mean values of individual coagulation 
variables were within the normal range 
and variations in their levels were 
generally similar between treatment 
groups.
The universal plasma is a safe 
alternative and represents an advance 
over the currently available blood 
group-specific plasma transfusion 
products.
Low
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for several years and has proven effective in a variety 
of therapeutic settings, but each PRT system has some 
weakness or shortfall in terms of efficacy and each of the 
major methods under development has a specific set of 
potential limits. The supportive and often prophylactic 
nature of blood component therapy in a variety of clinical 
situations complicates the clinical evaluation of novel 
blood products. Most clinical efficacy studies designed 
to compare PRT-treated and untreated plasma involve 
only small numbers of patients and are not, therefore, 
adequately powered to detect statistically significant 
minor differences. In addition, they assess increments 
in coagulation factor levels and changes in in-vitro 
coagulation blood tests rather than clinically meaningful 
outcomes. Concerns about low levels of plasmin 
inhibitor, protein S, or antitrypsin activity in PRT-treated 
plasma have not been confirmed in clinical studies, 
and claims of thrombosis or hyperfibrinolytic bleeding 
triggered by reduced protein S or low plasmin inhibitor 
potencies have not withstood critical review. Extensive 
clinical experience has shown that reduced levels of 
coagulation factors, as a result of PRT treatment, do not 
significantly impair the clinical efficacy or tolerance of 
plasma.
The first developed method to inactivate enveloped 
viruses in plasma protein preparations was SD 
treatment. SD-FFP has proven to be non-inferior to 
untreated FFP in the management of a wide range 
of congenital and acquired bleeding disorders. 
Furthermore, the major advantages of SD plasma 
over FFP and the other pathogen-inactivated plasmas 
are its extreme safety with respect to TRALI and the 
significantly lower likelihood of allergic reactions. 
Both advantages are interpreted as results of the 
dilutional effect of pooling. 
While MB-treated plasma was associated with 
apparently fewer allergic reactions than plasma, a single-
centre, retrospective haemovigilance investigation in 
France did not confirm this finding. 
Two other technologies, based on photochemical 
processes exploiting amotosalen (a psoralen) and 
riboflavin, both plus light treatment, have been 
developed more recently. There are few studies available 
so far on these technologies and the levels of evidence 
is low or moderate. 
Po ten t i a l  long- te rm s ide  e ffec t s  o f  the 
photosensitisers and their photoproducts are still 
a matter of debate, and, before these technologies 
are implemented widely, it must be shown that the 
photosensitisers and their photoproducts are absolutely 
safe, robust in daily routine practice, cost-effective and 
have controllable efficacy. 
Clinical experience with PRT-treated plasma has 
substantiated the product's safety; nevertheless, work 
in this field is in an early stage and the full potential of 
these technologies has yet to be determined. 
Safety
Introduction
The quest for maximum safety in transfusion has 
long been directed towards preventing the transmission 
of infections, particularly HBV, HCV and HIV. 
The procedures used for this purpose are highly 
effective, but a zero-risk level has not been reached. 
Nevertheless, a better understanding of donors' medical 
histories and the performance of blood tests to screen 
for infectious diseases have decreased the risk of 
transmitting infections by transfusion of blood products. 
Improvements in the sensitivity of tests, such as NAT, 
have contributed significantly to decreasing this risk. 
Systematic surveillance of transfusion-related adverse 
events and adverse reactions encompasses the entire 
transfusion chain and is aimed at increasing the safety 
of the transfusion process196. 
With regard to the safety of the blood supply, 
pathogen reduction might be an additional step. 
Table XV shows prospective safety levels of plasma 
inactivation methods for different pathogens15,55,197,198. 
Table XIII - Solvent/detergent-treated plasma: Octaplas LG® vs Octaplas®.
First author, 
year
Population N. of subjects Outcomes/results Recommendations/conclusions Level of
evidence
Jilma-
Stohlawetz P, 
2013
Healthy adult 
volunteers 
60 subjects 
received single 
transfusions 
of 1,200 mL of 
Octaplas® (in 
period 1) and 
the LG plasma 
product (in 
period 2) or vice 
versa.
Efficacy in terms of recovery of 
coagulation ractors and haemostatic 
variables (primary end-point): all 90% 
confidence intervals were within the 
equivalency interval (−10% to 10%).
The concentration of plasmin inhibitor 
(secondary endpoint): significantly 
higher α2-antiplasmin levels were found 
at 15 minutes (p=0.001) and 2 hours 
(p=0.019) after transfusion of the LG 
product compared to its predecessor
Recovery is indicative of the efficacy 
of the studied products to restore 
clotting factors and inhibitors. Values 
and variation of PT, aPTT, and protein 
C plasma concentrations were similar 
between treatments throughout the study 
period. In addition, the relative changes 
for PT, aPTT, and protein C were similar 
between treatments in the per protocol 
population.
Low/
moderate
PT: prothrombin time; aPTT: activated partial thromboplastin time.
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The clinical events are classified into three macro-
classes: non-infective, infective and mixed (Table 
XVI)198. 
In literature, most of the studies report TRALI, 
infections and acute transfusion reactions (ATR).
TRALI is characterised by acute hypoxaemia and 
non-cardiogenic pulmonary oedema during or within 6 
hours of transfusion. In 2002, the incidence of TRALI 
associated with plasma transfusions was 1:66,600 in 
Germany, which is comparable to the incidence of 
1;60,000 recorded by the French haemovigilance system 
and with the English finding of 1:65,000198. 
National haemovigilance programmes and 
surveillance of transfusion reactions in some countries 
(including the UK, USA, Canada and The Netherlands) 
have corroborated the association between TRALI and 
the presence of HLA in women, resulting in a transition 
to a strategy of predominantly male donors for plasma 
transfusion. There are many published reports claiming 
that the risk of TRALI is five to seven times higher for 
transfusions containing relatively large quantities of 
plasma (250-300 mL) compared with those containing 
smaller volumes of plasma (<30 mL)199. 
The infectious risks are associated with the 
transmission of bacteria, viruses and prions. Bacterial 
contamination of plasma is generally rare because of the 
frozen storage, although cases are still described in the 
literature. Five cases of bacterial contamination of FFP 
Table XIV - Clinical efficacy of a pathogen-reduced plasma product (PlasmaSafe®) evaluated without comparator.
First author, 
year
Population N. of patients Outcomes/results Recommendations/conclusions Level of
evidence
De Silvestro G, 
2007 
Patients with TTP 490 (879 
transfusion events)
PT ranged from 50-120%. 
aPTT ranged from 24-41 seconds.
Fibrinogen concentration ranged from 
1.42-6.84 g/L.
No increase of protein S.
PlasmaSafe® is a pharmaceutical-like 
product with a standardised content 
of coagulation factors, effective in 
correcting coagulation defects and in 
treating TTP.
Low/
moderate
TTP: thrombotic thrombocytopenic purpura; PT: prothrombin time; aPTT: activated partial thromboplastin time.
were reported between 2002 and 2003 in Canada and 
between 1997 and 2007 in Germany191,200. In general, 
pathogen inactivation/reduction is not effective against 
prions, and currently there are no donor tests for prion 
screening200. 
As described in haemovigilance reports, ATR have 
increased in the past few years. The rates of ATR 
associated with FFP in two retrospective studies were 
1:591 and 1:2.184 plasma units transfused200. 
Other common causes of adverse events associated 
with the transfusion of plasma are errors. For example, 
transfusion of an incorrect component or of one that does 
not meet the patient's specific requirements.
According to a cumulative analysis of all SHOT 
reports, and considering only plasma transfusions, the 
most common unpredictable transfusion reactions are 
ATR (allergic, severe febrile or anaphylactic). Adverse 
events can be classified into:
- transfusion reactions that are not preventable: TTI, 
transfusion-associated dyspnoea and ATR;
- possibly preventable transfusion reactions (by 
improved practice and monitoring): TACO, TRALI;
- adverse events caused by error: incorrect blood 
component transfused196. 
The mechanisms of action and spectra of pathogen 
inactivation of the various PRT differ greatly from one 
another. Table XVII reports the features of the pathogen 
inactivation methods applied to plasma15,66,201-203. 
Table XV - Comparison of prospective safety of different types of pathogen-inactivated plasma.
SD-FFP MB-FFP A-FFP R-FFP
Hepatitis B virus +++ + + N/A
Hepatitis C virus +++ +++ +++ N/A
HIV +++ ++ +++ +++
Parvovirus B19 − (NAT) − (+) N/A
Hepatitis A virus − (NAT) + − N/A
Encapsulated viruses +++ ++ ++ N/A
Non-encapsulated viruses − + + N/A
Bacteria +++ − +++ ++ (data are limited to certain types of bacteria)
Protozoa +++ −/+ +++ +++ (data are limited to certain types of protozoa)
SD-FFP: solvent/detergent-treated fresh-frozen plasma; MB-FFP: methylene blue-treated fresh-frozen plasma; A-FFP: amotasalen-treated fresh-frozen 
plasma; R-FFP: riboflavin-treated fresh-frozen plasma; HIV: human immunodeficiency virus; NAT: nucleic acid amplification testing; N/A: not applicable. 
Source: 15, modified from 55, 197, 198.
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Methods
Literature search strategy
A domain-specific search for safety issues was 
derived from the main literature strategy on MEDLINE. 
Safety data on technical approaches to pathogen 
inactivation in FFP for transfusion use were obtained. 
The review was performed using grey literature and 
previous HTA reports. Since the objective was an 
evaluation of the clinical and processing safety, the 
initial search was refined using the following keywords: 
adverse effects, adverse event, near miss, blood safety, 
safety management and haemovigilance. 
The sub-strategy utilised to gather information on 
the safety domain is shown below.
SAFETY (Search ((((("adverse ef fects" 
[Subheading]) OR "adverse effect" OR "adverse event" OR 
"near miss")) OR ("Drug Toxicity/classification"[Mesh] 
OR "Drug Toxicity/complications"[Mesh] OR "Drug 
Toxicity/prevention and control"[Mesh] OR "Drug Toxicity/
transmission"[Mesh] OR "Drug Toxicity/virology"[Mesh] 
OR "drug toxicity")) OR ("complications" [Subheading]) 
OR complication*)) OR ("Blood Safety"[Mesh] OR 
"Safety-Based Medical Device Withdrawals"[Mesh] 
OR "Safety Management"[Mesh] OR "Blood safety" 
OR "Safety Management" OR "transfusion safety")) OR 
haemovigilance OR hemovigilance).
No safety-specific search was performed in the 
Cochrane and CDR databases. No publication date, 
language or search field restrictions were applied.
A manual search of the references of selected 
literature, documents released by monitoring authorities 
(haemovigilance) and grey literature, were included in 
the safety research.
The websites of the following agencies were searched 
for guidelines: National Institute for Health and Care 
Excellence (NICE), UK; Scottish Intercollegiate 
Guidelines Network (SIGN), Scotland; Agency for 
Healthcare Research and Quality (AHRQ), USA; Agence 
Nationale d'Accréditation et d'Evaluation en Santé 
(ANAES), France; HTA Programme, England; Clinical 
Practice Guidelines, CMA Infobase, Canada; Canadian 
Task Force on Preventive Health Care (CTFPHC), 
Canada; MJA Clinical Guidelines, Australia; National 
Guidelines Clearinghouse, USA; The National Heart, 
Lung, and Blood Institute (NHLBI), USA; PRODIGY, 
National Health Service Department of Health, England; 
National Guideline Programme (PNLG), Italy; British 
Committee for Standards in Haematology; Italian 
Haematology Society, and the Italian Society for 
Transfusion Medicine and Immunohaematology (SIMTI). 
The list of European haemovigilance systems 
was obtained from the web-site of the International 
Haemovigilance Network. Grey literature was searched 
using the "Google Scholar" search engine. A number of 
elements in the reference lists of selected articles were 
also evaluated.
Selection criteria
Eligible studies were required to report on one 
or more of the safety outcomes identified, including 
frequency of relevant events and reactions. 
The definitions of clinical and processing safety 
outcomes are reported in Table XVIII. 
The following exclusion criteria were defined and 
studies not eligible on the basis of these criteria were 
not included in the analysis: 
- language: papers in languages other than English;
- relevance: studies focusing on efficacy data;
- study design: in vitro studies. 
The following inclusion criteria were defined to 
identify potentially relevant studies: 
- study design: randomised controlled trial, comparative 
or non-comparative observational study or case report; 
- outcome: studies that assessed at least one outcome 
defined in Table XVIII204. 
Results
The study selection process is illustrated in Figure 4.
The literature search revealed 497 potentially 
relevant citations for the safety domain evaluation. 
Nine studies were excluded because they were not in 
English and four because they were duplicates. Overall, 
484 records were analysed based on the study title and 
382 were excluded because not relevant to the research 
question. The 102 studies included were then screened 
by reading their abstracts and full texts. A total of 64 
further studies were excluded because the alternatives 
compared, the outcomes or the study design were not 
consistent with the aim of this analysis. A total of 17 
studies of the primary literature search were eventually 
included in the analysis.
The secondary literature search, which included 
grey literature (such as haemovigilance reports) and 
references of the studies included in the primary search, 
led to the detection 35 further studies.
The level of evidence of the studies was appraised 
by the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) scale.
Table XVI - The most frequent adverse events occurring 
during transfusion of plasma.
Non-infective Transfusion-related acute lung injury
Transfusion-associated circulatory overload
Acute transfusion reactions 
Infective Infections
Mixed Leucocyte-associated risks
Physicochemical reactions
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Safety of solvent/detergent-treated plasma vs untreated 
plasma
A systematic review205 by the Canadian Agency for 
Drugs and Technology in Health (CADTH) explored 
the safety of SD-FFP as an alternative to FFP or FP. 
Safety was assessed for all indications identified through 
a systematic literature search conducted on electronic 
databases including Medline, EMBASE and the CDR 
database. 
Safety outcomes included the frequency of relevant 
events such as TRALI, TACO and seroconversion for 
HTLV, HBV, HCV, HIV, PVB19 and CMV infections. 
Table XIX lists the safety outcomes investigated 
in eight out of the 12 studies included in the CADTH 
review. The remaining four studies were not considered 
because they did not meet our inclusion criteria. 
No cases of TRALI or TACO were observed in any 
of the studies considered. Adverse events associated 
with SD-FFP were rare and were, specifically, a rash, 
an urticarial reaction and a moderate anaphylactic 
reaction. No seroconversion for HIV, HBV or HCV 
was observed in 201 patients transfused with SD-FFP 
or in 55 patients transfused with FFP. One patient in the 
FFP group showed seroconversion for PVB19 but no 
patient transfused with SD-FFP had this complication. 
Overall, the adverse events and safety of SD-FFP were 
comparable to those of FFP, although comparative data 
for SD-FFP and FFP are limited and the authors of one 
study concluded that the impact of the two alternatives 
on the Canadian Health Service could not be determined.
The CADTH updated this systematic review in 
2010206, including another three studies dealing with the 
safety of SD-FFP as an alternative product to FP or FFP. 
One of these studies (Flesland, 2007207) is also included 
in our primary literature search and another (Scully, 
2007174) is not compatible with this report. Table XX 
shows the results of the only additional study meeting 
the inclusion criteria.
Safety of methylene blue-treated plasma vs untreated 
plasma
Politis et al. (2007)53 reported their 5-year 
experience of pathogen inactivation of MB-FFP in a 
multicentre observational study. Overall, 8,500 units 
of FFP treated with MB and 54,435 untreated units of 
FFP were transfused in four Greek hospitals between 
2000 and 2005. The only adverse reactions related to 
MB-FFP transfusion was one allergic reaction, not 
classified as serious, observed in a patient with TTP. 
However, 25 adverse reactions, five of which were 
classified as serious, were recorded in patients treated 
with FFP. The serious adverse reactions were:
- two cases of anaphylactic shock in patients not 
previously known to be IgA deficient;
- two bacterial infections (staphylococcal infections);
- one case of endotoxic shock.
Table XXI reports the incidence of adverse reactions 
to FFP and MB-FFP.  
No TRALI or seroconversion was reported in 
relation to either MB-FFP or FFP. The incidence of 
Table XVII - Features of the pathogen-inactivation methods for plasma.
Plasma product Methods Features
FFP Single unit pathogen-
reduced plasma
Non-photochemical 
treatment
Widely used 
Good viral safety if quarantined
No standard product 
No guarantee regarding emerging viruses
SD-FFP Pooled plasma Industrial method Inactivates enveloped viruses
Does not inactivate non-enveloped viruses (HAV and parvovirus B19)
Does not inactivate prions
Lower risk of TRALI
Less use of units transfused
Dilution of antibodies (anti-HLA)
Inactivation of prions
MB-FFP Single unit pathogen- 
reduced plasma
Photochemical
treatment; "in house"
Partially inactivates enveloped viruses 
Incomplete removal of the reagent
Does not inactivate prions
Possible removal of leucocytes 
A-FFP Single unit pathogen-
reduced plasma
Photochemical
treatment; "in house"
Inactivation of enveloped viruses
Inactivation of non-enveloped viruses
Inactivation of lymphocytes
Incomplete removal of inactivating agent
and its products
R-FFP Single unit pathogen 
reduced plasma
Photochemical
treatment; "in house"
Not inactivation of emerging viruses 
Effect regarding prion inactivation is not known
FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; MB-FFP: methylene blue-treated FFP; A-FFP: amotosalen-treated FFP; R-FFP: riboflavin-
treated FFP; HAV: hepatitis A virus; TRALI: transfusion-related acute lung injury. Source: 15, modified from: 66, 201, 202.
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serious allergic reactions was zero with MB-FPP, and 
1:10,877 with FFP. The differences were not, however, 
statistically significant (p=0.17 and p=0.62 respectively). 
The authors concluded that MB-FFP is safer than the 
untreated product, even in patients who require the 
transfusion of large quantities of plasma (Table XXII).
Safety of methylene blue-treated plasma vs 
photochemically treated plasma
A study by Adelaide Health Technology Assessment 
(AHTA)62 compared the safety of MB-FFP (Intercept® 
Blood System, Cerus Corporation, USA) and R-FFP 
(Mirasol® Pathogen Reduction Technology, Caridian-
BCT Biotechnologies, USA). The medical literature up 
to May 2011 was investigated through major databases. 
HTA reports were also analysed. 
Three studies assessed plasma transfusion, two were 
non-comparative studies and one was a comparative 
analysis between MB-FFP and untreated FFP and was 
included in our primary literature search (Politis, 2007)53.
de Alarcon et al. (2005)170, in a case series of 34 
patients with congenital coagulopathies recruited from 
a haemophilia research registry, related the incidence 
of acute reactions to the use of A-FFP. Thirteen patients 
received 77 transfusions of pathogen-inactivated plasma 
during surgery. The reactions were classified as mild 
if there were no changes in the patient's capability to 
carrying out activities, moderate if some change occurred, 
and severe in the case that important impairments to the 
performance of usual activities developed. One case of 
nausea was considered to be serious, resulting in a medical 
emergency. The authors reported that no patient resulted 
positive to A-FFP antibodies. Table XXIII shows the 
number of mild and moderated acute reactions associated 
with transfusions of A-FFP.
Cazenave et al. (2010)208 reported the adverse events 
that occurred in a series of 3,232 patients who received 
at least one transfusion of A plasma in two University 
hospitals/blood centres in Belgium and France. Overall, 
7,483 plasma units were transfused to patients with 
haematological disorders. Table XXIV shows the 
adverse events that occurred. The total number of 
adverse events was very low and the authors concluded 
that their relevance was dubious.
A systematic review209 compared the safety of MB-
FFP (Intercept® Blood System) to A-FFP (Mirasol® 
Pathogen Reduction Technology). A limited literature 
search was conducted on major databases, including 
Figure 4 - Study selection process for safety domain.
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PubMed, the Cochrane Library, University of York 
Centre for Reviews and Dissemination databases, 
ECRI, EuroScan, international health technology 
agencies, and a focused search on the Internet was 
performed, searching for evidence until September 
2009. One randomised controlled trial on the safety of 
A-FFP compared to that of FFP was also included. No 
comparative studies between the technologies analysed 
were included in the report. 
Mintz et al. (2006)172 compared A-FFP with 
conventional FFP in a randomised, controlled, double-
blind phase III trial. The study included 35 patients 
with TTP, 17 of whom were treated with A-FFP and 18 
with FFP. There were no significant differences in the 
patients' baseline characteristics. The overall incidence 
of adverse events was similar between the two groups 
(100% A-FFP vs 89% control; p=0.486). Most adverse 
events were mild or moderate in intensity. Three patients 
Table XIX -  Summary of studies on solvent/detergent-treated fresh-frozen plasma (SD-FFP) vs untreated fresh-frozen plasma 
(FFP).
Authors and year Type of study Intervention N. of patients Results
SD-FFP 
(Octaplas®)
Comparator
Williamson LM, 1999 RCT Liver transplantation/
disease 
25 FFP No seroconversion for HIV, HBV or 
HCV. One patient in the FFP group 
showed seroconversion for human 
parvovirus B19.
Chekrizova V, 
2006
Multicentre 
observational study
Liver transplantation/
disease
32 N/A No adverse events were observed.
Noddeland H, 2002 RCT Cardiovascular/surgery 19 36 Uniplas® and 
29 not transfused
No seroconversion for HTLA, CMV, 
parvovirus B19, HIV, HBV or HCV.
Haubelt H, 2002 Prospective cohort 
study
Cardiovascular/surgery 36 31 FFP No adverse events were observed.
Solheim BG, 1993 Prospective cohort 
study
Cardiovascular/surgery 20 20 FFP, 
26 no plasma
No seroconversion for HIV, HBV or 
HCV.
Santagostino E, 2006 Prospective cohort 
study
Coagulation disorder 17 N/A One rash reaction was observed.
No seroconversion for HTLA, parvovirus 
B19, HIV, HBV or HCV. 
Inabal A, 1993 Prospective cohort 
study
Coagulation disorder 11 N/A One urticarial reaction was observed 
A moderate anaphylactic reaction was 
observed in one patient.
No seroconversion for, CMV, HIV, HBV 
or HCV. 
Chekrizova V, 
2006
Cohort study Paediatric and 
gynaecological disease
41 N/A No adverse events were observed.
RCT: randomised controlled trial; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; CMV: cytomegalovirus; HTLA: 
high-titre, low-avidity antibodies. 
Table XX - Studies about SD-FFP vs untreated FFP: summary.
First author, year Type of study Intervention Comparator N. of transfusions Results
Chekrizova V, 2006 Prospective cohort study Unclear FFP 2,621 No transfusion reactions were observed
19 allergic reactions (8 mild, 6 moderate 
and 5 severe) 
SD-FFP: solvent/detergent-treated FFP; FFP: fresh-frozen plasma.
Table XXI - Incidence of adverse reactions following 
transfusion of fresh-frozen plasma (FFP) or 
methylene blue-treated fresh-frozen plasma 
(MB-FFP). 
Incidence/total 
n. of units
Statistical 
significance
FFP MB-FFP
Viral 0:54,435 0:8,500 p=NR
Bacterial 1:9,073 0:8,500 p=NR
Allergic 1:5,444 1:8,500 p=NR
Serious allergic 1:10,877 0:8,500 p=0.62
Anaphylactic 1:27,218 0:8,500 p=NR
FNHTR 1:9,073 0:8,500 p=NR
Other 1:54,435 0:8,500 p=NR
Total 1:2,177 1:8,500 p=0.17
FNHTR: febrile non-haemolytic transfusion reaction; NR: not reported.
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(18%) in the A-FFP group and five (28%) in the control 
FFP group experienced severe adverse events (p=0.691). 
For two patients in each treatment group, the observed 
severe adverse events were refractory or relapsed TTP. 
Adverse events were mainly due to multisystem diseases 
consequent to TTP. The authors concluded that the 
safety profile of A-FFP was not different from that of 
the control FFP. This study was funded by Cerus, the 
manufacturers of Intercept® (Table XXV).
Haemovigilance 
A haemovigilance system requires traceability of 
blood and blood products from donors to transfused 
patients and is an integral part of quality management 
in a blood system. Transfusion is a multistep process 
involving several different professionals as well as 
donors and recipients. An effective haemovigilance 
system is essential for continuous improvement of the 
quality and safety of blood products and to increase the 
safety, efficacy and efficiency of blood transfusions. 
An effective haemovigilance system is bi-directional 
tracking that collects and reports transfusion-related 
adverse reactions and events for a rigorous management 
of the information related to the transfusion process. Not 
all haemovigilance programmes collect the same type 
of information. For example in the United Kingdom 
and in Ireland they only collect information on the most 
serious risks connected to transfusions, while in France 
they collect all haemovigilance data, irrespective of the 
severity of the reactions.
European haemovigilance data
According to European legislation, by the 30th June 
of each year Member States must submit an annual 
report to the Commission, notifying the serious adverse 
reactions and serious adverse events received by their 
competent authority.
Table XXIII - Acute reactions following transfusion of 
amotosalen-treated fresh-frozen plasma: 
classification into mild and moderate 
reactions.
Acute reactions Mild (n.) Moderate (n.)
Skin rash 7 0
Urticaria 16 3
Bronchospasm 3 0
Haemoglobinuria 0 1
Haemolysis 0 0
Chills 3 4
Nausea 1 2
Table XXIV - Acute transfusion reactions following the 
administration of 7,483 units of amotosalen-
treated fresh-frozen plasma: classification 
into adverse events and severe adverse 
events.
Acute transfusion reactions Adverse 
events (n.)
Severe adverse 
events (n.)
Skin rash 2 1
Urticaria 3 1
Bronchospasm 1 1
Chills 3 1
Nausea 2 1
Tachycardia 3 3
Hypotension 3 3
Itching 2 2
Facial oedema 2 1
Laryngeal oedema 1 1
Dyspnoea 1 1
Fever 1 0
Table XXII - Summary of safety studies on methylene blue-treated fresh-frozen plasma (MB-FFP) vs untreated fresh-frozen 
plasma (FFP). 
First author, 
year
Type of study Units of plasma 
transfused
Incidence of adverse reactions Conclusions/
recommendations
Level of 
evidence
Politis C, 
2007
Multicentre 
observational 
study
8,500 units of MB-FFP 
54,435 units of FFP
MB-FFP
Allergic reactions 1:8,500
Total 1:8,500 
FFP
Bacterial infection 1:9,073
AR 1:5,444
SAR 1:10,877
Anaphylactic reactions 1:27,218
FNHTR  1:9,073
Other reactions 1:54.435
Total 1:2,177
No TRALI or seroconversion was 
reported in relation to either MB-FFP 
or FFP.  
MB-FFP is safer than FFP Low/moderate
AR: allergic reactions; SAR: serious allergic reactions; FNHTR: febrile non-haemolytic transfusion reactions; TRALI: transfusion-related acute lung injury. 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
335
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
Table XXV - Summary of studies on methylene blue-treated fresh-frozen plasma (MB-FFP) vs amotosalen-treated fresh-
frozen plasma (A-FFP).
First author, 
year
Type of 
study
Population Outcomes/results Conclusions/recommendations
de Alarcon P, 
2005
Case 
series
30 patients with congenital 
coagulopathies; 77 transfusions with 
A-FFP
Adverse events
Mild:
  Skin rash 7 
  Urticaria 16
  Bronchospasm 3
  Chills 3
  Nausea 1
Moderate:
  Urticaria  3
  Haemoglobinuria 1
  Chills 4
  Nausea 2
N/A
Cazenave JP, 
2010
Case 
series
3,232 transfusions with A-FFP Adverse events
  Skin rash 2
  Urticaria 3
  Bronchospasm 1
  Chills 3
  Nausea  2
  Tachycardia  3
  Hypotension  3
  Itching  2
  Facial oedema  2
  Laryngeal oedema  1
  Dyspnoea  1
  Fever  1
Serious adverse events
Skin rash  1
Urticaria  1
Bronchospasm  1
Chills  1
Nausea  1
Tachycardia  3
Hypotension  3
Itching  2
Facial oedema  1
Laryngeal oedema  1
Dyspnoea  1
The total number of adverse events 
was very low and the authors 
concluded that the relevance of the 
treatment of A-FFP regarding these 
events is dubious.
Mintz PD, 2006 RCT 17 TTP patients treated with A-FFP 
18 TTP patients treated with FFP
The incidence of adverse events was similar 
between groups 
(100% A-FFP vs 89% control; p=0.486).
The authors concluded that the 
safety profile of A-FFP was not 
different from that of control FFP.
N/A: not applicable; RCT: randomised controlled trial; TTP: thrombotic thrombocytopenic purpura.
The haemovigilance data received from Member 
States in 2012 (covering the period going from 1st January 
to 31st December) have been summarised by the Health 
and Consumers Directorate-General of the European 
Commission. All Member States, as well as Liechtenstein 
and Norway, submitted the template, but although all 
countries reported serious adverse reactions and serious 
adverse events, not all denominators were reported, raising 
questions on the availability/accuracy of these data. 
Overall, data from all countries supplying 
information from at least 80% of their facilities 
(hospital blood banks or blood establishments) were 
included in the analyses.
In total, 13,351,948* units of blood components 
were reported to have been transfused by facilities in the 
European Union and European Economic Area countries 
and 15.2% of these (2,029,496) were plasma units.
In total, 1,813 serious adverse reactions likely or 
certainly attributable to the blood or blood component 
transfused were reported by the 28 Member States, 
Liechtenstein and Norway (13.6 serious adverse reactions 
per 100,000 units transfused or, conversely, 7,365 units 
transfused per serious adverse reaction), 16% of which 
(290 serious adverse reactions) were related to plasma. 
The report did not, however, specify whether the units 
of plasma were pathogen-inactivated and, if so, which 
method had been used for the inactivation. Furthermore, 
the serious adverse reactions were not split by type210. 
*The total number of units transfused refers to 20 countries (AT, BE, BG, CZ, DK, 
EE, EL, ES, HR, IE, IT, LI, LT, MT, NL, NO, PT, RO, SE, and UK).
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German haemovigilance clinical data
German haemovigilance report
The Paul-Ehrlich-Institute211, a German research 
institution and medical regulatory body, summarised 
data reported since 2010 and compared the data of 
the preceding 13 years (1997-2009) with the current 
haemovigilance data. 
Table XXVI shows only the serious transfusion 
reactions to plasma transfusions.
Table XXVII reports the frequency of the serious 
transfusion reactions to plasma transfusion per 106 
transfused units.
Haemovigilance data on serious adverse reactions 
to FFP in Germany during 1997-2010 show that these 
reactions decreased. In 2010 only TACO and ATR 
occurred. The trend in the incidence of ATR increased 
and in 2010 29 events were confirmed, 20 of which were 
classified as serious. In 2009 and 2010, no bacterial 
and viral infections were reported. As a consequence of 
measures aimed at reducing immunogenic TRALI, the 
number of TRALI events decreased in 2009 and 2010 
compared to the number recorded in 1997-2008. 
Primary literature studies
In an observational cohort study in 2010, Funk et 
al.199 reported the frequency of TRALI related to plasma 
transfusions in Germany, during a period of 5 years 
(2006-2010). Data before and after the introduction 
of risk-minimisation measures (2008-2009) were 
compared. The risk minimisation strategies, limited to 
FFP, consisted of:
- use of female donors without a history of pregnancy 
for the production of FFP;
- use of female donors with a history of pregnancy 
but without detectable white blood cell antibodies 
for FFP production;
- testing of HLA class I-, HLA class II-, HNA 1a-, 
HNA 1b-, HNA 2a- and HNA 3a-antibodies.
During the period 2006-2010, 419 suspected cases of 
TRALI were reported and a total of 80 cases associated 
with plasma transfusions were confirmed (according 
to the International Haemovigilance Network criteria): 
75% of these were immune-mediated and 25% were 
non-immune-mediated. 
With regards to the rate of immune-mediated TRALI 
after administration of FFP, this decreased during the 
transitional period. The rate of TRALI per million units 
transfused was 12.7 in 2006/2007, 6.81 in 2008/2009 
and no cases were reported in 2010. 
Table XXVIII shows the absolute number of TRALI-
induced deaths and cases of non-immune-mediated 
TRALI during the pre-implementation period (2006-
Table XXVI - FFP-associated serious transfusion reactions in Germany between 1997 and 2010.
1997-2009 2010
Acute transfusion reactions 59 (grade I, 29; grade II, 8; grade III, 18; grade IV, 2)
Number of TRALI reports 586 60
Number of TRALI cases with antibody-positive FFP donors 89 0
TRALI-related fatalities due to FFP 16 0
Transfusion-transmitted bacterial infections 5 0
Transfusion-transmitted viral infections (HBV, HCV, HIV) 12 0
TACO ND 2
FNHTR ND 0
FFP: fresh-frozen plasma; TRALI: transfusion-related acute lung injury; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency 
virus; TACO: transfusion-associated circulatory overload; FNHTR: febrile non-haemolytic transfusion reaction.
Table XXVII - Frequency of serious transfusion reactions per 106 transfused units of plasma.
Frequency of transfused units (number of events)
1997-2000 2001-2004 2005-2008 2009 2010
Units of FFP transfused* 6.346×106 4.781×106 4.474×106 1.096×106 1.152×106
Serious acute (allergic) TR 
(grade III and IV)
0.47 (3) 2.51 (12) 2.91 (13) 13.69 (15) 17.36 (20)
Immune-mediated TRALI 1.42 (9) 5.23 (25) 11.18 (50) 4.56 (5) 0
TTI (bacterial)** 0.63 (4) 0 0.22 (1) 0 0
TTI (viral) 1.42 (9 HCV transmissions) 0.63 (3 HBV transmissions) 0 0 0
FFP: fresh-frozen plasma; TR: transfusion reaction; TRALI: transfusion-related acute lung injury; TTI: transfusion-transmitted infection; HCV: hepatitis 
C virus; HBV: hepatitis B virus. *Estimated consumption; **Results of microbiological analyses in confirmed cases of transfusion-transmitted bacterial 
infections: two agents with low (human)-pathogenicity and three agents with medium/high pathogenicity.
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2007), the transitional period (2008-2009) and the post-
implementation period (2010).
The comparison of the data from before and after 
implementation of the risk minimisation strategies 
revealed a significantly reduced risk of TRALI between 
2006-2007 and 2008-2009 (OR 0,54; 95% CI: 0.29-
0.98; p=0,0404) as well as between 2006-2007 and 
2010 (p=0.0002, OR not determined because no cases 
were recorded in 2010). Accordingly, the reported rate 
of TRALI-induced fatalities decreased from 2.97 cases 
per million FFP units transfused in 2006-2007 to 2.13 
cases per million FFP units transfused in 2008-2009, 
and no further cases in 2010. The authors concluded 
that a significant reduction of immune-mediated TRALI 
has been achieved through the implementation of risk 
minimisation measures.
United Kingdom haemovigilance clinical data
The UK haemovigilance report
SHOT is the United Kingdom's independent, 
professionally led haemovigilance scheme that collects 
and analyses anonymised information on adverse events 
and reactions to blood transfusion from all the healthcare 
organisations involved in transfusion of blood and blood 
components in the country.
This analysis examines the adverse events and 
adverse reactions in 2010, 2011, 2012 and 2013 
published in the annual SHOT reports204,212-214. 
The SHOT reports analyse data sent on a voluntary 
basis by several structures of the National Health 
Service. Table XXIX shows the total issues of pathogen-
inactivated plasma transfused in years 2010, 2011, 2012 
and 2013. 
Tables XXX, XXXI, XXXII and XXXIII show the 
number of cases of ATR, TACO, transfusion-associated 
dyspnoea and TTI due to plasma transfusions in the UK 
in the years 2010, 2011, 2012 and 2013, respectively. 
Acute transfusion reactions
In 2010, an anaphylactic reaction associated with 
MB-FFP transfusion was recorded in a young female 
who developed a rash and angioedema. 
In 2011, SD-FFP was implicated in three reactions: a 
severe reaction in an infant, a mild allergic reaction and 
an undefined reaction of low imputability. MB-FFP was 
implicated in a mild febrile reaction of low imputability 
in a neonate.
In 2012, there was a moderate allergic reaction 
associated with SD-FFP in a  young woman 
undergoing plasma exchange for haemolytic uraemic 
syndrome.
In 2013 there were two reactions associated with 
MB-FFP: a severe allergic (but not anaphylactic) 
reaction and a moderate allergic reaction. The two 
reactions associated with SD-FFP both occurred in 
adult patients undergoing plasma exchange: one patient 
developed severe hypotension and was later treated with 
standard plasma with no further problems. A second 
patient experienced anaphylaxis.
The authors of the report underline that the SD-
FFP-related transfusion reactions were less frequent 
and usually less severe than those related to FFP. 
This might be due to the dilution of donor allergens 
in a large pool of plasma, or to the denaturation of 
allergens through the SD process. The data reported 
in the SHOT 2010-2012 reports showed that the 
incidence of allergic reactions to plasma was 2:100,000 
with SD-FFP compared to 11.5:100,000 with standard 
plasma (p<0.001). Although "standard" SD-FFP is still 
available, all new stocks ordered by hospitals will be 
treated to eliminate prions.
Transfusion-related acute lung injury 
There were no reported cases of TRALI in 2010, 
2011, 2012 or 2013. Overall, in the United Kingdom 
rates of TRALI remained lower than in 2003-2004, when 
TRALI risk reduction strategies were first initiated. 
These included a reduction in plasma components from 
female donors.
Transfusion-associated circulatory overload
In general, the risk of TACO is higher for volumes 
of FFP greater than >1.000 mL. No cases of TACO 
were associated with SD-FFP or MB-FFP in the United 
Kingdom during the period 2010-2013.
Table XXVIII - Absolute number of TRALI-induced 
fatalities and non-immune-mediated TRALI 
episodes related to FFP during 2006-2010 
in Germany prior to risk minimisation 
strategies (2006-2007),  during the 
transitional period (2008-2009) and in 2010.
Period 2006-2007 2008-2009 2010 2006-2010
FFP 30 16 0 46
FFP: fresh-frozen plasma; TRALI: transfusion-related acute lung injury.
Table XXIX - Total units of pathogen-inactivated plasma 
issued in the UK in years 2010, 2011, 2012 
and 2013.
FFP SD-FFP MB-FFP
2010 292,884 57,487* ND
2011 288,242 63,214 14,960**
2012 282,721 77,669 15,894
2013 266,332 79,473 13,547
*Octaplas® manufactured by Octapharma Ltd.; **Paediatric/neonatal 
MB-FFP transfusions are expressed as single units; all other components 
are adult equivalent doses. FFP: fresh-frozen plasma; SD-FFP: solvent/
detergent-treated FFP; MB-FFP: methylene blue-treated FFP.
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Transfusion-associated dyspnoea
Between 2011 and 2013 there were no cases of 
transfusion-associated dyspnoea associated with SD-FFP 
or MB-FFP.
Transfusion-transmitted infections
The imputabilities associated with HBV transmission 
were level 3 (certain).
In 4 years, only one TTI has been recorded in the 
United Kingdom. This is due to the introduction of a 
number of precautionary measures:
Table XXX - Total acute transfusion reactions in the UK in the years 2010, 2011, 2012 and 2013.
2010 2011 2012 2013
FFP SD-FFP MB-FFP FFP SD- FFP MB-FFP FFP SD- FFP MB-FFP FFP SD- FFP MB-FFP
Unclassified 0 0 0 4 0 0 0 0 0 0 0 0
Hypotensive 3 0 0 2 0 0 2* 0 0 3 1 0
Mixed allergic/febrile 2 0 0 1 0 0 3 0 0 1 0 0
Anaphylactic 8 0 1 10 1 0 9** 0** 0** 11** 1** 1**
Allergic 26 1 0 25 1 0 13 1 0 11 0 1
Febrile 4 0 0 0 1 1 4 0 0 1 0 0
Total 43 1 1 42 3 3 31 1 0 27 2 2
*One of these is referred to as MB cryoprecipitate **Anaphylactic/severe allergic. FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; 
MB-FFP: methylene blue-treated FFP.
Table XXXI - Total episodes of TACO in the UK in the 
years 2010, 2011, 2012 and 2013.
2010 2011 2012 2013
FFP* FFP FFP FFP
TACO 3 3 7 2
*Untreated fresh-frozen plasma (FFP); TACO: transfusion-associated 
circulatory overload.
Table XXXII - Total episodes of transfusion-associated 
dyspnoea (TAD) in the UK in the years 
2010, 2011, 2012 and 2013.
2010 2011 2012 2013
FFP SD-FFP FFP FFP FFP
TAD 3 1* 2 1 2
*TAD associated with anaphylactic reactions; FFP: fresh-frozen plasma; 
SD-FFP: solvent/detergent-treated FFP.
Table XXXIII - Total transfusion-transmitted infections 
(TTI) associated with plasma in the UK 
in 2010, 2011, 2012 and 2013.
2010 2011 2012 2013
FFP FFP FFP FFP
TTI 0 2 1 0
FFP: fresh-frozen plasma.
- leucodepletion of all blood components (1999); 
- use of MB-FFP obtained outside the United Kingdom 
for children under 16 years of age (2002);
- importation of plasma fo  fractionation (1998);
- imported SD-FFP for adult patients with TTP 
(2006);
- exclusion of donors who have received a blood 
transfusion in the United Kingdom since 1980 
(2004).
Transfusion-associated graft-versus-host disease
There were no confirmed cases of transfusion-
associated GvHD in 2010, 2011, 2012 or 2013 in the 
United Kingdom. Only two cases have been reported since 
1994, when universal pre-storage leucodepletion was 
introduced and no cases have been reported since 2001. 
Overall, FFP is associated with more adverse 
events and adverse reactions than SD-FFP or MB-FFP. 
The greater number of alerts in the United Kingdom 
between 2010 and 2013 is related to ATR, even 
though these decreased in 2013 compared to 2010. 
The most frequent ATR are anaphylactic and allergic 
reactions and are uniquely associated with SD-FFP 
and MB-FFP. 
Irish haemovigilance clinical data
The Irish haemovigilance report
The Irish National Haemovigilance Office defines a 
haemovigilance programme and identifies unexpected 
or undesirable effects of transfusion of blood 
components by ensuring that they are reported in a 
timely and reliable manner. This analysis relates to the 
adverse events and adverse reactions published in the 
bi-annual national report215,216. 
Table XXXIV shows the total issues of pathogen-
inactivated plasma transfused in 2008, 2009, 2010 and 
2011.
Table XXXV lists the adverse reactions and adverse 
events registered in Ireland in 2008, 2009, 2010 and 2011.
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Tables XXXVIII and XXXIX show the numbers 
of adverse events that occurred in 2008, 2009 and 
2010, based on the strength of the recipient adverse 
reactions imputability and grade. 
In the French Haemovigilance system (and in 
general), SD-FFP is considered to be associated with a 
lower risk of inducing TRALI compared to other types 
of plasma. Allergic reactions, which increased between 
2008 and 2009, account for the greatest number of 
adverse events. In 2011, the French haemovigilance 
group phased out the production of MB-FFP because 
of the more frequent allergic reactions associated with 
this product compared to other types of pathogen-
inactivated plasma (SD plasma or A plasma). MB 
plasma was withdrawn from the French market from 
1st March, 2012.
Many retrospective studies conducted in Greece, 
UK, Spain and Austria report rare allergic events 
that can be explained by the continuous use of MB 
plasma223. 
In a retrospective study conducted in a single 
centre in Austria, Nussbaumer et al. (2012) found a 
significantly lower incidence of adverse events due to 
MB plasma than to Q-FFP. 
Muñiz-Diaz E et al. (2014), analysing Catalan 
haemovigilance data, observed that the total number 
of severe allergic/anaphylactic reactions following 
transfusions of MB-FFP is very low and that the rate 
of severe reactions to plasma was always below 1 per 
4,700224. 
The issue of allergic reactions to MB-FFP has been 
considered in detail by the Joint UK Blood Transfusion 
Services and National Institute of Biological Standards 
and Control Professional Advisory Committee. At 
present, there are no changes to the UK policy. SHOT 
data do not show significant differences in allergic 
reactions to MB-FFP or standard FFP. 
The SHOT report published in 2011 describes only 
one reaction, a mild febrile one, connected with MB-
FFP. Between 2007 and 2011, there were a total of 
eight reports of ATR to MB-FFP (1 including multiple 
components), of which five were severe reactions (3 
anaphylactic and 2 hypotensive)213. 
Since 2002, over 99% of all plasma transfused in 
Ireland has been subjected to a pathogen reduction 
process in the form of SD-FFP (Octaplas®), and the 
use of FFP has been restricted to patients undergoing 
liver transplantation. In Ireland, the use of SD-FFP 
is safe and the rare adverse reactions are ATR and 
TACO. 
Swiss haemovigilance clinical data
The Swiss haemovigilance report
Swissmedical (the Swiss Agency for Therapeutic 
Products) defines a haemovigilance programme and 
records unexpected or undesirable effects of transfusion 
of blood components. The haemovigilance report is 
published every year and describe the adverse reactions 
and other events that took place217-220.
Table XXXVI shows the total number of plasma 
transfusions in 2011, 2012 and 2013.
It is not specified whether the adverse reactions were 
associated with Q-FFP or SD-FFP. In 2011, the total 
number of FFP high imputability transfusion reactions 
was 26 (4% of total) of which 25 were allergic reactions 
and one a hypotensive event. 
The total distribution of the high-imputability 
transfusion reactions to plasma increased in 2012 
compared to 2011. In fact, out of 31 reactions, only one 
was associated with SD-FFP. The total risk of allergic 
transfusion reactions to plasma in 2012 was ~1:1,600. 
In 2013, there were 23 (3% of total) high-imputability 
reactions to plasma tranffusion and the total risk of 
allergic transfusion reactions to plasma had increased 
to ~1:2,000. 
No cases of transfusion-transmitted bacterial 
infection from FFP transfusions were reported in 2011, 
2012 or 2013. The risk of TRALI and transfusion-
associated GvHD has been significantly lower in 
recent years (1:100,000 plasma components issued). 
This is due to the implementation of several product-
specific measures, such as stricter donor selection, 
leucodepletion, irradiation, and restricting plasma 
donors to males and women who confirm that they have 
never been pregnant (to their knowledge). 
French haemovigilance clinical data
The French haemovigilance report
The annual French haemovigilance report is 
published by the Agence Nationale de Sécurité du 
Medicament et des Produits de Santé, previously known 
as the Agence Française de Sécurité Sanitaire des 
Produits de Santé. The notification of adverse events 
of all degrees is mandatory, while near miss errors are 
reported on a voluntary basis. 
Table XXXVII shows the amount of plasma 
transfused in 2008, 2009 and 201047,221,222. 
Table XXXIV -  Total units of FFP and SD-FFP distributed/
issued in Ireland in the years 2008, 2009, 
2010 and 2011.
FFP SD-FFP
2008 474 23,856
2009 475 23,401
2010 317 23,078
2011 264 22,890
FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP.
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Primary literature studies
Six articles were selected from the primary literature 
search; two of them commented and analysed the 
adverse reactions to MB-FFP AR France.
In a letter to the editor published on the Journal of 
Allergy and Clinical Immunology in 2013, Mertes et al.48 
analysed the mechanisms underlying allergic reactions 
after transfusion of MB-FFP. Table XL shows the most 
frequent severe allergic reactions observed between 
2005 and 2009, comparing MB-FFP to other types of 
treated plasma (Q-FFP and SD-FFP).
The authors investigated 34 reactions to MB-FFP and 
it was observed that: only one death could be related to an 
allergic reaction; in 19 of the 25 cases (75%), increased
serum tryptase concentrations were recorded; in 12 of 18 
cases (66%), histamine concentrations were increased; 
in three 3 of 17 cases MB skin tests were positive; in 
two cases sensitisation to MB, detected by positive flow 
cytometry basophil activation, was confirmed; in three 
cases an allergen that was not related to the transfusion was 
incriminated; in nine cases (26%) the responsibility of MB 
was ruled out by recent previous or subsequent uneventful 
exposure; in four cases a history of hypersensitivity 
reaction to a labile blood product was reported; finally, 
no cases of IgA deficiency were recorded. 
The authors concluded that although rare, allergic 
reactions to MB have been reported in various clinical 
settings. The results confirm that in some cases 
sensitisation to MB could be responsible for the allergic 
reaction observed and that this increased risk of allergic 
reactions could be elucidated.
Seltsam et al.49 replied to the comment by Mertes et 
al., claiming that between 2005 and 2009, three times 
more units of Q-FFP and SD-FFP than MB-FFP had 
been used. In addition, MB-FFP has been introduced in 
France in 2008, and relevant numbers of MB-FFP units 
were used in 2009 for the first time. These imbalances 
in the use of the different types of FFP limit the validity 
of comparative analyses concerning the frequency 
Table XXXVII - Total number of plasma transfusions in 
France in the years 2008, 2009 and 2010.
Year FFP Virus-inactivated plasma
2008 117,140 211,422*
2009 ND 371,658 (including 142,533 SD-FFP, 22,933 
A-FFP, 204,814 MB-FFP)
2010 ND 83,163 SD-FFP, 52,692 A-FFP, 
246,460 MB-FFP 
*Including SD-FFP, Q-FFP, A-FFP, MB-FFP. ND: no data;  FFP: 
fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; MB-FFP: 
methylene blue-treated FFP; Q-FFP: quarantined FFP; A-FFP: amotosalen-
treated FFP.
Table XXXV - Total plasma-related acute reactions and adverse events registered in Ireland in 2008, 2009, 2010 and 2011.
2008 2009 2010 2011
FFP SD-FFP FFP SD-FFP FFP SD-FFP FFP SD-FFP
FNHTR 0 0 0 0 0 0 0 0
Acute allergic and anaphylactic TR 0 1 0 1 1 0 0 0
Hypotensive TR 0 0 0 0 0 0 0 0
TACO 0 1 0 0 0 1 0 1
TAD 0 0 0 0 0 0 0 0
TRALI 0 0 0 0 0 0 0 0
TTI (bacterial) 0 0 0 0 0 0 0 0
TTI (viral) 0 0 0 0 0 0 0 0
FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; FNHTR: febrile non-haemolytic transfusion reaction; TR: transfusion reaction; TACO: 
transfusion-associated circulatory overload; TAD: transfusion-associated dyspnoea; TRALI: transfusion-associated acute lung injury; TTI: transfusion-
transmitted infection.
Table XXXVI - Total number of plasma transfusions in 
Switzerland in 2011, 2012 and 2013.
FFP (therapeutic units)*
2011 50,063
2012 49,832
2013 44,083
*FFP, Q-FFP or SD-FFP. FFP: fresh-frozen plasma; Q-FFP: quarantined 
FFP; SD-FFP: solvent/detergent-treated FFP.
of rare adverse events. The authors added the 2010 
haemovigilance data to their evaluation as well as 
data concerning a third type of pathogen-inactivated 
FFP, A-FFP. Tables XLI and XLII show the frequency 
of severe allergic reactions between 2000 and 2005 
and between 2008 and 2010 associated with the four 
methods of pathogen inactivation, on an imputability 
level from 2 to 4.
The authors  showed that  when the 2010 
haemovigilance data were included in the analysis, 
there were no statistically significant differences in 
the incidences of severe allergic reactions associated 
with the different types of plasma. Overall, including 
the 2010 haemovigilance data, it was not possible to 
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confirm a significantly higher incidence of serious 
adverse reactions for MB-FPP than for the other types of 
FFP. The authors concluded that the currently available 
haemovigilance data do not support the hypothesis of 
additional allergenic mechanisms specifically related 
to the MB/light pathogen inactivation process. The 
analysis of the 2011 haemovigilance data revealed 
that the incidence of severe reactions of imputability 
levels 3 and 4 was 1:15,926 for MB-FFP units and of 
1:31,374 for SD-FFP units and that the total number 
of severe allergic reactions associated with MB plasma 
in the years 2008-2011 had been 40, considering 
an imputability level of 2-4, or 45, considering an 
imputability level of 3 or 4.
Bost et al. (2013)225 analysed retrospective data 
on the four types of FFP: MB-FFP, Q-FFP, SD-FFP 
and A-FFP. These data were drawn from the national 
adverse event reporting database and the regional 
database system for blood deliveries in the Auvergne-
Loire Region (France). They compared the frequency 
of adverse events due to any of the four types of FFP 
over a 10-year period. 
Between January 2000 and October 2011, 105,964 
FFP units were delivered (40,631 units of Q-FFP, 19,015 
units of SD-FFP, 10,283 units of MB-FFP and 36,035 
units of A-FFP). The authors classified the adverse 
events as possible, probable or certain. Table XXVII 
shows the adverse events associated with SD-FFP, MB-
FFP and A-FFP, but not Q-FFP, because their analysis 
was beyond the aim of the study225. 
Statistical comparisons of adverse events did 
not reveal significant difference in adverse event 
rates between SD-FFP, MB-FFP and A-FFP. Finally, 
the authors concluded that FFP is safe and plasma 
inactivation with SD, MB or amotosalen can lead to 
fewer adverse events than those associated with Q-FFP. 
FFP was confirmed to be extremely safe in general, 
especially considering "severe" adverse events. All types 
of FFP were associated with extremely low incidences of 
adverse events. Moreover, the newly introduced A-FFP 
appears to be safe.
In 2010, Nubret et al.226 described two anaphylactic 
shock reactions occurring during infusion of MB-TTP in 
patients undergoing cardiac surgery. Clinical symptoms 
Table XL - The frequency of severe allergic reactions with imputability levels from 2 to 4 and 3 and 4 in France (2005-2009).
Imputability 2-4 Imputability 3 and 4
MB-FFP Q-FFP SD-FFP MB-FFP Q-FFP SD-FFP
N. 
of cases
Incidence N. 
of cases
Incidence N. 
of cases
Incidence N. 
of cases
Incidence N. 
of cases
Incidence N. 
of cases
Incidence
34 1/7,751 33 1/19,269 26 1/25,351 14 1/18,824* 15 1/42,279* 16 1/41,195*
*Significant differences between the different types of FFP (p<0.001). FFP: fresh-frozen plasma; MB-FFP: methylene blue-treated FFP; Q-FFP: quarantined 
FFP; SD-FFP: solvent/detergent-treated FFP.
Table XXXVIII - Number of recipient adverse reactions (all grades) in the years 2008, 2009 and 2010; imputability level 2-4. 
2008 2009 2010
FFP SD-FFP MB-FFP A-FFP FFP SD-FFP MB-FFP A-FFP FFP SD-FFP MB-FFP A-FFP
FNHTR 3 2 0 1 0 3 8 4 1 2 0 1
Allergy 57 32 30 2 0 48 114 7 11 26 124 19
Unknown 11 3 2 0 0 1 5 1 0 3 0 1
TRALI 4 1 0 0 0 1 1 0 0 0 6 1
TACO 1 3 0 0 0 2 3 0 1 1 3 0
FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; MB-FFP: methylene blue-treated FFP; A-FFP: amotosalen-treated FFP; FNHTR: febrile 
non-haemolytic transfusion reaction; TRALI: transfusion-associated acute lung injury; TACO: transfusion-associated circulatory overload.
Table XXXIX - Number of recipient adverse reactions, grade 3-4 in the years 2008, 2009 and 2010.
2008** 2009** 2010***
FFPs* SD-FFP MB-FFP A-FFP FFPs* SD-FFP MB-FFP A-FFP FFPs* SD-FFP MB-FFP A-FFP
Allergy 1 5 4 0 0 4 8 0 0 4 10 2
TRALI 2 0 0 0 0 0 1 0 0 0 0 0
TACO 0 0 0 0 0 0 2 0 0 1 0 0
Unknown 0 0 0 0 0 0 1 0 0 0 0 0
*Secured FFP; **Imputability 3-4; ***Imputability 2-3. FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; MB-FFP: methylene blue-
treated FFP; A-FFP: amotosalen-treated FFP; TRALI: transfusion-associated acute lung injury; TACO: transfusion-associated circulatory overload.
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exhibited by these two patients were consistent with 
grade III anaphylaxis to MB-FFP and the hypothesis was 
confirmed by histamine and tryptase levels in patient 1 
and by in vivo or in vitro tests with the patent and MB 
in patient 2226. 
Other haemovigilance clinical data 
Primary literature studies
In an observational study, Norda et al. (2006)227, 
reported the potential adverse effects of transfusing 
FFP, drawing on data in the Danish, French, and Quebec 
haemovigilance systems. The potential adverse effects 
were categorised according to the "Optimal use of 
blood: summaries of component characteristics" and the 
frequency of each adverse effect was been recalculated 
per 10,000 transfusions (Table XLIII).
The authors also reported other adverse effects not 
included in the categories described above (Table XLIV). 
The authors concluded that the adverse effects of 
particular relevance for patients are probably TRALI 
and sepsis, due to inadvertent bacterial contamination. 
Politis et al. (2014)223 analysed haemovigilance data 
in order to compare MB-FFP and Q-FFP, which have 
been in use for more than 11 years in Greece, focusing on 
safety and adverse events. The total clinical use of FFP in 
the study period 2001-2011 was 290,951 units. Of these, 
73,778 (25.4%) were MB-FFP units. No deaths related 
to plasma transfusions were reported, nor were there any 
cases of transmission of HBV, HIV, HCV or WNV. Table 
XLV shows the adverse events associated with MB-FFP. 
The rate per 10,000 units of MB-FFP was estimated 
to be 0.41 with a 95% CI of 0.10-1.06, and there were 
no serious adverse reactions (grade 2 or 3) to MB-FFP. 
The allergic reactions in three patients (one each with 
TTP, trauma and septicaemia) were classified as mild.
Overall, the incidence of adverse events was lower 
with MB-FFP (1:24,593) than with Q-FFP (1:3,620). 
Indeed, other adverse events, such as 18 febrile non-
haemolytic transfusion reactions (incidence 1:12,065), 
6 leucoreduced post-storage at the bedside (1:7,601) 
and three leucoreduced pre-storage (1:28,956) were 
reported for Q-FFP.
The authors concluded that the adverse event rate 
was lower with MB-treated plasma and that all adverse 
reactions experienced by the MB plasma recipients 
were mild.
In France, Dewachter et al. (2011)228 reported the 
first immediate IgE-mediated allergic reaction in a 
22-year old man admitted to an intensive care unit for 
severe haematemesis after the transfusion of MB-treated 
plasma. The MB-induced IgE-mediated anaphylaxis was 
confirmed clinically and with subsequent assessments 
of the allergic reaction, including skin tests and basophil 
activation tests. The authors concluded that allergic 
IgE-mediated reactions to MB are rare, whereas allergic 
reactions to patent blue V and isosulfan blue occur 
frequently. The frequency of the MB-associated allergic 
reactions is very low considering the widespread use of this 
blood product. Extensive investigation of all immediate 
reactions to MB-FFP transfusion is recommended. 
Table XLI - The frequency of severe allergic reactions with imputability from 2 to 4 and 3 and 4 in France (2005-2010).
MB-FFP Q-FFP SD-FFP A-FFP
N. of cases Incidence N. of cases Incidence N. of cases Incidence N. of cases Incidence
Frequency of severe allergic reactions with imputability level from 2 to 4 (2005-2010)
N/A N/A 33 1/19,274 N/A N/A 3 1/3,137
Frequency of severe allergic reactions with imputability level 3 and 4 (2005-2010)
24 1/21,250* 15 1/42,402* 20 1/37,114* 2 1/45,205
*There were no significant differences among Q-FFP, SD-FFP, and MB-FFP (Fisher's exact test, p=0.066; Pearson χ2 test, p=0.057). A-FFP was not included 
in the analysis because of the relatively low number of units for this period. FFP: fresh-frozen plasma; MB-FFP: methylene blue-treated plasma; Q-FFP: 
quarantined fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; A-FFP: amotosalen-treated FFP.
Table XLII - Frequency of severe allergic reactions with imputability from 2 to 4 and 3 and 4 in France (2008-2010).
MB/FFP Q/FFP SD-FFP A-FFP
N. of cases Incidence N. of cases Incidence N. of cases Incidence N. of cases Incidence
Frequency of severe allergic reactions with imputability level from 2 to 4 (2008-2010)
N/A N/A 5 1/23,778 N/A N/A 3 1/30,137
Frequency of severe allergic reactions with imputability level 3 and 4 (2008-2010)
24 1/21,250° 1 1/18,890 13 1/27,942° 2 1/45,205
 °There were no significant differences between SD-FFP and MB-FFP (Fisher's exact test, p=0.506; Pearson χ2 test, p=0.425). Q-FFP and A-FFP were not 
included in the analysis because of the relatively low numbers of units for this period. FFP: fresh-frozen plasma; MB-FFP: methylene blue-treated plasma; 
Q-FFP: quarantined fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; A-FFP: amotosalen-treated FFP.
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Secondary literature 
Flesland et al. (2007)207 compared Norwegian 
haemovigilance data on complications with the 
corresponding data from Sweden, United Kingdom and 
Denmark. The outcomes considered were immunological 
transfusion reactions, in particular TRALI. 
In 2004, there were 241 reports of transfusion 
complications in Norway, four of which were associated 
with SD plasma. The number of immunological 
transfusion reactions associated with the transfusion 
of SD plasma was two (5:100,000 transfusions), of 
which only one was classified as a serious complication 
(2.5:100,000 transfusions). Table XLVI shows the 
comparison of serious immunological transfusion 
reactions per implicated product per 100,000 plasma 
transfusions in Sweden, United Kingdom, Denmark and 
Norway. The data on Finnish immunological reactions 
were not published in the haemovigilance report.
The authors determined that the number of cases of 
TRALI in other countries that use SD-FFP method is 
greater than in Norway, where no cases of TRALI were 
associated with plasma-inactivated with SD.
Eder et al .  (2010)229 described suspected 
TRALI cases reported to the American Red Cross 
Hemovigilance Program in 2006, 2007 and 2008. 
The American Red Cross found that a female white 
blood cell antibody-positive donor was implicated 
in 75% (18 of 24) of the cases of probable TRALI 
deaths associated with plasma component transfusion 
between 2003 and 2005. This article reported the 
number of TRALI cases after the American Red Cross 
began distributing plasma from male donors in 2006. 
In total, the American Red Cross distributed 
1,638,055 plasma components in 2006, 1,702,419 in 
2007, and 1,729,128 in 2008. Table XLVII shows non-
fatal TRALI cases associated with plasma transfusions.
With regards to donor investigations in non-
fatal cases, the recipients' HLA antigen type was 
determined in nine out of 127 (7%) cases involving 
plasma transfusion were linked to a female, white 
blood cell antibody-positive donor in six cases in 
2008 compared to 29 cases in 2006 (OR: 0,20; 95% 
CI: 0.07-0.45). These six cases of non-fatal TRALI 
in 2008 involved female donors with blood groups 
O (two cases), A (one case), B (one case), and AB 
(two cases). The number of probable TRALI cases 
among reported fatalities that involved only plasma 
transfusion decreased significantly in 2008 (0 cases) 
compared to 2006 (6 cases; p=0.01) and 2007 (5 cases; 
p=0.03). The recipient's HLA type was available in nine 
Table XLIII - Frequency of adverse effects per 10,000 transfusions.
Non-haemolytic transfusion reaction 0.22 (Danish data); 0.35 (French data); 2.35 (Quebec data)
TACO 0.1 (Danish data); 2.06 (French data); 0.02 (Quebec data)
Sepsis due to inadvertent bacterial contamination 0.02 (French data); 0 (Quebec data)
TRALI 0.18 (Danish data); 0 (Quebec data)
Post-transfusion purpura 0.04 (French data)
TTI (viral) 0
Severe anaphylaxis with IgA deficiency and anti-IgA 0
Transfusion-associated GvHD 0
Citrate toxicity NR
Transmission of other pathogens not tested NR
Alloimmunisation against HLA-antigens NR
TACO: transfusion-associated circulatory overload; TRALI: transfusion-associated acute lung injury; TTI: transfusion-
transmitted infection; GvHD: Graft-versus-Host disease; NR: not reported.
Table XLIV - Frequency of other adverse effects per 10,000 transfusions.
Minor allergic reaction 16.2 (Quebec data)
Febrile non-haemolytic transfusion reaction 5.3 (Quebec data)
Allergic reaction (not specified) 2.6 (French data)
Immunological incompatibility 0.06 (French data); 2.9 (Quebec data)
Incorrect blood component issue 0.15 (Danish data)
Acute haemolytic transfusion reaction 0 (Danish data)
Unknown 1.3 (French data); 0.88 (Quebec data)
Other reaction 0.31 (French data); 0.9 (Quebec data)
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out of 38 (24%) cases. The authors concluded that the 
incidence of TRALI associated with plasma decreased 
by approximately 80% in 2008 with respect to 2006 (OR: 
0.21; 95% CI: 0.08-0.45). The aim of the American Red 
Cross was to continue the assessment of the effectiveness 
of the male-predominant plasma donor strategy. 
Emerging pathogens
There are always risks of HIV, HCV and HBV infections 
in relation to blood and plasma transfusions. However, these 
risks appear to be low in all developed countries. 
Special attention has been paid to HHV-8, HGV and 
vCJD. Only tests for HIV, HCV and HBV are currently 
carried out on a stable basis, while other tests for the 
identification of pathogens such as HAV, HEV and WNV 
are facultative.
There are two case reports of HEV transmission in 
patients transfused with MB plasma and A plasma.
In 2014, Hauser et al. 230 reported two cases of HEV 
transmission by two units of Intercept®-treated plasma 
originating from the same donor. They concluded that 
HEV transmission through A-FFP establishes resistance 
of HEV and suggested HEV screening for all blood 
donations in France.
In reference to vCJD, in 2004 the UK Department 
of Health implemented a risk-reduction measure, aimed 
at decreasing the risk of transmission of the disease-
causing prion. In particular, it "recommended the use of 
fresh-frozen plasma (FFP) sourced from countries with 
a low bovine spongioform encephalopathy prevalence 
for children born after 1 January 1996. In 2005 this 
was extended to all children under 16 years." Overall, 
"the English National Blood Service (NBS) imports FFP 
from volunteer US donors and, because of the higher 
prevalence of viral markers, this is subjected to a viral 
inactivation process (methylene blue and white light). 
In line with current UK guidelines, the specification for 
imported FFP restricts donors to those who have had 
virology testing within the previous 24 months, thus 
excluding new or lapsed donors"13. 
A summary of primary studies and grey literature 
studies about haemovigilance is presented in Table 
XLVIII.
A comparison of European haemovigilance clinical data
Table XLIX shows clinical haemovigilance data 
from various European countries. Only the last report 
published in the different countries has been considered.
Table XLV - Number of adverse events associated with methylene blue-treated fresh-frozen plasma.
MB-FFP (73,778 units)
N Incidence Incidence rate Imputability levels
Grade 1 Grade 2-3 1 2 3
Allergic/anaphylactic 3 1:24,593 3 0 0 1 2
FNHTR 0 0:73,778 0 0 0 0 0
TRALI 0 0:73,778 0 0 0 0 0
TACO 0 0:73,778 0 0 0 0 0
TAD 0 0:73,778 0 0 0 0 0
Bacterial 0 0:73,778 0 0 0 0 0
Other 0 0:73,778 0 0 0 0 0
Total 0 1:24,593 0 0 0 1 3
MB-FFP: methylene blue-treated fresh-frozen plasma; FNHTR: febrile non-haemolytic transfusion reaction; TRALI: transfusion-associated acute lung 
injury; TACO: transfusion-associated circulatory overload; TAD: transfusion-associated dyspnoea.
Table XLVI - Comparison of serious immunological transfusion reactions (TR) and episodes of TRALI in Sweden, UK, 
Denmark, Norway and Finland.
Country Period N. of immunological 
TR
N. of serious immunological TR 
associated with plasma transfusion per 
100,000 plasma transfusions
N. of reports of 
TRALI
Ratio per 
100,000 plasma 
transfusions
Sweden 2004 36 ND (FFP) 5 (FFP) 4.1
United Kingdom 2004 100 3.7 (FFP) 6 (FFP) 1.6
Denmark 1999-2003 45 5.6 (FFP) 4 (FFP) 1.5
Norway 2004-2005 241 2.5 (SD-FFP) 9 (SD-FFP) 0
Finland 2004-2005 ND ND 7 (FFP) 8.8
FFP: fresh-frozen plasma; SD-FFP: solvent/detergent-treated FFP; TRALI: transfusion-associated acute lung injury; ND: no data.
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The haemovigilance systems are very different from 
each other, so comparisons of the results obtained from 
different programmes need to be considered cautiously. 
Nonetheless, it can be concluded from the existing data 
that acute allergic and anaphylactic transfusion reactions 
are the most frequently occurring adverse events and 
that techniques to prevent TTI have a good safety and 
efficacy profile.
Fresh-frozen plasma vs solvent/detergent-treated plasma
In the United Kingdom, acute allergic and 
anaphylactic transfusion reactions were more frequent 
with FFP than with SD-FFP (respectively, 2.920 vs 0.079 
per 106 transfusions), but the reverse was seen in France 
(0 vs 7.412 per 106 transfusions).
TACO, transfusion-associated dyspnoea and TRALI 
were more frequent with FFP, while only one case of 
TACO was connected to SD-FFP use in Ireland and only 
one case of TRALI in France.
Fresh-frozen plasma vs methylene blue-treated plasma
In the United Kingdom, acute allergic and 
anaphylactic transfusion reactions were more frequently 
associated with FFP than with SD-FFP (respectively, 
2.920 vs 0.014 per 106 transfusions), but this was not 
the case in France (0 vs 33.384 per 106 transfusions).
Solvent/detergent-treated plasma vs methylene blue-
treated plasma
More acute allergic and anaphylactic transfusion 
reactions have been recorded in association with 
MB-FFP in France. In the United Kingdom, only one 
acute allergic and anaphylactic transfusion reaction 
was associated with SD-FFP and one with MB-FFP; 
however, expressing these numbers in relation to a 
number of plasma transfusions, this type of reaction was 
shown to be more frequent with SD-FFP than with MB-
FFP (respectively 0.079 vs 0.0135 per 106 transfusions);
In the United Kingdom, no TACO, transfusion-
associated dyspnoea or TRALI was observed in association 
with the use of SD-FFP or MB-FFP, while in France one 
case was associated with SD-FFP and two with MB-FFP;
In France febrile non-haemolytic transfusion 
reactions were more common with MB-FFP than 
with SD-FFP (respectively, 0.998 vs 3.277 per 106 
transfusions).
Amotosalen-treated plasma vs plasma prepared with all 
the other methods
It is not possible to compare data on A-FFP because 
this product is only available in France. However, 
considering only the French data, the method appears 
to have a safety profile comparable to that of other 
techniques. 
Processing outcome
During the clinical transfusion process (the 
phases of which are pre-transfusion, testing, 
screening and management of plasma), adverse 
reactions and adverse events can occur and it is 
difficult predict them. According to the Directive 
2002/98/EC of the European Parliament and of 
the Council of 27 January 2003, a serious adverse 
event is "any untoward occurrence associated with 
the collection, testing, processing, storage and 
distribution of blood or blood components, that 
might lead to death or life-threatening, disabling 
or incapacitating conditions for patients, or which 
results in, or prolongs, hospitalization or morbidity" 
and "Blood Establishments/the person responsible for 
the management of a hospital blood bank ('hospital 
transfusion laboratory' is used in this report for 
consistency with other chapters) shall notify… any 
serious adverse events related to the collection, 
testing, processing, storage and distribution of blood 
or blood components by the Blood Establishment 
which may have an influence on their quality and 
safety".
Table L reports the number of serious adverse 
reactions recorded in the SHOT report in 2013.
According to the SHOT "near miss events are defined 
as any error, which if undetected, could result in the 
determination of a wrong blood group or transfusion 
of an incorrect component, but was recognized before 
the transfusion took place"204.
No near misses were recorded in the 2013 SHOT 
reports. 
Moreover, according to the definition proposed by 
the International Haemovigilance Network a "near 
miss is an error or deviation from standard procedures 
or policies that is discovered before the start of the 
transfusion and that could have led to a wrongful 
transfusion or to a reaction in a recipient"231.
Table XLVII - Non-fatal TRALI cases associated with plasma transfusions in the USA.
Component 2006 2007 2008 2008 vs 2006 OR (95% CI)
Cases Rate per 
1,000,000
Cases Rate per 
1,000,000
Cases Rate per 
1,000,000
Plasma 26 19.5 12 7.0 7 4.0 0.26 (0.10-0.57)
TRALI: transfusion-associated acute lung injury; OR: odds ratio; 95% CI: 95% confidence interval.
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A potential transfusion error could be the unjustified 
use of plasma when there are therapeutic alternatives 
which are equally or more effective, and/or with lower 
costs/risks. Table LI describes the recommendations of 
"The Transfusion of Plasma in Adults" guidelines of the 
San Giovanni Hospital of Turin201. 
Interactions of the reagents used for plasma pathogen-
inactivation with biological components 
The quality of plasma depends on a number of 
factors such as its optimal freezing (core temperature 
of –30 °C within 60 minutes) and storage at <20 °C232. 
In addition, the processing features of the plasma 
inactivation method play a critical role in producing 
toxic effects and permanent binding with biological 
components. The residual toxicity and permanent 
binding between residual solvent or reagents used to 
inactivate plasma and lipids or proteins in the plasma 
are reported in Table LII.
The SD-method of inactivating pathogens in plasma 
generally has a low toxicity for biological components 
and low permanent binding. MB-FFP should be filtered 
in order to remove the MB.
Discussion
Complete safety of transfused blood components will 
never be reached because of an intrinsic risk due to the 
transmission of emerging pathogens. However, plasma 
pathogen-inactivation methods may be considered safe 
especially as regards the transmission of viruses and 
bacteria. Indeed, no transmission of HIV, HCV or HBV 
has been observed in the European countries analysed in 
the last years. As for the other clinical outcomes, there 
was a recent increase in the number of allergic reactions, 
while the actions taken by many countries to minimise 
the risk of TRALI have been appropriate. Overall, the 
number of cases of TRALI has dropped in recent years 
and is now tending to zero. 
The results emerging from the literature search do 
not enable a direct comparison between the different 
pathogen-inactivation methods. Few studies compare 
the various techniques with each other or with the 
conventional method. Furthermore, haemovigilance 
data are conflicting across European countries, in 
part because alerts are reported on a voluntary basis 
in some countries. However, according to the data 
reported above, the SD-FFP technique seems to have 
the best safety profile, even if the evidence supporting 
this statement is limited and the conclusion should be 
considered cautiously. The current review highlights 
the need to perform more comparative studies in order 
to assess the safety profiles of the various methods 
directly.
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Economic domain
Introduction
The Italian Society of Transfusion Medicine 
and Immunohaematology (SIMTI) recommends 
the transfusion of plasma to correct deficiencies of 
clotting factors, for which a specific concentrate is not 
available, in patients with active bleeding14. The most 
commonly utilised product is FFP, a blood component 
prepared from whole blood or collected by apheresis, 
frozen within time limits and at a temperature such 
as to preserve the labile clotting factors adequately14. 
The risk of transmitting viruses such as HIV, HBV, 
HCV, HAV and PVB19 through blood transfusions, 
along with causing TRALI and other serious adverse 
reactions, has driven the introduction of an increasing 
number of measures aimed at improving the safety 
of therapeutic transfusions62. So, currently there are 
many blood products available treated with the aim of 
reducing the risk of transmitting the abovementioned 
viruses and preventing TRALI and other serious adverse 
reactions. In detail these are plasma that has undergone 
viral inactivation with SD, MB, amotosalen and light or 
riboflavin and light. The widespread implementation of 
these approaches may have significant public health and 
economic implications. In publicly-funded health care 
systems, such as the Italian one, finite resources imply 
that not all possible technologies can be provided in any 
situation for all those who may need or want them. There 
is a conflict between what is technologically possible 
and what is economically feasible. 
Economic evaluations of health technologies 
should provide indications on how resources should be 
allocated or utilised to maximise health outcomes under 
economic constraints233. Thus, it is no longer sufficient 
to consider only aspects of safety, efficacy, clinical 
effectiveness and ethics in HTA reports; information 
on costs, cost-effectiveness, or opportunity costs from 
economic evaluations, is also needed233. Economic 
evaluation has been defined as a comparative analysis 
of alternative courses of action in terms of their costs 
and consequences234. The primary aim of this section 
is to provide information about the relative costs 
and cost-effectiveness of technologies for pathogen 
reduction in FFP. The economic domain is intended 
to summarise the economic evidence available when 
allocating resources between emerging, new and 
existing health technologies in order to inform value-
for-money judgments233,234.
Methods
Literature search
A literature search was conducted to obtain economic 
data on technical approaches to pathogen inactivation of 
FFP for transfusion use. The review was performed using 
the following databases: PubMed, the Cochrane Library 
and CRD database. Google and Google Scholar search 
engines were queried to search for additional material 
and information. References and abstracts of key papers 
and conference proceedings were also reviewed.
The following keywords were used in the search: 
plasma, fresh-frozen plasma, blood component 
transfusion, blood component, therapeutic plasma, 
riboflavin, UV, UVA light, UVA, Mirasol, amotosalen, 
methylene blue, Theraflex® MB plasma, solvent/
detergent, solvent/detergent-treated plasma, Octaplas®.
Since the objective was the evaluation of the 
economic aspects, the basic search was refined using 
the following key words: cost, cost-effectiveness, 
cost-utility, cost-benefit, economic evaluation, ICER 
(incremental cost-effectiveness ratio).
The search strategy was: 
ECONOMIC DOMAIN (((((((((Cost*) OR "Cost 
effectiveness") OR "Cost utility") OR "Cost benefit") 
OR "Economic evaluation") OR ICER) OR "Cost 
benefit analysis"[MeSH Terms]) OR ("Cost[MeSH 
Terms] AND Cost analysis"[MeSH Terms]))) AND 
((((((((Plasma[MeSH Terms]) OR "Fresh frozen plasma") 
Table L -  Number of serious adverse events recorded in 
the 2013 SHOT report.
IBCT 
   ABO incompatible
   ABO non-identical
   Wrong component type
   ABO identical
19 (FFP) of which:
  3 (FFP)
  1 (FFP)
  2 (FFP)
  1 (FFP)
RBRP 9 (FFP)
HSE 9 (FFP)
ADU 11 (FFP)
Anti-D immunoglobulin - prescription, 
administration and sensitisation 0
IBCT: incorrect blood component transfused; FFP: fresh-frozen plasma; 
RBRP: right blood - right patient; HSE: handling and storage errors; ADU: 
avoidable, delayed or undertransfusion.
Table LI -  Recommendations of "The Transfusion of 
Plasma in Adults" guidelines of "San Giovanni 
Hospital" (Turin, Italy).
Level of 
recommendation
Recommendation
E* Plasma should not be used to correct deficiencies 
of coagulation factors when there are specific 
completely inactivated or recombinant factors.
E* Plasma should not be used to correct hypoproteinaemia.
E* Plasma should not be used as a means to expand the 
intravascular volume.
E* Plasma should not be used in hypogammaglobulinaemia.
E* Plasma should not be used as a replacement fluid in 
plasma-exchange procedures.
E*: strong recommendation.
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OR "Blood component transfusion"[MeSH Term]) OR 
"Blood component") OR Therapeutic plasma))) AND 
((((((("Solvent/detergent") OR "Solvent/detergent-
treated plasma") OR Octaplas)) OR ((("Methylene 
blue"[MeSH Terms]) OR "Methylene blue") OR Theraflex 
MB plasma)) OR ((((((Amotosalen[Supplementary 
Concept]) OR Amotosalen)) AND ((((((UV) OR 
"Ultraviolet light") OR "UV light") OR "Ultraviolet 
A")) OR Mirasol))) OR intercept)) OR ((((((((UV) OR 
"Ultraviolet light") OR "UV light") OR "Ultraviolet A")) 
OR Mirasol)) AND Riboflavin))).
No publication date, language or search field 
restrictions were applied.
Selection criteria
The selection process was based on a set of inclusion 
criteria, reported in Table LIII.
Results
Results of the literature search
The literature search revealed 343 citations that 
were potentially relevant for the economic domain. All 
the records were analysed based on the study title and 
316 were excluded because not relevant to the research 
question. In a second step, studies included were 
screened by reading their abstracts and the full texts, if 
necessary. Overall, 19 articles were excluded because 
the alternatives compared or the study design were not 
consistent with the aim of this analysis. 
Eight studies eventually met the inclusion criteria. 
Of these, seven were economic evaluations and one was 
a HTA report. 
The flowchart in Figure 5 depicts the various stages 
of the literature selection process.
General characteristics of the selected studies 
Literature on cost-effectiveness was limited and 
only eight studies eventually met the inclusion criteria: 
one HTA report from the CADTH (2011)63 and seven 
economic analyses. 
No Italian studies were identified. Two out of the 
seven economic evaluations were conducted in the 
United Kingdom235,236, three in the United States237-239, 
one in Spain240 and one in Canada241. Some of them 
(n=2) were cost-effectiveness analyses reporting results 
in terms of cost per life-year saved (LYS) and cost per 
death avoided. Three economic studies and the CADTH 
report63 described both cost-effectiveness and cost-
utility analyses, so the authors also reported results in 
terms of cost per quality-adjusted life year (QALY) 
gained236,238,241. Finally, two economic studies reported 
only cost-utility analyses. The CADTH63 and Huisman 
et al.241 also conducted a budget impact analysis.
All the selected economic analyses adopted the 
healthcare payer perspective, including only direct 
healthcare costs. 
Comparators, cost drivers and outcome measures 
The papers selected for analysis in the present review 
explored the cost-effectiveness of only one PRT to treat 
plasma, that is SD. 
In more detail, four studies and the CADTH report63 
investigated the cost-effectiveness of SD-FFP vs FFP and 
three economic analyses considered the SD technique 
(without specifying the brand) vs FFP.
Studies included in the present analysis evaluated 
resource consumption associated with the intervention 
and comparators by considering different cost drivers, 
so results across the included studies are neither 
consistent nor comparable. The only cost driver 
considered in all the studies reviewed is the inactivation 
technique and FFP. Most of the studies63,236,238,241 
reported costs of treatment of infectious complications 
(HIV, HBV and HCV) and their sequelae (HBV and 
HCV-related compensated cirrhosis, HBV and HCV 
hepatocellular carcinoma, post liver transplant, etc.). 
Aubuchon et al.239 and Riedler et al.235 estimated 
costs related to the management of acute hepatitis, 
HIV infection and AIDS, but they did not take into 
account the sequelae of HCV or HBV infections. 
Instead, Pereira et al.240 considered costs associated 
with the treatment of acute symptomatic hepatitis 
and chronic hepatitis, follow-up of chronic hepatitis, 
decompensated cirrhosis and AIDS. 
Table LII - Interactions of the reagents used in different plasma inactivation methods with biological components.
SD-FFP MB-FFP A-FFP R-FFP
Compound toxicity Low Low High None
All active components removed Yes Yes (special filters) Yes (by adsorbing device) Not required
Residual level of active 
compounds
Undetectable or trace 
amount, 
far below toxicity level
Very low. Mutagenic 
effects improbable, 
but not excluded
Very low. Mutagenic 
effects improbable, 
but not excluded
Low levels of riboflavin 
are usually present 
in blood. Active component 
is removed
Permanent binding to lipids 
or proteins in plasma
No binding to proteins or 
residual lipids
Protein intercalated with 
phenothiazine-like dyes
Majority of amotosalen 
bound to lipids and 2% 
to proteins
Does not appear to bind 
Source: 232.
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With respect to non-infectious complications, which 
include TRALI, allergic reactions and TACO63, van Eerd 
et al.236 took into account all of these, while Huisman et 
al.238,241 considered only TRALI and allergic reactions. 
Riedler et al.235 and the CADTH63 estimated only costs 
associated with TRALI, excluding other non-infectious 
complications. In the analysis by Huisman et al.241, 
allergic reactions were the main cost driver of the model, 
while in the study by Riedler et al.235, the most important 
driver of cost-effectiveness was TRALI, because of its 
relatively high incidence and associated mortality rate.
Huisman et al.238,241 and van Eerd et al.236 included 
infectious and non-infectious transfusion-related 
complications. In particular, they considered: TRALI, 
severe allergic reactions, HAV, HBV, HCV, HIV, prion 
disease, PVB19, bacterial infections and two emerging 
infections (one acute [WNV-like] and the other chronic 
[HIV-like]). 
Figure 5 - Study selection process for economic domain.
Table LIII - Selection criteria for literature on economic evaluations of pathogen-reduction technologies applied to plasma 
for transfusion.
Category Inclusion criteria
Study design Full or partial economic evaluations
Study population Plasma transfusion recipients of all ages
Interventions and comparators FFP, riboflavin-treated plasma, UV light-treated plasma, Mirasol®, amotosalen, methylene blue, Theraflex®-MB 
plasma, solvent/detergent-treated plasma, Octaplas® solvent/detergent-treated plasma
Outcome measures Infectious and non-infectious complications, QALY, LYS, health utility 
Cost measures Direct costs (cost associated with treating infectious and non-infectious complications, intervention cost), social costs
Incremental cost-effectiveness ratio Cost per QALY gained, Cost per LYS, ICER
FFP: fresh-frozen plasma; UV: ultraviolet; QALY: quality-adjusted life years; LYS: life years saved; ICER: incremental cost-effectiveness ratio.
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One economic study237 did not evaluate the costs 
of complications, but it compared screening costs, 
such as HIV, HCV and HBV antibody testing, with SD 
treatment costs.
QALY, deaths avoided and LYS were utilised by 
authors as outcome measures.
Cost-effectiveness of solvent/detergent-treated plasma 
vs untreated plasma: evidence from the literature
Most of the selected studies (n=8) estimated the 
cost-effectiveness of SD-FFP vs untreated plasma. 
Three of these papers237,239,240 did not mention the 
particular brand of the SD, while the remaining five 
studies evaluated the cost-effectiveness of pooled SD-
FFP vs untreated FFP.
AuBuchon et al. 1994239 used a previously published 
Markov model to perform a cost-utility analysis for a 
hypothetical cohort of 61 patients receiving plasma 
transfusions. A unit of SD-FFP produced a net benefit 
of 35 minutes expressed in terms of quality-adjusted 
life expectancy at a cost of about $ 19. The ICER of 
SD-FFP was $ 289,300 per QALY, with an incremental 
cost of $ 142.5 million per 147 incremental QALY. So, 
SD-FFP was not recommended by the authors because 
it was very expensive and produced small benefits in 
terms of reducing the risk of viral infections.
In the study by Pereira (1999)240, base case results 
showed that SD-FFP infusion prolonged the quality-
adjusted survival by 1 hour and 11 minutes per patient, 
producing an incremental cost of $ 2,156,398 per 
QALY gained, with an average net incremental cost 
of $ 39.66 per unit of virus-inactivated plasma. Cost-
effectiveness was very sensitive to the cost of the 
virus-inactivation procedure, the patients' age and the 
rate of short-term mortality due to underlying diseases. 
The authors concluded that virus-inactivated plasma 
produced benefits but at a very high cost, because of the 
advanced age of plasma recipients, the high cost of virus-
inactivation procedures, the very low risk of infection by 
transfusion-transmitted viruses, and the poor prognosis 
of the patients' underlying diseases. 
In the study by Blumberg et al. 2000237 the cost-
effectiveness of three approaches to improve blood 
transfusion safety was evaluated. These approaches 
were: apheresis platelets vs random platelets, SD-treated 
plasma vs untreated plasma, and leucocyte-reduced 
vs unmodified transfusions in cardiac surgery. In the 
analysis of SD-FFP, the estimated risk of a fatal HIV-1, 
HBV or HCV infection was approximately 4.6% per 
year, implying the occurrence of an event every 22 
years, on average. The authors assumed that switching 
completely to SD-FFP, transmission of HIV-1, HBV or 
HCV by this route should not occur. The cost increment 
of using SD-FFP instead of FFP was $ 75.00 per unit, 
which is equivalent to $ 750,000 annually, considering 
the case mix of the specific centre. The cost per death 
prevented was approximately $17,000,000 dollars. SD 
plasma was a comparatively expensive approach to 
reduce mortality from transfusion complications.
The cost effectiveness of Octaplas® was evaluated in 
one HTA report63 and in four economic analyses235,236,238,241. 
In the analysis by the CADTH63 a Markov decision 
model was constructed to represent six possible 
transfusion-related complications (infections by 
HAV, HIV, HBV, HCV, or PVB19, and TRALI) in a 
hypothetical cohort of patients (with a 1-year mortality 
rate of 20%) receiving an average of four units of SD-
FFP vs FFP. SD-FFP resulted more costly and more 
effective than FFP. Treating a 50-year old patient, the 
incremental cost per QALY gained was $ 934,000 and 
the incremental cost per life-year gained was $ 1.3 
million. The probability of cost-effectiveness for SD-
FFP was 0% for any cost-effectiveness threshold less 
than $ 100,000 and only 6.3% if a $ 500,000/QALY 
threshold was adopted. In the budget impact analysis, 
potential savings resulting from the replacement of FFP, 
FP, apheresis plasma and cryosupernatant plasma with 
Octaplas® were calculated. The results showed that if 
100% of the demand of all forms of plasma was switched 
to Octaplas®, the additional cost would be about 16.5 
million Canadian dollars (C$) per year. If 50% of the 
total demand of all forms of plasma was switched to 
Octaplas®, the additional cost would be about C$ 8,2 
million per year. If Octaplas® replaced all forms of 
FFP, plasma from ongoing donations would go for 
fractionation, potentially enabling the health care system 
to save about C$ 3 million per year (in absolute terms) by 
increasing the volume of intravenous immunoglobulins 
and albumin. Even if the health care system would save 
C$ 3 million per year in absolute terms, in relative terms 
the yearly net loss would be C$ 13.5 million, because 
the incremental cost would be about C$ 16,5 million per 
year. The authors concluded that Octaplas® was not cost-
effective because it is associated with only a minimal 
reduction in disease burden at a higher cost than FFP. 
The high incremental cost per QALY resulted from low 
transfusion-related risks for FP or FFP due to advanced 
safety measures of blood transfusion, such as testing, 
donor screening, and deferral. Thus, by switching to 
Octaplas®, the health care system would incur a net loss.
In their study, Riedler et al.235 used a decision-tree 
model simulating a hypothetical cohort of patients 
aged up to 70 years. In their model a proportion of 
patients undergoing transfusion would experience 
adverse events, such as TRALI or HIV infection, and 
would therefore incur additional costs and mortality 
either immediately or over a period of several years. 
A sensitivity analysis was undertaken to evaluate the 
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robustness of the results. The discounted cost/LYS 
of SD-FFP in the UK increased with age. Indeed, in 
neonates it amounted to £ 22,728 while in the population 
≥70 years old it was £ 98,465. These results considered 
post-transfusion mortality. The authors also considered 
the scenario without post-transfusion mortality. In this 
case ICER values were lower than those of the base 
case. Indeed, in neonates the discounted cost/LYS 
amounted to £ 12,335 and in people ≥70 years old the 
ratio was £ 61,692. In the sensitivity analysis the cost/LYS 
was very sensitive to variations in incidence of TRALI, 
while it was less sensitive to variations in the cost of 
treating complications. The study demonstrated that 
SD-FFP was most cost-effective in children, as a result 
of their long life expectancy. The cost-effectiveness 
ratios calculated in this study were lower than the 
ones previously reported238,239, which ignored non-
infectious events such as TRALI. This analytical model 
showed that when non-infectious transfusion-related 
complications were taken into account, SD-FFP had a 
cost/LYS of £ 22,700-98,500 in the UK (depending on 
the age of the recipient). If a value of £ 50,000/LYS is 
taken as an "acceptable" cost-effectiveness threshold, the 
model suggests that SD-FFP is a cost-effective treatment 
for all patients up to the age of 48, and for older patients 
with a good clinical prognosis.
The model by van Eerd et al. 2010236 explored the 
cost-effectiveness of Octaplas® in the base case and in 
two alternative scenarios: (i) reduced risk of TRALI 
from FFP transfusions through the use of male plasma 
only; (ii) risk of TRALI from FFP based on SHOT242. 
In the base case analysis the incremental costs per LYS 
and QALY were £ 949 ($ 1,504) and £ 1,030 ($ 1,632), 
respectively. The total average cost per patient transfused 
with Octaplas®-inactivated plasma was £ 280.02 
($ 443.81), which is £ 27.97 ($ 44.33) more than the 
total cost of FFP transfusion. In the first scenario costs 
per LYS and QALY were higher than in the base case. 
The costs per life year and per QALY gained were £ 
4,836 ($ 7,665) and £ 5,246 ($ 8,315), respectively. This 
means that in this scenario, too, the use of Octaplas® was 
cost-effective adopting a threshold of £ 30,000 ($ 47,548) 
per QALY. A second scenario analysis, performed using 
SHOT data more conservatively, demonstrated that the 
total costs associated with FFP were reduced (compared 
to the base case) when the TRALI incidence was lowered. 
In this scenario, Octaplas® was more effective and more 
costly. The costs per life year and QALY gained were 
£ 968,909 ($ 1,535,654) and £ 868,172 ($ 1,375,993), 
respectively. Since TRALI is underreported in SHOT242, 
these results need to be interpreted with caution. The 
study suggested that Octaplas® represents good value for 
money vs FFP, which is considered the main comparator 
for critically ill patients who need a plasma transfusion.
Huisman et al. carried out two different cost-
effectiveness analyses of Octaplas® in 2014: one in the 
United States238 and one in Canada241. 
The former238 was conducted assuming a hypothetical 
cohort of 50-year old patients receiving plasma 
transfusions in the United States. Acute and long-term 
complications of plasma transfusions were modelled 
in a decision tree followed by a Markov model. The 
analysis involved a base case and two more scenarios: 
one excluding the risk of unknown emerging viruses and 
one using a historic (lower) price of FFP. 
In the base case analysis, the costs arising from 
transfusion-related complications were lower for 
Octaplas® than for FFP. Despite the higher product cost 
of Octaplas®, its overall cost for treatment was lower 
($ 525.86) than that of FFP ($ 549.73). Over a lifetime 
horizon, patients receiving Octaplas® accumulated 
slightly more life years (0.00613) and QALY (0.023) at 
lower cost than those treated with FFP. When the risk 
of unknown emerging viruses was excluded from the 
analysis, the incremental cost per QALY was $ 16,159 
and that of LYS was $ 289,633. In such a scenario, the 
incremental benefit of using Octaplas® rather than FFP 
was reduced as the risk of this complication was zero for 
both products. Since the costs for treatment of unknown 
emerging viruses were an important driver of the model, 
excluding these costs had a large impact on the total costs 
of FFP in the alternative scenario in which unknown 
emerging viruses were excluded. 
The second scenario analysis using a historic (lower) 
price of FFP (from 2008) showed that Octaplas® would 
have been cost-effective in comparison to FFP even if 
the latter had not undergone a price increase over the 
last 5 years. The authors concluded that Octaplas® can 
be considered the dominant treatment option over FFP 
because it is expected to produce cost savings while 
improving QALY.
Huisman et al. 2014241 carried out four different 
analyses in order to investigate the cost-effectiveness of 
Octaplas® vs FFP in 50-year old patients. The base case 
analysis showed that Octaplas® was dominant compared 
to FFP because it yielded an increase in QALY at lower 
costs (C$ 612.91 vs C$ 916.05), resulting in 595.74 
complications prevented per 10,000 transfused patients. 
FFP produced an average 16.571 QALY, corresponding 
to 16.588 life years while Octaplas® resulted in 0.005 
incremental life years (95% CI: 0.001-0.012) and 0.021 
incremental QALY (95% CI: 0.011-0.040). Transfusion 
costs were the main cost drivers (C$ 588.00) for 
Octaplas®, while for FFP treatment costs (C$ 384.00) and 
the costs of allergic reactions (C$ 373.86) were the most 
influential cost items. The probability that Octaplas® is 
cost-effective adopting a willingness to pay threshold 
of C$ 30,000 per QALY is greater than 98%. Octaplas® 
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was also dominant in the second analysis, excluding 
the risk of unknown emerging viruses, yielding 0.0007 
additional life years (95% CI: 0.0003-0.0012) and 0.013 
additional QALY (95% CI: 0.007-0.019) compared to 
FFP at a lower cost (C$ 148.09 vs C$ 761.00). Octaplas® 
can still be considered the dominant treatment option 
over FFP when lowering the cost of allergic reactions or 
reducing the risk of allergic reactions by 50%. Finally, in 
the last analysis, reducing the risk of allergic reactions by 
90%, Octaplas® had an ICER of C$ 2,551 per life year 
and C$ 1,085 per QALY gained, far below the generally 
accepted cost-effectiveness threshold. The authors also 
performed a budget impact analysis. In 2017, switching 
to Octaplas® would allow a saving of C$ 6,785,396 for 
the Canadian health care system, relative to the current 
scenario in which only FFP is used. 
Discussion
The results of the studies included in this analysis 
are summarised in Table LIV. 
This review was aimed at identifying economic 
evaluations of different PRT. There was a very limited 
number of studies evaluating the cost-effectiveness of 
techniques for pathogen inactivation. All the studies 
included focused on the cost-effectiveness of SD-treated 
plasma compared to FFP.
Studies with very different and sometimes 
incomparable results were included in the current review. 
One reason is that, given the complexity of transfusion 
risks and practices, economic evaluations are often based 
on assumptions and simplifications and only focus on 
specific aspects. The innovative techniques to prevent 
TTI by pathogen reduction make transfusion safety a 
moving target86.
If we consider the threshold commonly adopted as 
acceptable by the NICE in the UK (£ 20,000-£ 30,000/
QALY), four articles suggest that Octaplas® can be 
considered a cost-effective option, while the same PRT 
did not result cost-effective in the remaining studies. 
Some studies assessed the cost-effectiveness of SD-FFP, 
producing a wide range of costs per QALY estimates 
($ 289,000239, $ 2,156,398240, $ 934,000/QALY63) 
suggesting that the increased safety of SD-FFP does 
not justify its additional cost. Conversely, other studies 
showed that SD-FFP is the dominant alternative, 
producing more QALY or LYS at lower cost compared 
to FFP236,238,241 or that it can be considered cost-effective 
in specific cohorts of patients235.
Results of the selected studies revealed that the 
ICER of these technologies is very sensitive to several 
factors. The economic analyses reviewed considered 
different categories of patients and different cost 
drivers. The cost-effectiveness of Octaplas® vs FFP 
was analysed in the UK, in Canada and in the USA in 
a total of four articles as well as in the Canadian HTA 
report. Octaplas® proved to be the dominant treatment 
option over FFP in Canada241 and in the USA238, while 
it resulted in an ICER of £ 1,030 (corresponding to 
$ 1,640) compared with FFP in the UK236. These 
results conflict with those obtained by the CADTH63. 
The difference in results between the British analysis 
and the American and Canadian ones, may be due to 
differences in the populations of patients described. 
This is because a critically ill population with a reduced 
life expectancy was considered in the British model. 
When life expectancy is short, any long-term effects of 
chronic conditions (implying costs and poorer quality 
of life) diminish. In addition, the risk of experiencing 
allergic reactions per plasma transfusion was higher 
in the analysis by Huisman et al.238, since it concerned 
patients who received plasma transfusions on a regular 
basis. Other important factors that affect the results of 
the studies are transfusion-related complications and 
the costs considered. Studies reporting a very high 
ICER considered only rare infectious complications 
(HIV, HBV and HCV infections) and disregarded 
several relatively common non-infective events, such as 
TRALI237. However, in the CADTH analysis63, in which 
TRALI costs were included, the authors concluded 
that Octaplas® is not cost-effective using a threshold of 
C$ 30,000 per QALY (while the studies by Huisman 
et al.238,241 showed that Octaplas® was the dominant 
treatment compared to FFP). The remarkable variability 
in the studies' results may be due to differences in the 
models' assumptions and sources of data. The CADTH 
model63 assumed that the risk of transmitting HAV or 
PVB19 is the same for Octaplas® and FFP, while in 
the study by Riedler et al.235 the risk of transmitting 
HAV or PVB19 in the Octaplas® arm was set at zero. 
Although there are no large epidemiological studies 
evaluating this risk, the CADTH63 itself reported that 
no HAV or PVB19 infections have been published for 
Octaplas® using the current manufacturing and testing 
procedures. Moreover, the analysis by Riedler et al.235 
also included the risk of severe allergic reactions, which 
were excluded from the CADTH analysis63 because 
of lack of evidence, given the minimal rate of severe 
or minor allergic reactions associated with Octaplas®. 
Several studies showed a significant correlation 
of ICER with patients' age and prognosis235,240. The 
higher age of plasma recipients and their poor short-
term prognosis due to their underlying diseases are 
important factors that negatively influence the cost-
effectiveness of virus-inactivated plasma. In the study 
by Riedler et al.235, the cost-effectiveness ratios for 
SD-FFP were significantly lower for patients with a 
good short-term prognosis who were likely to survive 
for as long as would be normally expected at their 
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age (p<0.01). Finally, Pereira240 showed that the cost-
effectiveness ratio is very sensitive to the cost of the 
virus-inactivation procedure. 
It was not possible to perform a meta-analysis 
to increase the reliability of the results of this 
review because of the relevant differences in the 
intervention strategies considered and in the designs 
of the studies. 
Organisational domain
Introduction
Methods for pathogen inactivation of plasma can 
improve the safety of transfusions, reducing the risk of 
possible transmissible infections, even those for which 
there are currently no screening methods available. 
In the organisational domain, the implications of 
findings retrieved for the other aspects included in 
this assessment (i.e., efficacy and effectiveness, safety, 
economics, ethics, and social and legal/regulatory issues) 
were analysed, in terms of mobilisation and organisation 
of human and material resources and changes in 
processes and health care delivery.
Three different levels of analysis were taken into 
account: (i) within each blood centre, hospital blood 
bank, or industrial facility, (ii) among these structures, 
and (iii) at the level of the health care system (regional 
or national).
Health care systems and transfusion structures are 
all complex and different from each other. For this 
reason, organisational issues might vary depending on 
the context. Possible scenarios retrieved from experience 
in various settings that might be relevant in the Italian 
health care system are discussed in this section.
The aim of this section is to discuss the impact of 
the implementation of any kind of PRT for plasma 
(SD-FFP, MB-FFP, A-FFP, R-FFP) on organisational 
aspects (i.e. workflow, work process, patient flow, 
centralisation or decentralisation, human resources, 
training, collaboration, communication, teamwork, 
management), compared with the use of conventional 
FFP.
Methods
Sources
The organisational domain analysis drew on 
information from scientific literature retrieved from:
- Electronic databases:
 - MEDLINE via PubMed;
 - CRD databases:
 - DARE (Database of Abstracts of Reviews and 
Effects);
 - HTAi database;
 - NHS EED (National Institute for Health 
Research/Economic Evaluation Database);
 - Cochrane Library;
 - GIN (Guideline International Network);
 - NICE (National Institute for Health and Care 
Excellence);
 - TRIP (Transfusion and Transplantation Reactions 
in Patients).
- Other sources:
 - manual searches in references from selected literature;
 - regulatory institutions' or authorities' websites;
 - grey literature;
 - manufacturers' websites;
 - experts' opinion (clinician: Dr. Maria Bianchi, 
Blood Transfusion Department, "A. Gemelli" 
Teaching Hospital, Rome, Italy; industry: 
Kedrion S.p.A, Tuscany, Italy).
Search terms
The terms sought in all databases to refine the 
original search are specified below. No limits of 
publication date, language or study type were applied 
to the search strategy:  
ORGANISATIONAL DOMAIN "Organisa t ional 
aspects", "organizational aspects", staff, staffing, 
personnel, manpower, human resource*, competenc*, 
sk i l l* ,  t ra in* ,  co l labora te ,  co l labora t ion , 
c o m m u n i c a t i o n ,  t e a m w o r k ,  " t e a m  w o r k " , 
multiprofessional, "Health Care Facilities", manpower, 
services, "Health Personnel", "Delivery of Health 
Care", centralis*, centraliz*, decentralis*, decentraliz*, 
regionalis*, regionaliz*, "work process*", "work flow", 
workflow, management, managerial, "Patient Care", 
"Patient Care Team", "Patient Care Management", 
"patient flow".
Inclusion criteria 
Publications reporting any kind of information about 
organisational aspects were included.
Duplicates and publications considered not 
relevant based on the abstracts were excluded. 
Following the review of full texts, publications 
meeting inclusion criteria were considered for the 
analysis of this domain.
Quality appraisal
The main sources of information for the analysis 
were documents released by regulatory authorities 
such as Italian national/regional guidelines, European 
directives and Italian laws. This might entail a risk 
of bias, and can be considered a limitation of this 
review. Furthermore, information from experts (from 
clinical and industry backgrounds) might be limited by 
positions, knowledge asymmetry and time constraints. 
A quality assessment of the retrieved studies was not 
conducted.
Ta
bl
e 
L
IV
 - 
Su
m
m
ar
y 
of
 th
e 
re
su
lts
 o
f s
el
ec
te
d 
ec
on
om
ic
 s
tu
di
es
.
Fi
rs
t a
ut
ho
r, 
ye
ar
C
ou
nt
ry
, 
fu
nd
in
g 
Po
pu
la
tio
n 
(P
)/
in
te
rv
en
tio
n 
(I
)/
co
m
pa
ra
to
r (
C
) 
Ty
pe
 o
f a
ss
es
sm
en
t 
(s
tu
dy
 e
nd
po
in
t)
C
os
t i
te
m
s
St
ud
y 
re
su
lts
C
on
cl
us
io
n
A
uB
uc
ho
n 
JP
, 
19
94
U
SA
, N
/A
P:
 h
yp
ot
he
tic
al
 
pa
tie
nt
s (
ag
e 
no
t 
re
po
rte
d)
I: 
SD
-F
FP
 
C:
 u
nt
re
at
ed
 F
FP
CU
A 
(c
os
t/ 
Q
A
LY
 g
ai
ne
d)
Ev
al
ua
tio
n 
an
d 
m
an
ag
em
en
t o
f:
ac
ut
e 
he
pa
tit
is,
 H
IV
, A
ID
S
IC
ER
: $
 2
89
,3
00
/Q
A
LY
SD
-F
FP
 p
ro
du
ce
s 
lim
ite
d 
in
cr
em
en
ta
l 
be
ne
fit
s a
nd
 h
ig
h 
in
cr
em
en
ta
l c
os
ts
Pe
re
ira
 A
, 
19
99
 
Sp
ai
n,
 
M
in
ist
ry
 o
f 
H
ea
lth
P:
 h
yp
ot
he
tic
al
 
pa
tie
nt
s a
ge
d 
up
 
to
 7
0
I: 
SD
-F
FP
 
C:
 u
nt
re
at
ed
 F
FP
CU
A 
(c
os
t/ 
Q
A
LY
 g
ai
ne
d)
Tr
ea
tm
en
t o
f a
cu
te
 sy
m
pt
om
at
ic
 h
ep
at
iti
s
in
te
rf
er
on
 t
re
at
m
en
t 
an
d 
fo
llo
w
-u
p 
of
 
ch
ro
ni
c h
ep
at
iti
s, 
de
co
m
pe
ns
at
ed
 ci
rrh
os
is,
 
A
ID
S
un
it 
co
st 
of
 S
D
-F
FP
 a
nd
 F
FP
IC
ER
: $
 2
,1
56
,3
98
/Q
A
LY
V
ir
us
-i
na
ct
iv
at
ed
 p
la
sm
a 
pr
od
uc
es
 
lit
tle
 i
nc
re
m
en
ta
l 
be
ne
fit
 a
nd
 v
er
y 
hi
gh
 
in
cr
em
en
ta
l 
co
st
 d
ue
 t
o 
lo
w
 c
ur
re
nt
 r
is
k 
of
 i
nf
ec
tio
n 
w
ith
 t
ra
ns
fu
si
on
-tr
an
sm
itt
ed
 
vi
ru
se
s, 
th
e 
ad
va
nc
ed
 a
ge
 a
nd
 p
oo
r s
ho
rt-
te
rm
 p
ro
gn
os
is 
of
 m
os
t p
la
sm
a 
re
ci
pi
en
ts
Bl
um
be
rg
 N
, 
20
00
U
SA
, 
Ba
xt
er
, P
al
l 
Bi
om
ed
ic
al
, 
O
rth
o 
Bi
ot
ec
h
P:
 N
/A
I: 
SD
-F
FP
C:
 u
nt
re
at
ed
 F
FP
CE
A 
(c
os
t/d
ea
th
 a
vo
id
ed
)
H
IV
, H
CV
, H
BV
 a
nt
ib
od
y 
te
sti
ng
H
IV
 a
nt
ig
en
 te
sti
ng
IC
ER
: $
 1
7 
m
ill
io
n/
de
at
h 
av
oi
de
d
SD
-F
FP
 w
as
 a
 c
om
pa
ra
tiv
el
y 
ex
pe
ns
iv
e 
ap
pr
oa
ch
 t
o 
re
du
ce
 m
or
ta
li
ty
 f
ro
m
 
tra
ns
fu
sio
n 
co
m
pl
ic
at
io
ns
CA
D
TH
, 2
01
1 
Ca
na
da
, N
ot
 
re
le
va
nt
P:
 h
yp
ot
he
tic
al
 5
0-
ye
ar
 o
ld
 tr
an
sf
us
ed
 
pa
tie
nt
s
I: 
O
ct
ap
la
s®
C:
 F
FP
CU
A 
(c
os
t/Q
A
LY
 g
ai
ne
d)
 
CE
A 
(c
os
t/L
Y
 g
ai
ne
d)
Tr
ea
tm
en
t 
of
 T
R
A
LI
, H
AV
, H
B
V,
 H
C
V,
 
H
IV
 a
nd
 t
he
ir
 s
eq
ue
la
e,
 p
ri
on
 d
is
ea
se
, 
PV
B1
9,
 c
os
t p
er
 u
ni
t O
ct
ap
la
s®
 in
fu
sio
n
FF
P
IC
ER
=$
 9
34
,0
00
 p
er
 Q
A
LY
 a
nd
 $
 1
.3
 
m
ill
io
n 
pe
r L
Y
S
O
ct
ap
la
s®
 i
s 
no
t 
co
st
-e
ff
ec
tiv
e,
 b
ei
ng
 
as
so
ci
at
ed
 w
ith
 o
nl
y 
a 
m
in
im
al
 r
ed
uc
tio
n 
in
 d
ise
as
e 
bu
rd
en
 a
t a
 h
ig
he
r c
os
t t
ha
n 
FF
P
Ri
ed
le
r G
F,
 
20
03
 
U
K
, 
O
ct
ap
ha
rm
a 
U
K
P:
 h
yp
ot
he
tic
al
 
pa
tie
nt
s a
ge
d 
up
 to
 
70
 y
ea
rs
I: 
O
ct
ap
la
s®
C:
 F
FP
CE
A
(c
os
t/L
Y
 g
ai
ne
d)
Tr
ea
tm
en
t o
f T
RA
LI
, H
IV
, H
CV
, H
BV
 
un
it 
co
st 
of
 S
D
-F
PP
 a
nd
 F
FP
IC
ER
=£
 2
2,
72
8/
LY
 (n
eo
na
te
s)
IC
ER
=£
 9
8,
46
5/
LY
 (7
0-
ye
ar
-o
ld
 p
at
ie
nt
s)
IC
ER
=£
 8
2,
00
0/
LY
 (6
5-
ye
ar
-o
ld
 p
at
ie
nt
s)
Co
st/
LY
 <
£ 
50
,0
00
 (<
48
-y
ea
r-o
ld
 p
at
ie
nt
s)
Co
st/
LY
 <
£ 
30
,0
00
 (<
21
-y
ea
r-o
ld
 p
at
ie
nt
s)
 
In
cl
us
io
n 
of
 n
on
-in
fe
ct
io
us
 c
om
pl
ic
at
io
ns
 
su
gg
es
ts
 th
at
 S
D
-F
PP
 is
 c
os
t-e
ffe
ct
iv
e 
in
 
<4
8-
ye
ar
-o
ld
 p
at
ie
nt
s a
nd
 in
 o
ld
er
 p
at
ie
nt
s 
w
ith
 g
oo
d 
cl
in
ic
al
 p
ro
gn
os
is
H
ui
sm
an
 E
L,
 
20
14
 
U
SA
, 
O
ct
ap
ha
rm
a 
A
G
P:
 h
yp
ot
he
tic
al
 
co
ho
rt 
of
 5
0-
ye
ar
 
ol
d 
tra
ns
fu
se
d 
pa
tie
nt
s
I: 
O
ct
ap
la
s®
C:
 F
FP
CU
A 
(c
os
t/Q
A
LY
 g
ai
ne
d)
CE
A 
(c
os
t/L
Y
 g
ai
ne
d)
Tr
ea
tm
en
t 
of
 T
R
A
LI
, H
AV
, H
B
V,
 H
C
V,
 
H
IV
 a
nd
 th
ei
r s
eq
ue
la
e
Tr
ea
tm
en
t o
f p
rio
n d
ise
as
e, 
PV
B1
9,
 (s
ev
er
e)
 
al
le
rg
ic
 r
ea
ct
io
ns
, b
ac
te
ria
l i
nf
ec
tio
ns
 a
nd
 
em
er
gi
ng
 in
fe
ct
io
ns
un
it 
co
st 
of
 O
ct
ap
la
s®
 a
nd
 F
FP
O
ct
ap
la
s®
 d
om
in
an
t (
ba
se
 c
as
e)
IC
ER
=$
 1
6,
15
9/
Q
A
LY
 a
nd
 $
 2
89
,6
33
/L
Y
 
(e
xc
lu
di
ng
 th
e 
ris
k 
of
 u
nk
no
w
n 
em
er
gi
ng
 
vi
ru
se
s)
IC
ER
=$
 7
71
/Q
A
LY
 an
d 
$ 
2,
92
5/
LY
 (u
sin
g 
th
e 
hi
sto
ric
 p
ric
e 
of
 F
FP
)
O
ct
ap
la
s®
 is
 d
om
in
an
t o
ve
r F
FP
, p
ro
du
ci
ng
 
co
st 
sa
vi
ng
s a
nd
 in
cr
ea
sin
g 
Q
A
LY
.
H
ui
sm
an
 E
L,
 
20
14
Ca
na
da
, 
O
ct
ap
ha
rm
a 
A
G
P:
 H
yp
ot
he
tic
al
 
co
ho
rt 
of
 5
0-
ye
ar
-
ol
d 
tra
ns
fu
se
d 
pa
tie
nt
s
I: 
O
ct
ap
la
s®
C:
 F
FP
CU
A
(c
os
t/Q
A
LY
 g
ai
ne
d)
CE
A
(c
os
t/L
Y
 g
ai
ne
d)
Tr
ea
tm
en
t 
of
 T
R
A
LI
, H
AV
, H
B
V,
 H
C
V,
 
H
IV
 a
nd
 th
ei
r s
eq
ue
la
e
Tr
ea
tm
en
t o
f p
rio
n d
ise
as
e, 
PV
B1
9,
 (s
ev
er
e)
 
al
le
rg
ic
 r
ea
ct
io
ns
, b
ac
te
ria
l i
nf
ec
tio
ns
 a
nd
 
em
er
gi
ng
 in
fe
ct
io
ns
un
it 
co
st 
of
 O
ct
ap
la
s®
 a
nd
 F
FP
O
ct
ap
la
s®
 d
om
in
an
t  
 (b
as
e c
as
e,
 ex
cl
ud
in
g 
un
kn
ow
n 
vi
ru
se
s 
ev
en
 r
ed
uc
in
g 
al
le
rg
ic
 
re
ac
tio
n 
by
 5
0%
)
IC
ER
=C
$ 
1.
08
5/
Q
A
LY
 a
nd
 C
$ 
2.
55
1/
LY
 
(re
du
ci
ng
 a
lle
rg
ic
 re
ac
tio
ns
 b
y 
90
%
)
O
ct
ap
la
s®
 is
 d
om
in
an
t o
ve
r F
FP
, p
ro
du
ci
ng
 
co
st 
sa
vi
ng
s a
nd
 in
cr
ea
sin
g 
Q
A
LY
va
n 
Ee
rd
 M
C,
 
20
10
 
U
K
, 
O
ct
ap
ha
rm
a 
U
K
P:
 h
yp
ot
he
tic
al
 
co
ho
rt 
of
 c
rit
ic
al
ly
 
ill
 tr
an
sf
us
ed
 
pa
tie
nt
s (
ag
e 
no
t 
re
po
rte
d)
I: 
O
ct
ap
la
s®
C:
 F
FP
CU
A
(c
os
t/Q
A
LY
 g
ai
ne
d)
CE
A
(c
os
t/L
Y
 g
ai
ne
d)
Tr
ea
tm
en
t o
f 
se
ve
re
 a
lle
rg
ic
/a
na
ph
yl
ac
tic
 
re
ac
tio
ns
, T
A
CO
,  T
RA
LI
, H
IV
, H
CV
, H
BV
, 
H
AV
 a
nd
 th
ei
r s
eq
ue
la
e 
un
it 
co
st 
of
 O
ct
ap
la
s®
 a
nd
 F
FP
IC
ER
=£
 9
49
/Q
A
LY
 a
nd
 £
 1
,0
30
/L
Y
 (b
as
e 
ca
se
)
IC
ER
=£
 4
,8
36
/L
Y
 a
nd
 £
 5
.2
46
/Q
A
LY
 
(T
RA
LI
 ri
sk
 o
f F
FP
 c
or
re
ct
ed
 fo
r t
he
 u
se
 
of
 m
al
e 
pl
as
m
a 
on
ly
)
IC
ER
= 
£ 
96
8,
90
9/
LY
 an
d 
£ 
86
8,
17
2/
Q
A
LY
 
(T
RA
LI
 ri
sk
 o
f F
FP
 is
 b
as
ed
 o
n 
SH
O
T)
O
ct
ap
la
s®
 re
pr
es
en
ts 
go
od
 v
al
ue
 fo
r m
on
ey
 
ve
rs
us
 F
FP
, w
hi
ch
 is
 c
on
sid
er
ed
 th
e 
m
ai
n 
co
m
pa
ra
to
r 
fo
r 
cr
iti
ca
lly
 il
l p
at
ie
nt
s 
w
ho
 
ne
ed
 a
 p
la
sm
a 
tra
ns
fu
sio
n
N
/A
: n
ot
 a
va
ila
bl
e;
 F
FP
: f
re
sh
-fr
oz
en
 p
la
sm
a;
 C
U
A
: C
os
t–
ut
ili
ty
 a
na
ly
sis
; C
EA
: C
os
t-e
ffe
ct
iv
en
es
s 
an
al
ys
is;
 Q
A
LY
: q
ua
lit
y-
ad
ju
ste
d 
lif
e 
ye
ar
s; 
LY
S:
 li
fe
 y
ea
rs
 s
av
ed
; I
CE
R:
 in
cr
em
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s 
ra
tio
; 
TR
A
LI
: t
ra
ns
fu
sio
n-
re
la
te
d 
ac
ut
e 
lu
ng
 in
ju
ry
; T
A
CO
: t
ra
ns
fu
sio
n-
as
so
ci
at
ed
 c
irc
ul
at
or
y 
ov
er
lo
ad
; A
ID
S:
 a
cq
ui
re
d 
im
m
un
od
ef
ic
ie
nc
y 
sy
nd
ro
m
e;
 H
IV
: h
um
an
 im
m
un
od
ef
ic
ie
nc
y 
vi
ru
s; 
H
BV
: h
ep
at
iti
s B
 v
iru
s; 
H
CV
: 
he
pa
tit
is 
C 
vi
ru
s; 
PV
B1
9:
 p
ar
vo
vi
ru
s B
19
; H
AV
: h
ep
at
iti
s A
 v
iru
s; 
SH
O
T:
 S
er
io
us
 H
az
ar
ds
 o
f T
ra
ns
fu
sio
n.
 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
358
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Analysis 
We identified relevant data through a qualitative 
review of included evidence. Secondary research was 
prioritised. The methodology used to summarise the 
retrieved evidence is a narrative review. 
The structure of the analysis was based on clustering 
the four technologies under study and the comparator 
into three categories based on similarities and differences 
regarding their organisational impact: (i) FFP, (ii) 
"in-house" pathogen-inactivation methods, and (iii) 
industrial pathogen-inactivation methods.
Results
Results of the literature search
A total of 110 records were retrieved using the search 
process. Following review, three of these scientific 
papers were eventually included in the present analysis. 
The study selection process is illustrated in Figure 6. 
Further scientific papers and different types of literature 
were retrieved from other sources specified in the 
methods section and included according to inclusion 
criteria.
Additional scientific papers were retrieved from 
a manual search of the reference lists of the included 
studies. Further literature was taken from the TRIP 
and NICE databases, while no records were found in 
the GIN database. Legislative decrees and European 
Union directives were searched for in the websites 
of regulatory institutions or authorities. A total of 19 
scientific documents were selected from these sources 
and 20 documents were retrieved from the websites of 
manufacturers or regulatory institutions. 
Table LV lists the scientific papers included 
in the current review and indicates the respective 
topic13,35,43,58,66,86,95,112,198,232,243-251.
Delivery process
The transfusion chain is a process that covers the 
whole pathway of plasma, from its extraction from the 
donor, to the actual transfusion and follow-up (Figure 
7). The steps of this process that are common to all 
FFP, pathogen-inactivated or not, are the following: 
(i) collection; (ii) testing and other procedures to 
minimise risk of infections; (iii) preparation of FFP; 
(iv) storage; (v) distribution; and (vi) transfusion. 
Collection
Whole blood collection and/or plasmapheresis are 
carried out in blood collection facilities.
Testing and other procedures to minimise the risk of 
infections 
Blood donors are selected based on their history 
and clinical evaluation. The limits of selecting donors 
are well known, including those concerning the 
recognition of donors at risk of transmission of prions 
responsible for Creutzfeldt-Jakob disease (CJD) and, 
especially, its variant (vCJD), which appeared in 
recent years in some European countries13. Donors and 
blood units undergo systematic screening tests for a 
limited number of markers of transmissible diseases. 
Quarantine programmes allow the identification of 
viral agents possibly missed during initial screening. 
These encompass the preservation of frozen plasma for 
a period of at least 112 days (16 weeks), to be used only 
after receiving confirmation of the negative serological 
tests at the following donation76. 
Preparation of fresh-frozen plasma
Whole blood is fractionated by high speed 
centrifugation (preferably within 6 hours of collection 
and no later than 18 hours for cool blood units). Plasma 
is separated from the other blood components, and all 
products are packed separately in pre-connected bags. 
Collected plasma is rapidly frozen to –30 °C, which 
is the recommended temperature for storage. These 
procedures must be designed to avoid contamination 
and are performed either within hospital blood centres 
or in regional blood centres86.
Companies authorised to fractionate blood collected 
in Italy and the locations of their respective industrial 
establishments are indicated in Table LVI252. 
Additional methods for pathogen inactivation of FFP 
can be implemented during the FFP preparation phase 
to enhance the prevention of infectious risks. 
- The MB, amotosalen and riboflavin techniques 
are so-called "in-house" methods. Each single unit 
of FFP is thawed, the agent (MB, riboflavin or 
amotosalen) is added and, after incubation, each 
unit is subjected to light irradiation which activates 
the agent resulting in the inactivation of the 
pathogens. The product is then packed in the final 
bag and refrozen; its composition is comparable 
to that of FFP. Staff involved in the inactivation 
of plasma through any of these systems must 
be qualified laboratory technicians, who should 
process each bag in a maximum time of 15 minutes. 
This process can be carried out industrially or in 
blood bank facilities86.
- Additional steps are involved in the SD method 
of pathogen inactivation; plasma bags from single 
donors must be sent from the facilities where the 
FFP is prepared to the industrial plant where the 
inactivation is performed. In Italy, bags from the 
southern and northern regions of Italy are initially 
stored in two intermediate industrial deposits, 
whereas bags from central regions and Sardinia go 
directly to the plant. Once the bags of plasma have 
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arrived at the industrial facilities, they undergo a 
physical/visual quality check and document control. 
Batches of 60-380 L of plasma are then pooled to 
create a standardised biopharmaceutical product with 
uniform plasma protein concentrations, through a 
process that requires 180 minutes. A sample of the 
pool is tested for infections and the inactivation 
process is applied to the whole pool. The plasma is 
then packed and refrozen86. 
All industrial processes must respect quality 
requirements set by the European GMP and must obtain 
Plasma Master File certification253-255. 
Storage
FFP inactivated by "in-house" methods is kept at 
all times in hospital blood banks, whereas industrially 
pathogen-inactivated FFP units are stored in interim 
warehouses belonging to the company before being 
distributed to hospital blood banks.
The storage temperature of all FFP, inactivated 
by any method, is maintained at all times at –20 ºC 
or lower in accordance with WHO directions76,256,257. 
Temperature conditions are monitored and recorded 
throughout the supply chain.
In addition, FFP undergoing SD treatment is stored 
and transported in compliance with the European 
Table LV - Papers included in the organisational domain 
analysis and related topics.
First Author, year Country Related topic
British Committee 
for Standards in 
Haematology, 200413
United Kingdom Delivery process 
MacLennan S, 2006198 United Kingdom Delivery process/culture
Jimenez-Marco T, 201458 Spain Delivery process
Seltsam A, 201386 Germany Delivery process
Rock G, 201135 Canada Delivery process/structure
Ofosu FA, 2008243 Canada Delivery process
Liumbruno GM, 2011244 Italy Delivery process/structure
Biesert L, 1998112 Switzerland Process-related costs
Hellstern P, 2004245 Germany Process-related costs
Sharma AD, 2000246 USA Process-related costs
Solheim BG, 200666 Norway Process-related costs
Koenigbauer UF, 2000247 USA Process-related costs
Ruggeri M, 2014248 Italy Process-related costs
Pamphilon D, 200095 United Kingdom Management
Solheim BG, 2008232 Norway Management
Vamvakas EC, 2010249 USA Management
Klein HG, 200743 USA Culture
Klein HG, 2009250 USA Culture
Alter HJ, 2008251 USA Culture
Figure 6 - Study selection process for organisational domain.
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Pharmacopoeia monograph "Human Plasma for 
Fractionation" (0853).
Distribution 
In Italy, SD-FFP plasma units are distributed by the 
industry in an on-demand basis to hospital pharmacies/
blood transfusion departments, or delivered to regional 
pharmaceutical depots, depending on the type of 
distribution model (decentralised or centralised, 
respectively). In both cases, the same amount of plasma 
collected is returned, excluding bags that might have 
not met quality checks. In order to respect the cold 
chain, the plasma is transported in certified vehicles 
at a temperature of –20 °C or below76,256,257. 
"In-house" inactivated plasma, on the other hand, 
does not require transportation between facilities, since 
the pathogen inactivation process is carried out within 
the hospital blood centre.
Transfusion
The decision to perform a transfusion must be based 
on clinical practice guidelines and determined by the 
treating clinician13, who requests blood units from the 
hospital's transfusion medicine department.
A qualified specialist in transfusion medicine 
supervises the entire process and decides which blood 
product to use (SD-FFP or "in-house" inactivated 
FFP). Frozen plasma may be thawed only when 
it is absolutely certain that the transfusion will be 
performed. Each unit must be immersed in a water bath 
at a maximum temperature of +37 ºC or it may be kept 
for a maximum of 6 hours at +4 ºC before transfusion 
if it is intended to improve a coagulopathy256. 
However, not all patients requiring transfusion are 
eligible for all types of inactivated plasma. MB-FFP 
is contraindicated in pregnant and nursing women, 
premature babies and for intrauterine transfusions, 
patients with severe renal failure, patients with 
methaemoglobinaemia associated with glucose-6-
phosphate dehydrogenase deficiency, and patients 
with congenital deficiency of glucose-6-phosphate 
dehydrogenase16. A-FFP is contraindicated in patients 
with a history of allergy to amotosalen or psoralens. 
The contraindications to R-FFP and SD-FFP are 
the same as those to FFP58,86. SD-FFP has been 
recommended by clinical guidelines for a series of 
patients, including those with TTP and other thrombotic 
microangiopathies, and patients with acquired 
coagulation factor deficiencies, probably because of the 
greater standardisation of its content of these factors232. 
FFP units that have been issued but not used must be 
disposed of by the hospital transfusion laboratory; they 
must not be refrozen or reissued to another patient256.
Throughout the transfusion chain, many stakeholders 
cooperate and interact in the delivery process of FFP:
- international, national and regional authorities;
- blood establishments; i.e., any structure or body that is 
responsible for any aspect of the collection and testing 
of human blood or blood components, whatever their 
intended purpose, and their processing, storage, and 
distribution when intended for transfusion;
- hospital blood banks; i.e., a hospital unit which 
stores, distributes and may perform compatibility 
tests on blood and blood components exclusively 
for use within hospital facilities, including hospital-
based transfusion activities;
- hospital transfusion medicine departments;
- companies and drug authorities involved in industrial 
pathogen-inactivation of plasma (Table LVII).
Quality assurance 
Quality must be assured and monitored throughout 
the process at the different levels (health care system, 
within and between blood establishments, blood banks, 
transfusion medicine departments, and industry) 
following national and international standards.
All plasma and plasma products
In Europe, Directive 2002/98/EC254,257-263 of the 
European Parliament and of the Council of 27th 
January 2003, amending Directive 2001/83/EC253, 
sets standards of quality and safety for the collection, 
testing, processing, storage and distribution of human 
blood and blood components. The Directive 2005/61/
EC267 of 30th September 2005 implements Directive 
2002/98/EC254 with respect to Community standards 
and specifications relating to a quality system for blood 
establishments.
Activities related to blood components and the 
production and transfusion of plasma derivatives are 
regulated in Italy by Law n. 219 of 21st October 2005, 
"New legislation on transfusion activities and national 
production of blood derivatives"265.
Plasma suppliers are monitored in compliance with 
the agreement "Accordo Stato-Regioni" dated December 
16th 2010 (Legislative Decree 281/1997, article 4266), 
Table LVI  -  Companies authorised to fractionate blood 
collected in Italy and the locations of their 
industrial plants.
Company Location
Baxter Manufacturing S.p.A Rieti, Italy
CSL Behring S.p.A. Bern, Switzerland
Grifols Italia S.p.A Barcelona, Spain
Kedrion S.p.A. Bolognana, Gallicano and Lucca, 
Italy
Octapharma Italy S.p.A Stockholm, Sweden
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Legislative Decree 261/2007259 and Legislative Decree 
191/2005258 (implementing Directive 2002/98/EC). 
Eligibility criteria for blood/plasma donors are determined 
in compliance with the Decree of the Ministry of Health of 
3rd March 2005 "Protocols for determining the suitability 
of blood and blood components donors"267 (implementing 
Directive 2004/33/EC), with the Legislative Decree of 
20th December 2007, n. 261259 (which revokes Legislative 
Decree of 19th August 2005, n. 191258), and the Guide 
to the preparation, use and quality assurance of blood 
components of the European Council10.
GMP, denoting minimum organisational, structural 
and technological requirements for health care 
institutions that offer blood transfusion and/or blood 
collection services (blood establishments), are also 
determined by the above-mentioned agreement266. In 
accordance with the stipulations, each Italian Region, 
as a competent authority, assesses blood establishments 
and hospital blood banks, and grants or denies them 
authorisation to operate. Moreover, the Regions carry 
out periodic inspections in their blood establishments 
and blood banks at least every 2 years277 (see Box 1).
As far as concerns the risk of vCJD, donor exclusion 
criteria are specified in the "Protocols for determining 
the suitability of blood and blood components donors"267 
as determined by the Italian Ministerial Order dated 
29th March 2004268. Furthermore, the Italian Health 
Institutions' Position Paper "Management of reports 
of CJD infected donors"269 and the Committee for 
Medicinal Products for Human Use Position Statement 
on Creutzfeldt-Jakob disease and plasma-derived 
products (EMA)270 do not allow the clinical use of 
plasma and plasma-derived medicinal products after 
donation reports of CJD.
"In-house" pathogen-inactivated plasma 
Pathogen inactivation by "in-house" methods is 
performed in accordance with the European Directive 
93/42/EEC271. Equipment, kits and reagents are CE-
labelled and are, therefore, subject to the regulations 
for medical devices entering the market. Illumination 
equipment must conform with Directives 89/336/EEC 
(EMC), 73/23/EEC, and 98/37/EC and norms EN 
61326-1:1997/2000, EN 61010-1:2001272-276 (security 
rules for electrical apparatus for measuring, regulation 
and the laboratory).
Industrially pathogen-inactivated plasma
In Europe, plasma must comply with European 
Pharmacopoeia Monographs and Good Manufacturing/
Laboratory Practices.
Individual donations are tested for infective agents 
by biological qualification laboratories in accordance 
with the European Pharmacopoeia monograph on 
Table LVII -  Companies and reference markets involved 
in pathogen-inactivation.
Pathogens Companies Methods Marketing 
approval
Viruses
Bacteria
Parasites
Cerus Amotosalen + UV CE
Caridian Riboflavin + UV CE
MacoPharma Methylene blue CE
Baxter Methylene blue CE
OctaPharma Solvent/detergent AIC (Italy)
Kedrion Solvent/detergent AIC (Italy)
Human Plasma for Fractionation (0853). Inspection 
and approval according to GMP are required for 
the processing, storage and transport of blood and 
blood components, including plasma, to be used for 
manufacturing medicinal products such as SD-FFP278,279. 
The plasma product requires Plasma Master File 
certification, EMA/CPMP/BWP/4663/03. The Plasma 
Master File contains common information on plasma, 
from collection to the plasma pool, relevant to the 
manufacture of all intermediate fractions including 
cryoprecipitate, all constituents of the excipient and 
all active substance(s), which are part of medicinal 
products or medical devices, for which such a file is 
applicable.
Structure 
As stated in the previous section, the process of donor 
recruitment and screening, and collection and preparation 
of blood units are performed in a primary care setting, i.e., 
blood establishments or hospital blood banks.
Infectious disease tests are performed in blood 
establishments where "in-house" pathogen inactivation 
procedures are performed35. 
The SD-FFP method for pathogen inactivation 
is standardised and carried out at a centralised 
manufacturing centre where plasma is processed as a 
large pool (500-2,500 donations) and provided to users 
frozen in 200 mL bags35. 
The settings in which "in-house" technologies can be 
used are different from those for the SD process, which 
can only be carried out in industrial establishments. 
The procedure for obtaining SD-FFP involves plasma 
inactivation in centralised laboratories with storage in 
centralised depots, allowing economies of scale and 
streamlining of the activity of laboratories in hospital 
blood banks. 
The most important drivers of economies of scale are:
- centralisation of large plasma stocks in a single 
storage site, thanks to the possibility of long-term 
conservation of plasma (2 years);
- the cost of training production chain staff, who 
are specialised in the activities of the pathogen 
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inactivation procedure in the industrial setting;
- the cost of acquisition of sophisticated technologies;
- all overhead costs that are incurred in the production 
chain.
In addition, a centralised storage site enables a more 
streamlined system of governance of the plasma, in 
which production, consumption and distribution are 
planned and programmed at the governmental level.
As stated in the previous paragraphs, the centralisation 
of pathogen inactivation also involves standardisation 
of procedures that reduce associated risks and facilitate 
control255,278. 
Process-related costs
The most important cost drivers in all processes 
are related to adverse events derived from plasma 
transfusion and the concentration of coagulation factors 
and other plasma proteins in plasma.
Many studies have demonstrated that the dilution 
and neutralisation of antibodies and allergens during the 
industrial process of SD plasma pooling can reduce the 
incidence of allergic reactions and TRALI in recipients. 
It has been reported that the transition from FFP to SD-
treated plasma significantly reduces the incidence of 
adverse reactions, and subsequently involves significant 
savings. A study by Ruggeri et al. (2014)248 demonstrated 
that the savings per patient arising from the use of SD-
FFP (vs FFP) were between € 2,800 and € 3,200 in the 
case of a mild reaction, between € 2,500 and € 4,600 in 
the case of a moderate reaction and between € 34,000 
and € 44,000 if resuscitation procedures were needed. 
We did not identify studies investigating this aspect in 
relation to "in-house" methods.
SD-FFP generates better standardisation of the 
content of clotting factors and greater effectiveness 
on coagulation tests compared to FFP and MB-FFP, 
eliminating the biological variability across single units 
of FFP13,280; therefore, the use of SD-FFP is particularly 
recommended in special populations such as TTP 
patients and liver transplantation candidates. 
Management
The key areas in which to identify critical management 
issues and opportunities of each of the five methods are 
transfusion chain management and appropriate staff 
training in withdrawal/collection of plasma, pathogen 
inactivation (in either blood centres or industrial plants), 
transport and cold chain management, thawing and 
patient management for the transfusion.
Our analysis shows that the organisational model 
and network generated around SD-FFP creates a 
better structured and controllable organisational 
environment, due to centralisation in industries 
managing the main steps of the transfusion chain 
(processing, storage and distribution). This greater 
control is of benefit not only to the safety of the 
final product (industrial pathogen inactivation is 
guaranteed by GMP authorisation from national health 
authorities), but also to the planning of regional and 
national governmental bodies that have the goal of 
ensuring plasma self-sufficiency13,241,245. 
Culture
A series of concerns within the medical community 
limited the acceptance and diffusion of pathogen 
inactivation when it was an emerging technology. First, 
there were doubts about blood safety including risks 
Box 1 - The entry into force of the State-Regions 
Agreement of 16 December 2010.
Law n. 10 of 26th February 2011 determined the procedures 
for plasma and all other blood products to be compliant with 
European standards, to be adopted before 31st December 2014 
(later extended to 30th June 2015), according to Law n. 219 
of 21st October 2005, which resolved fundamental guidance 
regulating the production of pharmaceutical products derived 
from plasma collected within the Italian territory, as well as 
import and export of blood and blood products.
The agreement between the Italian State and the Regions 
defined the “Structural, technological and organizational 
requirements for health care institutions that offer blood 
transfusion and/or blood collection services” and the “Model 
for monitoring visits of blood establishments”, as disposed 
by Legislative Decree n. 261 of 20th December 2007 (Art. 5), 
incorporated the European Directive 2002/98/EC.
Along with decree n. 261/2007, the State-Regions agreement 
stipulates that certification of compliance with European 
structural, technological and organisational requirements 
be achieved through regional processes of authorisation 
and accreditation. It is thus mandatory that all regions and 
autonomous provinces check facilities on-site at least every 
2 years, by means of a regional monitoring team consisting 
of at least one registered evaluator approved by the National 
Blood Centre).
With Legislative Decree n. 216 of 29th December 2011, the 
Ministry of Health:
(i) established the national list of evaluators for the transfusion 
system, through the National Blood Centre, who can perform 
the tasks required by Legislative Decree n. 261 of 20th 
December 2007 (Art. 5).
(ii) defined, for the issuance of the Ministerial Decree 
stipulated by Law n. 96 of 4th June 2010 (Art. 40, Par. 4), 
submission procedures to be used by blood establishments 
and pharmaceutical companies for obtaining assessment by 
the Italian Medicines Agency (AIFA)
(iii) decided, pending the complete implementation of the 
State-Regions agreement to be ready by 31st June 2015, the 
procedures for AIFA to assure the marketing of pharmaceutical 
blood products obtained from plasma collected in the Italian 
territory, as well as the export of these products for processing 
within European Union countries, while the National Institute 
of Health ensures state monitoring.
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resulting from the presence of residual chemicals in the 
final product. The limits of the technologies (inability to 
inactivate agents such as spores, prions, and certain small 
non-encapsulated viruses, and non-existence of a method 
able to treat whole blood or all components) led to the 
value and cost-effectiveness of PRT being questioned. 
So did the success of the control of emerging pathogens 
with the routine strategies of surveillance and screening. 
PRT were not recommended back then on the evidence 
available alone43. 
It was important to the scientific community to 
balance the introduction of PRT against the risk of giving 
rise to new unwanted effects such as loss of coagulation 
factors, toxicity and neoantigenicity251. 
Even after licensing in Europe and in other 
countries, and given delayed regulatory approval in the 
USA and Canada, the medical community agreed on 
the importance of post-marketing surveillance studies, 
recommended by regulatory authorities and supported 
by manufacturers and/or blood suppliers. A system of 
surveillance for adverse reactions linked to the national 
haemovigilance systems, as well as further research 
in terms of development of novel PRT, seem to be 
necessary to improve blood safety250,281,282. 
Nonetheless, there was a demand for a transition to a 
proactive approach to the prevention of TTI, given their 
continued emergence or re-emergence and the fact that 
the interval between the first recognition that a disease is 
transfusion-transmitted and the eventual implementation 
of a donor-screening test to prevent that transmission, 
had historically been long. This perception suggested 
that the risk-benefit balance and cost-effectiveness could 
be positive in the long run283. 
A large amount of evidence on the safety and efficacy 
of PRT has since been accrued. The gradual introduction 
of PRT into guidelines worldwide and their consequent 
regulation can be taken as a measure of the adoption and 
diffusion of these technologies.
Discussion
The analysis of organisational aspects was carried 
out by dividing infectious risk prevention procedures 
into three groups: traditional FFP, "in-house" pathogen 
inactivation procedures (grouped together and assumed 
to have the same organisational impact) and the SD-FFP 
industrial method.
Few studies have investigated organisational 
aspects of PRT; in fact, most of the information was 
retrieved from documents released by monitoring 
authorities, grey literature, and manufacturers' 
handbooks. This creates a risk of bias due to insufficient 
or selective inclusion of information sources and data, 
and can be considered as a limitation of our review. 
Organisational changes emerging from the adoption of 
PRT occur mainly in the stages of processing, storage 
and distribution of plasma. 
"In-house" pathogen inactivation procedures are 
performed in blood establishments on single donor bags, 
blood units are stored in the hospital blood bank, and 
transport between facilities is not, therefore, required 
but enough storage space must be available. On the 
other hand, industrial pathogen inactivation procedures 
require that collected blood is transported to and from 
the manufacturer's facilities implementing logistics 
for the maintenance of the cold chain, while pathogen 
inactivated blood units are stored in interim depots 
before being distributed to hospital blood banks.
The strengths of PRT linked to these differences are 
that plasma undergoing "in-house" pathogen inactivation 
procedures is not pooled, thereby lowering the risk of 
a whole plasma pool being contaminated by a single 
infected bag of plasma, whereas the industrial method 
guarantees standardisation of the final product.
With regards to quality control, SD-FFP is a 
pharmaceutical product, whereas "in-house" procedures 
use medical devices and the resulting plasma is not 
considered a drug. This fact underlies the difference 
between the regulatory systems for the two groups of 
technologies. 
In Europe, quality control and validation of 
procedures for producing pathogen-inactivated FFP are 
guided by the guidelines of the European Community and 
the EMA, under State Laboratory control and marketing 
authorisation issued by national health authorities. This 
explains its wide and growing use in transfusion practice 
in Europe and the USA as an alternative to FFP that has 
not undergone pathogen inactivation.
Italian transfusion services can currently cover the 
supply of pathogen-inactivated FFP in three ways: (i) 
purchasing it from private manufacturing companies 
which produce and distribute such FFP in various 
European countries; (ii) sending plasma collected in 
hospital blood banks/blood establishments to a private 
company with appropriate facilities for SD treatment, 
which then returns the product to hospital blood banks 
for clinical use; (iii) producing the FFP in an accredited 
hospital blood bank laboratory with specific kits and 
machines using "in-house" methods.
Ethical domain
Introduction
The ethical domain has been identified as a key 
element of HTA since its conception in the 1970s. This 
domain aims to analyse the ethical questions raised 
by the use of a given technology: since technologies 
are always introduced into societies or organisations 
with their own set of values, the implementation of the 
technologies can have ethical consequences.
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The second purpose of the ethical domain is to 
analyse in detail the ethical issues that are inherent 
in the HTA process. In this sense, an ethical analysis 
should not be considered as a "one session" task, but 
rather as a support through the whole HTA process, 
from the prioritisation of topics, to the definition of 
research questions, and to the choice of methodologies 
to summarise results and draw conclusions. 
The present study does not include this analysis. 
However, the working group on ethics oversaw the 
whole HTA process, particularly checking that no 
conflicts of interests were present and that the choice 
of both end-points and comparators was "ethically" 
justified (see Introduction). 
Methods
A considerable number of models and frameworks 
can be used to conduct ethical assessments in HTA289-292. 
The EUnetHTA model was chosen from among several 
possibilities233. This model is based on six different topics, 
which together cover nineteen issues. The issues stem 
from the general values of the population, the aims of the 
health care system and the values arising from the use of 
a technology. This ethical evaluation was conducted by a 
team including four bioethicists (one with a background 
in philosophy and three with medical training).
Each issue was first clarified, and then its relevance 
considered, information sources were identified, and the 
literature was searched. Not all issues were considered 
relevant. The information was gathered from the following 
sources: the ongoing assessment of safety, efficacy and 
cost-implications; the literature; and philosophical 
analysis of the logic and coherence of the argumentations. 
The results of the analysis do not explicitly include 
the set of issues. The answers to the set of questions 
have been summarised and organised into paragraphs.
Literature search
A three-part literature search was applied: (i) all 
participants in the HTA project were requested to notify 
the ethics group if they found contributions discussing 
ethical issues. One article was notified; (ii) a search was 
made for HTA reports on the topic in online databases. 
Fifteen references were found, of which ten were 
available; and (iii) PubMed and the Cochrane Library 
were searched for articles on ethical topics relating to 
PRT for plasma. 
The PubMed query was based on the following scheme: 
ETHICAL DOMAIN  ( ( ( ( ( ( ( ( e t h i c s [ M e S H 
Terms]) OR ethics[MeSH Subheading]) OR "ethics, 
istitutional"[MeSH Terms]) OR "ethical aspects") OR 
"ethical issue") OR "ethical consideration") OR ethic*)).
Overall, the search yielded 916 contributions from 
scientific journals: four focused searches relating to 
specific issues were found in PubMed. Sixty-four articles 
were considered of possible interest.
Information selection
The contributions notified by all participants in 
the HTA project were considered not relevant to the 
purpose of the ethical domain. Instead, the contents of 
ten HTA reports were scrutinised. This activity revealed 
that none, except for the contribution from the Health 
Council of The Netherlands288, contained a section on 
the ethical domain. However, even the contribution of 
the Health Council of The Netherlands was considered 
not relevant. 
Concerning the articles in PubMed and the Cochrane 
Library, titles and abstracts of the 916 were screened 
by two independent reviewers to verify whether they 
contained information on "ethical" topics relating to 
PRT for plasma. No reference was considered relevant. 
Results
Two specific contributions on ethical issues relating 
to use of PRT for plasma were found but were considered 
not relevant. Seventeen articles were considered as 
useful but not specific289-305. The ethical assessment was, 
therefore, essentially based on discussion of the issues 
under question, which relied on information from the 
other sections of the current report.
The morally relevant issues identified were first 
summarised and then organised into paragraphs. 
Pathogen reduction technologies for plasma
Human plasma is used as a therapeutic product or 
as source material for the production of pharmaceutical 
fractionated products. An optimal plasma product should 
not only have a satisfactory content of coagulation and 
antithrombotic factors, but also be as safe as possible, 
reducing the risk of transfusion reactions and minimising 
the transmission of infectious agents. 
The development of increasingly sensitive laboratory 
screening methods and restrictive donor criteria have 
greatly decreased the risk of transmission of many 
pathogens through blood transfusion. In this context, 
the issue of transfusion-associated infections with HIV, 
HBV and HCV seems to be adequately managed.
Residual risks do, however, always remain. These 
particularly concern pathogens for which no detection 
method exists (i.e. emerging viruses) and the so-called 
"window period", in which blood levels of a disease 
marker are too low for detection88. In other words, the 
risk of transmission is not static, as new pathogens 
continue to emerge, old ones change their properties 
and epidemiological patterns, and new information 
and technologies become available to change our 
understanding of the risks.
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Since the beginning of the 1990s, considerable 
progress has been made in reducing or preventing the 
transmission of blood-borne pathogens in plasma by 
implementing different methods, i.e. PRT. These seem 
to be a promising alternative to expanded testing of FFP 
and donor deferral.
The present assessment aims to analyse the ethical 
questions raised by the use of the four PRT currently 
available for plasma, i.e. SD, MB, amotosalen and 
riboflavin.
Beneficence/non-maleficence
The first step in conducting an ethical analysis 
concerning health technologies consists in considering 
risks (principle of non-maleficence) and benefits 
(principle of beneficence) for patients and the society. 
The term "risk" refers to the possibility that harm may 
occur, while the term "benefit" refers to something 
of positive value related to health or welfare. In 
other words, people are treated in an ethical manner 
by protecting them from harm, but also by making 
efforts to secure their well-being. In some cases, the 
calculation and weighting of risks and benefits can be 
difficult.
With respect to the risk-benefit ratio of using SD, MB, 
amotosalen and riboflavin, the major concern regards 
their impact on the integrity of blood components and 
the toxicity of the chemicals utilised. Ideally, the active 
substances in PRT should be selectively toxic to a broad 
range of pathogens but, at the same time, non-toxic to 
blood cells/proteins and transfusion recipients. 
PRT have been subjected to preclinical and clinical 
testing (see the sections on efficacy and safety). 
Available data suggest that they provide adequate safety 
margins: in particular, the safety of the techniques in 
relation to TTI is high and the number of other adverse 
events associated with the various methods is low. 
Nevertheless, long-term side effects still remain a 
matter of debate88 and studies are particularly difficult 
to perform in this case. 
Furthermore, PRT seem to be effective overall in 
increasing blood safety, although more robust data 
would be desirable. 
In the context of further studies on the safety and 
efficacy of PRT for plasma particular attention should 
be paid to haemovigilance monitoring and controlled 
post-marketing studies. In fact, only the latter are able 
to demonstrate the added value of these technologies 
and, in the near future, support the identification of the 
safest and most effective PRT. 
Every effort should be made to comply with the 
European Union Directive 2002/98/EC, which states 
that: "it is important to introduce a set of organised 
surveillance procedures to collect and evaluate 
information on the adverse or unexpected events or 
reactions resulting from the collection of blood or blood 
components in order to prevent similar or equivalent 
events or reactions from occurring thereby improving 
the security of transfusion by adequate measures. To 
this end a common system of notification of serious 
adverse events and reactions linked to the collection, 
processing, testing, storage, and distribution of blood 
and blood components should be established in 
Member States". 
To sum up, although the conclusion that the risk-
benefit ratio of using PRT is favourable should be 
consolidated through additional data, it seems that the 
clinical use of these technologies can be considered 
justified from an ethical point of view.
Autonomy
The second step in conducting ethical assessments 
concerning health technologies regards the patient's 
freedom and responsible choice. This aspect is connected 
to the issue of informed consent, an essential prerequisite 
to the beginning of any medical intervention. 
Informed consent is generally considered as a process 
by which the health care provider discloses appropriate 
information to a competent patient, so that the patient 
can make a voluntary choice to accept or refuse the 
treatment. In this sense, informed consent is connected 
with the principles of autonomy and the issue of self-
determination. 
In order to be valid, informed consent requires 
that the individual has the capacity to make the 
decision, that the choice is voluntary, that the patient 
is provided with appropriate information, in a format 
that he or she can understand, regarding the benefits, 
risks, consequences and alternatives to the proposed 
treatment, and that the individual's decision is correctly 
documented289-293. 
In the field of transfusion medicine, there is lively 
debate on whether separate informed consent should 
be obtained from patients for transfusion of blood/
blood components and plasma-derived medicinal 
products294-302. However, it is generally agreed that the 
minimum elements to be discussed with a patient before 
requesting his or her consent to a transfusion should 
include303:
- clarification of the reason for the transfusion, i.e. the 
purpose and anticipated benefit of the transfusion, 
and the consequences of not having the transfusion;
- the alternatives to transfusion, which may include 
the possibility of an autologous transfusion;
- clarification of the risks associated with transfusion;
- patients should also be given the chance to ask 
questions and should be informed of their right to 
refuse a transfusion.
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In Italy, written informed consent or dissent is 
requested for transfusion of blood or plasma-derived 
medicinal products306.
As noted, before a patient is asked to consent to a 
transfusion, the risks associated with the transfusion 
must be clarified. Therefore, patients should always 
be informed that more "equivalent" methods exist 
for pathogen reduction and which method is used. 
Furthermore, patients should be provided with 
appropriate information, in a format that they can 
understand, regarding the potential benefits and risks 
associated with the method (including the potential long-
term side effects). Finally, they should be informed that 
transfusion of pathogen-reduced blood products is safe, 
even if a residual risk always remains.
Justice and equity
In health care systems based on the idea of solidarity 
(i.e. National Health Services), one of the main 
principles for the provision of care is guaranteeing equal 
access to effective care for those in need. A scarcity of 
health care resources does, therefore, necessarily lead to 
cost-effectiveness considerations and the prioritisation 
of health care policies. In this sense, the use of a certain 
technology may influence the fairness of the health 
care system, or require special considerations in order 
to ensure that justice is not compromised. Moreover, 
in order to achieve maximum uniformity in health care 
policy-making and to guarantee equal access to effective 
care, harmonisation would seem to be desirable when 
making decisions about the use or non-use of a certain 
technology.
The available cost-effectiveness studies on different 
pathogen inactivation approaches show contradictory 
and sometimes incomparable results. Most of these 
studies are, in fact, limited to the comparison of 
only two different PRT, i.e. SD and riboflavin. Given 
that the generalisability of available evidence is 
limited, it is not possible to determine whether the 
implementation of PRT fulfils the criteria of equal 
resource allocation, or, in other words, to state whether 
broad implementation of any of the technologies is 
acceptable in terms of justice. Thus, cost-effectiveness 
studies on PRT for plasma need to be performed and 
new data should be collected. Only such studies will 
be able to demonstrate the added value in economic 
terms of these technologies and, potentially, identify 
the most cost-effective one.
Discussion
From the ethical point of view, important points to 
be considered during decision-making about the use 
of PRT for plasma are that: although the risk-benefit 
ratio of using these technologies seems favourable, this 
conclusion should be consolidated through additional 
data; before a transfusion of pathogen-reduced blood 
products, patients should always be informed about 
the method used and its potential benefits and risks, 
clarifying that a minimal risk always remains: and it is 
still uncertain whether the implementation of PRT fulfils 
the criteria of equal (just) resource allocation.
Legal domain
Introduction
The legal domain aims to analyse the juridical 
questions and aspects raised by the use of a certain 
technology, in this case those technologies concerning 
blood use. Since technologies are always ruled by 
European Directives and National Decrees with a set 
of norms, their implementation has legal implications. 
Some issues are directly related to the patient and his or 
her basic rights, such as autonomy, informed consent, 
protection of data and quality management. Other issues 
are linked to the technology, such as authorisations, 
equality in health care access, acquisition processes, high 
standard settings, product safety, guarantees, control 
and harmonisation of PRT for plasma. However, some 
of these elements were considered not relevant to this 
research and are not analysed here.
The analysis of legal aspects was carried out at 
national and European levels. In Europe blood directives 
define quality and safety standards for the testing, 
processing, storage and distribution of human blood 
and blood components. Thus, various regulations and 
documents of the European Union and the Council of 
Europe were taken into account.
Methods
Information sources
Legal aspects of HTA concerning PRT for plasma 
were examined through an analysis of legal texts of the 
European Union.
Our work was based on finding and reviewing the 
main European regulations. These belong to a large, 
complex, heterogeneous set of biojuridical material 
generated within the European Union and the Council 
of Europe. This documentation is diversified in terms 
of force (some documents are binding, others simply 
steering) and origin (the bodies of enactment differ). 
However, despite different degrees of detail, we found 
common elements in the discipline of information 
and consent, protection of privacy, and access to 
treatment. 
A considerable number of models and frameworks 
can be used to conduct legal assessments within the 
HTA framework284,287. Among several possibilities, the 
EUnetHTA Core Model was chosen233. This model is 
based on seven different topics. 
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The legal evaluation was conducted by a group 
composed of three bioethicists, two of whom are jurists 
and one a physician.
Information selection 
Different European and national legislative 
documents were analysed. In principle, the European 
Union regulatory framework, which sets high standards 
for establishing pathogen reduction and harmonising 
the procurement of safe blood in Europe, is still under 
development. Since the early 1990s, SD-FFP has been 
considered as a blood product in Germany and in France. 
In most of the other European countries it used to be 
considered as a medicinal product, and it was often 
permitted during the registration process on the basis 
of its obvious viral safety, although no efficacy against 
non-enveloped viruses had been found. 
SD-FFP was first introduced in 1991 in the German 
Federal State of North Rhine-Westphalia, and replaced 
FFP in 1993 following a successful clinical trial in 
1992 in Norway. Today, ordinary medicinal licensing 
is required for SD-FFP in European countries except 
for France307, where it is classified as a labelled blood 
product. Octaplas® is now a licensed biopharmaceutical 
product in 29 countries worldwide. Octapharma has 
also developed Uniplas®/UniplasLG®, which differs 
from Octaplas®/OctaplasLG® only by the fact that 
anti-A and anti-B are removed, meaning that it can be 
universally transfused to patients of any blood group. 
Uniplas®/UniplasLG® is not licensed in the USA or the 
European Union.
Several European countries have established national 
programmes to monitor the occurrence of different 
adverse events. Unfortunately, in countries in which 
different methods for safeguarding plasma are used in 
parallel, adverse events are not always differentiated with 
respect to the type of plasma used, making it difficult 
to interpret and compare data accurately. The French 
haemovigilance report of 2009 described a relatively 
higher incidence of allergic events connected to MB-FFP 
than to Q-FFP. The authors of a French case report found 
evidence of potential cross-reactivity between patent 
blue V, a food colourant widely used in Europe, and MB, 
which may explain such allergic reactions to MB-FFP. 
This is in contrast with previous publications. Recently, 
allergic reactions in patients receiving blood products 
have become a special focus of interest in the French 
haemovigilance programme. It should be specified that 
this focus has emerged from sentence n. 357463 of the 
Conseil d'Etat, between MacoPharma and the Agence 
Française de Sécurité Sanitaire des Produits de Santé308. 
The available information from Belgium, indicating no 
difference between the safety profiles of MB-treated and 
untreated plasma, is the most promising.
Results
Authorisation and safety
Numerous legislative acts regarding the quality, 
control, safety and traceability of technologies have been 
produced at national and European levels. 
In the European Union, Directive 2002/98/EC outlines 
particular requirements for the processing of blood 
supplies and sets out standards for blood establishments 
in reference to responsibilities, quality management, 
documentation, record keeping, traceability, adverse 
events, storage and transport. This Directive states that 
"in order to safeguard public health and to prevent the 
transmission of infectious diseases, all precautionary 
measures during their collection processing, distribution 
and use need to be taken making appropriate use of 
scientific progress in the detention and inactivation 
and elimination of transfusion transmissible pathogenic 
agents"254. 
In addition, Directive 2001/83/EC253 of the European 
Parliament and of the Council of 6th November 2001 on 
the Community code relating to medicinal products for 
human use and European Union Directive 2004/33263 
set out technical requirements for blood and blood 
products in all Member States and defined some of 
the aforementioned standards. The treatment of human 
blood is regulated in Directive 61/2005/CE264, adopted in 
Italy through Legislative Decree n. 207 of 9th November 
2007260 (published in the Official Journal of the Italian 
Republic n. 261 of 9th November 2007). Directive n. 
61/2005/CE264 had, in turn, implemented the previous 
Directive 2002/98/CE254, concerning quality and safety 
standards of the collection, testing, processing, storage 
and distribution of human blood and blood components. 
Moreover, Directive n. 62/2005/CE262 was adopted by 
the Italian Legislative Decree n. 208 of 9th November 
2007261 (Official Journal of the Italian Republic n. 261 
of 9th November 2007 - Ordinary Supplement n. 228). 
Directive 62/2005/CE262 implements the previous 
Directive 2002/98/CE254 regarding the quality and safety 
of whole blood and blood components. 
The quality and safety of technologies are regulated 
by articles 20 and 25 of the Italian Legislative Decree 
261/2007259 and, at the European level, by Directive 
2002/98/CE254. In particular, specific guidelines on the 
quality and safety of blood components (such as tests to 
be performed; information provided and obtained from 
donors; information regarding the suitability of blood 
and plasma donors and screening of donated blood) 
are provided by articles 16-23 of Directive 2002/98/
CE254. Articles 11-13 define a quality system for blood 
establishments and the requirement to keep a record of 
the previous year's activity. 
Indeed, in accordance with Annex II of Directive 
2002/98/CE254, 22 Member States receive annual 
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reports from blood establishments on the previous 
year's activities. Italian Law n. 219/ 2005265 defines, in 
clause 5, the basic package of health care services to be 
provided in the field of transfusion activities, relying on 
specific agreements within the Permanent Conference 
for Relations between the State, the Regions and the 
Autonomous Provinces of Trento and Bolzano on the 
respective responsibilities for the uniform delivery of 
transfusion services included in the basic package, across 
the country (Clause 6 Law 219/2005)265.
Clause 5 of the Italian Legislative Decree 261/2007259 
states that "The Regions and the Autonomous Provinces, 
in order to implement the legislation in force, shall 
organise inspections and appropriate control measures 
in blood establishments and collection units, with the 
aim of verifying their compliance with the requirements".
Moreover, additional obligations for Member States 
are established by clauses 5-8 of Directive 2002/98/
EC254. Clause 5 states that "Each Member State must 
ensure that activities relating to the collection and 
testing of human blood and blood components, whatever 
the intended purpose, and to their preparation, storage 
and distribution when intended for transfusion, are 
undertaken only by the competent authority for that 
purpose". 
Clause 6 regulates hospital blood banks, while clause 
8 defines the inspection and control measures. Each 
"Member State must ensure that the competent authority 
organises inspections and appropriate control measures 
in blood establishments to check that the requirements 
of Directive 2002/98 are complied with". 
With regards to the need for national and European 
registers on PRT, it is worth clarifying that Medical 
Device Directives require a European databank for 
medical devices, which has been developed under 
the name of "EUDAMED" (EUropean DAtabase 
on MEdical Devices). The aims of EUDAMED are 
to strengthen market surveillance and transparency 
in the field of medical devices by providing the 
competent authorities of Member States with fast 
access to information on manufacturers and authorised 
representatives, devices, certificates, vigilance and 
clinical investigation data, as well as to contribute to a 
uniform application of the Directives, in particular in 
relation to registration requirements.
EUDAMED contains registrat ion data of 
manufacturers, authorised representatives and 
devices; data relating to certificates issued, modified, 
supplemented, suspended, withdrawn or refused; data 
obtained in accordance with the vigilance procedure; 
and data on clinical investigations. 
In Italy, SISTRA (Sistema Informativo dei Servizi 
Trasfusionali) is the information system established 
by Italian Ministry of Health Decree of 21st December 
2007309, developed as a strategic support for the 
achievement of the objectives set out in Law 219/2005265: 
"self-sufficiency of blood and blood products, transfusion 
safety, basic levels of care and uniform development of 
transfusion medicine". 
SISTRA enhances the flow of information between 
the Italian Ministry of Health, the Regions and the 
Autonomous Provinces of Trento and Bolzano and 
the National Blood Centre, encouraging regional and 
national interactions, as well as a detailed analysis of 
consumption and production data.
Informed consent, information and data protection
It is important to provide information on technologies 
in such a way that the patient can truly understand it. 
The principle of informed consent consists in the right 
of patients to obtain all necessary information in order 
to make a well-informed and responsible decision and to 
have greater participation in their treatment. According 
to clause 5 of the Oviedo Convention report310 the 
information must be appropriate with respect to the 
goals, the nature of the intervention and the potential 
consequences and risks for the patient. 
Regarding FFP, another salient regulation is the 
"Additional Protocol to the Convention on Human 
Rights and Biomedicine concerning Biomedical 
Research"311, in which clauses 13 and 14 regulate the 
information to be provided to patients, as well as their 
informed consent. The Declaration of Helsinki is another 
important document concerning informed consent317. 
Informed consent is an essential prerequisite for 
the patient's free and responsible choice to begin any 
medical intervention. Indeed, informed consent is 
generally considered as a process by which the treating 
health care provider discloses appropriate information 
to a competent patient, so that the patient may make 
a voluntary choice to accept or refuse treatment. In 
order to be valid, informed consent requires that the 
individual should have the capacity to make the decision, 
that the choice should be voluntary, that the individual 
be provided with appropriate information, in a format 
that he or she can understand, regarding the benefits, 
risks, consequences of and alternatives to the proposed 
treatment; and that the decision is made carefully289,293. 
Whether separate informed consent for blood 
transfusions should be required is the object of 
debate294,302. However, there is general agreement that 
before being asked to consent to a transfusion, there 
should be discussion with the patient about the reason 
for the transfusion, i.e. the purpose and anticipated 
benefit of the transfusion, including the consequences 
of not performing the transfusion, the alternatives to 
transfusion, which may include the possibility of an 
autologous transfusion, and clarification of the risks 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
370
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
associated with transfusion. Patients should also be given 
the opportunity to ask questions and should be informed 
of their right to refuse a transfusion303.
In Italy, informed consent to blood transfusion is 
required by the Ministerial Decree of 3rd March 2005 
"Characteristics and modalities for blood and blood 
by-products donation". It is worth mentioning clause 
11 ("Informed consent of the recipient") which specifies 
that the recipient of blood products should be previously 
informed that such procedures can never be completely 
risk-free, and that he or she must express written consent 
or dissent to the transfusion306.
Nevertheless, the practice of obtaining a valid consent 
for blood transfusion is still highly heterogeneous across 
the country and should be conformed as soon as possible. 
As noted, an element to be discussed with patients 
requiring a transfusion concerns its risks. Patients 
should be informed of potential damages due to the PRT. 
Moreover, they should be informed of residual risks 
concerning pathogens for which no detection method 
exists (i.e. emerging viruses) or the "window period", 
in which blood levels of specific disease markers are 
too low for detection. 
To achieve this goal, some requirements have 
to be fulfilled. Particular attention must be paid to 
the statement within Directive 2002/98/EC: "It is 
important to introduce a set of organised surveillance 
procedures to collect and evaluate information on the 
adverse or unexpected events or reactions resulting 
from the collection of blood or blood components 
in order to prevent similar or equivalent events or 
reactions from occurring thereby improving the 
security of transfusion by adequate measures. To 
this end a common system of notification of serious 
adverse events and reactions linked to the collection, 
processing, testing, storage, and distribution of blood 
and blood components should be established in 
Member States"254. For this reason, haemovigilance 
programmes must be implemented as extensively as 
possible. The first haemovigilance programme in 
Italy was presented in a document from the Italian 
National Health Service in 2004/2005. Since 2009, all 
haemovigilance data are collected on SISTRA and are 
available on the websites of both the Italian National 
Health Service and the National Blood Centre. 
In the same vein, Directive 2002/98/EC states, in 
clauses 14-15, that "Member States must ensure that blood 
establishments implement a system for identifying each 
single blood donation and each single blood unit and 
components thereof, enabling full traceability to the donor 
as well as to the transfusion and the recipient thereof"254.
In brief, data on potential harm due to PRT for plasma 
must be collected and patients should be informed of 
them. As a consequence, informed consent forms must 
be updated from time to time. The right to have access to 
full information and to safeguard one's privacy imposes 
on authorities the duty to guarantee proper, safe access 
to personal data, as affirmed in Directive 95/46/EC of 
the European Parliament and of the Council313. In more 
detail, this Directive establishes that: 
1) Member States shall prohibit the processing of 
personal data revealing racial or ethnic origin, 
political opinions, religious or philosophical beliefs, 
trade-union membership, and the processing of data 
concerning health or sexual habits. 
2) Paragraph 1 shall not apply where: (i) the patient has 
given his or her explicit consent to the processing 
of those data, unless the laws of the Member State 
explicitly claim that the prohibition referred to in 
paragraph 1 may not be lifted even in the presence 
of the patient's consent; (ii) processing is necessary 
to carry out the obligations and specific rights of 
the controller in the fulfilment of law, when it is 
authorised by national law providing for adequate 
safeguards; (iii) processing is necessary to protect 
the vital interests of the patient or of another person 
who is physically or legally incapable of giving his 
or her consent; (iv) processing is carried out in the 
course of its legitimate activities with appropriate 
guarantees by a foundation, association or any 
other non-profit-seeking body with a political, 
philosophical, religious or trade-union aim and if 
the processing relates solely to the members of the 
body or to persons who have regular contact with it, 
in connection with its purposes and if data are not 
disclosed to a third party without the consent of the 
data subjects; or (v) the processing relates to data 
which are manifestly made public by the data subject 
or are necessary for the establishment, exercise or 
defence of legal claims. 
3) Paragraph 1 shall not apply where processing of 
the data is required for the purposes of preventive 
medicine, medical diagnosis, provision of care or 
treatment or management of health-care services, 
and where those data are processed by a health 
professional under national law or rules established 
by national competent bodies, under the obligation 
of professional secrecy or by another person also 
subject to an equivalent obligation of secrecy. 
4) Subject to the provision of suitable safeguards, 
Member States may, for reasons of substantial public 
interest, lay down exemptions in addition to those 
laid down in paragraph 2 either by national law or 
by decision of the supervisory authority. 
5) Processing of data relating to offences, criminal 
convictions or security measures may be carried out 
only under the control of an official authority, or if 
suitable specific safeguards are provided under national 
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law, subject to derogations which may be granted by 
the Member State under national regulations providing 
suitable safeguards. However, a complete register 
of criminal convictions may be kept only under the 
control of an official authority. Member States may 
establish that data relating to administrative sanctions 
or judgments in civil cases shall also be processed under 
the control of an official authority. 
6) Derogations from paragraph 1 provided in paragraphs 
4 and 5 shall be notified to the Commission. 
7) Member States shall determine the conditions under 
which a national identification number or any other 
identifier of general application may be processed; 
moreover, clause 8 of the European Convention 
on Human Rights "Right to respect for private and 
family life" claims that314:
 - Everyone has the right to respect for his or her 
private and family life, home and correspondence.
 - There should not be any interference by a public 
authority with the exercise of this right, except 
for cases regulated by law and if it is necessary 
in the interests of national security, public safety 
or the economic well-being of the country, for the 
prevention of disorder or crime, for the protection 
of health or morals, or for the protection of the 
rights and freedoms of others. 
Finally, we recall the Sentences of the European Court 
of Justice of the 20th May 2003 C-465/00, C-138/01, 
C-139/01315 and the Working Document on research on 
biological materials of human origin by the Committee 
on Bioethics (DH-BIO) of 18th March 2014316. 
In addition, patients should be given some time 
to think about their treatment and take a decision, 
especially if this involves assimilating complex technical 
information or a tough weighting of risks and benefits 
of the procedure. It should be assessed beforehand if a 
given technology allows such time for consideration. 
Unfortunately, European dispositions do not 
establish time limits for the provision of informed 
consent. Effective informed consent implies allowing 
the patient the time necessary to consider alternatives. 
We believe that sufficient time is implied in an adequate 
and appropriate informed consent. It is also true that 
informed consent may require more time for specific 
patients310-313. 
However, there are situations in which a patient's 
health state requires immediate action. In emergency 
situations it is unlikely that such pre-transfusion discussion 
can take place. This could be, for example, because the 
patient does not have the capacity to understand the 
situation. In these cases, since prior consent for blood 
transfusion is usually considered necessary, then we must 
consider that such prior consent should also be required 
for all the other potential interventions that might be 
required during a medical or surgical procedure, such 
as, for example, magnetic resonance imaging, X-rays 
and anaesthesia317. With regards to emergency situations 
and informed consent issues we could cite clause 9 of 
the Oviedo Convention and clauses 15 and 16 of the 
"Additional Protocol to the Convention on Human Rights 
and Biomedicine concerning Biomedical Research". 
Moreover, implementing a requirement to obtain and 
document specific consent for blood transfusions could 
require deeper insight into the patient's role within medical 
decision-making processes. It is, however, crucial to 
remember that the consent process is not merely a form-
filling exercise in the physician-patient relation. 
Justice and equity 
As mentioned above, guaranteeing equal access 
to effective care for those in need is one of the main 
principles for the provision of health care in systems 
based on solidarity (i.e. National Health Services). 
Limited health care resources do, therefore compel cost-
effectiveness considerations and prioritisation of health 
care measures. In this sense, the use of technologies may 
influence the fairness of healthcare systems, or require 
special considerations in order to ensure that justice is 
not compromised.
The European Union has produced many documents 
on healthcare matters within Member States, such as: 
Decision n. 1350/2007/EC of the European Parliament 
and of the Council, establishing a second programme of 
Community Action in the field of health (2008-2013)318; 
the White paper of the European Commission "Together 
for Health: A Strategic Approach for the EU 2008-
2013"319; the Communication from the Commission to 
the Council, the European Parliament, the European 
Economic and Social Committee and the Committee 
of the Regions e-Health - making healthcare better 
for European citizens: an action plan for a European 
e-Health Area320. With regard to cross-border healthcare 
assistance in Europe the most relevant documents include 
the 2011/24/UE Directive of the European Parliament 
and the Council, concerning the application of patients' 
rights in cross-border healthcare321; Recommendation 
Rec (2006)18 of the Committee of Ministers to Member 
States on health services in a multicultural society322; and 
the Council of the European Union Directive on cross-
border healthcare adopted on 28th February 2011323. It 
is also worth recalling the judgment of the Court of 
Justice of the European Union issued on 28th April 1998 
(C-120/95)324. 
Finally, regarding the possibility of infringing 
some intellectual property right, at the European 
level the reference standard for the patentability of 
biotechnological inventions is Directive 98/44/EC of 
the European Parliament and of the Council325.
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Discussion
We feel that the respect of safety, quality, and security 
as well as of consent, information- and data- protection 
is fundamental. In Italy, the current quality standards of 
transfusion medicine activities and the quality standards and 
safety levels of therapeutic blood and blood products are 
good, especially regarding the lack of TTI. Haemovigilance 
and clinical risk management systems contribute to the 
evolution of comprehensive blood and blood product 
safety. Nevertheless, the continuous improvement and 
optimisation required by the "Good Practice Guidelines 
for Blood Establishments and Hospital Blood Banks" must 
be pursued in order to align our country's standards to the 
European Union's higher standards.
The application of guidelines/criteria for the 
appropriate management and clinical utilisation of blood 
resources is of paramount importance as it represents a 
fundamental "parallel tool" for blood and blood product 
self-sufficiency, as well as being a safety measure per se. 
However, greater legislative uniformity among regions 
and specific provision for the application of the best 
PRT are still crucial. 
In conclusion, although many documents concerning 
blood management have been produced, there is still a 
relevant lack of homogeneous guidelines in Italy. 
Social domain
Introduction
The social domain is one of the basic areas in a HTA. 
This domain "takes the patient as a point of departure 
in its analysis of the manifold social implications of 
health technology. The focus of the domain is on the 
diverse social arenas where the patient lives and acts 
during the period of sickness and treatment"326. These 
"social places", in which health technologies are put in 
use, include hospitals, out-hospital clinics, home care, 
general practitioners' offices, daily life, homes, schools, 
and workplaces. People deal with health technologies 
with feelings (hope, fear, uncertainty, etc.), experiences, 
and meanings, in personal and social ethical frameworks. 
In other words, the social analysis is concerned with 
all those aspects that involve the human being and his 
or her role in different arenas (as a citizen, employee, 
consumer, family member, etc.) in the society.
Moreover, the social domain, just as the ethical 
analysis, can support the HTA process as a whole (e.g., 
by prioritising topics/issues, defining/framing research 
questions). For practical reasons, in our HTA process the 
social assessment was conducted as a separate section 
of the HTA process.
Methods
Two kinds of issues should be addressed in a social 
analysis of PRT for plasma from the individual's point 
of view (patient first, but also health professionals 
involved in plasma management): (i) the resources 
required for the health technology in question, aimed 
at producing satisfactory results (first of all, safety and 
clinical benefit) 327 through the use and management of 
the health technology itself; (ii) experiences, feelings 
(e.g. hopes, fears), actions/reactions and social changes/
consequences (e.g. working capacity, relationships) 
produced by the given health technology. 
Furthermore, the social analysis addresses aspects that 
are also important for all the other domains of the HTA328. 
There are several theoretical frameworks for carrying 
out a social analysis326,329-338 Of these, we chose and 
applied the EUnetHTA model which considers three 
different topics (major life issues; individual issues; 
communication) covering nine issues (Table LVIII).
Each issue was first defined, and then its relevance 
considered, information sources identified, and literature 
searches performed. All issues were considered relevant 
to the technology in question. The results of the analysis 
explicitly include the set of issues, with the topics 
organised into two main paragraphs.
The social assessment was carried out by a team of 
four ethicists (three of them with social research skills/
experience).
The main sources of information for the social 
analysis were literature identified in international 
databases (PubMed, Cochrane Library, CRD) and the 
specific assessments provided by other HTA domains 
in this process.
Literature search
A three-step literature search was applied: (i) all 
participants in the HTA project were asked to notify the 
social analysis group if they found specific contributions 
discussing social issues. No contributions were notified; 
(ii) a search was made for HTA reports on the topic in 
online databases. Fifteen references were found, but five 
of them were not available; and (iii) PubMed and the 
Cochrane Library were searched for clauses on social 
topics relating to PRT for FFP. 
The PubMed query was based on the following 
scheme: 
SOCIAL ASPECTS ("family" OR "caregiver" OR "daily 
life" OR "communication" OR "informed consent" OR 
"return to work" OR "hospital stay" OR "perceptions" 
OR "preference" OR "expectation" OR "quality of life").
Twenty-six contributions of possible interest for the 
social domain were identified.
Information selection 
The contents of the ten HTA reports available were 
scrutinised. None of them contained a specific section 
on the social domain.
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As far as concerns articles in PubMed and the 
Cochrane Library: the titles and abstracts of the 916 
papers were screened by two independent reviewers to 
verify whether they contained specific information on 
"social" topics concerning PRT for plasma. Of the 916 
screed articles, 29 were of possible relevance for the 
social domain. Their titles and abstracts were scrutinised 
and four were considered to contribute slightly to 
answering the set of EUnetHTA social domain questions, 
although none explicitly addressed the social issues 
related to PRT for plasma50,121,223,339. 
Finally, socially relevant data gathered from other 
HTA domains were considered.
Results
Four PRT for plasma (SD, MB, amotosalen and 
riboflavin) are the object of the present analysis. These 
PRT have been developed in different times to reduce/
prevent the transmission of blood-borne pathogens in 
plasma and, consequently, to increase the safety of plasma 
products for individuals and for society as a whole. 
The socially relevant issues identified were first 
summarised and then organised into two main 
paragraphs, according to the EUnetHTA social domain 
table of issues.
Major life areas/individual issues
In general, social areas concerning the patient (family 
life, hospital/home care, work, leisure time, lifestyle, 
cultural activities) are directly influenced to variable 
extents, by the technologies in question, because the 
availability of plasma that is as safe as possible implies 
a longer and better quality life for the patient, without 
neglecting the value connected to clinical benefits (cf. 
efficacy, safety, legal and ethical domains). This could 
allow patients to maintain/pursue their roles with regards 
to functioning and relations in a socially appropriate 
way in major life areas, because their physical and 
psychological status could improve (cf. ethical, efficacy 
and safety domains).
Safe plasma is also relevant to health professionals 
involved in different levels of the health care service in 
which daily clinical routine requires the use of blood 
components, to employees of plasma product companies, 
and to the social environment (namely work, family and 
friends) of the patient.
Furthermore, human, technical, economic, cultural, 
physical, emotional, personal, social, juridical, and 
organisational support and resources are needed, in 
general, to assure the following satisfactory results: 
fair availability of safe blood components, irrespective 
of regional contexts within a country; safe blood 
management in daily clinical/organisational routines; 
and an increasingly safe production of plasma (cf. 
organisational and legal domains). 
In particular,  adequate juridical/technical 
regulations should be considered as a resource for 
helping patients to benefit fully from a technology: 
for example, the European Union Directive 2002/98/
EC states the need to set up organised surveillance 
procedures to collect/evaluate information on the 
adverse/unexpected events/reactions resulting from 
the collection and transfusion of blood or blood 
components. Likewise, an appropriate quality control 
and organisational framework for plasma delivery 
should be considered as a resource. Furthermore, it 
is socially relevant to address the matter of which 
economic/financial resources the patient can (or 
cannot) count on, to activate the use of the technology. 
Moreover, depending on personal orientations, patients 
may react to a technology in a positive or negative 
way, for example with preferences/perceptions (such 
as a critical attitude towards "scientific" medicine 
in favour of "alternative" medicine) and existential 
experiences/feelings (e.g.: the person's values as a 
human being, or depending on his/her social status; 
changes in self-conception/esteem) (cf. also efficacy, 
safety, legal and ethical domains). 
Finally, although a free and responsible choice is 
needed to make sure that the patient has acted adequately 
Table LVIII - Issues considered in the EUnetHTA social domain assessment.
Topic Issue
Major life areas H0001 - Which social areas does the use of the technology influence? 
H0002 - Who are the important others that the use of the technology may affect in addition to the patient?
H0003 - What kind of support and resources are needed or might be released as the technology is put to use? 
H0004 - What kinds of changes does the use of the technology generate in the patient’s role in the major life areas? 
H0005 - What kind of changes does the implementation and  use of the technology mean for the patient’s physical 
              and psychological functioning in his or her major life areas? 
Individual H0006 - How do patients and important others react and act upon the technology? 
Communication H0007 - What is patients' and important others' knowledge and understanding of the technology? 
H0008 - How is the information regarding the use of the technology processed and exchanged? 
H0009 - What are the consequences in decision making?
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towards the technology, this should not be reduced to a 
mere signature on an informed consent form (cf. legal 
and ethical domains).
Communication
Personal and social knowledge and understanding 
about PRT-FFP are crucial both for an adequate 
perception of the technology in question and for the 
socially accepted cost-effectiveness ratio in the light of 
the core values of the welfare-based Italian National/
Regional Health Service (centrality of the person's 
health; universal, fair and humanitarian access to health 
care provisions, economic/organisational sustainability 
of the health service).
Nowadays, traditional media (radio, television, 
newspapers, magazines) and web-based media (social 
networks, blogs, institutional/patients'/citizens' websites, 
etc.) offer a large amount of information, which is 
not, however, synonymous with providing full, real 
knowledge, understanding and awareness of all the 
aspects of PRT-FFP, which include the real clinical 
benefits gained through plasma inactivation technologies, 
but also the fact that the risk of transmission of pathogens 
is very low but not absent, and that close haemovigilance 
and post-marketing surveillance programmes are needed 
in order to continue to collect information on risks 
and benefits of the technology (cf. also current use of 
technology, safety and ethical domains); furthermore, 
continuous updated cost-effectiveness analyses on the 
technology in question are needed to understand the 
financial outlay required from the National Health 
Service (i.e.: from citizens), but also to identify and 
share a possible, defined economic threshold for the 
reimbursement of these technologies. At present, the 
available cost-effectiveness analyses (cf. economic 
domain) seem to suggest that the best option for plasma 
pathogen inactivation is the SD method. It is crucial, from 
the social point of view, to define how the information 
regarding the use of the technology is processed 
and exchanged. The qualitative and quantitative 
multidisciplinary adequacy of the information about the 
technology in question must, therefore, be continuously 
verified340. From the qualitative point of view, institutional 
information strategies, shared by the Ministry of Health 
and citizens/patients' organisations, should be designed 
and updated in the light of biomedical advances. From 
the quantitative point of view, every possible effort 
must be made in order to provide citizens with clear 
and understandable information, and to avoid forms 
of triumphalism and dramatization or demonization 
of the technology. Furthermore, information should be 
free from conflicts of interest (cf. also organisational 
domain). Social information campaigns should be aimed 
at avoiding public mistrust towards the technology or 
towards medicine in general. Finally, patients should be 
involved and empowered in decision-making processes, 
also through citizens/patients' associations (cf. also 
organisational and ethical domains)341-349. 
Discussion
The ever-present threat of emerging and re-emerging 
infectious diseases and the risk of clinical repercussions 
from the transfusion of blood products drive the need 
for new technologies. 
PRT offer a new approach to improve blood safety 
and their adoption has been gradual, but steady over the 
past decade. The technologies and methods discussed in 
this HTA report highlight on the complexity of finding 
a balance between effective pathogen inactivation in 
blood products and acceptable quality and functionality 
of the haemostatic components.
Overall, the assessment did not reveal a dominant 
strategy for pathogen inactivation of FFP. The vast 
majority of the studies considered investigated the safety, 
efficacy and economic aspects of SD-FFP, MB-FFP, 
R-FFP and A-FFP, but comparative studies among the 
pathogen inactivation technologies were limited. 
The evidence-based indications for the use of 
plasma and PRT-treated plasma are few and specific. 
PRT-treated plasma has, in fact, been in clinical use 
for several years and proven effective in a variety 
of therapeutic settings, but each PRT system has 
some weakness or gap in terms of efficacy and each 
of the major methods in development has a specific 
set of potential concerns unique to the method. The 
supportive and often prophylactic nature of blood 
component therapy in a variety of clinical situations 
complicates the clinical evaluation of these novel 
blood products. 
Efficacy
Most clinical efficacy studies designed to compare 
PRT-treated and untreated plasma involve only 
small numbers of patients and are not, therefore, 
adequately powered to detect statistically significant 
minor differences. In addition, they assess increments 
in coagulation factor levels and changes in in-vitro 
coagulation blood tests rather than clinically meaningful 
outcomes. Concerns about the low levels of plasmin 
inhibitor, protein S, or antitrypsin activity in PRT-
treated plasma have not been confirmed in clinical 
studies, and claims of thrombosis or hyperfibrinolytic 
bleeding triggered by reduced protein S or low plasmin 
inhibitor potencies have not withstood critical review. 
Extensive clinical experience has shown that reduced 
levels of coagulation factors, as a result of PRT, do not 
significantly impair the clinical efficacy or tolerance of 
the treated plasma.
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The first method developed to inactivate enveloped 
viruses in plasma protein preparations was SD 
treatment. SD-FFP has proven to be non-inferior to 
untreated FFP in the management of a wide range 
of congenital and acquired bleeding disorders. 
Furthermore, the major advantages of SD plasma over 
FFP and the other types of pathogen-inactivated plasma 
are its extreme safety with respect to TRALI and the 
significantly lower likelihood of provoking allergic 
reactions. Both advantages are interpreted as results 
of the dilution effect of pooling. 
While MB-treated plasma was associated with 
apparently fewer allergic reactions than plasma, a single-
centre retrospective haemovigilance investigation in 
France did not confirm this finding. 
The difficulty of comparing the frequency of adverse 
events recorded in different haemovigilance reports, 
because of different reporting procedures, has been 
confirmed.
Two other technologies, based on a photochemical 
process involving amotosalen (a psoralen) or riboflavin, 
both plus light treatment, have been developed more 
recently. There are few studies available on these 
technologies and the level of evidence they provide is 
low or moderate. 
Potential long-term side effects of photosensitisers 
and their photoproducts still remain a matter of debate, 
and, before broad implementation of these photoactive 
techniques, it must be shown that they are safe, robust 
in daily routine, and cost-effective and that their efficacy 
is controllable. 
Clinical experience with PRT-treated plasma has 
substantiated that the products are safe, although this 
work is in an early stage of exploration and the full 
potential of these technologies has yet to be determined. 
Safety domain
Blood component transfusions will never be 
completely safe because of an intrinsic risk of 
transmitting emerging pathogens to the recipients. 
However, plasma pathogen inactivation methods may 
be considered safe especially as regards the transmission 
of viruses and bacteria. No cases of HIV, HCV or HBV 
transmission have been observed in the European 
countries analysed in the last few years. As far as 
concerns other clinical outcomes, there has recently 
been an increase in allergic reactions, while the actions 
taken by many countries to minimise the risk of TRALI 
have been appropriate. Overall, the number of cases of 
TRALI has been very low in recent years and tended to 
zero in the past year. 
The results of the literature search did not enable 
a direct comparison between the different pathogen-
reduction methods. Overall, there are few studies that 
compare the various techniques with each other or with 
the conventional method. Furthermore, haemovigilance 
data are conflicting across European countries because 
the alerts are reported on a voluntary basis in some 
countries. However, with these caveats, according to 
the data collected, the SD-FFP technique seems to have 
the best safety profile, even if evidence supporting 
this statement is limited and this conclusion should be 
considered cautiously. It became clear from this review 
that more comparative studies need to be performed in 
order to assess the safety profile of the various methods 
directly.
Economic domain
Cost-effectiveness studies included in this literature 
review are limited to the comparison of SD-FFP vs FFP. 
Some articles took into account the SD technique, while 
others examined the branded product (Octaplas®). The 
results of the studies are conflicting and not comparable. 
The variability of the results depends on differences in 
study designs, study populations and assumptions. The 
evidence included in this assessment primarily indicates 
that the cost-effectiveness of the SD-FFP technique 
compared to FFP depends on several factors, such as the 
patients' age and therefore life expectancy, the health status 
of patients undergoing plasma transfusion and the related 
transfusion complications considered. Evidence on cost-
effectiveness is very limited: a good cost-effectiveness 
profile was observed only in certain subgroups of patients. 
Thus, criteria for denying the new component should be 
established and would be acceptable from an ethical point 
of view. The wide heterogeneity of results and the lack of 
comparative evidence for the SD technique make the cost-
effectiveness of this method uncertain. Further research 
is needed to investigate the cost-effectiveness of other 
PRT and to obtain more reliable results. Organisational 
analyses investigating "real practice" issues should be 
carried out in order to identify relevant and common cost 
drivers of the various approaches to pathogen inactivation 
for future cost-effectiveness studies. Moreover, different 
outcome measures should be considered to improve 
the effectiveness estimates and to carry out evaluations 
from a social perspective too, in order to present a 
broader overview of the impact of alternative plasma 
products on patients and on the health care system. 
Finally, value-specific thresholds for interventions to 
improve blood safety should be defined also for clinical 
outcome measures, since the cost-utility approach can be 
insufficient in this clinical area.
Organisational domain
The analysis of organisational aspects was carried 
out by dividing infectious risk prevention procedures 
into three groups: traditional FFP, "in-house" pathogen 
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inactivation procedures (grouped together and assumed 
to have the same organisational impact) and the SD-FFP 
industrial method.
Few studies have investigated organisational aspects 
of PRT; in fact, most of the information was retrieved 
from documents released by monitoring authorities, 
grey literature, manufacturers' handbooks and experts' 
opinions, which creates a risk of bias due to insufficient 
or selective inclusion of information and data, and can be 
considered a limitation of our review. Furthermore, data 
from experts were limited by their positions, knowledge 
asymmetry and time constraints, but the information 
included was analysed critically. 
Organisational changes resulting from the adoption 
of PRT occur mainly in the stages of processing, storage 
and distribution of plasma. "In-house" pathogen-
inactivation procedures are performed in hospital blood 
centres on single donor bags, blood units are stored in 
the hospital blood bank and transport between facilities 
is not, therefore, required but enough storage space must 
be available. On the other hand, industrial pathogen 
inactivation procedures require collected blood to be 
transported to and from the manufacturer's facilities, 
involving logistics for the maintenance of the cold 
chain, while pathogen inactivated blood units are stored 
in interim depots before being distributed to hospital 
blood banks. The strengths of these different PRT are 
that plasma prepared with "in-house" procedures is not 
pooled, thus reducing the risk of a whole plasma pool 
being contaminated due to a single infected bag, while 
plasma prepared with the industrial method requires 
EMA Plasma Master File certification, which guarantees 
full traceability of the plasma, simplification and 
standardisation of the transfusion chain and the quality 
of information at the European level.
With regards to quality control, SD-FFP is a 
pharmaceutical product, whereas "in-house" procedures 
use medical devices and the resulting plasma is not 
considered as a drug. This fact underlies the difference 
between the regulatory systems for the two groups of 
technologies. In Europe, quality control and validation 
of SD-FFP are guided by the guidelines of the European 
Council and the EMA, under State Laboratory control 
and marketing authorisation is issued by national health 
authorities.
Ethical domain
From the ethical point of view, important points to 
consider during decision-making about SD-FFP, MB-
FFP, A-FFP and R-FFP are that the risk-benefit ratio of 
using these PRT seems to be favourable, although this 
conclusion should be consolidated by additional data, 
and before a transfusion of pathogen-reduced blood 
products, patients should always be informed about the 
PRT used and its potential benefits and risks, clarifying 
that a minimal risk always remains. 
It is still uncertain whether the use of SD-FFP, 
MB-FFP, A-FFP and R-FFP fulfils the criteria of just 
resource allocation.
Legal domain
The legal domain descriptive analysis at national 
and European levels considered the directives and laws 
which define quality, and safety standards for the testing, 
processing, storage and distribution of human blood and 
blood components. Within the documentation studied, 
we found common elements concerning the discipline 
of information, consent, protection of privacy and access 
to treatment. There are no ad hoc directives on pathogen 
reduction at the European level and a set of homogeneous 
guidelines is also lacking in the Italian scenario. 
Social domain
The analysis of the social domain revealed the need 
for further analyses to safeguard the uniform access to 
blood services for patients. Economic evaluations should 
play a critical role for this purpose. 
The Authors declare no conflicts of interest.
References
1) Psychogios N, Hau DD, Peng J, et al. The human serum 
metabolome. PLoS One 2011; 16: e16957.
2) Benjamin RJ, McLaughlin LS. Plasma components: 
properties, differences, and uses. Transfusion 2012; 52: 
9S-19S.
3) Sherwood L. Human Physiology: From Cells to Systems. 8th 
ed. Belmont, CA: Brooks/Cole-Cengage Learning; 2013. 
4) Strumia MM, McGraw JJ. The development of plasma 
preparations for transfusions. Ann Intern Med 1941; 15: 80-8. 
5) Gosselin RC, Marshall C, Dwyre DM, et al. Coagulation 
profile of liquid-state plasma. Transfusion 2013; 53: 579-90. 
6) Grazzini G, Mannucci PM, Oleari F. Plasma-derived 
medicinal products: demand and clinical use. Blood Transfus 
2013; 11: s2-5.
7) Burnouf T. Plasma fractionation. ISBT Science Series 2012; 
7: 62-7. 
8) Labarinas S, Arni D, Karam O. Plasma in the PICU: why and 
when should we transfuse? Ann Intensive Care 2013; 3: 16.
9) Alhumaidan H, Cheves T, Holme S, Sweeney J. Stability of 
coagulation factors in plasma prepared after a 24-hour room 
temperature hold. Transfusion 2010; 50: 1934-42.
10) Council of Europe. Guide to the Preparation, Use and Quality 
Assurance of Blood Components. Recommendation No R 
(95) 15 on the Preparation, Use and Quality Assurance of 
Blood Components. 17th ed. Strasbourg: Council of Europe 
Press; 2013.
11) Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded 
treatment? Transfus Med 2012; 22: 315-20.
12) Kappler S, Ronan-Bentle S, Graham A. Thrombotic 
microangiopathies (TTP, HUS, HELLP). Emerg Med Clin 
North Am 2014; 32: 649-71.
13) O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.; 
British Committee for Standards in Haematology, Blood 
Transfusion Task Force. Guidelines for the use of fresh-frozen 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
377
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
plasma, cryoprecipitate and cryosupernatant. Br J Haematol 
2004; 126: 11-28.
14) Liumbruno G, Bennardello F, Lattanzio A, et al; Italian 
Society of Transfusion Medicine and Immunohaematology 
(SIMTI) Work Group. Recommendations for the transfusion 
of plasma and platelets. Blood Transfus 2009; 7: 132-50.
15) Italian National Institute of Health. Giampaolo A, Barca A, 
Catalano L, Hassan HJ. Proceedings of national meeting on 
appropriate use of blood, Rome, February 25-26, 2003. In: 
Rapporti ISTISAN 04/10. Italian National Institute of Health 
2004; ix: 1-186.
16) Seghatchian J, de Sousa G. Pathogen-reduction systems for 
blood components: the current position and future trends. 
Transfus Apher Sci 2006; 35: 189-96.
17) Moor AC, Dubbelman TM, VanSteveninck J, Brand A. 
Transfusion-transmitted diseases: risks, prevention and 
perspectives. Eur J Haematol 1999; 62: 1-18.
18) Bihl F, Castelli D, Marincola F, et al. Transfusion-transmitted 
infections. J Transl Med 2007; 5: 25.
19) Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk 
of transfusion-transmitted viral infections. The Retrovirus 
Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-90.
20) AuBuchon JP, Dodd RY. Inactivation of microbial 
contaminants of blood components. Clin Lab Med 1992; 
12: 787-803.
21) Molaro GL. La prevenzione del rischio trasfusionale infettivo 
e immunologico con il plasma fresco congelato trattato con il 
metodo del solvente/detergente. Blood Transf 2001; 46: 1-9.
22) Friedman C, Newsom W. IFIC Basic Concepts of Infection 
Control. 2nd ed. - Revised 2011. International Federation of 
Infection Control; 2011.
23) World Health Organization. Screening Donated Bloods for 
Transfusion-Transmissible-Infections. Available at: http://
www.who.int/bloodsafety/ScreeningTTI.pdf. Accessed on 
10/12/2014.
24) Leparc GF. Nucleic acid testing for screening donor blood. 
Infect Med 2000; 17.
25) Jongerius JM, Wester M, Cuypers HT, et al. New hepatitis 
B virus mutant form in a blood donor that is undetectable 
in several hepatitis B surface antigen screening assays. 
Transfusion 1998; 38: 56-9.
26) Jerome KR. Lennette's Laboratory Diagnosis of Viral Infections. 
4th ed. New York: Informa Healthcare USA, Inc; 2010. 
27) Bianco C. Choice of human plasma preparations for 
transfusion. Transfus Med Rev 1999; 13: 84-8.
28) del Río-Garma J, Alvarez-Larrán A, Martínez C, et al. 
Methylene blue-photoinactivated plasma versus quarantine 
fresh frozen plasma in thrombotic thrombocytopenic purpura: 
a multicentric, prospective cohort study. Br J Haematol 2008; 
143: 39-45.
29) Molaro GL. [Universal leucodepletion. Part one]. Il Servizio 
Trasfusionale 2000; 29. [In Italian.]
30) Dodd RY, Notari EP 4th, Stramer SL. Current prevalence 
and incidence of infectious disease markers and estimated 
window-period risk in the American Red Cross blood donor 
population. Transfusion 2002; 42: 975-9.
31) Dodd RY, Leiby DA. Emerging infectious threats to the blood 
supply. Annu Rev Med 2004; 55: 191-207.
32) Mohr H, Knüver-Hopf J, Gravemann U, et al. West Nile virus 
in plasma is highly sensitive to methylene blue-light treatment. 
Transfusion 2004; 44: 886-90. 
33) Leydold SM, Farcet MR, Kindermann J, et al. Chikungunya 
virus and the safety of plasma products. Transfusion 2012; 
52: 2122-30.
34) Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical 
inactivation of chikungunya virus in plasma and platelets 
using the Mirasol pathogen reduction technology system. 
Transfusion 2013; 53: 284-90.
35) Rock G. A comparison of methods of pathogen inactivation 
of FFP. Vox Sang 2011; 100: 169-78.
36) Mundt JM, Rouse L, Van den Bossche J, Goodrich RP. 
Chemical and biological mechanisms of pathogen reduction 
technologies. Photochem Photobiol 2014; 90: 957-64.
37) Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-
treated plasma: a virus-inactivated substitute for fresh frozen 
plasma. Blood 1992; 79: 826-31.
38) Garwood M, Cardigan RA, Drummond O, et al. The effect 
of methylene blue photoinactivation and methylene blue 
removal on the quality of fresh-frozen plasma. Transfusion 
2003; 43: 1238-47.
39) Naegelen C, Isola H, Dernis D, et al. Evolution of techniques 
for preparation of labile blood products (LBP): pathogen 
inactivation in LBP. Transfus Clin Biol 2009; 16: 179-89.
40) Webert KE, Cserti CM, Hannon J, et al. Proceedings of a 
Consensus Conference: pathogen inactivation - making 
decisions about new technologies. Transfus Med Rev 2008; 
22: 1-34.
41) Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation 
by solvent/detergent treatment and the manufacture of SD 
plasma. Vox Sang 1998; 74: 203-6.
42) Seltsam A, Müller TH. UVC irradiation for pathogen 
reduction of platelet concentrates and plasma. Transfus Med 
Hemother 2011; 38: 43-54.
43) Klein HG, Anderson D, Bernardi MJ, et al. Pathogen 
inactivation: making decisions about new technologies. 
Report of a consensus conference. Transfusion 2007; 47: 
2338-47.
44) European Directorate for the Quality of Medicines & 
HealthCare. Symposium on Implementation of Pathogen 
Reduction Technologies for Blood Components. Executive 
Summary. Strasbourg, France; 2010.
45) Osselaer JC, Debry C, Goffaux M, et al. Coagulation function 
in fresh-frozen plasma prepared with two photochemical 
treatment methods: methylene blue and amotosalen. 
Transfusion 2008; 48: 108-17.
46) French Ministry of Health. [Decision of 20 October 
2010 establishing the list and the characteristics of blood 
components.] JORF 28 November 2010. [In French.]
47) Agence Française de Sécurité Sanitaire des produits de Santé 
(AFSSAPS). Haemovigilance Annual report 2010. Available 
at: http://ansm.sante.fr/var/ansm_site/storage/original/
application/365a9 7e590280fb1192c05a838cb97bb.pdf. 
Accessed on 02/12/2014.
48) Mertes PM, Demoly P, Alperovitch A, et al. Methylene blue-
treated plasma: an increased allergy risk? J Allergy Clin 
Immunol 2012; 130: 808-12.
49) Seltsam A, Mueller TH. Updated hemovigilance data do not 
show an increased risk of allergic reactions to methylene 
blue-treated plasma. J Allergy Clin Immunol 2013; 131: 
1253-4.
50) Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute 
lung injury: reports to the French Hemovigilance Network 
2007 through 2008. Transfusion 2011; 51: 2102-10.
51) Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H. 
Photoinactivation of viruses in human fresh plasma by 
phenothiazine dyes in combination with visible light. Vox 
Sang 1991; 60: 207-13.
52) Seghatchian J, Struff WG, Reichenberg S. Main properties of 
the THERAFLEX MB plasma system for pathogen reduction. 
Transfus Med Hemother 2011; 38: 55-64. 
53) Politis C, Kavallierou L, Hantziara S, et al. Quality and safety 
of fresh-frozen plasma inactivated and leucoreduced with the 
Theraflex methylene blue system including the Blueflex filter: 
5 years' experience. Vox Sang 2007; 92: 319-26.
54) Murphy WG. Pathogen reduction: state of reflection in 
Ireland. Transfus Clin Biol 2011; 18: 488-90.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
378
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
55) De Silvestro G, Bagatella P, Tison T, et al. Virus-inactivated 
plasma - Plasmasafe: a one-year experience. Blood Transfus 
2007; 5: 134-42.
56) Equitani F, Mistretta G, Mele L, et al. Methylene blue-
photoinactivated fresh frozen plasma is an effective and 
safe treatment for inherited and acquired coagulopathies and 
bleeding disorders. Blood 2003; 102: 138b.
57) Navarro L, Lozano M, Puig L, Almazan C. Amotosalen 
(Intercept®) for the Inactivation of Pathogens for Transfusion 
Therapy. Catalan Agency for Health Information, Assessment 
and Quality. INAHTA Briefs Issue 2009/103.
58) Jimenez-Marco T, Ruiz-Alderton D, Bautista-Gili AM, 
Girona-Llobera E. Role of riboflavin- and UV light-treated 
plasma in prevention of transfusion-related acute lung injury. 
Transfus Med Hemother 2014; 41: 172-5.
59) INTERCEPT Use Overview. 2014 Cerus Corporation. 
Available at: http://www.interceptbloodsystem.com/intercept-
in-use/overview. Accessed on 10/12/2014.
60) Hellstern P, Solheim BG. The use of solvent/detergent 
treatment in pathogen reduction of plasma. Transfus Med 
Hemother 2011; 38: 65-70.
61) Irsch J, Lin L. Pathogen inactivation of platelet and plasma 
blood components for transfusion using the INTERCEPT 
Blood System™. Transfus Med Hemother 2011; 38: 19-31.
62) Adelaide Health Technology Assessment (AHTA) Technology 
Report, July 2011. Technologies for the inactivation/reduction 
of pathogens in blood products.
63) Canadian Agency for Drugs and Technologies in Health, 
CADHT Technology Report, March 2011. Octaplas compared 
with fresh frozen plasma to reduce the risk of transmitting 
lipid-enveloped viruses: an economic analysis and budget 
impact analysis.
64) FDA News Release. FDA approves Octaplas to treat 
patients with blood clotting disorders. January 17, 2013. 
Available at: http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm336009.htm. Accessed on 
02/12/2014.
65) FDA News Release. FDA approves first pathogen reduction 
system to treat plasma. December 16, 2014. Available at: http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm427111.htm. Accessed on 20/12/2014.
66) Solheim BG, Seghatchian J. Update on pathogen reduction 
technology for therapeutic plasma: an overview. Transfus 
Apher Sci 2006; 35: 83-90.
67) World Health Organization. Fact sheet N° 279. Blood safety 
and availability. Updated June 2014. Available at: http://
www.who.int/mediacentre/factsheets/fs279/en/. Accessed 
on 02/12/2014.
68) World Health Organization. WHO Library Cataloguing-in-
Publication Data: Towards 100% voluntary blood donation: 
a global framework for action. Available at: www.who.
int/bloodsafety/voluntary_donation/en/. Accessed on 
02/12/2014.
69) Polizzotto MN, Wood EM, Ingham H, Keller AJ; Australian 
Red Cross Blood Service Donor and Product Safety Team. 
Reducing the risk of transfusion-transmissible viral infection 
through blood donor selection: the Australian experience 2000 
through 2006. Transfusion 2008; 48: 55-63.
70) Special Issue: The evolving paradigm of patient blood 
management. Transfusion 2014; 54: 2587-790.
71) Clarke P, Will RG, Ghani AC. Is there the potential for an 
epidemic of variant Creutzfeldt-Jakob disease via blood 
transfusion in the UK? J R Soc Interface 2007; 4: 675-84.
72) European Centre for Disease Prevention and Control. 
Questions on variant Creutzfeldt-Jakob disease and blood 
transfusion; 2011. Available at: http://ecdc.europa.eu/
en/publications/_layouts/forms/Publication_DispForm.
aspx?ID=477&Lis t=4f55ad51-4aed-4d32-b960-
af70113dbb90. Accessed on 02/12/2014. 
73) Food and Drug Administration. Guidance for Industry. 
Revised Preventive Measures to Reduce the Possible 
Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) 
and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood 
and Blood Products. Available at: http://www.fda.gov/
BiologicsBloodVaccines/GuidanceComplianceRegula
toryInformation/GuidanceSDefault.htm. Accessed on 
02/12/2014.
74) Blajchman MA. The clinical benefits of the leukoreduction 
of blood products. J Trauma 2006; 60: S83-90.
75) International Atomic Energy Agency. Effects of ionizing 
radiation on blood and blood components: A survey. Vienna: 
IAEA-TECDOC-934; 1997.
76) World Health Organization. Annex 4 Guidelines on viral 
inactivation and removal procedures intended to assure the 
viral safety of human blood plasma products. WHO Technical 
Report, Series No. 924, 2004.
77) D'Alessandro A, Zolla L. Proteomics for quality-control 
processes in transfusion medicine. Anal Bioanal Chem 2010; 
398: 111-24.
78) Fournier-Wirth C, Coste J. Fitting new technologies into the 
safety paradigm: use of microarrays in transfusion. Dev Biol 
(Basel) 2007; 127: 61-70.
79) Fournier-Wirth C, Jaffrezic-Renault N, Coste J. Detection of 
blood-transmissible agents: can screening be miniaturized? 
Transfusion 2010; 50: 2032-45.
80) Velthove KJ, Over J, Abbink K, Janssen MP. Viral safety 
of human plasma-derived medicinal products: impact of 
regulation requirements. Transfus Med Rev 2013; 27: 179-83.
81) Burnouf T. Modern plasma fractionation. Transfus Med Rev 
2007; 21: 101-17.
82) Klamroth R, Gröner A, Simon TL. Pathogen inactivation 
and removal methods for plasma-derived clotting factor 
concentrates. Transfusion 2014; 54: 1406-17.
83) Unger U, Poelsler G, Modrof J, Kreil TR. Virus inactivation 
during the freeze-drying processes as used for the manufacture 
of plasma-derived medicinal products. Transfusion 2009; 
49: 1924-30.
84) Stadler M, Gruber G, Kannicht C, et al. Characterisation of 
a novel high-purity, double virus inactivated von Willebrand 
factor and factor VIII concentrate (Wilate). Biologicals 2006; 
34: 281-8.
85) Burnouf T, Radosevich M. Nanofiltration of plasma-derived 
biopharmaceutical products. Haemophilia 2003; 9: 24-37.
86) Seltsam A, Müller TH. Update on the use of pathogen-reduced 
human plasma and platelet concentrates. Br J Haematol 2013; 
162: 442-54.
87) Picker SM. Current methods for the reduction of blood-borne 
pathogens: a comprehensive literature review. Blood Transfus 
2013; 11: 343-8.
88) Picker SM. Pathogen reduction technologies: the best solution 
for safer blood? J Blood Disorders Transf 2012; 3: 5.
89) Pock K, Heger A, Janisch S, et al. Thrombin generation 
capacity is impaired in methylene-blue treated plasma 
compared to normal levels in single-donor fresh-frozen 
plasma, a licensed solvent/detergent-treated plasma (Octaplas) 
and a development product (Uniplas). Transfus Apher Sci 
2007; 37: 223-31.
90) Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis 
and HTLV-III viruses by exposure to tri(n-butyl)phosphate 
and sodium cholate. Lancet 1986; 1: 706-10.
91) Liumbruno GM, Franchini M. Solvent/detergent plasma: 
pharmaceutical characteristics and clinical experience. J 
Thromb Thrombolysis 2015; 39: 118-28.
92) Hambleton J, Wages D, Radu-Radulescu L, et al. 
Pharmacokinetic study of FFP photochemically treated with 
amotosalen (S-59) and UV light compared to FFP in healthy 
volunteers anticoagulated with warfarin. Transfusion 2002; 
42: 1302-7.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
379
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
93) Ciaravino V, Hanover J, Lin L, et al. Assessment of safety in 
neonates for transfusion of platelets and plasma prepared with 
amotosalen photochemical pathogen inactivation treatment 
by a 1-month intravenous toxicity study in neonatal rats. 
Transfusion 2009; 49: 985-94.
94) Seifried E, Henschler R, Müller MM. European perspectives 
on implementation. In: AuBuchon JP, Prowse C, editors: 
Pathogen Inactivation: The Penultimate Paradigm Shift. 
Bethesda: AABB Press; 2010. p. 261-78.
95) Pamphilon D. Viral inactivation of fresh frozen plasma. Br J 
Haematol 2000; 109: 680-93.
96)  Solheim BG, Svennevig JL, Mohr B, et al. The use of 
Octaplas in patients undergoing open heart surgery. In: 
Müller-Berghaus G, editor. DIC: Pathogenesis, Diagnosis 
and Therapy of Disseminated Intravascular Fibrin 
Formation. Amsterdam: Elsevier; 1993. p. 253-62.
97)  FDA Blood Products Advisory Committee 104th 
Meeting, September 20, 2012. Issue Summary - 
Topic II: Safety and efficacy of Octaplas LG, solvent/
detergent, ligand gel affinity chromatography treated 
plasma. Available at: http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/
B l o o d V a c c i n e s a n d O t h e r B i o l o g i c s /
BloodProductsAdvisoryCommittee/UCM319773.pdf. 
Accessed on 02/12/2014.
98)  Department of Health measures currently in place in the UK 
to reduce the potential risk of vCJD transmission via blood. 
April 2013. Available at: https://www.gov.uk/government/
news/measures-currently-in-place-in-the-uk-to-reduce-the-
potential-risk-of-vcjd-transmission-via-blood. Accessed on 
02/12/2014.
99)  Lozano M, Cid J, Müller TH. Plasma treated with methylene 
blue and light: clinical efficacy and safety profile. Transfus 
Med Rev 2013; 27: 235-40.
100) Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat 
platelets in platelet additive solution with the Mirasol® 
pathogen reduction technology system. Transfus Med 
Hemother 2013; 40: 44-8.
101) Meddeviceonline. CaridianBCT Receives CE Mark For 
Mirasol Pathogen Reduction Technology System For 
Plasma. Available at: http://www.meddeviceonline.com/doc/
caridianbct-receives-ce-mark-for-mirasol-0001.Accessed on 
02/12/2014.
102) Edwin Poots, MLA Tours Terumo BCT Northern Ireland, 
Manufacturing Facility. 2015 TERUMO BCT. Available at: 
https://www.terumobct.com/location/japan/about-terumobct/
press-room/Pages/21-AUG,-2014---Edwin-Poots,-MLA-
Tours-Terumo-BCT-Northern-Ireland,-Manufacturing-
Facility.aspx. Accessed on 02/12/2014.
103) Marschner S, Goodrich R. Pathogen reduction technology 
treatment of platelets, plasma and whole blood using 
riboflavin and UV light. Transfus Med Hemother 2011; 
38: 8-18.
104) Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness 
of solvent/detergent treatment of plasma derivatives: a data 
collection from Plasma Protein Therapeutics Association 
member companies. Transfusion 2009; 49: 1931-43.
105) Burnouf T, Goubran HA, Radosevich M, et al. Impact of 
Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity 
in solvent/detergent-treated plasma. Biologicals 2007; 35: 
349-53.
106) Horowitz B: United States: solvent/detergent plasma. In: 
AuBuchon JP, Prowse CV, editors. Pathogen Inactivation: 
The Penultimate Paradigm Shift. Bethesda: AABB Press; 
2010. p. 217-28.
107) Roberts P, Sims G. Use of vegetable-derived Tween 80 for 
virus inactivation by solvent/detergent treatment. Biologicals 
1999; 27: 263-4.
108) Klein HG, Dodd RY, Dzik WH, et al. Current status of 
solvent/detergent-treated frozen plasma. Transfusion 1998; 
38: 102-7.
109) Piquet Y, Janvier G, Selosse P, et al. Virus inactivation of fresh 
frozen plasma by a solvent detergent procedure: biological 
results. Vox Sang 1992; 63: 251-6.
110) Andreu G: France: solvent/detergent plasma. In: AuBuchon 
JP, Prowse CV, editors. Pathogen Inactivation: The 
Penultimate Paradigm Shift. Bethesda: AABB Press; 2010. 
p. 137-51.
111) Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture 
and in-vitro characterization of solvent/detergent-treated 
plasma. Vox Sang 1992; 63: 178-85.
112) Biesert L, Suhartono H. Solvent/detergent treatment of human 
plasma--a very robust method for virus inactivation. Validated 
virus safety of OCTAPLAS. Vox Sang 1998; 74: 207-12.
113) Heger A, Svae T-E, Neisser-Svae A, et al. Biochemical 
quality of the pharmaceutical licensed plasma OctaplasLG 
after implementation of a novel prion protein (PrPSc) 
removal technology and reduction of the solvent/detergent 
(SD) process time. Vox Sang 2009; 97: 219-25.
114) Ekiaby M, Sayed MA, Caron C, et al. Solvent-detergent 
filtered (SD-F) fresh frozen plasma and cryoprecipitate 
minipools prepared in a newly designed integral disposable 
processing bag system. Transfus Med 2010; 20: 48-61.
115) El-Burnouf T, Goubran HA, Radosevich M, et al. A process 
for solvent/detergent treatment of plasma for transfusion at 
blood centres that use a disposable bag system. Transfusion 
2006; 46: 2100-8.
116) El-Ekiaby M, Radosevich M, Goubran H, et al. New methods 
of plasma fractionation - a presentation of the 'mini-pool' 
fractionation procedure developed in Egypt. ISBT Science 
Series 2009; 4: 99-106.
117) Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral 
safety of solvent/detergent-treated blood products. Blood 
Coagul Fibrinolysis 1994; 5: S21-8; discussion S29-30.
118) Solheim BG, Rollag H, Svennevig JL, et al. Viral safety 
of solvent/detergent-treated plasma. Transfusion 2000; 40: 
84-90.
119) Pelletier JP, Transue S, Snyder EL. Pathogen inactivation 
techniques. Best Pract Res Clin Haematol 2006; 19: 205-42.
120) Heger A, Bailey A, Neisser-Svae A, et al. Removal of 
prion infectivity by affinity ligand chromatography during 
OctaplasLG® manufacturing--results from animal bioassay 
studies. Vox Sang 2012; 102: 294-301.
121) Svae TE, Neisser-Svae A, Bailey A, et al. Prion safety of 
transfusion plasma and plasma-derivatives typically used for 
prophylactic treatment. Transfus Apher Sci 2008; 39: 59-67.
122) Agner SJ. Virus inactivation in blood components by 
photoactive phenothiazine dyes. Transfus Med Rev 2002; 
16: 61-6.
123) Seghatchian J, Krailadsiri P. What's happening? The quality 
of methylene blue treated FFP and cryo. Transfus Apher Sci 
2001; 25: 227-31.
124) Seghatchian J, Walker WH, Reichenberg S. Updates on 
pathogen inactivation of plasma using Theraflex methylene 
blue system. Transfus Apher Sci 2008; 38: 271-80.
125) Lozano M, Cid J. Pathogen inactivation: coming of age. Curr 
Opin Hematol 2013; 20: 540-5.
126) Mohr H, Lambrecht B, Seltz A. Photodynamic virus inactivation 
of blood components. Immunol Invest 1995; 24: 73-85.
127) Williamson LM, Cardigan R, Prowse CV. Methylene blue-
treated fresh-frozen plasma: what is its contribution to blood 
safety? Transfusion 2003; 43: 1322-9. 
128) Mohr H. Methylene blue and thionine in pathogen 
inactivation of plasma and platelet concentrates. Transfus 
Apher Sci 2001; 25: 183-4.
129) Wainwright M, Mohr H, Walker WH. Phenothiazinium 
derivatives for pathogen inactivation in blood products. J 
Photochem Photobiol B 2007; 86: 45-58.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
380
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
130) Abe H, Yamada-Ohnishi Y, Hirayama J, et al. Elimination of 
both cell-free and cell-associated HIV infectivity in plasma 
by a filtration/methylene blue photoinactivation system. 
Transfusion 2000; 40: 1081-7. 
131) Knuver-Hopf J, Mohr H. Parvovirus B19 is sensitive to 
photodynamic and photochemical treatment. Abstract Book 
VIII European Congress of the ISBT; 2003; 94.
132) Knuver-Hopf J, Schaefer W, Groener A, et al. Human 
parvovirus in plasma is highly sensitive to methylene blue/
light treatment. Vox Sang 2010; 99: 1-516.
133) Gironés N, Bueno JL, Carrión J, et al. The efficacy of 
photochemical treatment with methylene blue and light for 
the reduction of Trypanosoma cruzi in infected plasma. Vox 
Sang 2006; 91: 285-91.
134) Achour A. Phenothiazines and prion diseases: a potential 
mechanism of action towards oxidative stress. Int J 
Antimicrob Agents 2002; 20: 305-6.
135) Amaral L, Kristiansen JE. Phenothiazines: potential 
management of Creutzfeldt-Jacob disease and its variants. 
Int J Antimicrob Agents 2001; 18: 411-7.
136) Wagstaff DJ. Dietary exposure to furocoumarins. Regul 
Toxicol Pharmacol 1991; 14: 261-72.
137) Lin L, Cook DN, Wiesehahn GP, et al. Photochemical 
inactivation of viruses and bacteria in platelet concentrates 
by use of a novel psoralen and long-wavelength ultraviolet 
light. Transfusion 1997; 37: 423-35.
138) Cid J, Ramiro L, Martínez N, et al. Quantitative and qualitative 
analysis of proteins in fresh frozen plasma obtained from 
whole blood donations and prepared with two photochemical 
treatments. Transfus Apher Sci 2008; 39: 115-21.
139) Cazenave JP. Photochemical inactivation of pathogens in 
platelets and plasma: five years of clinical use in routine and 
hemovigilance. Towards a change of paradigm in transfusion 
safety. Transfus Clin Biol 2011; 18: 53-61.
140) Roback JD, Conlan M, Drew WL, et al. The role of 
photochemical treatment with amotosalen and UV-A light 
in the prevention of transfusion-transmitted cytomegalovirus 
infections. Transfus Med Rev 2006; 20: 45-56.
141) Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses 
in platelet concentrates by photochemical treatment 
with amotosalen and long-wavelength ultraviolet light. 
Transfusion 2005; 45: 580-90. 
142) Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet 
components treated with amotosalen and ultraviolet A 
pathogen inactivation method: results of a meta-analysis of 
randomized controlled trials. Vox Sang 2012; 103: 322-30.
143) Grellier P, Benach J, Labaied M, et al. Photochemical 
inactivation with amotosalen and long-wavelength ultraviolet 
light of Plasmodium and Babesia in platelet and plasma 
components. Transfusion 2008; 48: 1676-84.
144) Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol 
PRT system for pathogen reduction of platelets and plasma: 
an overview of current status and future trends. Transfus 
Apher Sci 2006; 35: 5-17.
145) Reikvam H, Marschner S, Apelseth TO, et al. The Mirasol® 
pathogen reduction technology system and quality of platelets 
stored in platelet additive solution. Blood Transfus 2010; 
8: 186-92.
146) Douki T, Laporte G, Cadet J. Inter-strand photoproducts 
are produced in high yield within A-DNA exposed to UVC 
radiation. Nucleic Acids Res 2003; 31: 3134-42.
147) Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-
light based pathogen reduction: extent and consequence of 
DNA damage at the molecular level. Photochem Photobiol 
2004; 80: 15-21.
148) Silliman CC, Khan SY, Ball JB, et al. Mirasol pathogen 
reduction technology treatment does not affect acute lung 
injury in a two-event in vivo model caused by stored blood 
components. Vox Sang 2010; 98: 525-30.
149) Allain JP, Bianco C, Blajchman MA, et al. Protecting the 
blood supply from emerging pathogens: the role of pathogen 
inactivation. Transfus Med Rev 2005; 19: 110-26.
150) Kiang Tan L, Lam S, Low S, et al. Evaluation of pathogen 
reduction systems to inactivate Dengue and Chikungunya 
viruses in apheresis platelets suspended in plasma. Advances 
in Infectious Diseases 2013; 3: 1-9.
151) Burnouf T, Chou ML, Cheng LH, et al. Dengue virus 
inactivation by minipool TnBP/Triton X-45 treatment of 
plasma and cryoprecipitate. Vox Sang 2013; 104: 1-6.
152) Heger A, Kannicht C, Römisch J, Svae TE. Normal levels of 
ADAMTS13 and factor H are present in the pharmaceutically 
licensed plasma for transfusion (Octaplas®) and in the 
universally applicable plasma (Uniplas) in development. 
Vox Sang 2007; 92: 206-12. 
153) Heger A, Brandstätter H, Prager B, et al. Universal pooled 
plasma (Uniplas®) does not induce complement-mediated 
hemolysis of human red blood cells in vitro. Transfus Apher 
Sci 2015; 52: 128-35.
154) Macopharma. Blood Safety Website. Available at: http://
www.macopharma.com/en/theraflex-methylene-blue-MB 
plasma. Accessed on 02/12/2014.
155) Steinmann E, Gravemann U, Friesland M, et al. Two pathogen 
reduction technologies--methylene blue plus light and 
shortwave ultraviolet light--effectively inactivate hepatitis C 
virus in blood products. Transfusion 2013; 53: 1010-8.
156) INTERCEPT eNews delivers product news & information 
updates. Available at: http://www.interceptbloodsystem.
com/product-overview/intercept-plasma. Accessed on 
02/12/2014.
157) de Cock P et al. The Mirasol Evaluation Program: use of 
Mirasol pathogen reduction technology for platelets in 
routine clinical practice. Transfusion 2008; 48: 156A.
158) Custer B. Update on pathogen reduction technology. ISBT 
Science Series 2013; 8: 80-84
159) Mirasol® pathogen reduction technology (PRT) system. A 
simple, proven system with built-in flexibility. Available 
at: https://www.terumobct.com/location/asia-pacific/
Documents/306690275A-MiraSimplicity-web.pdf Accessed 
on 02/12/2014.
160) Evans G, Llewelyn C, Luddington R, et al. Solvent/detergent 
fresh frozen plasma as primary treatment of acute thrombotic 
thrombocytopenic purpura. Clin Lab Haematol 1999; 21: 
119-23.
161) Williamson LM, Llewelyn CA, Fisher NC, et al. A 
randomized trial of solvent/detergent-treated and standard 
fresh-frozen plasma in the coagulopathy of liver disease 
and liver transplantation. Transfusion. 1999; 39: 1227-34. 
162) Flamholz R, Jeon HR, Baron JM, Baron BW. Study of 
three patients with thrombotic thrombocytopenic purpura 
exchanged with solvent/detergent-treated plasma: is its 
decreased protein S activity clinically related to their 
development of deep venous thromboses? J Clin Apher 
2000; 15: 169-72.
163) Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/
detergent-treated plasma in patients with a prolonged 
prothrombin time. Vox Sang 2000; 79:161-7.
164) Atance R, Pereira A, Ramírez B. Transfusing methylene 
blue-photoinactivated plasma instead of FFP is associated 
with an increased demand for plasma and cryoprecipitate. 
Transfusion 2001; 41: 1548-52.
165) de la Rubia J, Arriaga F, Linares D, et al. Role of methylene 
blue-treated or fresh-frozen plasma in the response to plasma 
exchange in patients with thrombotic thrombocytopenic 
purpura. Br J Haematol 2001; 114: 721-3.
166) Haubelt H, Blome M, Kiessling AH, et al. Effects of 
solvent/detergent-treated plasma and fresh-frozen plasma 
on haemostasis and fibrinolysis in complex coagulopathy 
following open-heart surgery. Vox Sang 2002; 82: 9-14.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
381
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
167) Noddeland H, Töllöfsrud S, Svennevig J, et al. Universal 
solvent/detergent-treated fresh frozen plasma (Uniplas--
rationale and clinical properties. Thromb Res 2002; 107: 
S33-7.
168) de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis 
during liver transplantation is enhanced by using solvent/
detergent virus-inactivated plasma (ESDEP). Anesth Analg 
2002; 94: 1127-31. 
169) Alvarez-Larrán A, Del Río J, Ramírez C, et al. Methylene 
blue-photoinactivated plasma vs. fresh-frozen plasma 
as replacement fluid for plasma exchange in thrombotic 
thrombocytopenic purpura. Vox Sang 2004; 86: 246-51.
170) de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma 
prepared with amotosalen HCl (S-59) photochemical pathogen 
inactivation: transfusion of patients with congenital coagulation 
factor deficiencies. Transfusion 2005; 45: 1362-72.
171) García-Noblejas A, Osorio S, Durán AI, et al. Pulmonary 
embolism in a patient with severe congenital deficiency 
for factor V during treatment with fresh frozen plasma. 
Haemophilia 2005; 11: 276-9.
172) Mintz PD, Neff A, MacKenzie M, et al. A randomized, 
controlled phase III trial of therapeutic plasma exchange with 
fresh-frozen plasma (FFP) prepared with amotosalen and 
ultraviolet A light compared to untreated FFP in thrombotic 
thrombocytopenic purpura. Transfusion 2006; 46: 1693-704.
173) Santagostino E, Mancuso ME, Morfini M, et al. Solvent/
detergent plasma for prevention of bleeding in recessively 
inherited coagulation disorders: dosing, pharmacokinetics 
and clinical efficacy. Haematologica 2006; 91: 634-9.
174) Scully M, Longair I, Flynn M, et al. Cryosupernatant and 
solvent detergent fresh-frozen plasma (Octaplas) usage at a 
single centre in acute thrombotic thrombocytopenic purpura. 
Vox Sang 2007; 93: 154-8. 
175) Mikkola R, Gunn J, Heikkinen J, et al. Use of blood products 
and risk of stroke after coronary artery bypass surgery. Blood 
Transfus 2012; 10: 490-501.
176) Mikkola R, Heikkinen J, Lahtinen J, et al. Does blood 
transfusion affect intermediate survival after coronary artery 
bypass surgery? Scand J Surg 2013; 102: 110-6.
177) Stanojkovic Z, Balint B, Antic A, et al. Clinical efficacy 
of riboflavin and ultraviolet light inactivated fresh frozen 
plasma evaluated with INR-quantification. Transfus Apher 
Sci 2012; 47: 33-7. 
178) Bindi ML, Miccoli M, Marietta M, et al. Solvent detergent 
vs. fresh frozen plasma in cirrhotic patients undergoing liver 
transplant surgery: a prospective randomized control study. 
Vox Sang 2013; 105: 137-43.
179) Bartelmaos T, Chabanel A, Léger J, et al. Plasma transfusion 
in liver transplantation: a randomized, double-blind, 
multicenter clinical comparison of three virally secured 
plasmas. Transfusion 2013; 53: 1335-45. 
180) Beeck H, Hellstern P. In vitro characterization of solvent/
detergent-treated human plasma and of quarantine fresh 
frozen plasma. Vox Sang 1998; 74: S219-23.
181) Aznar JA, Molina R, Montoro JM. Factor VIII/von 
Willebrand factor complex in methylene blue-treated fresh 
plasma. Transfusion 1999; 39: 748-50.
182) Doyle S, O'Brien P, Murphy K, et al. Coagulation factor 
content of solvent/detergent plasma compared with fresh 
frozen plasma. Blood Coagul Fibrinolysis 2003; 14: 283-7.
183) Depasse F, Sensebé L, Seghatchian J, et al. The influence of 
methylene blue light treatment and methylene blue removal 
filter on fibrinogen activity states and fibrin polymerisation 
indices. Transfus Apher Sci 2005; 33: 63-9.
184) Heger A, Römisch J, Svae TE. Stability of solvent/detergent-
treated plasma and single-donor fresh-frozen plasma during 
48 h after thawing. Transfus Apher Sci 2005; 33: 57-67.
185) Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical 
treatment of plasma with amotosalen and long-wavelength 
ultraviolet light inactivates pathogens while retaining 
coagulation function. Transfusion 2006; 46: 1168-77.
186) del Río-Garma J, Pereira A, Arroyo JL, et al; Spanish 
Group of Apheresis (Grupo Español de AféresisGEA). 
ADAMTS-13 activity and von Willebrand factor levels 
in methylene-blue photo-inactivated plasma processed by 
either the Springe method or an 'in house' system. Vox Sang 
2008; 95: 101-5.
187) Lawrie AS, Green L, Canciani MT, et al. The effect of prion 
reduction in solvent/detergent-treated plasma on haemostatic 
variables. Vox Sang 2010; 99: 232-8.
188) Theusinger OM, Baulig W, Seifert B, et al. Relative 
concentrations of haemostatic factors and cytokines in 
solvent/detergent-treated and fresh-frozen plasma. Br J 
Anaesth 2011; 106: 505-11.
189) Ettinger A, Miklauz MM, Hendrix BK, et al. Quality of 
proteins in riboflavin and UV light-treated FFP during 1 
year of storage at −18°C. Transfus Apher Sci 2012; 46: 15-8.
190) Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of 
cryoprecipitate from riboflavin and UV light-treated plasma. 
Transfus Apher Sci 2012; 46: 153-8.
191) Keller MK, Krebs M, Spies C, et al. Clotting factor activity 
in thawed Octaplas® LG during storage at 2-6°C for 6 days 
from a quality assurance point of view. Transfus Apher Sci 
2012; 46: 129-36.
192) Cid J, Caballo C, Pino M, et al. Quantitative and qualitative 
analysis of coagulation factors in cryoprecipitate prepared 
from fresh-frozen plasma inactivated with amotosalen and 
ultraviolet A light. Transfusion 2013; 53: 600-5.
193) Rock G, Clark WF, Anderson D, et al; Members of 
the Canadian Apheresis Group. ADAMTS-13 may not 
predict disease or outcome in patients with thrombotic 
thrombocytopenic purpura. Thromb Res 2013; 131: 308-12.
194) Jilma-Stohlawetz P, Kursten FW, Walasek C, et al. Safety 
of a universal, virus-inactivated and prion-depleted, 
pharmaceutical-quality plasma: a randomized, double-blind, 
clinical trial in healthy volunteers. Transfusion 2011; 51: 
1228-40. 
195) Jilma-Stohlawetz P, Kursten FW, et al. Recovery, safety, 
and tolerability of a solvent/detergent-treated and prion-
safeguarded transfusion plasma in a randomized, crossover, 
clinical trial in healthy volunteers. Transfusion 2013; 53: 
1906-17.
196) Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion 
(SHOT) haemovigilance and progress is improving 
transfusion safety. Br J Haematol 2013; 163: 303-14.
197) Stramer SL, Hollinger FB, Katz LM, et al. Emerging 
infectious disease agents and their potential threat to 
transfusion safety. Transfusion 2009; 49: 1S-29S.
198) MacLennan S, Barbara JA. Risks and side effects of therapy 
with plasma and plasma fractions. Best Pract Res Clin 
Haematol 2006; 19: 169-89.
199) Funk MB, Guenay S, Lohmann A, et al. Benefit of 
transfusion-related acute lung injury risk-minimization 
measures--German haemovigilance data (2006-2010). Vox 
Sang 2012; 102: 317-23.
200) Pandey S, Vyas GN. Adverse effects of plasma transfusion. 
Transfusion 2012; 52: 65S-79S. 
201) Evidence-Based Medicine Group. San Giovanni Battista 
Hospital, Turin, Italy. [The transfusion of plasma in adults.] 
November 2006. Available at: http://old.cpo.it/lineeguida/
lgplasma.pdf. Accessed on 10/12/2014. [In Italian.] 
202) McCullough J. Pathogen inactivation: a new paradigm for 
preventing transfusion-transmitted infections. Am J Clin 
Pathol 2007; 128: 945-55.
203) Neisser-Svae A, Bailey A, Gregori L, et al. Prion removal effect 
of a specific affinity ligand introduced into the manufacturing 
process of the pharmaceutical quality solvent/detergent (SD)-
treated plasma OctaplasLG. Vox Sang 2009; 97: 226-33. 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
382
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
204) Bolton-Maggs PH, Poles D, Watt A, Thomas D; on behalf of 
the Serious Hazards of Transfusion (SHOT) Steering Group. 
The 2013 Annual SHOT Report (2014). 
205) Canadian Agency for Drugs and Technologies in Health, 
CADHT Technology report, 2007. A systematic review of 
clinical, laboratory and safety outcomes associated with use 
of Octaplas in multiple clinical indications. 
206) Canadian Agency for Drugs and Technologies in Health, 
CADHT Technology report, 2010. Update. A systematic 
review of clinical, laboratory and safety outcomes associated 
with use of Octaplas in multiple clinical indications. 
207) Flesland O. A comparison of complication rates based on 
published haemovigilance data. Intensive Care Med 2007; 
33: S17-21.
208) Cazenave JP, Waller C, Kientz D, et al. An active 
hemovigilance program characterizing the safety profile of 
7483 transfusions with plasma components prepared with 
amotosalen and UVA photochemical treatment. Transfusion 
2010; 50: 1210-9.
209) Canadian Agency for Drugs and Technologies in Health, 
CADHT Systematic Review, 2010. Pathogen Reduction 
Technologies for Blood Products: A Review of the Clinical 
Effectiveness, Cost-Effectiveness, and Guidelines.
210) European Commission, Health and Consumers Directorate-
General, 2013. Summary of the 2013 annual reporting of 
serious adverse events and reactions (SARE) for blood 
and blood components. Available at: http://ec.europa.eu/
health/blood_tissues_organs/docs/blood_sare_2013_en.pdf. 
Accessed on 01/12/2014.
211) The Paul-Ehrlich-Institut. Assessment of the Reports 
of Serious Adverse Transfusion Reactions pursuant 
to Section 63 c AMG (Arzneimittelgesetz, German 
Medicinal Products Act), 2010. Available at: http://
w w w. p e i . d e / S h a r e d D o c s / D o w n l o a d s / v i g i l a n z /
haemov ig i l anz /pub l ika t ionen /haemov ig i l ance -
repor t -2010 .pdf?__b lob=pub l i ca t ionF i l e&v=5 . 
Accessed on 01/12/2014. 
212) Knowles S, Cohen H; on behalf of the Serious Hazards of 
Transfusion (SHOT) Steering Group. The 2010 Annual 
SHOT Report (2011). Available at: http://www.shotuk.org/
shot-reports/. Accessed on 01/12/2014. 
213) Bolton-Maggs PH, Cohen H; on behalf of the Serious 
Hazards of Transfusion (SHOT) Steering Group. The 2011 
Annual SHOT Report (2012). Available at: http://www.
shotuk.org/shot-reports/. Accessed on 01/12/2014. 
214) Bolton-Maggs PH, Poles D, Watt A; on behalf of the Serious 
Hazards of Transfusion (SHOT) teering Group. The 2012 
Annual SHOT Report (2013). Available at: http://www.
shotuk.org/shot-reports/. Accessed on 01/12/2014. 
215) Irish National Haemovigilance Office. NHO REPORT 
2008/2009. Available at: http://www.giveblood.ie/Clinical_
Services/Haemovigilance/Publications/. Accessed on 
01/12/2014. 
216) Irish National Haemovigilance Office. NHO REPORT 
2010/2011. Available at: http://www.giveblood.ie/Clinical_
Services/Haemovigilance/Publications/. Accessed on 
01/12/2014. 
217) Swissmedica l .  Haemovig i lance  Annua l  repor t 
2010. Available at :  ht tps:/ /www.swissmedic.ch/
marktueberwachung/00138/00188/index.html?lang=en. 
Accessed on 02/12/2014. 
218) Swissmedica l .  Haemovig i lance  Annua l  repor t 
2011.  Available at :  ht tps: / /www.swissmedic.ch/
marktueberwachung/00138/00188/index.html?lang=en. 
Accessed on 02/12/2014.
219) Swissmedica l .  Haemovig i lance  Annua l  repor t 
2012. Available at :  ht tps:/ /www.swissmedic.ch/
marktueberwachung/00138/00188/index.html?lang=en. 
Accessed on 02/12/2014.
220) Swissmedica l .  Haemovig i lance  Annua l  repor t 
2013. Available at :  ht tps:/ /www.swissmedic.ch/
marktueberwachung/00138/00188/index.html?lang=en. 
Accessed on 02/12/2014.
221) Agence Française de Sécurité Sanitaire des produits de 
Santé (AFSSAPS). Haemovigilance Annual report 2008. 
Available at: http://ansm.sante.fr/Mediatheque/Publications/
Information-in-English. Accessed on 02/12/2014.
222) Agence Française de Sécurité Sanitaire des produits de 
Santé (AFSSAPS). Haemovigilance Annual report 2009. 
Available at: http://ansm.sante.fr/Mediatheque/Publications/
Information-in-English. Accessed on 02/12/2014.
223) Politis C, Kavallierou L, Hantziara S, et al. Haemovigilance 
data on the use of methylene blue virally inactivated fresh 
frozen plasma with the Theraflex MB plasma System in 
comparison to quarantine plasma: 11 years' experience. 
Transfus Med 2014; 24: 316-20. 
224) Muñiz-Diaz E, Puig L. Allergic and anaphylactic reactions 
to methylene-blue-treated plasma in Catalonia in the period 
2008-2013. Blood Transfus 2014; 12: 628-30.
225) Bost V, Odent-Malaure H, Chavarin P, et al. A regional 
haemovigilance retrospective study of four types of 
therapeutic plasma in a ten-year survey period in France. 
Vox Sang 2013; 104: 337-41.
226) Nubret K, Delhoume M, Orsel I, et al. Anaphylactic shock 
to fresh-frozen plasma inactivated with methylene blue. 
Transfusion 2011; 51: 125-8.
227) Norda R, Tynell E, Akerblom O. Cumulative risks of early 
fresh frozen plasma, cryoprecipitate and platelet transfusion 
in Europe. J Trauma 2006; 60: S41-5.
228) Dewachter P, Castro S, Nicaise-Roland P, et al. Anaphylactic 
reaction after methylene blue-treated plasma transfusion. Br 
J Anaesth 2011; 106: 687-9.
229) Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction 
of transfusion-related acute lung injury risk with male-
predominant plasma strategy in the American Red Cross 
(2006-2008). Transfusion 2010; 50: 1732-42.
230) Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E 
transmission by transfusion of Intercept blood system-treated 
plasma. Blood 2014; 123: 796-7.
231) International Haemovigilance Network. Proposed Standard 
Definitions For Surveillance Of Non Infectious Adverse 
Transfusion Reactions; 2011. Available at: http://www.ihn-org.
com/wp-content/uploads/2011/06/ISBT-definitions-for-non-
infectious-transfusion-reactions.pdf. Accessed on 01/12/2014.
232) Solheim BG. Pathogen reduction of blood components. 
Transfus Apher Sci 2008; 39: 75-82.
233) EUnetHTA Joint Action 2, Work Package 8. HTA Core 
Model® version 2.0; 2013. Available at: http://www.corehta.
info/BrowseModel.aspx. Accessed on 10/12/2014.
234) Drummond MF, Sculpher MJ, Torrance GW, et al. Methods 
for the economic evaluation of health care programmes. 3rd 
ed. Oxford: Oxford University Press; 2005.
235) Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-
effectiveness of solvent/detergent-treated fresh frozen 
plasma. Vox Sang 2003; 85: 88-95.
236) Van Eerd MC, Ouwens JN, De Peuter MA. Cost-effectiveness 
study comparing pharmaceutically licensed plasma for 
transfusions (OctaplasLG®) versus fresh frozen plasma 
(FFP) in critically ill patients in the UK. Transfus Apher Sci 
2010; 3: 251-9.
237) Blumberg N, Heal JM. Mortality risks, costs, and decision 
making in transfusion medicine. Am J Clin Pathol 2000; 114: 
934-7.
238) Huisman EL, de Silva SU, de Peuter MA. Economic 
evaluation of pooled solvent/detergent treated plasma versus 
single donor fresh-frozen plasma in patients receiving plasma 
transfusions in the United States. Transfus Apher Sci 2014; 
51: 17-24.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
383
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
239) AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness 
of solvent-detergent-treated plasma. In search of a zero-risk 
blood supply. JAMA 1994; 272: 1210-4.
240) Pereira A. Cost-effectiveness of transfusing virus-inactivated 
plasma instead of standard plasma. Transfusion 1999; 39: 
479-87.
241) Huisman EL, van Eerd MC, Ouwens JN, de Peuter MA. 
Cost-effectiveness and budget impact study of solvent/
detergent (SD) treated plasma (OctaplasLG®) versus fresh-
frozen plasma (FFP) in any patient receiving transfusion in 
Canada. Transfus Apher Sci 2014; 51: 25-34. 
242) Taylor C, Cohen H, Mold D, Jones H; on behalf of the 
Serious Hazards of Transfusion (SHOT) steering group. 
The 2008 Annual SHOT Report; 2009. Available at: http://
www.shotuk.org/shot-reports/report-and-summary-2009/. 
Accessed on 01/12/2014.
243) Ofosu FA, Freedman J, Semple JW. Plasma-derived 
biological medicines used to promote haemostasis. Thromb 
Haemost 2008; 99: 851-62.
244) Liumbruno GM, Panetta V, Bonini R, et al. Institutional 
authorization and accreditation of Transfusion Services and 
Blood Donation Sites: results of a national survey. Blood 
Transfus 2011; 9: 436-54.
245) Hellstern P. Solvent/detergent-treated plasma: composition, 
efficacy, and safety. Curr Opin Hematol 2004; 11: 346-50.
246) Sharma AD, Sreeram G, Erb T, Grocott HP. Solvent-
detergent-treated fresh frozen plasma: a superior alternative 
to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 
2000; 14: 712-7.
247) Koenigbauer UF, Eastlund T, Day JW. Clinical illness 
due to parvovirus B19 infection after infusion of solvent/
detergenttreated pooled plasma. Transfusion 2000; 40: 
1203-6.
248) Ruggeri M, Marietta M, Krusius T. Plasma S/D: le ragioni 
di una scelta. J Health Sci 2014; 17.
249) Vamvakas EC, Blajchman MA. Blood still kills: six strategies 
to further reduce allogeneic blood transfusion-related 
mortality. Transfus Med Rev 2010; 24: 77-124.
250) Klein HG, Glynn SA, Ness PM, et al. Research opportunities 
for pathogen reduction/inactivation of blood components: 
summary of an NHLBI workshop. Transfusion 2009; 49: 
1262-8.
251) Alter HJ. Pathogen reduction: a precautionary principle 
paradigm. Transf Med Rev 2008; 22: 97-102.
252) Official Journal of Italian Republic n. 80, 7 April 2015. 
Decreto Ministeriale 5 dicembre 2014. "Individuazione 
dei centri e aziende di frazionamento e di produzione di 
emoderivati autorizzati alla stipula delle convenzioni con le 
regioni e le province autonome per la lavorazione del plasma 
raccolto sul territorio nazionale".
253) Official Journal of the European Union n. L 311, 28 
November 2001. Directive 2001/83/CE on the Community 
code relating to medicinal products for human use. 
254) Official Journal of the European Union n. L 33, 8 February 
2003. Directive 2002/98/EC of the European Parliament and 
of the Council of 27 January 2003 setting standards of quality 
and safety for the collection, testing, processing, storage 
and distribution of human blood and blood components and 
amending Directive 2001/83/EC
255) Official Journal of the European Union n. L 262, 14 October 
2003. Commission Directive 2003/94/EC of 8 October 
2003 "laying down the principles and guidelines of good 
manufacturing practice in respect of medicinal products 
for human use and investigational medicinal products for 
human use". 
256) World Health Organization. Safe Blood and Blood Products: 
Manual on the Management, Maintenance and Use of 
Blood Cold Chain Equipment. Geneva: WHO; 2005. 
Available at: http://www.who.int/bloodsafety/Manual_on_
Management,Maintenance_and_Use_of_Blood_Cold_Chain 
_Equipment.pdf. Accessed on 01/12/2014.
257) Di Fazio C. Studio sulla validazione del congelamento del 
plasma. Undergraduate dissertation. Biomedical engineering, 
Engineering school. Università degli studi di Padova. 2012.
258) Official Journal of Italian Republic n. 233, 6 October 2005. 
Decreto Legislativo 19 agosto 2005 n. 191. "Attuazione 
della direttiva 2002/98/CE che stabilisce norme di qualità 
e di sicurezza per la raccolta, il controllo, la lavorazione, 
la conservazione e la distribuzione del sangue umano e dei 
suoi componenti". 
259) Official Journal of Italian Republic n. 19, 23 January 2008. 
Decreto Legislativo 20 dicembre 2007, n. 261. "Revisione del 
decreto legislativo 19 agosto 2005, n. 191, recante attuazione 
della direttiva 2002/98/CE che stabilisce norme di qualità 
e di sicurezza per la raccolta, il controllo, la lavorazione, 
la conservazione e la distribuzione del sangue umano e dei 
suoi componenti". 
260) Official Journal of Italian Republic n. 261, 9 November 
2007. Decreto Legislativo 9 novembre 2007, n. 207. 
"Attuazione della direttiva 2005/61/CE che applica la 
direttiva 2002/98/CE per quanto riguarda la prescrizione in 
tema di rintracciabilità del sangue e degli emocomponenti 
destinati a trasfusioni e la notifica di effetti indesiderati ed 
incidenti gravi". 
261) Official Journal of Italian Republic n. 261, 9 November 2007. 
Decreto Legislativo 9 novembre 2007, n. 208. "Attuazione 
della direttiva 2005/62/CE che applica la direttiva 2002/98/
CE per quanto riguarda le norme e le specifiche comunitarie 
relative ad un sistema di qualità per i servizi trasfusionali". 
262) Official Journal of the European Union n. L 256, 1 ottobre 
2005. Commission Directive 2005/62/CE of 30 September 
2005 implementing Directive 2002/98/EC of the European 
Parliament and of the Council as regards Community 
standards and specifications relating to a quality system for 
blood establishments.
263) Official Journal of the European Union n. L 91, 30 March 
2004. Commission Directive 2004/33/CE of 22 March 
2004 implementing Directive 2002/98/EC of the European 
Parliament and of the Council as regards certain technical 
requirements for blood and blood components. 
264) Official Journal of the European Union n. L 256, 1 October 
2005. Commission Directive 2005/61/EC of 30 September 
2005 implementing Directive 2002/98/EC of the European 
Parliament and of the Council as regards traceability 
requirements and notification of serious adverse reactions 
and events. 
265) Official Journal of Italian Republic n. 251, 27 October 
2005. Legge 21 Ottobre 2005, n. 219. "Nuova disciplina 
delle attività trasfusionali e della produzione nazionale degli 
emoderivati" 
266) Official Journal of Italian Republic n. 113, 17 May 2011. 
Conferenza permanente per i rapporti tra lo Stato, le Regioni 
e le Province Autonome di Trento e Bolzano. Accordo 16 
dicembre 2010. Accordo, ai sensi dell'articolo 4 del decreto 
legislativo 28 agosto 1997, n. 281, tra il Governo, le Regioni 
e le Province autonome di Trento e Bolzano sui requisiti 
minimi organizzativi, strutturali e tecnologici delle attività 
sanitarie dei servizi trasfusionali e delle unita' di raccolta e 
sul modello per le visite di verifica. (Rep. Atti n. 242/CSR 
del 16 dicembre 2010). 
267) Official Journal of Italian Republic n. 85, 13 April 2005. 
Decreto del Ministro della Salute 3 marzo 2005: Protocolli 
per l'accertamento della idoneità del donatore di sangue e di 
emocomponenti. 
268) Ordinanza 29 marzo 2004 Ministero della Salute. Non 
idoneità alla donazione di sangue di coloro che hanno 
soggiornato nel Regno Unito. Gazzetta Ufficiale della 
Repubblica Italiana, n. 102, 3 maggio 2004. 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
384
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
269) Centro Nazionale Sangue, Agenzia Italiana del Farmaco e 
Istituto Superiore di Sanità. Gestione delle segnalazioni di 
donatori con malattia di Creutzfeldt-Jakob (post donation 
information). Position paper 2012.
270) CHMP Position statement on Creutzfeldt-Jakob disease 
and plasma-derived and urine-derived medicinal products. 
European Medicines Agency (EMA); London: Jun 23, 2011. 
EMA/CHMP/BWP/303353/2010. 
271) Official Journal of the European Union n. L 169, 12 July 
1993. Directive 93/42/CEE of the Council of 14 June 1993, 
concerning medical devices. 
272) Official Journal of the European Union n. L 139 del 23 May 
1989. Directive 89/336/CEE of the Council of 3 May 1989 on 
the approximation of the laws of the Member States relating 
to electromagnetic compatibility. 
273) Official Journal of the European Union n. L 077, 26 March 
1973. Directive 73/23/CEE of the Council of 19 February 
1973 on the harmonisation of the laws of Member States 
relating to electrical equipment designed for use within 
certain voltage limits. 
274) Official Journal of the European Union n. L 331, 07 December 
1998. Directive 98/37/EC of the European Parliament and 
of the Council of 22 June 1998 on the approximation of the 
laws of the Member States relating to machinery. 
275) European HAS (Harmonised standards): EN 61326:1997. 
Electrical equipment for measurement, control and laboratory 
use - EMC requirements - Part 1: General requirements.
276) International standards: EN 61010-1:2001 (General 
requirements) Safety requirements for electrical equipment 
for measurement, control, and laboratory use - Part 1: General 
requirements.
277) European Commission Health and Consumer Protection 
Directorate General Public Health and Risk Assessment 
Directorate. European Blood Inspection System. Common 
European Standards and Criteria for the Inspection of Blood 
Establishments Reflecting European good practice within the 
area addressing the quality and safety of blood. 2003-2008. 
278) Official Journal of the European Union L 102, 7 April 
2004. Directive 2004/23/EC of the European Parliament 
and of the Council of 31 March 2004 on setting standards 
of quality and safety for the donation, procurement, testing, 
processing, preservation, storage and distribution of human 
tissues and cells. 
279) Official Journal of the European Union n. L 159, 26 June 
2003. Commission Directive 2003/63/EC of 25 June 2003 
amending Directive 2001/83/EC of the European Parliament 
and of the Council on the Community code relating to 
medicinal products for human use. 
280) Sheffield WP, Bhakta V, Talbot K, et al. Quality of frozen 
transfusable plasma prepared from whole blood donations 
in Canada: an update. Transfus Apher Sci 2013; 49: 440-6.
281) AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood 
supply in the United States: opportunities and controversies. 
Ann Intern Med 1997; 127: 904-9. 
282) Bacterial contamination of blood components: risks, 
strategies, and regulation: joint ASH and AABB educational 
session in transfusion medicine. Hematology/the American 
Society of Hematology Education Program. 2003.
283) Jorquera JI. Safety procedures of coagulation factors. 
Hemophilia 2007; 13: 41-6.
284) Van der Wilt GJ, Reuzel R, Banta HD. The ethics of assessing 
health technologies. Theor Med Bioeth 2000; 21: 103-15.
285) Hofmann B. Why ethics should be part of health technology 
assessment. Int J Technol Assess Health Care 2008; 24: 
423-9.
286) Sacchini D, Virdis A, Refolo P, et al. Health technology 
assessment (HTA): Ethical aspects. Med Health Care Philos 
2009; 12: 453-7.
287) Assasi N, Schwartz L, Tarride JE, et al. Methodological 
guidance documents for evaluation of ethical considerations 
in health technology assessment: a systematic review. Expert 
Rev Pharmacoecon Outcomes Res 2014; 14: 203-20.
288) Health Council of the Netherlands. Pathogen reduction 
in blood products. The Hague: Health Council of the 
Netherlands, 2003; publication no. 2003/16E.
289) Refolo P, Sacchini D, Minacori R, Spagnolo AG. [Internet 
use in clinical trials]. Clinica Terapeutica 2014; 165: e79-85. 
[In Italian.]
290) Berto D, Peroni M, Milleri S, Spagnolo AG. Evaluation of 
the readability of information sheets for healthy volunteers 
in phase-I trials. Eur J Clin Pharmacol 2000; 56: 371-4.
291) Refolo P, Minacori R, Mele V, et al. Patient-reported 
outcomes (PROs): the significance of using humanistic 
measures in clinical trial and clinical practice. Eur Rev Med 
Pharmacol Sci 2012; 16: 1319-23.
292) Minacori R, Sacchini D, Cicerone M, Spagnolo AG. Insurance 
and clinical trials. Contemp Clin Trials 2012; 33: 573. 
293) Refolo P, Mele V, Minacori R, Spagnolo AG. [Patient-
reported outcomes (PRO): Historical profile, definitions, 
classifications and problems.] Clinica Terapeutica 2012; 
163: 39-45. [In Italian.]
294) National Advisory Committee on Bioethics. Department of 
Health. Specific Informed Consent for Blood Transfusion: 
The Ethical Considerations; 2013. Avaialble at: http://www.
dohc.ie/working_groups/Current/nacb/SpecificConsent_
Blood%20Transfusion.pdf?direct=1. Accessed on 
10/12/2014.
295) Rodriguez del Pozo P. Paying donors and the ethics of blood 
supply. Med Ethics 1994; 20: 31-5.
296) Buyx AM. Blood donation, payment, and non-cash 
incentives: classical questions drawing renewed interest. 
Transfus Med Hemother 2009; 36: 329-39.
297) McQuillen MP. Ethical lessons learned from the use of 
therapeutic plasma exchange in neurologic disease. Ther 
Apher 2000; 4: 190-4.
298) Sazama K. The ethics of blood management. Vox Sang 2007; 
92: 95-102.
299) Sazama K. Managing infectious or untested autologous blood 
components: the ethical dilemma of private rights versus 
public safety. Arch Pathol Lab Med 2005; 129: 1212-3.
300) Farrugia A1, Penrod J, Bult JM. Payment, compensation and 
replacement--the ethics and motivation of blood and plasma 
donation. Vox Sang 2010; 99: 202-11.
301) Weiskopf RB. The ethics of blood management. Vox Sang 
2007; 93: 91.
302) Sacchini D, Liumbruno GM, Bruno G, et al. Ethical and 
deontological issues in Transfusion Medicine. Blood Transfus 
2013; 11: 14-23.
303) Farrell AM, Brazier M. Patients should consent to blood 
transfusion. Br Med J 2010; 341: c4336.
304) Holland PV. Consent for transfusion: is it informed? Transfus 
Med Rev 1997; 11: 274-85.
305) Court EL, Robinson A, Hocken DB. Informed consent and 
patient understanding of blood transfusion. Transf Med 
2011; 21: 183-9.
306) Official Journal of Italian Republic n. 85, April 13th, 
2005. Decreto del Ministro della Salute 3 marzo 2005: 
"Caratteristiche e modalità per la donazione del sangue e di 
emocomponenti". 
307) Judgment of the Court (First Chamber) 13 March 2014, 
(Approximation of laws - Directive 2001/83/EC - Directive 
2002/98/EC - Scope - Labile blood product - Plasma prepared 
by means of an industrial process - Simultaneous or exclusive 
application of the directives - Option for a Member State 
to provide for a more rigorous regime for plasma than for 
medicinal products) - (C 512/12). 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
385
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
Pathogen reduction technologies of plasma: HTA
308) Conseil d'Etat sentence no. 357463 between MacoPharma 
and the Agence Française de Sécurité des Produits de 
Santé, France. Available at: https://www.legifrance.gouv.fr/
affichJuriAdmin.do?oldAction=rechJuriAdmin&idTexte=
CETATEXT000029288214&fastReqId=233964865&fastP
os=1. Accessed on 10/12/2014.
309) Official Journal of Italian Republic n. 3, 16 January 
2008. Italian Ministerial Decree 21 December 2007. New 
legislation on transfusions and national production of blood 
products.
310) Council of Europe, Convention for the Protection of Human 
Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention on Human 
Rights and Biomedicine, Oviedo, 4-IV-1997.
311) Additional Protocol to the Convention on Human Rights and 
Biomedicine, concerning Biomedical Research, Strasbourg, 
25.I.2005
312) World Medical Association. WMA Publishes its Revised 
Declaration of Helsinki, 2013. Available at: http://www.
wma.net/en/40news/20archives/2013/2013_28/. Accessed 
on 10/12/2014.
313) Official Journal of the European Union n. L 281, 23 
November 1995. European Parliament And Council, 
Directive 95/46/EC of 24 October 1995 on the protection of 
individuals with regard to the processing of personal data 
and on the free movement of such data. 
314) European Convention For The Protection Of Human Rights 
And Fundamental Freedoms, Rome 4.XI.1950.
315) Court Of Justice Of European Union, Judgment 20 May 2003, 
Joined Case C-465/00, C-138/01, C-139/01.
316) Committee On Bioethics (DH-BIO) Working document on 
research on biological materials of human origin, DH-BIO/
INF (2014) 3, Strasbourg, 18 March 2014. 
317) National Advisory Committee on Bioethics - Department of 
Health. Specific Informed Consent for Blood Transfusion: 
The Ethical Considerations; January 2013. Available 
at: http://health.gov.ie/wp-content/uploads/2014/07/
SpecificConsent_Blood-Transfusion1.pdf. Accessed on 
10/12/2014.
318) Repealed by Decision No 1350/2007/EC of the European 
Parliament and of the Council of 23 October 2007 establishing 
a second programme of Community action in the field of health 
(2008-13). Official Journal L 301 of 20.11.2007.
319) Commission, White Paper "Together for Health: A Strategic 
Approach for the EU 2008-2013, COM (2007) 630
320) Commission of the European Communities, Communication 
from the Commission to the Council, the European 
Parliament, the European Economic and Social Committee 
and the Committee of the Regions e-health - making 
healthcare better for European citizens: an Action plan 
for a European e-Health area, {SEC(2004)539}, Brussels, 
30.4.2004, COM (2004) 356 final.
321) European Parliament - Council of the European Union. 
2011/24/UE Directive of the 9 March 2011 concerning the 
application of patients' rights in cross-border healthcare.
322) Council of Europe, Committee of Ministers. Recommendation 
Rec(2006)18 on health services in a multicultural society 
(adopted by the Committee of Ministers on 8 November 2006 
at the 979th meeting of the Ministers' Deputies).
323) Council of the European Union. Directive on cross-border 
healthcare, 28/02/2011.
324) Court of Justice of the European Union 28/04/1998 (C-
120/95).  Judgment of the Court of 28 April 1998. Nicolas 
Decker v Caisse de maladie des employés privés. Reference 
for a preliminary ruling: Conseil arbitral des assurances 
sociales - Grand Duchy of Luxemburg. Free movement of 
goods - Articles 30 and 36 of the EC Treaty - Reimbursement 
of medical expenses incurred in another Member State - 
Prior authorisation of the competent institution - Purchase 
of spectacles.
325) Official Journal of the European Union L 213, 30 July 
1998. Directive 98/44/EC of the European Parliament and 
of the Council of 6 July 1998 on the legal protection of 
biotechnological inventions. 
326) EUnetHTA, Work Package 4 (2008). The HTA Core Model, 
HTA Core Model for Medical and Surgical Interventions 
(v 1.0r). Available at: http://www.eunethta.eu/outputs/
hta-core-model-diagnostic-technologies-10r. Accessed on 
11/07/2014.
327) Ovretveit J. The contribution of new social science research 
to patient safety. Soc Sci Med 2009; 69: 1780-3.
328) Lehoux P, Williams-Jones B. Mapping the integration of 
social and ethical issues in Health Technology Assessment. 
Int J Technol Assess Health Care 2007; 23: 9-16.
329) Whyte SR. Questioning misfortune the pragmatics of 
uncertainty in Eastern Uganda. Cambridge: Cambridge 
University Press; 1997. 
330) Bech U. Risk society. Towards a new modernity. New Delhi: 
Sage; 1992. 
331) Bourdieu P. Social being, time and the sense of existence. In: 
Bourdieu P, editor. Pascalian Meditations. New York: Polity 
Press; 2000. p. 206-45. 
332) Good BJ. Medicine, rationality, and experience an 
anthropological perspective. Cambridge: Cambridge 
University Press; 1994. 
333) Foucault M, Martin LH, Gutman H, Hutton PH. Technologies 
of the self: a seminar with Michel Foucault. Amherst: 
University of Massachusetts Press; 1988. 
334) Jackson M. Minima ethnographic intersubjectivity and the 
anthropological project. Chicago: University of Chicago 
Press; 1998. 
335) Latour B. 'Constitution' I: we have never been modern. 
London: Prentice Hall; 1993. 
336) Kleinman A. Introduction: medical Anthropology as 
intellectual career. In: Kleinman A, editor. Writing at the 
Margin. Discourse between Anthropology and Medicine. 
Berkeley/Los Angeles/London: University of California 
Press; 1995. p. 1-20. 
337) Bijker WE, Law J., editors. Shaping technology/building 
society. Studies in sociotechnical change. Cambridge, MA: 
MIT Press; 1992. 
338) Harbers H. Inside the politics of technology: agency and 
normativity in the co-production of technology and society. 
Amsterdam: Amsterdam University Press; 2005. 
339) Reid S, Johnson L, Woodland N, Marks DC. Pathogen 
reduction treatment of buffy coat platelet concentrates in 
additive solution induces proapoptotic signaling. Transfusion 
2012; 52: 2094-103. 
340) Denis J-L, Lehoux P, Champagne F. Knowledge utilization in 
health care: From fine-tuning dissemination to contexualizing 
knowledge. In: Lemieux-Charles L, Champagne F, 
editors. Using knowledge and evidence in health care: 
multidisciplinary perspectives. Toronto: University of 
Toronto Press; 2004. p. 18-40.
341) Ross SE, Lavis JN, Rodriguez C, et al. Partnership 
experiences: Involving decision-makers in the research 
process. J Health Serv Res Policy 2003; 8: 26-34.
342) Bastian H. Speaking up for ourselves. The evolution of 
consumer advocacy in health care. Int J Technol Assess 
Health Care 1998; 14: 3-23.
343) Mitton C, Smith N, Peacock S, et al. Public participation in 
health care priority setting: A scoping review. Health Policy 
2009; 91: 219-28.
344) Gauvin F-P, Abelson J, Giacomni M. Conceptualizing public 
involvement in the context of health technology assessment 
agencies. Soc Sci Med 2010; 70: 1518-26.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI 
Se
rvi
zi 
Srl
386
Cicchetti A et al
Blood Transfus 2016; 14: 287-386  DOI 10.2450/2016.0065-16
345) Lehoux P, Daudelin G, Abelson J. The unbearable lightness 
of citizens within public deliberation processes. Soc Sci Med 
2012; 74: 1843-50.
346) Lehoux P, Blume SS. Technology assessment and the 
sociopolitics of health technologies. J Health Polit Policy 
Law 2000; 25: 1083-120.
347) Lehoux P, Saint-Arnaud J, Richard L. The use of technology 
at home. What patient manuals say and sell vs. what patients 
face and fear. Sociol Health Illn 2004; 26: 617-44.
348) Lehoux P, Daudelin G, Demers-Payette O, Boivin A. 
Fostering deliberations about health innovations: what do we 
want to know from publics? Soc Sci Med 2009; 68: 2002-9.
349) Mooney G. "Communitarian claims" as an ethical basis for 
allocating health care resources. Soc Sci Med 1998; 47: 
1171-80.
Correspondence: Stefania Vaglio 
Italian National Blood Centre
Via Giano della Bella 27
00162 Rome, Italy
e-mail: ricerca.cns@iss.it
Appendix I
Working team
The current report results from a joint effort 
between the Postgraduate School of Health 
Economics and Management (Altems) - Università 
Cattolica del Sacro Cuore (UCSC) and the Italian 
National Blood Centre (INBC). This research 
project, led by Professor Americo Cicchetti, 
Director of Altems, involved Dr. Giancarlo M. 
Liumbruno, Director of the INBC, four clinical 
experts from the INBC, a biomedical engineer from 
Altems, three health economists from Altems, a 
health economist and two clinical experts from the 
Health Technology Assessment Unit of "Gemelli" 
Teaching Hospital - UCSC, four bioethicists from 
the Institute of Bioethics of the UCSC, three with a 
clinical background and one with a background in 
philosophy and, finally, two jurists from the Institute 
of Bioethics of UCSC. Authorship of each section 
is reported below:
1 - The health problem and current use of the 
technologies: Giuseppina Facco, Stefania 
Vaglio, Giuseppe Marano, Giuliano Grazzini 
(INBC).
2 - Description and technical characteristics of 
the technologies: Giuseppina Facco, Stefania 
Vaglio, Giuseppe Marano, Giuliano Grazzini 
(INBC).
3 - Clinical efficacy: Giuseppina Facco, Stefania 
Vaglio, Giuseppe Marano, Giuliano Grazzini 
(INBC).
4 - Safety: Alessandra Fiore (Altems).
5 - Economic domain: Matteo Ruggeri, Federica 
Romano, Paola Codella (Altems).
6 - Organisational domain: Marco Marchetti, 
Alexandra Berrino, Irene Urbina (Health 
Technology Assessment Unit of "Gemelli" 
Teaching Hospital-UCSC).
7 - Ethical domain: Pietro Refolo, Dario Sacchini, 
Roberta Minacori, Antonio G. Spagnolo 
(Institute of Bioethics of the UCSC).
8 - Social domain: Dario Sacchini, Pietro Refolo, 
Roberta Minacori, Antonio G. Spagnolo 
(Institute of Bioethics of the UCSC).
9 - Legal domain: Emanuela Midolo, Marina 
Casini, Antonio G. Spagnolo (Institute of 
Bioethics of the UCSC).
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